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Abstract 
As medical technology has advanced, outcomes have improved for many 
malignancies, and thus survival rates for those diagnosed with cancer are 
progressively increasing each year. However, as a consequence of the disease 
process and cancer treatment, patients commonly experience adverse physiological 
and psychological changes. Determining the impact of these side effects ort 
functional capacity and quality of life (QoL), as well as investigating intervention 
strategies that maintain the ability to facilitate recovery post-treatment, is essential 
for the cancer patient, as survival rates continue to rise. 
Twelve patients undertaking an intensive treatment reg1me of high-dose 
chemotherapy, followed by peripheral blood stem cell transplantation were recruited 
into this investigation. Jhe study participants were aged between 16 to 64 years and 
had been diagnosed with either advanced breast cancer, leukaemia, lymphoma, 
multiple myeloma or rhabdomyosarcoma. Functional capacity and quality of life 
were assessed pre-transplant (Phase I - PI), post-transplant (Phase II - PII) and 
following a 12-week intervention period (Phase III - Pili). Functional capacity 
measures included body composition, energy expenditure, aerobic capacity, muscular 
strength, immunological status and function and bone turnover. Pre- and post-
transplant measures demonstrated that undertaking a transplant was associated with 
adverse changes to body composition, muscular strength, aerobic fitness, 
immunological status, and bone turnover, which together maintain the potential to 
influence functional capacity in the short- and longer-term. The treatment regime 
was also associated with adverse changes in total QoL. 
Participation in regular physical activity has been linked with numerous 
physiological and psychological benefits in healthy and certain diseased populations. 
However, the potential benefits derived through participation in exercise are less 
clear for patients with cancer. This investigation was designed to extend current 
evidence regarding exercise, functional capacity and QoL in peripheral blood stem 
cell transplant patients, and therefore post-treatment, the study group was divided 
equally into a control group (CG) or exercise intervention group (EG). The exercise 
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intervention protocol was of a moderate intensity and mixed type nature. Exercising 
patients participated in aerobic exercise three times per week, for 20-40 minutes at an 
intensity of 70-90% of their maximum heart rate. Additionally, resistance training, 
which involved the performance of one set, 8-20 repetitions of 3-6 machine and free 
weight exercises, was scheduled twice per week. 
Patients in the exercise group demonstrated a faster recovery oflean tissue (p<O.Ol), 
aerobic capacity (p<0.05), muscular strength (p<0.05) and QoL (p<0.05) when 
compared with the non-exercising patients. Additionally, by 3-months post-
transplant, exercising patients were experiencing higher peak ventilation (p<0.05), 
lower body strength (p<O.Ol) and QoL (p<0.05), when compared with the controls, 
and were demonstrating comparable aerobic capacity to healthy age-matched 
controls. Patients had improved body composition, aerobic capacity, peak 
ventilation and body strength at Pill, when compared with pre-transplant measures 
(p<0.05). Correlations performed on QoL data with aerobic capacity data indicated 
that those who were experiencing a higher level of fitness were more likely to also 
experience a higher QoL (R=-0.685; p<0.05), and fewer (R=-0.630; p<0.05) and less 
severe (R=-0.708; p<O.Ol) QoL problems. 
Following the intervention period, the bone turnover changes observed in the 
exercise participants indicated an uncoupling of formation and resorption activity, 
favouring formation. The control group failed to demonstrate these changes during 
the same period, and although preliminary, collectively the results suggest that 
participation in the intervention protocol may have a favourable influence on bone 
metabolism. In contrast to the other functional capacity measures, participation in 
the exercise intervention had no impact on immunological changes across the testing 
phases as was evident by both exercising and non-exercising patients demonstrating 
a delayed recovery for lymphocyte, CD3+, and CD4+ cell counts. Importantly 
though, while exercise did not facilitate the recovery of these immune cells, immune 
recovery was not adversely effected, demonstrating that participation in the 
prescribed exercise program was of no detriment to immune status and function for 
these patients. 
IV 
In summary, participation in exercise following cancer treatment facilitates the 
recovery of numerous physiological variables, which in tum influences functional 
capacity and QoL. Additionally, patients maintain the capacity to return to higher 
than pre-transplant functional capacity and QoL, in as little as three months 
following treatment. This investigation not only highlights the need to integrate 
exercise into the care plan of patients with cancer following treatment, but also 
provides evidence demonstrating that participation in an exercise program can assist 
in 'bridging the gap' between treatment cessation, and returning to a 'normal' 
lifestyle. 
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CHAPTER ONE 
INTRODUCTION 
((Cancer is a word, not a sentence" (Author Unknown) 
Chapter One, Introduction 
1. Introduction 
Exercise has been prescribed since the fifth century BC when Hippocrates stated that 
"Eating alone, will not keep a man well; he must also take exercise. For food and 
exercise, while possessing opposite qualities, yet work together to produce health"242 • 
A general consensus now exists that both regular physical activity and a moderate to 
high level of aerobic fitness are associated with a reduction in chronic disease 
morbiditr83 and all-cause mortality242 . Dr William Foege, former Director of the 
Centers for Disease Control in Atlanta, USA, suggested that "physical activity may 
provide the shortcut we in public health have been seeking for the control of chronic 
diseases, much like immunization has facilitated progress against infectious 
diseases"242• It is believed by many authorities that 50-80% of chronic diseases 
could be prevented or at least postponed by exercise, proper nutrition, weight control, 
smoking cessation and stress management326. 
Suggested mechanisms that link a physically active lifestyle to a reduction in all-
cause mortality include a decreased incidence of heart disease and a reduction in 
certain forms of cancer110• It is also associated with a reduction in the length of the 
terminal period of partial and total dependencl46 and an enhanced quality of life445 . 
In addition to these associations, participation in regular exercise leads to other 
health benefits such as improved cardiovascular114' 119 and musculoskeletal 
function351 , development and maintenance of joint flexibility6 and psychological 
benefits270. Furthermore, beneficial changes in haemodynamic, metabolic, hormonal, 
respiratory and neurological function have been reported with improved exercise 
capacity119. In general, exercise has been shown to improve health and wellbeing, 
enhance functional capacity and the ability to perform daily activities, and in tum, 
quality of life, while reduce the risk of developing chronic and debilitating 
conditions. Just as numerous health benefits have been related to a physically active 
lifestyle, the relationship between sedentary living and a higher incidence of 
particular lifestyle diseases has also been shown. 
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Chapter One, Introduction 
1.0.1 Physical activity participation rates 
Despite the well-documented association between physical inactivity and the 
prevalence of adverse health, participation in physical activity remains considerably 
lo~42 • The public health burden is significant because more people are at risk of 
physical inactivity than any other single risk factor for chronic disease. In response, 
several countries including the United States have established national objectives to :;: 
reduce sedentary lifestyles and to increase moderate daily physical activity levels in 
children, adolescents, adults and the elderly. Unfortunately, evidence from the US 
initiative showed that many of the goals related to physical activity and fitness were 
not mer42 • Poor physical activity participation rates were further highlighted in a 
more recent American investigation that demonstrated the continued widespread 
erosion of physical activity patterns with increasing age among adolescents and 
adults63• The results also indicated that although males had somewhat better physical 
activity patterns than females, the decay in participation rates with age was greater 
for males when compared to females. 
An Australian survey of exercise participation rates estimated that approximately two 
thirds of the Australian population participated in some form of exercise for 
recreation, fitness or sporr. Thirty-seven per cent of those surveyed chose walking 
as the preferred type. However, based on the frequency, intensity and duration of 
exercise undertaken, 69% of adults were classified as s~dentary or having low 
exercise levels. 
Physical activity is a modifiable risk factor of lifestyle diseases33 and these 
inadequate participation rates highlight the need for policy objectives to improve 
participation and to promote physically active lifestyles worldwide. In summary, 
there is considerable evidence of the benefits of exercise to both physical and 
psychological health. Moreover, there exists a plethora of evidence highlighting the 
role of exercise in the prevention of certain lifestyle diseases, and the benefits 
attained through physical activity in individuals with cardiovascular disease, 
hypertension, rheumatic disease, diabetes mellitus, pulmonary disease and renal 
disease. However, specific information concerning the benefits to cancer patients 
3 
Chapter One, Introduction 
and the nature, type and intensity of exercise required to optimise these benefits, is 
limited. 
1.1 Cancer 
Cancer refers to more than 100 different disorders all characterised by disturbances 
in cell growth and development control165' 376. It involves a multistage process of 
initiation, promotion, progression and metastasis, with complex origins involving 
genetic, environment and gene-environment interactions. Cancer is not one disease, 
but rather a grouping of diseases characterised by mvastve, metastatic cell 
proliferation, with each having a distinct etiology and pathology. 
1.1.1 Cancer incidence and mortality rates 
The second leading cause of morbidity and mortality in the United States, accounting 
for more than 20% of all deaths, is cancer326• 350. Each year, approximately 
1 300 000 people in the US are diagnosed with cancer and approximately 500 000 
people will die from the disease147• Although the lifetime probability of developing 
cancer is greater in males (43.48%) than females (38.34%), women maintain a higher 
risk of developing any cancer before 60 years of age147• 
In 1990 diseases of the circulatory system represented the major cause of death 
(41.8%) within Australia, with heart disease and cerebrovascular disease contributing 
to 31.3% and 7.4% respectively. During this same period, cancer contributed to 
26.9% of deaths. Since the late 1960s, substantial decreases have occurred in the 
mortality rates from each of the major vascular causes of death2• In contrast, the 
incidence of cancer has progressively increased. In 1997, malignant neoplasms were 
associated with 27% of deaths, while ischaemic heart disease and cerebrovascular 
disease represented 22.5% and 9.4% respectively1• 
Approximately 80 000 new cancer cases are diagnosed each year in Australia1 with 
males experiencing a 1 in 3 and females a 1 in 4 lifetime risk of developing cancer179. 
Tracheal, bronchial and lung malignancies are the leading cause of male cancer 
deaths (24%), followed by cancer of the prostate (13%) and colon (10%)1• Females 
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are at greatest risk from breast cancer, which accounts for 17% of all female cancer 
deaths. Tracheal, bronchial and lung cancer (14%) and colon cancer (11 %) represent 
the next most common female cancers 1• The risk of cancer increases with advancing 
age401 , with greater than 83% of cancer deaths occurring over the age of 65 and the 
highest incidence and mortality rates seen in the 85+ age group. 
As technology has advanced, outcomes have improved for many malignancies, and~ 
thus survival rates (defined as a relative combined 5-year statistic) from those 
diagnosed with cancer are progressively increasing each year. US data illustrates 
that when taking into account all cancer sites, the most recent survival rate estimate 
is 59%148• Additionally, the survival rate estimate is approximately 50-80% for those 
undertaking 'intensive' cancer treatments, specifically bone marrow and peripheral 
blood stem cell transplantation 166. As survival rates continue to rise, addressing 
research issues such as facilitating recovery post-treatment and improving quality of 
life, is essential. 
1.2 Exercise and cancer prevention 
It is now believed that approximately 50-80% of all cancers are related to 
environmental and lifestyle causes133• 326• Therefore a large proportion of these 
cancers may be prevented through the adoption of health practices including proper 
nutrition, weight control, exercise, smoking cessation and stress management. Of 
particular relevance to this thesis is the relationship between exercise participation 
and risk of cancer. 
Physical activity has an inverse relationship with coronary heart disease, whereas its 
influence on cancer is less clear281 . However between 1980 and 1990, evidence 
indicated that physical activity was associated with decreased overall cancer 
mortality and decreased incidence of specific types of cancer110• 347• 376• During the 
course of a Harvard-based study, it was identified that after adjustment for age and 
smoking, cancer mortality rates were highest in those who exercised the least110. 
While there is an increasing tendency for investigations to illustrate the protective 
effect of exercise162, currently the exact relationship between physical activity and 
all-cancer mortality remains controversial. 
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Evidence for the role of exercise in the prevention of cancer has been derived from 
studies investigating animals or by classifying human subjects into groups according 
to their occupational or leisure-time activity and then comparing the incidence of 
cancer within the different groups. Animal experiments10• 24• 348• 350 have shown that 
increased physical activity is associated with a 25-100% retardation of tumour 
growth in rats. Additionally, the growth, size and metastatic spread of experimental 
tumours is significantly decreased when exercise training is initiated prior to cancer 
induction, and when moderate training occurs post-cancer development. Prior to 
carcinogen treatment, exercised rats elicit a lesser incidence of tumours than their 
sedentary peers. Moreover, when training is discontinued in cancerous mice, tumour 
growth accelerates until it matches that of the control animals. 
Studies of various occupational groups have attempted to determine the relationship 
between work-related physical activity and cancer risk. These investigations 
compare individuals working in physically demanding occupations with those 
working in sedentary roles. Other studies categorise people's leisure time as 'active' 
or 'sedentary', and then compare cancer incidence between the groups. While the 
majority of these investigations illustrated a protective effect on cancer by 
participating in occupational or leisure activity, particularly for colon cancer, the 
association was not always shown447• In a review regarding leisure time physical 
activity, it was stated that no pattern of consistency emerged, and in several cases the 
significance of the association was in the opposite direction199• 
Investigations of former athletes typically categorise subjects based on previous, 
rather than current exercise habits and then compare the prevalence of cancer among 
different groups. Lower mortality rates299• 339, higher mortality rates, and no 
mortality rate differences32\ have been associated with former athletes when 
compared to their sedentary peers. Other investigations have found that greater 
physical activity was associated with a decreased risk of rectal and colon cancer280, 
lower prevalence of breast and reproductive system cancers 125, but an increased risk 
of skin carcinoma 111' 151 • 
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Although each of the above mentioned studies have associated limitations348• 350, 
evidence is mounting to support the notion that participation in physical activity is 
linked with a reduction in cancer risk. In a number of studies designed to investigate 
the effects of different types and intensities of activity Hill (1999)162 indicated that 
four hours of recreational walking or cycling was associated with protection against 
colon cancer. Energy expenditure comparable to walking or jogging more than 5.5 
miles per day has been reported as necessary to decrease prostate cancer risk212. 
Women who participate in approximately 30-minutes of daily exercise, an amount 
frequently recommended by authorities, show a substantial reduction in breast cancer 
risk29 • In addition, women who are active both recreationally and at work have a 
40% risk reduction403 • Others have found that participation in physical activity of 
four hours per week reduces the risk of breast cancer by more than 50% when 
compared with inactive women, while one to three hours of weekly physical activity 
can reduce risk by approximately 30%303. Although the exact volume of activity 
required to reduce overall cancer risk remains unclear, it seems likely that a threshold 
of activity exists, whereby lower amounts of exercise are of insignificant benefit425 . 
1.2.1 Mechanisms by which exercise may influence the presence/absence of 
cancer 
The mechanisms be which physical activity might influence the course of cancer has 
been most frequently studied in colorectal cancer patients. The findings indicate that 
increased amounts of occupational activity, participation in exercise in adulthood, 
active recreation and levels of total activity, relate to a lower incidence and mortality 
from colon cancer3• 39• 54• 122• 134• 211 . Possible mechanisms of association include a 
reduction in intestinal transit time, which leads to a reduction in the contact time of 
potential faecal carcinogens with the colon. Additionally, peristalsis is increased 
with vagal stimulation and aerobic exercise is associated with an increase in vagal 
tone. In tum, transit rate is enhanced in the segments of the colon innervated by the 
vagus nerve. Exercise has also been shown to have a stimulatory influence on the 
secretion of gastro-entero-pancreatic hormones to levels that improve intestinal 
motility. 
Physical activity has been hypothesised to protect against breast cancer through its 
effect on endocrine function125 ' 163• 251 . A proposed strategy of primary breast cancer 
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prevention is through reduced exposure of the breast to oestrogen and progesterone, 
and is based on a series of observations of the effect of physical activity during 
adolescence on menstrual and ovulatory patterns. Although evidence for such an 
association is limited294, high physical activity has been correlated with late age at 
menarche, early onset of menopause, anovulation and low body fat. This mechanism 
has particular appeal because it is not dependent on hormonal manipulation by an 
exogenous agent30. It has also been suggested that the population attributable risk 
estimates for diet and physical exercise are of similar magnitude to those for family 
history and reproductive and hormonal factors386• 
As for breast cancer, hormones may also take an aetiologic role in the prevalence of 
prostate cancer. Males diagnosed with prostate cancer have higher endogenous 
testosterone levels compared with healthy controls, and cancerous prostate tissue has 
been reported to have higher testosterone levels when compared with nondiseased 
tissue275• 376 • Additionally, lower testosterone levels have been detected among male 
distance runners and this may act to reduce the risk of prostate cancer in active men. 
The physical activity-prostate cancer hypothesis is compatible with the standard 
treatment regime being anti-testosterone therapy, which acts to reduce testosterone 
levels to those observed after castration. However, the relatively sparse and 
inconsistent evidence limits universal support for this hypothesis and more research 
is required220• 
Other mechanisms by which exercise may influence the presence of all types of 
cancer have also been proposed. Cancer is a disease of altered immunology and it 
has therefore been suggested that the observed effects of exercise in reducing cancer 
risk may relate to altered immune functioning, where regular and moderate intensity 
activity may have a favourable effect on the number and functioning of specific 
immune cells199• 231 • Exercise can also be used as an effective technique for daily 
stress management, which may influence the release of catecholamines and the 
subsequent effect of these hormones on immune system function417. Reduction in 
serum cholesterol levels and body fat are two other mechanisms which have the 
potential to influence cancer risk, as increased levels of these substances are 
associated with the production of more potent forms of oestrogen 133. Regular 
physical activity may also modify the risk of neoplasia indirectly by initiating other 
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lifestyle changes such as avoiding smoking or alcohol abuse and the maintenance of 
a healthy diet. 
By contrast, an increased cell division after injury from exercise may enhance the 
chance of metaplasia, while high intensity activity may suppress immune function350• 
The accumulation of X-irradiation during the diagnosis and treatment of injuries, the 
consumption of performance-enhancing drugs and excessive exposure to ultraviolet 
radiation during activities such as swimming, may increase the likelihood of the 
development of cancers. Furthermore, the shift to oronasal breathing from nasal 
breathing and the increased ventilatory rate evident during exercise participation may 
increase the exposure to airborne pollutants and carcinogens. 
It seems evident that a simple determination of the possibility of an association 
between physical activity and a reduction in cancer risk may never be reached, given 
the multitude of possible initiators and promoters, their interactions and individual 
characteristics199• 348• Even if a positive association is identified, manifestations of 
cancer in physically active individuals may still arise. 
1.3 Cancer treatment 
Treatment for cancer is highly varied and ultimately depends on a number of factors 
including the age of the patient, the location of the tumour, whether the tumour is of 
haematological or solid nature, and the extent of metastasis. Deciding which option 
will provide the highest possible cure rate and the highest possible quality of life is 
the primary objective used when deciding the treatment regime36' 401 • Treatment 
choice primarily includes surgery, chemotherapy, radiation therapy, or a combination 
of the three. Unfortunately, each treatment option has the risk of potential adverse 
effects that may range from changes in the ability to perform daily activities to major 
organ dysfunction and secondary cancers, and social and psychological effects155. 
Currently, surgery maintains a primary role in the therapeutic management of solid 
tumours and has an essential diagnostic and palliative role401 • When surgery is not a 
treatment option, radiotherapy (RT) or chemotherapy (CT) is usually administered. 
Radiotherapy represents a common form of treatment for malignant tumours and can 
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be applied locally or regionally. It may be utilised as either symptomatic or 
recovering treatment401 and is used alone or in conjunction with surgery and/or 
CT241 • Less morbidity and acute mortality is associated with RT and it is a potential 
treatment option when patients have other pathologies that would increase risk 
associated with a surgical procedure. Unfortunately, treatment regimes are often 
lengthy. 
The endocrine, renal, immune, cardiovascular, gastrointestinal, pulmonary and 
musculoskeletal system can sustain late effects from RT50. The side effects are 
directly associated with the body area receiving treatment and the vital organs in that 
field241• 413 • The radiosensitivity of the tissue, radiation fractions, treatment timing 
and energy source may ultimately dictate the intensity of the side effects experienced 
by the patient. However, it is important to acknowledge that not all side effects are 
dose-dependent, with a primary example being fatigue. Interstitial pneumonitis, 
intrapulmonary inflammation, pneumonitis, reduced lung volumes and pulmonary 
fibrosis are just some of the pulmonary complications affiliated with RT. While 
pericarditis is the most common cardiac complication associated with RT, other 
cardiac problems may develop and include myocardial fibrosis and accelerated and 
radiation-induced coronary artery disease. 
The value of CT in lengthening survival and optimising performance status and 
quality of life has been successfully established328 and it is therefore considered a 
central treatment strategy for the management of cancer51 • The systemic treatment of 
CT maintains the ability to destroy cells that are in a particular growth or division 
stage241• 413 • However, antitumour CT regimes are unable to differentiate between 
cancerous and 'normal' cells and thus side effects are observed in healthy tissue241• 
401 
Cardiovascular complications may encompass congestive heart failure, ischaemic 
changes, myocarditis, cardiac necrosis and dysrhythmias241• 401 . Hypersensitivity 
reaction such as anaphylaxis; shaking, chills and febrile reactions; dyspnoea, 
hypotension and bronchospasm; and urticaria and erythematous rashes, tend to be 
relatively common (4-30%) in patients receiving particular CT regimes. Since bone 
marrow elements are rapidly dividing, these cells are particularly vulnerable to 
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destruction by CT or RT, and therefore myelosuppression encompasses a common 
side effect. Pneumonitis, pulmonary edema, and methotrexate and bleomycin 
toxicity constitute some of the pulmonary complications that are associated with CT. 
Additionally, renal complications and veno-occlusive disease207, electrolyte 
imbalances, and neurological complications including dizziness, headache, slight 
confusion, seizures, and hallucinations, are other known side effects. Changes in 
body composition and gastrointestinal side effects such as enteritis, typhlitis, nausea, 
vomiting, and diarrhoea, have also been associated with this treatment option. 
1.3.1 Bone marrow transplantation and peripheral blood stem cell 
transplantation 
Irradiation and some cytostatic drugs elicit a steep dosage-versus-antitumour effect 
relationship, with a correlation existing between the higher the dose, the more 
effective eradication of the malignant cells. However, due to the toxicity on normal 
tissues such as the bone marrow or gastrointestinal epithelium, dosage escalations 
above 150-250% of the conventional used dosages of drugs are prevented, and 
therefore CT doses are often insufficient to cure specific cancers250• 397. Failure to 
find exploitable differences between malignant and normal cells have frustrated 
attempts to develop more effective agents that would allow the highly selective 
therapy required for tumour eradication. The primary cause of morbidity and 
mortality with high-dose CT is infection secondary to severe and prolonged 
myelosuppression 371 • 
Optimism has encompassed the growth of new therapies, such as bone marrow 
transplants (BMT) and more recently peripheral blood stem cell transplants (PBST), 
following high dosages of anticancer drugs250' 397• This enables circumvention of the 
dosage-limiting effect of bone marrow toxicity, dramatically elevating anti-tumour 
efficacy. There has been a dramatic increase in the use of BMT over the past decade, 
with a 51% increase in the number of institutions performing the procedure in the 
United States12• 
Peripheral blood stem cell transplantation differs from BMT as it involves the 
infusion of stem cells, rather than bone marrow, following a high-dose treatment 
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regime. Peripheral blood stem cells are crucial to the recovery of patients following 
a transplant since all mature blood cells evolve from these 'mother' cells. Stem cells 
differ from other blood cells in that they are capable of unlimited self-renewal and 
differentiation. The role of self-renewal is the ability of the cell to reproduce itself 
into another identical cell, thus maintaining a steady number of these cell types in the 
body. Differentiation is the process of generating one or more subsets of mature 
cells that eventually evolve into erythrocytes, neutrophils, eosinophils, basophils, 
lymphocytes, monocytes or platelets. When stem cells are infused into a patient's 
bloodstream they have the capacity to migrate to the interior of certain bones, 
colonise and begin producing immature cells known as committed progenitors. 
These cells alternatively produce colonies of cells that eventually mature into 
erythrocytes, leukocytes and thrombocytes. 
Patients undergo either an autologous or allogeneic BMT or PBST. The process of 
an allogeneic transplant requires either bone marrow or peripheral blood stem cells 
derived from an identical sibling, or less commonly from other human leukocyte 
antigens (HLA) - matched family donors, or from matched unrelated donors397• 
Given that a proportion of patients do not have a matched donor, increasing numbers 
of patients receive autologous stem cells taken prior to the administration of high 
dosage therapy. 
More recently, autologous PBST have been performed instead of autologous BMT, 
and have expanded treatment options for thousands of patients diagnosed with life-
threatening diseases. A clear advantage of the use of peripheral blood progenitor 
cells (PBPC) when compared with bone marrow progenitor cells, is the lack of 
anaesthesia required for the bone marrow harvest81 . In addition, decreased incidence 
of transplant-related toxicities including pulmonary and liver effects may be 
associated with PBST compared with BMT. When PBPC are used, a faster recovery 
of haemopoiesis and thus shorter hospitalisation periods exist397. Furthermore, 
autologous PBST resulted in fewer septic episodes, less intensive care admissions, 
reduced erythrocyte and thrombocyte transfusions, a decline in the use of anti-
infectious and parenteral nutrition and less hospital costs when compared with 
autologous BMT. 
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Initially only patients with acute leukaemia who failed to respond to standard CT 
were treated with bone marrow and stem cell transplantation18• 206• However, the 
potential implications for this therapy were expanded as the number of long-term 
survivors after transplantation increased. Bone marrow transplants and PBST are 
presently considered a potential cure for acute leukaemia, aplastic anaemia, inborn 
errors of metabolism, severe immunodeficiency syndromes, and chronic 
myelogenous leukaemia. Encouraging results have been demonstrated for other life-
threatening conditions including Hodgkin's disease and non-Hodgkin's lymphoma, 
breast cancer, ovarian cancer, brain tumours, multiple myeloma, small cell lung 
cancer, testicular cancer and paediatric solid tumours such as neuroblastoma80• 126. 
However, the type of disease, the stage to which it has progressed, the 
responsiveness of the disease to prior treatment, and the patient's age and general 
physical condition are all factors used to determine whether a patient is considered a 
suitable candidate for a PBST. 
With the exception of leukaemia, diseases treated by PBST are primarily not 
disorders that start in, or involve, bone marrow. Rather they are 'malignant' or 
cancerous tumours located elsewhere in the body that are responsive to treatment 
with high-dose CT and/or RT. However, as previously noted, the doses required to 
destroy the cancer, also destroy the patient's bone marrow. Therefore, without the 
PBPC, the ability to manufacture blood cells needed to defend against infection, 
transport oxygen and prevent bleeding is adversely affected397. 
The process of undertaking a PBST has been divided into four primary stages and 
includes397: progenitor cell harvest; cryopreservation of harvested cells; pre-
transplantation chemotherapy and/or radiotherapy; and reinfusion of the 
cryopreserved stem cells to 'rescue' the patient from bone marrow toxicity. 
The ability to obtain sufficient stem cells to restore haematological function and 
successful pre-transplant treatment of the patient, is a prerequisite for successful 
PBST397• Mobilisation of PBPC may be accomplished by using CT, RT, colony 
stimulating factors (CSF), alone or in combination with particular CSF or 
interleukin-3. 
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Initially the patient is usually treated with a standard-dose CT397 and once the tumour 
burden has been minimised, peripheral stem cells are collected after cytokine 
mobilisation through one or more aphaeresis procedures126• The process of 
extracting stem cells from the bloodstream (peripheral stem cell harvest) is 
performed with the patient being connected to an aphaeresis device. Hospital 
admission is usually two to four days and, in order to provide for adequate venous 
access, a two lumen dialysis catheter is implanted. However, the procedure may be 
performed using conventional infusion needles if peripheral vein catheters permit. 
During the harvest, patients may experience symptoms including lightheadedness, 
coldness, numbness around the lips, or cramping in the hands. Typically, one to 
three leukopheresis sessions are necessary, with each session taking approximately 
three to four hours and processing nine litres of blood. Once the stem cells have 
been collected, the cells are preserved using a cryopreservation process. 
The tumour type being treated dictates the type of antitumour CT or RT 
administered397• However, most transplantation schemes are given over three to six 
days, with a 'washout' period of one or two days prior to infusion of the stem cells. 
The transplantation process begins with an intensive course of high-dose CT, called 
the 'conditioning regimen'. The primary objective of this component is to destroy 
any residual malignant cells in the patient's body, and then the 'tumour-free' marrow 
or the stem-cells are used to 'rescue' the patient from the high-dose CT/RT damaging 
and lethal effects126. The results of this conditioning regimen is a period of 
profound pancytopenia, and severe and absolute neutropenia371 , with significant risk 
of infections and cytotoxic side effects, ranging in intensity from minimal to life-
threatening. 
Approximately one to two days later, following the administration of high dosage 
treatment, stem cells are reinfused by transporting the stem cell solution to syringes 
and administering it by intravenous bolus or by infusion397. 
During the first four to five weeks after transplantation, the appearance of the first 
neutrophil, the presence of the higher absolute neutrophil counts and platelet 
recovery usually occurs, with the rate of recovery of this initial phase being related to 
the number and quality of mature progenitor cells infused371 . A more stable and 
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complete haematopoietic recovery is generally associated with the subsequent 
phases, and is secondary to the transplantation of intermediate and early progenitor 
stem cells, or to the persistence of similar endogenous cells. This latter phase occurs 
beyond five weeks post-transplant106. 
Patients are usually characterised as thrombocytopenic and granulocytopenic during 
the first weeks post-transplantation397• The duration of absolute neutropenia is often.:: 
correlated with the incidence of infectious complications due to the intensive CT 
regimen371 . Normal leukocyte and platelet levels are usually observed approximately 
two to three weeks post reinfusion. However, patients continue to be at increased 
risk of developing infections during the first few months despite normal leukocyte 
levels. 
The American Society of Clinical Oncology (1994i0 noted that standard practice in 
protecting patients against CT -associated infection has been CT dose modification or 
dose delay, selective use of prophylactic antibiotics, or the administration of 
progenitor cell support. However, improved supportive care methods have arisen 
with the inclusion of the use of growth factors or CSF. This assists haematopoietic 
recovery137, reduces the duration of profound neutropenia371 , reduces the number and 
duration of the peripheral stem cell harvest sessions, decreases the risk of infection 
and febrile events and therefore reduces the number of hospitalisation days. 
Although growth factors significantly accelerate neutrophil recovery and reduce 
hospitalisation, there is no significant effect on the number of septic episodes and 
febrile days, or the recovery of platelets371 • Furthermore, CSF are worthwhile in 
improving neutrophil recovery past the presence of the first granulocyte, but have no ,; 
consequence on the length of period during which granulocytes are absent397. 
Although the success of cancer treatment is continually improving, this success has 
not been without cost72. Increased risk of late physical effects of treatment, social 
consequences and psychological sequelae have been ascertained as significant issues 
adversely affecting patients' quality of life. Neitzert and colleagues (1998) in 
Coumeya et al (2000)80 noted that cytopenias, asthenia, functional capacity losses, 
sleeping difficulties and psychological distress, comprise some of the acute and 
chronic side effects that can be experienced by BMT patients. Body image, 
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relationship, reproductive and fertility changes, work-related fears, the issue of 
insurance, and questions regarding existential and spiritual well-being, constitute 
other issues that must be dealt with by patients undergoing cancer treatment155. 
Reduced physical performance and fatigue have also been identified as universal 
problems following a BMT and are known limitations on the ability to perform 
occupational and leisure activities, making it difficult to resume normal daily lives 101 . 
Forty percent of BMT patients require a year to fully recover their physical 
functioning, and 30% of patients are unable to return to work within the first two 
years post-transplant105. 
1.4 Cancer rehabilitation 
Consistent evidence illustrates that cancer patients are likely to experience a decline 
in their physical and psychological functioning, and that this deterioration in function 
may persist for months, following treatrnent77 . Therefore, the need for intervention 
strategies that will assist in mitigating the effects of diagnosis and treatment on 
quality of life and/or hasten recovery is obvious77• Increased survival rates have 
placed more attention on the need for effective rehabilitative procedures50• 121• 429 and 
cancer rehabilitation has emerged as a specialisation within both oncology and 
rehabilitation 121 • Although cancer rehabilitation (CR) has been recognised as an 
essential component of cancer care, few programs provide effective rehabilitation 
programs that address both functional and psychological issues181 • 
The rehabilitation process has been considered as "accommodation, or adjustment to 
personal needs for survival"100• The dynamic process of rehabilitation should be 
directed toward the goal of enabling persons to function at maximum levels in all life 
domains, within the limitations imposed by cancer107. The Oncology Nursing 
Society defined CR as "a process by which individuals, within their environments, 
are assisted to achieve optimal functioning within the limits imposed by cancer"41• 
237
• This definition broadened the pool of candidates, the scope of the required needs 
and interventions, and allowed CR to be considered a conceptual approach as well as 
a specific program that addresses survivorship issues. 
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Watson (1990)414 believes that a global definition is required for the advancement of 
cancer care. One such definition where "cancer rehabilitation is a dynamic, health-
oriented process designed to promote maximum levels of functioning in individuals 
with cancer-related health problems", would be appropriate, since all cancer patients 
are encompassed under this broad definition. Although others129• 181 have supported 
this definition, it was also noted that a contemporary cancer rehabilitation program 
must be designed with an emphasis on all facets of wellness. Therefore, CR should -
consider any aspect of an individual's quality of life that is affected by cancer and its 
treatment. This may include such factors as psychological and social functioning, 
work-related issues, sexual functioning, nutrition, exercise and fitness, and pain and 
symptom management41' 129. 
Dietz (1981) in Watson (1990)414 introduced the notion of adaptive cancer 
rehabilitation which consisted of four primary categories: preventive, which aims to 
optimise physical functioning while reduce morbidity and disability; restorative, 
which refers to the control, circumvention or elimination of neoplasia; supportive, 
which is the type of rehabilitation implemented in those patients who will experience 
periods of remission or control of their cancer, but never 'cure'; and palliative, which 
is utilised when the disease is active and advanced, with the aim being to attenuate 
the disability. 
Adaptive CR was then later modelled by Watson (1992)415 (Figure 1.1). The model 
depicts that CR or an optimal functioning plan (OFP) is a process that begins with a 
diagnosis, and is continued until the optimal level of functioning is achieved and 
maintained. Once disease parameters have been identified, a cancer health care . 
program is developed whereby treatment options are discussed and initiated. 
Concurrently, an optimal functioning plan is developed to ensure the promotion of 
rehabilitation throughout the entire cancer care process. At the same time prevention 
guidelines are developed and may relate to the prevention or reduction of secondary 
problems stemming from the cancer and its treatment, and/or longer-term prevention 
via the implementation of positive health promoting behaviours in the patient and 
family. 
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The design and implementation of a follow-up health plan completes the model415 • 
Follow-up practices should consist of various time fixed activities in which an active 
role is taken by the patient. During this period, emphasis is shifted from a disease 
focus and placed on health issues. 
Figure 1.1 Cancer rehabilitation model or optimal functioning plan 
Cancer Care Process 
Identification and Measurement of Cancer 
Development of Cancer Health Care Program 
Therapeutic Cancer Intervention 
Follow-up Sequence 
The OFP centres on attaining the maximum physical function, adequate and 
sustained nutritional intake, a practical level of independence in performing daily 
living activities, an optimistic yet realistic outlook, and effective management of the 
cancer phenomena415 . Additionally, the physician and other rehabilitation health 
care team members need to anticipate sequelae and initiate preventive strategies to 
alleviate or minimise side effects that will influence a patient's quality of life129• 
Where appropriate, the primary aim should be to restore the patient to functioning 
levels that existed prior to cancer diagnosis which may include returning the patient 
to work, school, domestic activities, and social interaction. For those patients where 
this goal is unrealistic, the principal aim should be to return the patient to their 
maximal functioning level, to relieve any discomfort, increase mobility and promote 
independence41 • 161• 444. 
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Regardless of what model is applied to cancer rehabilitation, a number of defining 
attributes can be applied: 
> quality and not quantity of life should be the primary concern; 
> the patient's needs govern the activity prescribed and performed; 
> optimal functioning and independence are principal concerns; 
> the process is dynamic, and relevant at any stage of the disease process; and 
> the patient must maintain a sense of control168 • 
Finally, CR aims to achieve positive outcomes for all patients with the belief that 
when a patient is optimally functioning, the individual is experiencing the best 
possible quality of life. 
While a number of cancer rehabilitation programs are in place, the development of 
these services has been notably slow154. A review of cancer rehabilitation programs 
performed nearly 20 years ago identified that patient education was the primary 
feature in all programs studied154• Unfortunately, many years later, the 'typical' 
cancer rehabilitation program still does not include physical exercise388, is 
predominantly psychologic in nature and is less likely to appropriately address the 
physical and functional side effects experienced by the cancer patient77• 
1.4.1 Exercise as a component in cancer rehabilitation 
Exercise pre-, during and post-treatment has been recommended since 1975, for 
those with cancer to prevent the sequelae of disuse and to maintain functional 
capacity405. It has also been suggested that, regardless of the level of disability, all 
individuals should be encouraged to participate in an activity program that is 
designed to meet their specific requirements290• Unfortunately, empirical data 
concerning the place of exercise in the rehabilitation or palliative care of the cancer 
patient is lacking227' 350. 
Ideally, cancer treatment should be initialised and completed with the patient in the 
best physiological and psychological condition possible. The benefits of exercise 
will enhance the likelihood of increased endurance throughout the rigours of cancer 
treatment, and greater independence post-treatment426. The vicious cycle of 
19 
Chapter One, Introduction 
depression, hypokinesis and progressive tissue loss could be broken through 
participation in a moderate exercise program353. An increase in physical activity may 
stimulate appetite, assist in the conservation of lean tissue, reduce the speed of the 
clinical course of the disease, optimise functional capacity, increase the age at death 
and improve the remaining quality of life350• A review of physical exercise and 
cancer research 124 demonstrated that improvements in functional capacity, body 
composition, nausea, and fatigue were physiological changes. Positive outcomes in 
locus of control, mood states, self-esteem and psychological well-being, were 
identified as psychologic changes associated with participation in physical activity. 
Exercise provides a structured and purposeful daily activity415, which increases 
opportunities for social interaction, creates a tone of optimism and promotes overall 
wellness181 . Patients may view exercise participation as a means by which they 
maintain a certain degree of control and responsibility over the course of their 
treatments, unlike their perceived/real degree of control in the decision-making 
process of other treatment options. Greater than 50% of people diagnosed and 
treated for cancer resume active lives226• Specific health programming during cancer 
care would benefit these patients in 'bridging the gap' between treatment cessation 
and returning to a 'normal' life. 
1.4.2 Lack of referral 
The development of rehabilitation strategies is potentially being hindered by health 
professionals and family members who may advise patients to 'take it easy' and 'get 
plenty of rest' 425 • Traditionally, cancer programs are only offered to those with 
obvious cancer-related disabilities, rather than to all diagnosed cancer patients414. 
Given that the success of rehabilitation efforts is potentially dependent on effective 
rehabilitation programs, team communication and referral pattems15\ it is important 
to promote the potential benefits derived through cancer rehabilitation programs to 
the community and appropriate health professionals. 
The theory of planned behaviour states that people will intend to perform a behaviour 
when they evaluate it positively, perceive it to be under their own control, and 
believe that important others think the behaviour will be of benefit (Ajzen, 1991, in 
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Coumeya & Friedenreich, 1999 79). Research findings derived from patients with 
breast cancer have suggested that lack of personal experience with the situation may 
mean that patients are more likely to rely on the views of significant others when 
deciding on behaviours that should be adopted79. In clinical populations, it seems 
plausible to suggest that health professionals, particularly treating clinicians, would 
be perceived as important others. Thus encouragement from these individuals is 
essential in facilitating participation in post-cancer treatment care such as exercise. 
Interestingly, 60% of a breast cancer population studied reported that their physician 
failed to mention exercise as an important rehabilitative strategy442 • 
The efficacy and cost-effectiveness of cardiac rehabilitation has been proven, yet it 
still remains an underutilised and poorly referred form of cardiac care86. Reasons 
such as limited access and funding, professional scepticism regarding the efficacy of 
the program and the provision of risk-factor modification by the treating physician 
(making formal rehabilitation appear unnecessary) are given for low referral rates86• 
This highlights not only the need for continual research in cancer rehabilitation but 
also the importance of health professionals' support. Greater emphasis on 
rehabilitative measures by health professionals is required to ensure that each cancer 
patient is assisted in achieving their ideal possible function given their limitations 
and environmenf43 • Once referral has been given, continual encouragement is 
necessary to ensure that patients will act on recommendations129. "Physicians have 
the opportunity and responsibility to promote regular physical activity'' 119 with 
regard to the 'normal' population. It has also been reported that "Physicians should 
routinely refer and vigorously encourage"228 cardiac patients to participate in 
rehabilitation programs. While cancer rehabilitation research might still be 
considered preliminary, there is sufficient evidence to support the use of these two 
quotes within the cancer domain. 
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1.5 General research purpose 
Convincing evidence demonstrates that undergoing cancer treatment induces 
numerous physiological and psychological effects that may lead to a dramatic 
influence on quality of life. Most work cited in the area of exercise and cancer 
rehabilitation has investigated breast cancer patients who have undergone 
conventional treatment regimens. This investigation sought not only to investigate a 
unique cancer patient population, but to also study a population subjected to 
extensive and intensive cancer treatment. Peripheral blood stem cell transplant 
patients have often undergone conventional treatment prior to undertaking high-dose 
chemotherapy and/or radiotherapy followed by PBST. It is therefore a purpose of 
this thesis to determine the functional side effects of a PBST. Additionally, the 
effect of the transplant procedure on quality of life will be considered and 
investigated. 
Evidence of the positive response of cancer survival rates to various treatment 
strategies including exercise, provides a background to another purpose of this 
investigation which was to evaluate the potential of exercise to enhance post-
treatment recovery and quality of life. Specifically the investigation will: 
Objective 1: 
To investigate changes between pre- and post-transplant measures of functional 
capacity and quality of life. 
Research hypothesis for primary objective 1: 
Functional capacity and quality of life decreases following a PBST (as 
determined via pre- and post-transplant measures). 
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Objective 2: 
To investigate the role of a three-month duration, moderate intensity and mixed type 
exercise program in the recovery of functional capacity and quality of life, post-
PEST. 
Research hypothesis for primary objective 2: 
Exercising PBST patients experience a faster recovery of functional capacity 
and quality of life, when compared with non-exercising patients (as determined 
by pre- and post-exercise intervention measures). 
Objective 3: 
To investigate the relationship between functional capacity and quality of life of 
PBST patients. 
Research hypothesis for primary objective 3: 
Functional capacity is related to quality of life. 
Objective 4: 
To investigate the ability of PBST patients to participate in, and tolerate the three-
month, moderate intensity, mixed type, intervention program. 
Research hypothesis for primary objective 4: 
Patients undergoing a PBST can participate in regular exercise following 
treatment. Further, PBST patients can tolerate an exercise prescription that 
involves both overload and progression. 
In order to meet these objectives, this investigation has been divided into 5 studies, 
which are extensively covered in Chapters 4- 8. As noted earlier, this thesis aimed 
to assess changes in two primary factors, functional capacity and quality of life. 
Measures of aerobic fitness are predominantly used throughout the literature to 
determine functional capacity. However, functional capacity is not just aerobic 
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fitness and many of the side effects reported following treatment may influence 
functional capacity. Therefore, in order to provide a comprehensive assessment of 
functional capacity, several physiological measures were included - aerobic capacity, 
muscular strength, body composition, energy expenditure, immunological changes, 
and bone turnover. The final study involved the assessment of quality of life, and 
determined the relationship between functional capacity and quality of life. 
This thesis has been organised to firstly provide a literature review and general 
methodology that are relevant to all measures assessed (Chapter 2 & 3). More 
specifically, Chapters 2 and 3, address the available literature regarding exercise 
prescription for cancer patients, and provide reasoning for the exercise prescription 
implemented in the intervention program. Thereafter, the following Chapters 
address the literature, objectives, methodological procedures, results and discussion, 
which are specific to each study (Chapters 4- 8). Finally, Chapter 9 integrates the 
findings of the five studies and demonstrates how the conclusions drawn from the 
studies meet the original objectives. The organisation of this thesis has been 
illustrated in Figure 1.2. 
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Figure 1.2 Organisation of thesis 
-1 Chapter 1: Introduction 
Chapter 2: General Literature Review - Current review of the 
~ 
literature regarding exercise prescription in cancer rehabilitation. This 
chapter provides the basis behind the exercise intervention program 
prescribed in this investigation. The literature reviewed in this chapter is 
relevant to all study chapters. 
Chapter 3: General Methodology- This chapter describes in detail the 
methodological procedures that relate to recruitment, time of testing, 
~ implementation of intervention, location of intervention and testing, and 
statistical procedures employed. The information provided within this 
chanter is ::u:rl'lin relfwl'lnt for l'!ll stnclv c:hl'lnters. 
Chapter 4: Study 1 
- Changes in energy expenditure and body composition 
following a PBST and participation in an exercise program Introduction 
I--
Chapter 5: Study 2 Literature Changes in aerobic capacity and muscular strength following 
Review a PBST and participation in an exercise program 
Chapter 6: Study 3 Methodology 
- Changes in immunological status and function following a 
PBST and participation in an exercise program Results 
-
Chapter 7: Study 4 
Changes in bone turnover following a PBST and 
Discussion 
participation in an exercise program 
Summary 
Chapter 8: Study 5 
I-- Changes in QoL following a PBST and participation in an 
exercise program 
---
Chapter 9: Discussion and Summary - Integrates the findings of the 5 
studies, addresses the study limitations and provides recommendations for 
future research. 
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GENERAL LITERATURE REVIEW 
((I do not recommend that patients with malignancy jump into an 
exercise program, walk into it, maybe, but not jump into it" 
Carl Simonton in Uhlenbruck (1991/94 
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2. General Literature Review 
2.0 Introduction 
It is well known that the benefits of exercise training are short-lived and that 
continuous regular exercise is required to sustain long-term health benefits. 
Research reported by the American College of Sports Medicine (ACSM)4 illustrates 
that significant losses in cardiorespiratory fitness occur following only two weeks of 
detraining and that a 50% reduction in aerobic capacity can occur after only 4-12 
weeks of detraining. This detraining effect has significant implications when applied 
to the cancer population. 
Firstly, cancer patients are at risk of a reduction in functional capacity during the 
period of diagnosis to treatment initiation. The decline in exercise participation and 
thus the risk of functional capacity losses during this period has been documented77' 
80
• Additionally, BMT patients commonly receive conventional treatment regimens 
prior to undertaking a BMT80. Therefore, the risk of functional capacity losses 
between the period of cancer diagnosis and BMT initiation is particularly high for 
these patients. 
The second period where patients are at risk of detraining effects, is during the 
treatment process itself. Exercise participation rates for BMT patients during 
treatment are low and have been observed via an observational design 
investigation80• Forty percent of BMT patients within this study did not participate 
in any cycling exercise, and 24% of participants did no exercise at all. Further, for 
those who did partake in some exercise, the mean daily cycling/walking duration was 
less than eight minutes. 
Functional capacity has been measured following cancer treatment. The exercise 
capacity of the cancer patient at this stage is in the range of 3-6 metabolic equivalents 
(METS) (that is, 10.5-20.5 mllkg/minf For patients who have undergone a BMT, 
their MET values have been calculated to be less than 5101 • 
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Evidence is available to support the notion that cancer diagnosis, treatment and its 
associated prolonged bed rest lead to a substantial loss of physical performance, 
beginning at diagnosis and continuing following treatment. However, the literature 
also provides data which demonstrates the benefits that can be sustained by cancer 
patients through exercise participation, throughout all stages of the cancer 
continuum. The benefits reported by eleven studies investigating the association of 
exercise and rehabilitation among cancer patients have been summarised by 
Friedenreich and Courneya (1996)124. Improvements in functional capacity (as 
measured by aerobic capacity), work capacity, heart rates at a given power, 
maximum workloads, and body composition, as well as beneficial changes in nausea, 
natural defense mechanism, and fatigue levels were noted. The effects of 
participation in physical activity are not limited to improved physiological 
functioning since beneficial changes in feelings of control, independence, self-
esteem, self-confidence, social interaction, depression, tension, anxiety and fear have 
also been documented105' 247 . Ultimately, these physiological and psychological 
improvements have led to positive changes in quality oflife80• 
2.1 Exercise prescription for cancer patients 
When describing the process involved in developing an exercise reg~me, Carl 
Simonton quoted, "I do not recommend that patients with malignancy jump into an 
exercise program, walk into it, maybe, but not jump into it"394• Further, " ... .if 
patients can sit in a chair, do not let them lie in bed; if they can· walk, do not let them 
sit'.426 . While exercise has been shown to instigate changes for cancer patients, the 
exercise variables prescribed, including the type, frequency, intensity and duration of 
exercise undertaken will determine the degree and nature of these changes. 
2.1.1 Exercise Variables 
Type 
When determining the type of exercise that is appropriate for the patient factors that 
need to be considered include safety, patient preference, convenience, platelet 
counts, and potential bone metastases425 . The ACSM (1991)3 recommends that 
exercise involving large muscle groups and which is rhythmical and aerobic in nature 
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should be prescribed for patients with cancer. Additionally, non-weight bearing 
activities are preferable when skeletal or muscle integrity is compromised, and 
dynamic lifting on machines should be encouraged to enhance muscle strength. 
(a) Aerobic exercise 
Aerobic exercise is primarily prescribed for improvements in cardiorespiratory 
fitness, cardiovascular efficiency and weight control3. One of the best exercise 
modes for cancer patients is walking, since it constitutes an activity performed 
regularly during daily activities and is useful in the maintenance of the basic 
elements of proprioception important for mobility and balance426 . Due to the upright 
nature of walking, position dependent dehydration and orthostatic hypotension can 
be counteracted. Another primary advantage of this type of exercise is that major 
muscle groups are utilised and that the systems required for energy production 
(particularly the aerobic energy system) are stimulated. Lastly, it is a convenient 
mode for patients regardless of age or disease status, and does not require specific 
exercise materials or equipment. When patients are at risk of stress fractures, cycling 
or swimming provide good alternatives. During periods of hospitalisation, 'hallway' 
exercises have been prescribed with the aim of minimising loss of functional 
capacity 426• 
Prescription 
A proper assignment of duration, frequency and mode of activity are required for 
favourable cardiovascular changes and adequate exercise intensity is paramount if 
oxygen transport is to be sufficiently taxed35 . While a training intensity consistently 
'low', is likely to be ineffectual in eliciting a training effect, the risk of adverse 
physiological consequences is elevated when exercise is maintained at a consistently 
high intensitl. 
An exercise intensity corresponding to 50-85% of calculated maximal aerobic 
capacity (V02 max) or 65-90% of calculated or predicted HR maximum (HRmax) is 
an effective training stimulus to elicit physiological improvements in cancer 
patients3' 425 . For those who are deconditioned following diagnosis and treatment, 
maintaining a HR intensity of 60% HRmax is sufficient425 . Calculation of the HR 
reserve (HRR) is another method of determining exercise intensity. Classifying the 
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working HR range by using the HRR requires three steps: subtracting the resting HR 
from the maximal HR to obtain the HRR; then taking 60-80% of the HRR, and 
finally adding each HRR value to the resting HR to obtain the training HR range187 • 
However, since a patient's HRR represents a relatively narrow range425 and given the 
possibility of observing unusually high working HR, using a percentage of HRmax 
may be a more appropriate guide to training intensity, when compared with the HRR 
method. 
The rating of perceived exertion (RPE) scale represents another means of 
determining workload intensity5. The original RPE scale used rankings from 6-20 
with a scale of 7 and 19 being reflected as the perception of working at a very, very 
light intensity, and a very, very, hard intensity, respectively48. This scale was revised 
to an 11 point scale, starting at 0 'nothing at all', and finishing at 10 'very, very 
heavy (almost maximum)'. Calculation of a RPE involves the integration of signals 
by the brain, from the peripheral working muscles and joints, and from the central 
circulatory, pulmonary and nervous systems. These signals, perceptions and 
experiences are then integrated or summed into a configuration of perceived 
exertion35 . Perceived exertion ratings of 12-14, when using the 20 point scale, and 4 
on the new scale represent an effective exercise intensity that usually approximates 
with 70-85% ofHRmax. Ratings of 15 or higher, indicate the need for a reduction in 
intensity5. The use ofRPE within clinical populations is only effective when all the 
effort sensations from a training intensity perspective is contingent upon one effort 
sense not overriding another. If one sensation, such as leg pain, overrides another 
sensation such as breathing, then use of the RPE scale could potentially be limited35 . 
Caution is required when prescribing unsupervised programs and lower HR ranges of 
40-65% of the estimated HRR426, or a working intensity corresponding to 60% V02 
max
161 
should be utilised. If the patient experiences an elevated pulse greater than 10 
minutes post-exercise or dyspnea during the exercise program, the intensity needs to 
be reduced426 . However, symptoms such as these usually only occur when the 
patient allows their pulse to move outside the suggested target HR range. 
When training duration is relatively short and intensity is low, patients should 
perform exercise more frequent1l25 . A strategy presently being applied is the 'half-
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rule-of-thumb"426 . This involves assessing what duration and intensity a patient can 
comfortably tolerate and beginning with half that much, several times of day, with 
appropriate rest intervals between exercise sessions. This program is then monitored 
and adjusted to suit the functional capacity of the patient. As function improves, 
duration lengthens and frequency can be reduced425. 
The literature suggests that in relation to 'healthy adults', improvements in V02 max 
tends to plateau when frequency of training is increased above three days per week4. 
The value of the added improvement in maximal oxygen uptake is small when 
training is increased to more than five days per week. In contrast, no meaningful 
alterations in vo2 max have been shown when training is less than two days per 
week. While the majority of exercise and cancer rehabilitation research has applied a 
three days per week frequency regimen, more research is required to assess whether 
these principles proven for the 'healthy' population, also apply to cancer patients. 
Exercise prescription utilised in cancer research 
As noted earlier, Friedenreich and Coumeya (1996)124 reviewed the literature on the 
association of exercise and rehabilitation among cancer patients. Eleven studies 
were identified, including two unobtainable unpublished conference proceedings, 
two doctoral dissertations and seven published research studies. Table 2.1 provides a 
summary of the work reviewed. Five of these studies employed an exercise 
intervention utilising a cycle ergometer, three times per week, of intensity between 
60-85% HRmax, for a period of 10-12 weeks. One other interventional project 
implemented a similar design to those already mentioned, using a cycle ergometer, 
that lasted 4-6 weeks, but also included a 6-month, 2-3 times per week, moderate 
intensity activity of any type in a supervised setting. The remaining intervention 
study employed a home-based walking program whereby patients exercised 4-5 
times per week, gradually increasing their duration from 10-45 minutes, across a 3-6 
month period. One other investigation not included within the review, was 
performed on autologous BMT patients. This intervention study implemented a 6-
week, daily walking program, of 90% maximum HR, starting with a discontinuous 
duration of 15 minutes, and progressing to a continuous 30 minute duration104. It is 
clear that while various protocols have been employed, the majority of studies have 
worked within the exercise variables recommended, ·and have shown promising 
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results in measures that maintain the potential to enhance functional capacity and 
quality of life. 
Table 2.1 Review of literature concerning exercise intervention and cancer 
(adapted from Friedenreich & Coumeya, 1996124) 
MacVicar& 16 Exercise, Control & Quasi-experimental 
Winningham, Healthy 
1986 
Winningham & 42 Exercise, Placebo & 
MacVicar, 1988 Control 
Mac Vicar et al, 45 Exercise, Placebo & Randommsed 
1989 Control controlled trial 
stratified by 
functional capacity 
Winningham et al, 24 Exercise & Control 
1989 
Nelson, 1991 108 54 cases: 40 
exercisers, 14 
non exercisers 
54 controls, 46 
exercisers, 8 
Young- 71 Exercisers and Retrospective cohort 
McCaughan& non exercisers 
Sexton, 1991 
Peters, 1992 13 Exercise Quasi-experimental 
(pre- and post-test 
comparison 
Mock et al, 1994 14 Exercise & Control Randornised 
controlled trial 
(b) Resistance exercise 
Resistance training is an effective means for developing musculoskeletal strength 
and is often prescribed for fitness, health and the prevention and rehabilitation of 
orthopaedic injuries 117. Increases in muscle mass, bone density, connective tissue 
thickness and associated increases in muscle strength and endurance, constitute the 
primary physiological adaptations most often associated with resistance training. It 
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is worth noting that for decades, cardiac rehabilitation programs have focused almost 
exclusively in improving cardiorespiratory endurance, while ignoring muscular 
fitness development404• Moreover, it was hypothesised that resistance training was 
potentially hazardous for the cardiac patient due to the risk of cardiovascular 
complications from adverse haemodynamic responses. Continuing research within 
this domain now indicates that resistive exercise testing and training are safe and 
effective for patients appropriately screened, even at relatively high workloads. With 
reference to cancer patients, it has been cautioned that resistive exercises may result 
in increased blood pressure and thus elevate the risk for haemorrhage 5°. Therefore, it 
is essential to ensure blood counts are within normal ranges, particularly platelets, 
prior to patients participating in a resistance training program. 
Everyday lifting, carrying and moving activities require a certain degree of strength. 
The return to daily vocational and avocational activities is therefore facilitated by 
improvements in muscular strength for those patients who have lost strength through 
the disease process404. When strength is improved, daily activities can be performed 
at a lower energy cost and with greater efficiency. Improved work tolerance derived 
from peripheral adaptations in trained skeletal muscle (increased enzyme activity and 
intramuscular fuel stores), in conjunction with greater self-confidence and self-
image, enhance the ability of patients to resume routine daily activities and to 
participate in aerobic activities at a lower oxygen cost404 . 
Prescription 
The effectiveness of a strength training program depends on several factors, 
including frequency, volume (the repetitions and sets performed in conjunction with 
the resistance) and mode (free weights versus variable resistance, dynamic versus 
isometric, concentric versus eccentric contractions)117• One common factor in recent 
effective strength training and rehabilitation programs has been the inclusion of at 
least one set of the maximal or near maximal number of repetitions possible for each 
exercise performed. The greatest strength gains appear to result from resistances 
yielding 4-6 repetition maximum (RM), while increasing the number of repetitions to 
12-20 RM favours the increase in muscle endurance. Programs that emphasise 
exercising with a resistance that allows 8-15 repetitions are traditionally classified as 
'moderate intensity', and are usually recommended for most of the adult nonathlete 
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populations117• The ACSM (1990)4 noted that 8-12 repetitions per bout of exercise is 
generally recommended to elicit improvements in both muscular strength and 
endurance. 
The ACSM (1990)4 and Feigenbaum and Pollock (1997)117 performed a review of 
the literature with regard to appropriate strength training regimens. The literature 
supports the recommendation of prescribing single-set programs performed to 
fatigue, and identifies that the quality (intensity) of training is more important for 
developing muscular strength in sedentary people, than the quantity of training. It 
has therefore been recommended that single set programs are equally effective as 
multiple set programs in the first three to four months of strength training in 
previously untrained individuals. In addition, time efficiency is improved when 
performing single set programs, which should generally translate with greater 
exercise program compliance. 
Muscle recuperation, muscle development and the prevention of overtraining or 
detraining are dependent on the allocated rest period. Based on current findings, it 
seems evident that no single optimal frequency of strength training exists for all 
muscle groups. Current guidelines suggest that a minimum of two, or two to three 
days per week, is the most appropriate, as this allows time for recuperation, is less 
time-consuming, improves compliance and produces health and fitness benefits in 
the untrained person. 
In summary, for healthy people under 50 years, the goal is to be able to complete one 
set of 8-12 repetitions to volitional fatigue. However, guidelines established by the 
American Heart Association and the American Association of Cardiovascular and 
Pulmonary Rehabilitation for cardiac patients, recommend a lower intensity program 
that may reduce the risk of orthopaedic injury and which consists of one set of 10-15 
repetitions. Depending on patient status, this lower intensity program would be 
performed to a level perceived as moderate or comfortably hard or to volitional 
fatigue. Others have also noted that appropriate strength gains can be attained in 
higher-risk patients, patients with low functional capacity and those who fatigue 
easily, by performing only one set of 12-15 repetitions for specified muscle groups 
with no time limit404 . 
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Although the side effects of cancer, treatment and bed rest highlight the need for 
muscle training, no research could be identified that implemented resistance training 
as part of an exercise intervention design. 
(c) Mobility exercise 
Mobility, range of motion or stretching exercises are effective in maintaining joint 
and muscular flexibility, while assisting in the prevention of contractures429. These 
exercises should be integrated in the warm-up and cool-down phases of all exercise 
sessions and should be performed on days when side effects of the disease and its 
treatment prevent participation in aerobic or strength training. 
Progression 
The key to a successful program is starting slowly and building gradually426• The 
goal of progression is to gently exert without reaching exhaustion, by continually 
adjusting one or a combination of intensity, frequency, or duration. Following a 
difficult treatment or infectious illness period, an effective starting point must be 
determined. In order to avoid overexertion, an empiric rule is to advise "wait until 
you feel better one day, then wait one more day before returning to the regular 
exercise program"425• When resuming the exercise program after a period of rest 
induced by treatment or hospitalisation, the exertionallevel should be reduced to that 
of one week prior to the interruption and HR and RPE should be closely monitored. 
It has also been recommended that the exertionallevel should be reduced if the HR is 
higher than 75% HRmax. A training intensity of 60-75% HRmax should be 
maintained for a least two sessions, before progressing425• 
2.1.2 Considerations during exercise prescription 
Although exercise prescription guidelines for cancer patients exist, and have been 
shown to induce benefits, there are a number of important considerations that need to 
be addressed prior to patients participating in a regular exercise program. Firstly, 
while many chronic illnesses have a distinct and single etiology, this is not the case 
for cancer425• Adequate knowledge regarding the type of cancer presented, its 
complications, course and treatments is essential in order to devise safe and effective 
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exercise programs for cancer patients3' 5. Prior to exercise testing, the type of cancer 
needs to be classified, the extent of metastasis determined and the body organs and 
regions likely to be affected in both the short- and longer-term by the cancer and its 
treatment should be acknowledged. For example, patients with multiple myeloma, 
are particularly susceptible to bone fracture, pulmonary tumours may impair gas 
exchange, while hepatic tumours may alter metabolic and coagulation responses -
with all cases having specific implications when designing an exercise program. 
Other information required includes: 
>- patient's previous and current functional status; 
>- the presence of other illnesses independent of the cancer; 
>- therapy previously, presently and likely to be undergone and their actual and 
potential side effects; 
>- exercise programming implications; and 
>- the timing of future tests and treatment administration429 . 
A personal history examination should also examine both family and personal history 
of cardiovascular disease, respiratory diseases, diabetes, obesity, and elevated blood 
pressure and blood lipid abnormalities. Furthermore, patients should be screened for 
past and present musculoskeletal problems (prior injuries, prosthesis, bone pain), 
sensory limitations (difficulty with vision, balance, neuropathies) and any other 
factor that may influence the development or maintenance of an exercise regimen, 
including personal health behaviours such as diet and cigarette smoking3' 369' 426. 
Guidelines and recommendations of an exercise regimen should address the needs of 
two primary types of patients - those accustomed to previous exercise and those who 
have led a sedentary lifestyle429 . Of those patients who were previously active, 
education regarding the need for appropriate changes to their 'usual' exercise routine 
is required. These patients are often ·unaware of how cancer and associated 
treatments may influence their ability to participate in exercise. For previously 
sedentary patients, fatigue and/or weakness experienced by partaking in physical 
activity may be interpreted as evidence of their need to rest or 'take it easy'. Patients 
should be educated that these symptoms are not inevitable consequences of their 
illness and treatment. 
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The exercise physiologist must be familiar with the 'contraindications to exercise' 
list for cancer patients5' 426, some of which include the development of an irregular 
pulse, resting pulse rate greater than 1 OObpm, chest pain, pallor and low blood 
counts. Vigorous activity should be discouraged two-three hours prior to blood 
analyses, as blood cell counts and serum enzyme levels may be affected429 . Fever or 
infection are also contraindications for exercising and the patient should be advised 
to exercise the day after they feel better429 . It has been further recommended that 
patients should refrain from activity on the same day as intravenous 
chemotherapy426. This guideline was based on the findings of one study (Unverferth 
et al, 1983 in Winningham et al, 1986429) which reported a significant increase in 
cardiac dysrhythmias in the first two to six hours following chemotherapy 
administration. Blood count levels are considered by many to be a crucial indicator 
of exercise participation. Most researchers dealing with cancer patients are guided 
by the following American recommendations426 : platelet counts should be greater 
than 50 000/mm3, haemoglobin more than 10g/dl, white blood cell counts greater 
than 3 000/mm3 and absolute granulocyte counts higher than 2 500/mm3• Others, 
however, have been guided by slightly lower values of platelet counts greater than 20 
x 109/L and leukocyte counts above 1.5 x 109/L104. 
Finally an important consideration relevant to the success of exercise programs and 
exercise intervention studies is that of program acceptance. Convenience of the 
program including the duration of the sessions, time of scheduling and location, and 
the exercising environment such as cleanliness and atmosphere, are likely factors that 
will influence program acceptance. 
In summary, participation in an exercise program has the potential to induce 
physiological and psychological benefits for patients diagnosed and being treated for 
cancer. Recommendations for exercise prescription are available and have been 
shown throughout the literature to be 'appropriate' and 'safe' for certain patient 
groups, in particular, breast cancer patients. However, due to the nature of the 
disease process and the treatment options available, it is crucial to consider a number 
of factors prior to exercise prescription. 
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"Physical activity may provide the shortcut we in public health have 
been seeking for the control of chronic diseases, much like immunization 
has facilitated progress against infectious diseases", Dr William Foege, 
former Director of the Centers for Disease Control in Atlanta, USA242 
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3. Study Design and General Methodology 
3.1 Study design 
This study recruited PBST patients and assessed their functional capacity and quality 
of life at three primary testing phases - pre-transplant (PI), post-transplant (PII) and 
three months post-PH (PHI). One measure was also assessed at the end of the first 
and second month of the intervention period (Il and I2, respectively). Following 
testing PII, patients entered either the control group (CG) or the exercise group (EG). 
Figure 3.1 provides a graphical demonstration of the study design. 
Figure 3.1 Study design 
Patient Identification 
Initial Meeting: 
Collection of informed consent and 
necessary patient history information. 
Testing dates were scheduled. 
Not interested No contact with 
investigator 
When initial meeting was post-PBST 
Allocation to intervention 
group - CG or EG 
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3.2 Patient type 
A primary objective of this investigation was to illustrate that even those cancer 
patients who undergo 'high-dosage' treatment, are still able to participate and 
tolerate a planned regular exercise program, and could benefit from its 
implementation. When assessing cancer types and their associated treatment, it is 
difficult to find a more intensive treatment regimen than an allogeneic or autologous 
BMT, or PBST. Unfortunately, as was noted in the first two chapters, patients suffer 
from a number of adverse side effects and can experience major life-threatening 
complications as a result of undergoing this form of treatment. In tum, it was 
recognised that these post-transplant complications could potentially hinder the 
design of an investigation and thus influence the ability to draw research conclusions. 
Autologous BMT or PBST patients experience fewer post-transplant complications 
when compared with allogeneic patients. Therefore, in order to meet the primary 
objectives without jeopardising the project design, it was determined that only 
autologous patients would be recruited into the study. 
As was highlighted in chapter one, initially only patients with acute leukaemia who 
failed to respond to standard chemotherapy were treated with BMT and PBST18' 206• 
However, BMT and PBST are currently considered a viable treatment option for 
patients with acute leukaemia, aplastic anaemia, chronic myelogenous leukaemia, 
Hodgkin's disease, non-Hodgkin's lymphoma, breast cancer, ovarian cancer, brain 
tumours, multiple myeloma, small cell lung cancer, testicular cancer and paediatric 
solid tumours such as neuroblastoma80' 126 . Consequently, by studying patients 
undergoing this procedure, a wide range of cancer patients can be investigated. 
3.3 Ethical approval of research 
Following an assessment of autologous transplants undertaken each year within two 
Oncology treating hospitals, it was predicted that the study would be able to recruit 
from a pool of approximately 80 patients across a one-year period. Ethical approval 
was sought and obtained from the Queensland University of Technology (Appendix 
I) and two Brisbane hospitals (Appendix II & Ill). 
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3.4 Determination of sample size and recruitment of subjects 
When determining the appropriate sample size, a number of factors were considered: 
~ the primary objectives of the study; 
~ statistical requirements of 80% power and 5% significance level; and 
~ the level of physiological change that would be considered both clinically and 
statistically significant. 
Unfortunately, limited data were available throughout the literature to assist in 
determination of an appropriate sample size. During the development of the study, 
no data were available for PBST patients. Aerobic capacity data collected during 
exercise intervention studies performed on breast cancer patients were therefore 
utilised in the calculations. It was determined that a minimum of 16 subjects per 
group, and thus 32 subjects in total, would be required to detect a one standard 
deviation (SD) difference in aerobic capacity. A difference of one SD was 
considered both statistically and clinically significant. 
However, the predicted identifiable subject pool of 80 was largely overestimated and 
consequently attaining a total of 32 subjects was not possible. This was 
acknowledged by the time two subjects had been recruited, completed the first two 
testing phases, and were close to undertaking the final testing session. Sample size 
calculations were reassessed based on the aerobic capacity, muscular strength, and 
body composition results obtained from these subjects. Due to large changes being 
observed as a result ofthe transplant and the intervention program, it was determined 
that only 12 subjects, 6 in each group, were required to detect a 1 SD difference, with 
power and significance set at 80% and 5%, respectively. 
Across the 15-month recruitment and testing period, 4 patients were approached 
from one hospital (hospital A), while 12 were approached from the other (hospital 
B). All twelve patients from hospital B, were recruited into the investigation, while 
no patients were recruited from hospital A. Patient characteristics including the 
· support network and living distance from the centre were potential reasons for non-
participation. Additionally, the manner in which subjects were informed of the 
investigation was another potential factor relating to study involvement. The BMT 
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nurse co-ordinator at hospital A, informed patients who met the inclusion criteria, of 
the study by presenting them with the study's subject information letter and package. 
Discussion between the patient and BMT co-ordinator or treating physician 
regarding participation in the project was limited. By contrast, eligible patients 
treated at hospital B, were informed of the study by their treating physician and were 
strongly encouraged to participate. In summary, specific patient characteristics, and 
the treating physician's referral and encouragement were considered important in the 
recruitment of subjects. 
Twelve patients diagnosed with a variety of malignancies including acute myeloid 
leukaemia, breast cancer, multiple myeloma, lymphoma, and rhabdomyosarcoma, 
were recruited between October 1997 and December 1998. Nine patients underwent 
one autologous PBST, while three patients underwent three consecutive transplants. 
3.5 Autologous peripheral blood stem cell transplant procedure 
A brief description follows of the PBST protocol administered to the patients within 
the study. Peripheral blood stem cells were collected and cryopreserved prior to 
hospital admission. Shortly after admission, a high-dose chemotherapy regimen, 
specific to the neoplasm under treatment, was initiated. During this period, patients 
may have received doses of antinausea medicines, sedatives, diuretics, and 
intravenous fluids. At least 24-hours following the last chemotherapy 
administration, the previously cryopreserved stem cells were then transplanted. 
Once stem cell reinfusion had been completed, patients were able to leave the 
hospital, usually the following day if considered 'well', were not vomiting, had a 
carer and lived within thirty minutes of the hospital. However, patients were 
required to return daily for approximately two weeks for clinical review. 
While the risk of developing oral mucositis, pharyngitis and other gastrointestinal 
complications is particularly high during this two week period, readmission to 
hospital usually only occurs when the patient experiences a high risk fever in 
conjunction with hypotension or tachycardia, or experiences mucositis and requires 
pain relief. The clinician's judgement is also a factor with regard to both hospital 
release and readmission. Importantly, both hospital release and readmission are 
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based on clinical symptoms rather than haematological counts. Generally, 60% of 
patients who have undergone a PBST at the recruiting hospital are readmitted. 
However, in contrast, 92% of the study sample required readmission. 
The high-dose chemotherapy (HDC) regimen administered at the Wesley Hospital is 
considered to be either a 'light' or 'heavy' program. Women with breast cancer 
generally undertake a lighter program while all other patients undertake a heavier 
HDC regime. The HDC regime, usually lasting five days, was different for various 
diagnoses. The majority of patients with haematological malignancy received 
busulfan melphalan containing combinations. However, patients with Hodgkin's 
disease received BEAM, and the two patients with high-risk stage II breast cancer 
received high-dose cyclophosphamide and epirubicin with three high-dose cycles 
followed by stem cell support. Finally, the one patient with stage IV breast cancer, 
received an experimental program of thiotepa, iphosphamide and taxol for three 
cycles with stem cell support. 
3.6 Exclusion criteria 
Patients expenencmg specific contraindications that may have influenced safe 
participation in the exercise program were not eligible for inclusion into the study. 
The exclusion criteria were originally defined in accordance with the 
contraindication guidelines outlined in Winningham (1994 )425 and were as follows: 
);> white blood counts <3 000 cells/mm3 
);> absol~te granulocyte counts <2 500 cells/mm3 
);> platelet counts <50 000 cells/mm3 
);> hemoglobin levels <1 0 g/dL 
Patients who were diagnosed with multiple myeloma were also considered ineligible 
due to the risk of bone fracture. However, more patients presented with these 
exclusion criteria than expected, and consequently the number of potential patients 
for this investigation substantially declined. To enhance the ability to recruit subjects 
without jeapordising patient safety, the exclusion criteria were altered according to 
recommendations from treating physicians. This involved the inclusion of multiple 
myeloma patients into the study, and if patients were considered 'well' with no 
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clinical symptoms, participation was allowed even during periods of low blood 
counts, with the treating physician's approval. 
3.7 Recruitment of subJects into experimental groups 
Once- patients had received and read the subject information letter and package 
(Appendix N), and noted that they were interested in participating in the study, an 
initial meeting was scheduled. The initial meeting provided an opportunity to obtain 
informed consent, all relevant patient history information and to schedule the testing 
phases. Depending on when the patient was informed of the study, the initial 
meeting was either pre- or post-transplant. For this reason, only 7 out of 12 patients 
entered the study at PI, while the remainder entered the study at PII. 
Initially, patients were to be randomly. divided into two groups, with age 
stratification, as they presented to the study. Unfortunately, the slow recruitment rate 
and low subject numbers meant randomisation was difficult. Therefore, the two 
groups were matched as closely as possible, by taking into account factors that had 
the potential to influence the level of change in an intervention project. 
Two factors addressed throughout the literature that maintain the potential to 
influence the level of change in an intervention study are age and gender139 . 
Previously active individuals could also potentially sustain greater benefits by 
maintaining exercise during treatment, when compared with previously inactive 
individuals initiating exercise during cancer treatment77• It therefore seemed 
reasonable to ensure that past exercise experience was taken into account, and that 
the CG and EG consisted of similar 'exercise experience' prior to undertaking a 
PBST and during the treatment process itself. During the initial investigator/patient 
interview, sufficient information was collected that allowed the level of regular 
exercise participation in the past ten years to be determined. The patient was 
categorised as 1, 2, 3 or 4 with the numbers being equivalent to no regular exercise, 
limited and sporadic exercise, regular exercise prior to diagnosis, and regular 
exercise at diagnosis and up until transplant, respectively. If the patient engaged in 
no planned, regular exercise program, or only recreational activity across the 
previous ten year period, they were allocated a 1. Exercise participation, once to 
44 
Chapter Three, Study Design and General Methodology 
twice per week at some stage across the ten-year period was considered as being 
limited and sporadic. Regular exercise was considered to be participation in some 
form of aerobic exercise and/or resistance training, three times per week for a 
minimum of thirty minutes. If the patient discontinued regular exercise at diagnosis 
they were classified as a 3, and given regular participation was being maintained at 
the time of the interview, patients were allocated a 4. Other non-medical factors that 
were deemed potential confounding variables and therefore considered when 
formulating the control and exercise group, included marriage status or support 
network, weight at PII and living distance from the exercise centre. 
Medical variables considered when devising the experimental groups included 
original diagnosis, the number of transplants undertaken and the treatment regimen 
implemented. It has been reported that the degree of rigour posed by the BMT 
hospitalisation experience could also influence the physical and psychosocial status 
of the patient1\ whereby the impact of undergoing a BMT would be less for those 
patients who experienced fewer post-BMT complications. For this reason, patients 
were not allocated a group until PII had been completed. 
Table 3.1 summarises the characteristics of the two groups. While certain variables 
such as the mean age, weight at PII and living distance from the centre appear 
different between the two groups, these differences were not statistically significant 
(p=0.052, 0.466, and 0.209, respectively). Additionally, the investigator tried to 
ensure that both the statistical mean and range were similar for all factors, between 
the two groups. For example, both groups contained a 64-year-old male, and both 
groups contained a patient who lived in close proximity to the centre (within lOkms) 
and a patient who lived more than an hours drive from the centre (lOOkms). Finally, 
with respect to the prognosis of the patients under investigation, it was previously 
found that 50-80% of patients undertaking a PBST would become a long-term 
survivor166. By comparison, at the time of completion of this thesis, 4 patients in 
total (2 control and 2 exercise group participants) had died. The control group 
participants had been diagnosed with multiple myeloma and non-Hodgkin's 
lymphoma, while the exercise participants had been diagnosed with 
rhabdomyosarcoma and non-Hodgkin's lymphoma. 
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Table 3.1 Group characteristics 
Age(years) Mean= 54.5 Mean= 39.5 
Median= 54 Median= 40.5 
--~--------~~R_an~g~e-=_4_6_-__ 64 ________ -+_R_an~g~e-= __ 16_-__ 64 ________ __ 
Gender 
-------"""! Marriage status 
Previous exercise 
history* 
4 males 3 males 
2 females 3 females 
Married/significant Married/significant 
relationship = all 6 patients relationship = 5 out of 6 
Sin le = 1 out of6 
1 = 1 patient 
2 = 3 patients 
3 = 1 patient 
4 = 1 atient 
1 = 1 patient 
2 = 3 patients 
3 = 1 patient 
4 = 1 atient 
-------"""i Weight at PII Mean= 71.82kg Mean= 87.35kg 
SD=26.09kg 
Ran e= 68.8k 
SD = 23.71kg 
Ran e= 62.9k 
Living distance Mean = 80km 
from the centre Ran e = 10 - 150km 
-------"""! Diagnosis 1 x acute myeloid leukaemia 
Number of 
translants 
High dose 
chemotherapy 
regime (HDC) 
1 x high risk stage II breast 
cancer (BC) 
2 x multiple myeloma 
1 x non-Hodgkin's 
lymphoma (NHL) 
1 x sta e IV BC 
1 transplant = 4 patients 
3 trans !ants = 2 atients 
'Lighter' program= 
2 patients 
'Heavy' program = 
4 atients 
Mean= 33km 
Range = 5 - 1 OOkm 
1 x lymphoblastic 
lymphoma/leukaemia 
1 x high risk stage II BC 
1 x rhabdomyosarcoma 
3xNHL 
1 transplant = 5 patients 
3 trans !ants = 1 atient 
'Lighter' program = 
1 patient 
'Heavy' program= 
5 atients 
* 1, 2, 3 or 4 is equivalent to no regular exercise, limited and sporadic exercise, regular 
exercise prior to diagnosis, regular at diagnosis and up until transplant, respectively. 
3.8 Testing phases 
This investigation consisted of three primary testing phases, PI, PII and Pili, and two 
additional testing phases, I1 and I2, for the immunological parameters assessed. 
Phase I was scheduled as close as possible prior to the transplant. As noted in 
Chapter 2, patients are at risk of a decline in functional capacity and quality of life 
during the period between diagnosis and treatment cessation. This investigation 
aimed to assess the impact of a PBST and it was therefore essential to ensure that the 
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data collected was reflective of the impact of a PBST, and not other factors that 
might have occurred prior to the transplant. For the seven patients recruited pre-
transplant, PI was scheduled between one to three days prior to the start of high-dose 
chemotherapy. 
It was crucial that PII be implemented as close as possible to treatment 
cessation/stem cell reinfusion. However, as previously noted, while some patients 
undertook one transplant, others were required to undergo three transplants, and 
others still were required to undertake RT following transplantation (three patients, 
one in the control group, and two in the exercise group). Due to the diversity of the 
treatment regimens present within the group investigated, PII was standardised as the 
number of days following treatment cessation. Day of treatment cessation (day 0) 
was classified as the day of stem cell infusion (for those undertaking three 
transplants, this reflects the day of stem cell infusion of the last transplant) or the 
final day of RT. Patients were usually discharged from hospital either on the day 
stem cells were reinfused or the following day. However, within 1-2 weeks 
following stem cell infusion, 92% of the study sample were readmitted into hospital 
for an additional 1-2 weeks due to post-transplant complications, such as the 
development of a fever. Phase II was scheduled as close as possible to discharge 
from hospital and occurred with a range of 17-21 days following treatment- day '0'. 
Testing PII then became the reference point for the consecutive testing phases with 
I1, I2 and Pili scheduled at approximately one-month, two-months, and three-months 
following PII. Table 3.2 summarises the timing of medical events and testing phases. 
Table 3.2 Timing of medical events and testing phases 
Day of hospital 
from stem cell · 
(no. of days 
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3.9 Experimental groups 
Patients entered the study at either PI or PII. During these first two testing phases, 
the effect of the transplant was being assessed and all patients were considered to be 
in the same group (SG). Immediately after PII, patients were allocated to either the 
controVstretching group (CG) or the exercise intervention group (EG). 
3.9.1 The intervention program 
Control group: An adequate control group is required to ensure that changes 
observed are a result of the intervention, and not confounding variables such as 
'investigator attention' or 'patient interaction and support'. In order to ensure that 
these variables did not become confounding factors, investigator/patient contact and 
patient/patient contact was standardised across the intervention period between the 
CG and EG. To ensure the patients allocated to the CG maintained a level of 
enthusiasm and expectation for results, a stretching program was implemented. 
While participation in the stretching program could potentially lead to mobility 
improvements, it was unlikely that the program would lead to significant 
improvements in the physiological variables being assessed. The stretching program 
was implemented three times per week, within the patient's home environment. The 
variables of the program are outlined in Table 3.3. The investigator travelled to the 
patient's home either once or twice per week, which meant that the patient performed 
the stretching program unsupervised, once-twice per week. At least one telephone 
call was implemented during the weeks where the investigator could only visit the 
patient's home on one occasion. Progression of the stretching program was achieved 
by increasing the total number of stretches performed within each session and by 
holding each stretch for a longer period. 
Exercise group: The intervention implemented in the EG consisted of a three-
month duration, moderate intensity, mixed type (aerobic and resistance training) 
exercise program. 
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Aerobic program: Patients were required to participate in aerobic exercise, three 
times per week. At least two out of three of these sessions were performed on a 
treadmill and cycle ergometer at the Queensland University of Technology (QUT) 
Human Movement Studies Clinic, Brisbane. The third session was unsupervised and 
could be any form of aerobic exercise, as long as the participants met the required 
intensity and duration. Patients chose walking, jogging, cycling or swimming during 
their unsupervised sessions. 
The intensity of each session at the centre was regulated via the assessment of HR 
and RPE. During the first four weeks of the twelve week program, exercise intensity 
was measured via the use of Polar™ HR monitors, worn continuously during the 
sessions, in conjunction with regular use of the revised Borg RPE scale3• During 
subsequent weeks, the use of the HR monitors declined and RPE scale increased. 
Reducing reliance on the HR monitors for assessing intensity throughout the sessions 
was deemed important to ensure that patients could successfully exercise at an 
appropriate intensity in an unsupervised setting, without the need for equipment. All 
unsupervised sessions were assessed via the RPE method. 
Progression was achieved through a combination of intensity and duration. The 
program was initiated at an intensity represented by 70% of the calculated maximum 
HR, for a total exercise duration of twenty minutes. This was twenty minutes of total 
exercise time, which meant for those patients whose function was at the lower end of 
the range, rest periods between shorter bouts of exercise (two to five minutes) were 
required. By the end of the three-month period, patients were working at an intensity 
between 70-90% of calculated HRmax for a total exercise duration of forty minutes. 
There were no restrictions placed on the patients with regard to whether exercise was 
of a continuous duration, or divided into several bouts with rest periods or the 
resistance program between bouts. 
Resistance program: Side effects from cancer and treatment may lead to 
limitations in neuromuscular coordination which may be exacerbated by fatigue. For 
this reason, during the initial phases of the program, patients were required to 
perform all resistance training with the use of weight training machines. Following 
the first six to eight weeks of training, two free weight exercises were introduced. 
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The initial weight program consisted of a 'seated bench press', 'lat pulldown' and 
'leg press' (as shown by Figure 3.2a, b & c, respectively). These three exercises 
were chosen as they utilise most of the major upper and lower body muscle groups 
including the pectorals, latissimus dorsi, deltoids, rhomboids, triceps, biceps, 
quadriceps, gluteal, hamstring and calf muscles. 
Figure 3.2 Initial resistance exercises 
(a) Seated bench press (b) Lat pull down (c) Leg press 
As familiarity improved and patients progressed, an 'upright row' (Figure 3.3a) using 
a 'Smith machine', was introduced, usually within the fifth to sixth week of the 
program. Lastly, by week eight, the 'seated shoulder press' (Figure 3.3b) and 
'lunges' (Figure 3.3c), using free weights were introduced. 
Figure 3.3 Resistance exercises progressively introduced 
(a) Upright row (b) Seated shoulder press (c) Lunges 
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Verbal instructions and practical demonstrations were given on how to use each 
piece of equipment, the correct body posture required, and the appropriate breathing 
technique. Each exercise was implemented throughout a full range of motion and 
was undertaken at a slow pace, to the count of three for the lifting and lowering 
motion. Patients were required to undertake two resistance training sessions per 
week, at the QUT, Human Movement Studies Clinic. A minimum of 48-hours rest 
was required between each session. This rest simply applies to the performance of 
resistance training and thus the patient was able to participate in aerobic exercise 
during this period. 
The number of repetitions performed to fatigue is an important consideration when 
designing a strength program and should reflect the goal of the program. Greater 
strength gains are yielded when repetitions of 4-6 repetition maximum (RM) are 
applied. By increasing the repetition range to 12-20RM, muscular endurance will be 
favoured. The term 'high-intensity' programs are usually applied to strength 
programs utilising a 1-6RM, and 'moderate-intensity' programs are generally 
considered as those implementing an 8-15RM program117 • While improvement in 
muscular strength was a primary aim for this population, other factors such as weight 
training experience, risk of injury, and blood counts were also considered when 
deciding an appropriate repetition range for the population investigated. 
The resistance program was progressed in a number of ways. Firstly, the number of 
exercises performed during each session increased from three to six across the three-
month period. Secondly, for the initial six weeks, repetitions were set at 15-20, and 
the weight was set at a level which induced failure between this repetition range. 
Failure was determined as the time when the patient was unable to perform the 
movement through full range of motion with correct body posture. During weeks 7-
12, the repetition range was lowered (8-12 repetitions) and the weight lifted was 
increased (weight lifted ensured 'failure' between the designated repetition range). 
While three sets of 8-12 repetitions performed three times per week is a typical 
prescription for many strength programs, the optimal number of sets required per 
. . . . 1117 
exerctse sessiOn remams controversta . However, the existing literature 
demonstrates that single set programs are as equally effective as multiple set 
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programs when aiming for strength gains in an untrained population. In addition, the 
amount of time required to perform a single set program is considerably less than a 
multi-set program 117. Another factor to consider when prescribing weight training, is 
the frequency of the sessions. The literature suggests that when prescribing for 
'beginners', a minimum of two days per week is appropriate as it allows time for 
recuperation and produces similar benefits when compared with more frequent 
programs117 . Therefore, it was determined that only one set of each exercise, two 
times per week would be performed throughout the duration of the program. The 
intervention characteristics for both the CG and EG are reported in table 3.3. 
Table 3.3 Intervention variables for the control and exercise group 
Stretching program 
F=3 xwk 
1st 4 wks: 20 stretches 
2nd 4 wks: 25 stretches 
3rd 4 wks: 30 stretches 
~ Each stretch was performed twice 
~ Stretches were performed for all 
major muscle groups each session 
~ Stretches were taken to the point 
of discomfort, not pain 
~ Stretches were held for 15-30 
seconds 
Aerobic exercise 
program 
F=3 xwk 
I= 70-90% of 
HRmax 
T=20-40 
minutes 
Resistance exercise 
program 
F=2xwk 
Sets= 1 
Wt = to failure 
Reps= 
1st 6 wks: 15-20 
2nd 6 wks: 8-12 
* F =frequency, I= intensity, T =duration, Wt =weight, Reps= repetitions 
3.10 Statistical analysis of data 
Physiological and quality of life data were collected at PI, PII, and PHI. However, 
data were also collected at I1 and I2 for immunological measures. Prior to statistical 
analysis, data were tested for normal distribution and were considered 'normally 
distributed' when all ofthe following criteria were met: 
~ the mean lies within 10% of the median 
~ the SD is no more than 50% of the mean 
~ the skewness CE lies between -3 and +3 
~ the kurtosis CE lies between-3 and + 3 
52 
Chapter Three, Study Design and General Methodology 
When the data did not meet these criteria, the results were log-transformed, and then 
re-tested for normal distribution. Statistical procedures were applied either on 
'normally distributed' original or log-transformed data, and the level of significance 
was set at 5% (two-tailed). Table 3.4 represents the data set, which were dealt with 
during the statistical analysis of body composition, aerobic capacity, muscular 
strength, bone turnover and quality of life measures. 
Table 3.4 
analysis 
Representation of the data set commonly dealt with during statistical 
Group 
Control Group (CG) 
1 
.;....> 2 () 
il) 3 ·~ ~ 4 
,.-.._ 
(/.) 5 
c::> 6 (/.) 
'-' 
§" n 
0 Exercise Group (EG) 0 
~ 
.;....> 
.8 () (/.) il) ·~ ~ (/.) 
MD = missing data 
x = data point 
1 
2 
3 
4 
5 
6 
n 
n(SG) 
Testing phases 
PI PII Pili 
X X X 
MD X X 
MD X X 
X X X 
X X MD 
MD X X 
3 6 5 
X X X 
MD X X 
X X X 
X X X 
MD X X 
X X X 
4 6 6 
7 12 11 
In order to answer the questions raised by the thesis, a number of comparisons were 
required: 
>- between PI and PH data of the SG; 
>- between PI and PH, PH and PHI, PI and PHI data of the CG and EG; and 
>- between PHI of the CG and the EG. 
Multiple simple t-tests were inappropriate due to the risk of increasing the presence 
' 
of a Type I error. Therefore, a 2-way repeated-measures analysis of variance (RM-
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ANOVA) was used to determine the group by phase interaction (exercise by time). 
As a consequence of the repeated measures data set being incomplete (that is n= 7, 
12 and 11 at PI, PII arid PIII, respectively) a random effects mixed model (REMM) 
was applied. Unlike the standard approach of a 2-way RM-ANOVA, the REMM 
was able to accommodate the partially incomplete records and relatively small 
sample size, while maximising power183 . As a factor of the model specifications, 
subjects were treated as random effects. Furthermore, simple contrasts were defined 
and tested within the model. Therefore, the following information was derived via 
the use of the REMM: 
);> mean and standard errors for each of the testing phases (PI, PII, Il, I2 and Pili) 
for each group (SG, CG and EG); 
);> testing phase contrasts- comparisons between PI and PII, PI and PIII, and PII 
and PIII for the SG, CG and EG; and 
);> group contrasts - comparisons between PI, PII and PHI measures of the CG and 
EG. During these comparisons, the model accounted for baseline measures of 
the variable under investigation. 
Although only 4 subjects were used to assess energy expenditure changes across the 
testing phases, the data were analysed in the same manner as previously described. 
Additionally, the assessment of immunological changes across time, required 2 
additional testing phases. Again, these data were analysed via the use of the REMM. 
Therefore, the REMM approach has been applied during data analysis throughout 
Chapters 4-9. Any other statistical methods used to analyse data have been outlined 
in the relevant chapters. 
The standard 2-way RM-ANOV A was also applied to the physiological and QoL 
data measured, and as such restricted the analysis to cases with data available at all 
testing phases (2 control subjects and 4 exercising subjects). As a consequence of 
the reduced sample size, statistical power decreased and no statistical differences 
were detected in the analysis of all functional capacity and quality of life measures. 
However, the trend of change between pre- and post-transplant, and pre- and post-
intervention period were similar to that observed via the use of the REMM, lending 
support for the use of the latter model. 
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CHAPTER FOUR 
STUDY ONE 
Changes in energy expenditure and body 
composition following a PBST and participation 
• • In an exercise program 
((Eating alone, will not keep a man well; he must also take exercise. For 
Food and exercise, while possessing opposite qualities, yet work 
together to produce health" Hippocrates in McGinnis (1992/42 
Chapter Four, Study One 
List of abbreviations specific to Chapter four 
ALL Acute lymphoblastic leukaemia 
BW Body weight 
CG Control group 
EI Energy intake 
EG Exercise group 
FFM Fat free mass 
FM Fat mass 
%BF Percentage body fat 
PBST Peripheral blood stem cell transplant 
PI Phase I 
PII Phase II 
Pill Phase III 
REE Resting energy expenditure 
SG Study group 
TEE Total energy expenditure 
TEF Thermogenesis of food 
V02 max Maximal aerobic capacity 
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4. Changes in energy expenditure and body composition following a 
PBST and participation in an exercise program 
4.0 Introduction 
It is well recognised that if total energy expenditure (TEE) exceeds energy intake 
(EI), a reduction in body weight will result. A decrease in body weight following 
treatment for cancer is a common side effect170, particularly for patients undergoing a 
PBST. Elevated metabolic demands and impaired protein-sparing mechanisms, in 
conjunction with reduced energy intake, inactivity, and specific chemotherapeutic 
and steroid treatment regimens may be contributing reasons for the negative energy 
balance observed in some cancer patients67' 115 . Furthermore, changes in the energy 
balance and body composition of a patient have the potential to impose deleterious 
effects on functional capacity. 
Since conventional medicine has failed to improve body composition following 
treatment, it is important to examine other intervention strategies known to influence 
both EE and body composition. Exercise is one such intervention strategy. 
However, a primary concern for patients, health professionals and carers might be 
that increasing participation in physical activity may lead to an exacerbation of the 
patient's weight reduction. It is important to note that these concerns may be 
contributing to the common advice offered to patients such as 'take it easy' and 'get 
plenty of rest'. Evidence providing support for the use of exercise in correcting an 
energy imbalance and body composition is required to alter this notion. 
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4.0.1 Purpose 
Objective 1: To investigate changes between pre- and post-PBST measures of TEE 
and body composition. 
Research hypothesis for objective 1: 
Total energy expenditure will be elevated and body composition will be 
adversely affected following a PBST (as determined by pre- and post-transplant 
measures). 
Objective 2: To investigate the role of a three-month duration, moderate intensity, 
mixed type exercise program on TEE and body composition, post-PBST. 
Research hypothesis for objective 2: 
Participation in the exercise program will lead to an increase in TEE. 
Additionally, the exercising patients will experience an improvement in body 
composition, specifically an increase in functionaltissue, during this same 
period. 
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4.1 Literature Review 
The energy balance equation states that energy intake is equivalent to energy 
expended and energy stored410. "Human accommodation and adaptation to changes 
in energy intake have been an area of controversy for decades"340. While it is well 
established that EE alters with changes in intake, there is inconsistency in the 
available data with regards to the magnitude of such change. Another controversial 
issue is how EE alters to accommodate for additional energy requirements during 
such periods as pregnancy, lactation and growth340 . While this investigation will 
review the literature with regards to both sides of the energy equation, of primary 
importance to this investigation are the changes observed in TEE. 
4.1.1 Total energy expenditure 
Total energy expenditure (TEE) is comprised of resting energy expenditure (REE), 
thermogenesis, physical activity and the energy cost of growth88 . Due to the age of 
the subjects in this investigation, the energy cost of growth is considered negligible 
and therefore only REE, thermogenesis and the energy cost of physical activity will 
be discussed. Sixty to seventy per cent of TEE is explained by resting metabolic 
rate62 or REE, while approximately 10% or less of TEE can be explained by the 
thermogenic effect of food20 L 340• 
An experimental variation in TEE of 8.5% under sedentary and controlled living 
conditions and 12% under free-living conditions has been suggested by reliability 
studies142. Resting metabolic rate, body composition, gender, age, pregnancy and 
particular disease states can contribute to variations in TEE. It has been cautioned 
that this variation should be considered when undertaking interventional studies and 
when attempting to compare TEE between subjects or other investigations142 . 
TEE has been described as 'quite robust', as it remams relatively stable when 
challenged by external stimuli such as excess energy intake, exercise intervention 
and some diseased and stressed states142• The lack of net change in TEE is often a 
consequence of counteracting effects whereby one component of TEE is elevated 
while another is reduced142 . Nevertheless, in many conditions including cancer, an 
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energy imbalance is evident through significant weight changes. For this reason it is 
important to begin to investigate changes in EE in order to understand the etiology of 
this energy imbalance. Unfortunately, while investigations assessing REE changes 
within the cancer population could be identified, few were found that calculated 
TEE177. 
In a study of premenopausal and perimenopausal women with breast cancer, REE 
was assessed via indirect calorimetry, while the average daily EE was estimated on 
the basis of self-reports using a structured physical activity diary. The assessments 
quantified changes between the pre- and post-treatment period (women were either 
treated with radiation or chemotherapyi01 • Resting energy expenditure, expressed as 
kilocalories per kilogram lean body mass per day, increased significantly between 
the pre- and post-treatment period, as did TEE and EE from physical activity. 
However, the increases in the latter two variables were slight and insignificant. In 
contrast,-it was identified in a non-small cell lung cancer patient group that TEE was 
reduced when compared with age- and sex-matched controls. The researchers 
reported that while REE increased in these patients, physical activity levels 
demonstrated a corresponding decline, and taken together these changes led to a 
reduction in TEE 177• 
Another investigation assessed both the TEE and patterns of physical activity in 
survivors of childhood malignancy410 . Children treated for acute lymphoblastic 
leukaemia (ALL) maintained a reduced TEE when compared with healthy sibling 
controls and other children treated for a variety of malignancies. The reduction in 
TEE was explained by reduced patterns of physical activity, whereby energy 
expended above basal metabolic rate declined. 
Obviously, more work quantifying changes in TEE in cancer patients is required 
before any conclusions can be made with regard to the effect of treatment on TEE. 
Further, the studies outlined above used relatively unreliable techniques to assess 
TEE, with none using the more accurate doubly-labelled water method. It seems 
plausible that the use of this technique in the area has the potential to provide more 
definitive results. 
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4.1.1.1 Resting energy expenditure 
Sleeping metabolic rate and the energy cost of arousal comprises REE, which can be 
defined as the minimum rate of energy expended in an awake, relaxed individual, 
resting on a bed, following an overnight fast314. 
While REE is elevated in many cancer patients, this observation has not bee11 
consistene31 and may be dependent on tumour types50• Sakurai and Klein (1998i31 
reviewed eleven investigations that assessed changes in REE as a result of treatment 
in a variety of patients diagnosed with gastrointestinal, gynaecological, 
genitourinary, colorectal, stomach, bronchial, sarcoma, esophageal, and metastatic 
cancer. Normal, elevated and decreased REE states were reported by these 
investigations. Two of the eleven studies were undertaken on greater than 150 
patients, and both studies found patients experiencing hypo-, normo- and hyper-
metabolic states. Unfortunately, the majority of the studies reviewed failed to 
control for factors that have the potential to influence REE such as dietary intake, 
nutritional status, infection, fever, and recent cancer therapy31 . Additionally, few 
studies measuring REE have adequately accounted for changes in body composition. 
An increase in the mass of vital organs relative to total fat free mass (FFM) has the 
capacity to produce alterations in TEE which appear as hypermetabolism, but which 
are in fact independent of changes in the metabolic activity per unit weight of 
tissue178 . 
Inconsistent findings have been found by others, not reviewed by Sakurai and Klein 
(1998)331 • No change in REE was observed in gastrointestinal cancer patients when 
compared with controls420• In contrast, patients being treated for breast cancer 
showed an increase in REE201 . While the increase in REE expressed per kg of FFM 
was related in part to the decreased FFM observed during the same period, the 
overall REE (kcal/day) increase was unexpected and could not be explained by 
available data. Newly diagnosed lung cancer patients also demonstrated a 
disturbance in energy balance, which included an elevation in REE (> 110% of 
predicted)372• Inflammation and central tumour localisation reflected by C-reactive 
protein values were found as contributing factors to this elevation. Similar findings 
were found in unresectable pancreatic cancer patients. These patients showed a 
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significant increase in REB compared with controls when expressed in relation to 
total body weight (>33%), FFM (>28%) or body cell mass (BCM) (>37%)n5. 
An elevated REB was also observed in hypermetabolic non-small cell lung 
carcinoma patients123 . However, this returned to normal within three months of 
curative surgery. Those patients characterised with normal metabolism showed no 
REB change following surgery, as did those patients with tumour recurrence. A 
further investigation performed on small cell lung cancer patients noted while 
hypermetabolism was found, it was considered small, and that a reduction of tumour 
mass results in a reduction in REB 178 • These findings lend support to the hypothesis 
that tumours have the potential to elevate basal metabolic rate. 
In vitro studies reported by Jebb et al (1994)178 suggest that the oxygen consumption 
of human tumour cells is comparable with that of organs such as the liver, kidney 
and brain. Given this theory, the rise in REB observed in cancer patients cannot be 
explained by the tumour alone, and therefore the energy expended from other body 
tissues must also rise. Several theories have been proposed for the mechanism of 
elevated BE in other tissues and include a disordered substrate cycle, an elevation in 
Cori cycle activity, a rise in protein turnover or the effect of tumour-derived 
proteins178 . All theories may contribute to the rise and given the magnitude of 
change in REB, the ability to dissect its individual compartments may be difficult178, 
if not impossible. Another unclear issue proposed was how the increase in REB 
related to TEE. It seems possible that the energy expended on physical activity and 
the thermogenesis of food (TBF) may alter to stabilise TBB178 . 
4.1.1.2 Energy intake and thermogenesis of food 
Limited data are available that directly assess the energy cost of thermogenesis in 
cancer patients. Many studies maintain the assumption that approximately 10% of 
TEE is spent on TEF, with TEF being influenced by food, thermogenic agents 
(caffeine or nicotine), exposure to cold and emotional arousal96 . However, this 
assumption may be violated due to the adverse effects that symptoms commonly 
experienced by cancer patients such as nausea, vomiting and pain, have on appetite 
and food intake. Many chemotherapeutic agents, including dactinomycin, 
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bleomycin, cyclophosphamide, 5-fluorouracil, methotrexate and vincristine, all have 
the potential to reduce food intake by causing constipation, nausea, vomiting, 
diarrhea, dry mouth and mouth sores67 . Patients who have received high-dose CT or 
RT, such as PBST patients, are at a particularly high risk of experiencing these 
symptoms68. Although supportive care is continually improving the control of such 
symptoms 178, some patients still find it difficult, if not impossible to consume food68 . 
In the one study identified that assessed TEF, a reduced thermogenesis of food was 
reported in weight-losing gastrointestinal cancer patients420• It was suggested that 
the decline in diet-induced thermogenesis was an element of starvation adaptation, 
subsequent to weight loss, and that the weight loss seen in cancer cachexia is not 
caused by altered thermogenesis. 
While energy intake is an important determinant of overall energy balance178, it is 
also a crucial factor in TEF. Therefore investigations reporting energy intake data 
can lend some information to changes in this component of EE. Responses (978 out 
of 1667) to a 'health behaviour and readiness to pursue life-style changes' 
questionnaire showed that 55% of cancer respondents ate fewer than five daily 
servings of fruit and vegetables95 . Prostate carcinoma patients reported eating 
significantly fewer servings when compared with breast carcinoma patients 
(p<O.OOl). A study performed on breast cancer patients indicated that energy intake 
significantly decreased across the course of a treatment regimen, was 'erratic' and 
appeared to be responsive to the timing oftreatment94. Finally, in relation to children 
undergoing a BMT, suboptimal nutritional support and the need for intravenous 
fluids (usually at the expense of nutrition) were given as potential reasons for basal 
energy requirements barely being met. Importantly, others have found that although 
weight-losing patients exhibit a reduction in food intake per kilogram of their usual 
weight, when current weight is taken into account, food intake per kilogram of body 
weight does not fall 150. 
In contrast to weight-losing cancer patients, certain types of cancer, in particular 
breast cancer, make weight gain more likely. While length of treatment, type of 
treatment, menopausal status, and alterations in physical activity levels are all 
potential causes of this observed weight gain, an increase in energy intake is 
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regarded as the most likely cause96• However, an increase in energy intake is not a 
consistent finding in women being treated for breast cance~01 and it is therefore 
inappropriate to state that energy intake is the primary cause of weight gain. 
Patients have been recommended to increase their energy intake during treatment 
with the aim of maintaining an energy balance 5°. Protein intake recommendations 
range from 1.5g/kg/day to 2.5g/kg/day, and increase further when surgery, radiation 
or chemotherapy treatment is present50. Obviously the need to increase EI during 
treatment will be dependent on EE. It is difficult to support recommendations for an 
increase in EI, when findings relating to changes in EE following cancer diagnosis 
and treatment remain inconsistent. 
4.1.1.3 Physical activity 
Anecdotally, habitual levels of activity appear to reduce in 'sick' patients177 . A 
recent review of the literature on physical activity in women with breast cancer noted 
that while few carefully conducted studies were found, decreasing levels of physical 
activity were reported, and were associated by some with the gain in weight often 
observed in these patients201 . Others have found an increase in the energy expended 
during physical activity in premenopausal and perimenopausal patients with breast 
cancer, between the pre- and post-treatment period201 . The increase observed 
however, was not significant and the results should be considered with caution due to 
the lack of measurement undertaken prior to surgery and during treatment. Declines 
in physical activity levels have also been identified in non-small cell lung cancer 
patients177• It was suggested that this was a spontaneous decline to counterbalance 
an elevation in REE. However, a reduction in muscle mass, and therefore potentially 
functional capacity, is associated with decreased activity levels209 and thus it should 
not be considered as an appropriate means of balancing the energy equation. 
While investigations have evaluated changes in physical activity levels in response to 
treatment periods, it is also necessary to determine the longer-term changes. One 
such study assessed the TEE and patterns of physical activity in a group of children 
who were considered as being in remission from childhood malignancy, for a 
minimum period of eighteen months. The study demonstrated that children treated 
64 
Chapter Four, Study One 
for ALL maintained reduced patterns of physical activity when compared with 
healthy sibling controls and other children treated for a variety ofmalignancies410 • 
Although evidence is limited, it is sufficient to conclude that energy expended on 
physical activity predominantly decreases following cancer diagnosis and treatment. 
As mentioned earlier, since participation in physical activity is associated with an 
increase in energy expended, health care providers and carers may find it difficult to 
recommend participation in physical activity post-treatment, particularly for weight-
losing patients. However, these fears may be unfounded and it is crucial to begin to 
investigate how the energy balance is influenced through the integration of exercise 
post-treatment. Unfortunately, no investigations could be found that addressed this 
issue in the cancer population and only limited data can be drawn upon from other 
population studies for recommendations. 
Total energy expenditure increased by 12%, in young obese boys following four 
weeks of aerobic training at an intensity of 50-60% V02 max37. In contrast, while 
resting metabolic rate and BE associated with exercise training increased in a study 
of healthy elderly persons, TEE showed no significant elevation 143• The observation 
was explained by a compensatory reduction in physical activity related energy 
expenditure during the remainder of the day. This counterbalancing reduction in 
energy expended performing 'daily activities', to the increase in EE spent performing 
physical activity, is not an ideal response in cancer patients, since the primary goal of 
an exercise intervention would be to improve the ability to perform daily activities. 
Extensive research is required in the cancer population to determine the effect of 
exercise on energy balance. 
4.1.2 Impact of cancer treatment on body weight and body composition 
Weight change is a common side effect following cancer and may be dependent on 
the cancer type, stage or treatment50. A positive imbalance between energy intake 
and expenditure leads to the storage of accumulated energy as excess body fat411 , in 
most cases. This imbalance is a result of either excessive energy intake or reduced or 
impaired energy expenditure, or a combination of both. Alternatively, metabolic 
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disturbances and an energy intake too low to meet metabolic requirements can lead 
to weight loss362 • 
Cancer cachexia, or progressive loss of body weight, protein and lipid stores, and 
body cell mass (BCM), is a common involuntary symptom of cancer patients115' 170' 
177
' 
331
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. The word cachexia simply means 'bad condition' and is used to describe 
any disease that results in host tissue wasting390 . Inui (1999)170 reported literature 
statistics illustrating that approximately half of all cancer patients demonstrate a 
syndrome of cachexia, characterised by adipose tissue and muscle mass loss. 
Cachexia tends to become more pronounced with disease progression, and solid 
tumour patients seem to be at a greater risk, as are children and the elderly. Given 
that the percentage of patients experiencing weight loss varies amongst cancer types, 
it seems evident that some tumours predispose cachexia more than others, with 
' 
gastrointestinal cancer being associated with the most marked weight loss177' 390. It 
should be remembered that weight loss is a statistically significant predictor of 
survival, independent of tumour type and stage, and performance status, and thus 
cancer cachexia is clinicaliy important99 . 
Cancer cachexia has previously been classified as consisting of three stages: 
>- preclinical, during which there are abnormal acid and lipid profiles, however, the 
patient does not exhibit any clinical signs of the condition; 
>- hypermetabolic, whereby patients begin to exhibit lethargy and early weight loss 
signs; and 
>- hypometabolic, where metabolic rate is below normal and energy intake is 
diminished. This final stage is also associated with marked debilitation, 
weakness and biochemical evidence of a negative nitrogen balance67' 274. 
Although the etiology of cachexia is not certain, a reduction in food intake during 
turriour growth, an EE imbalance and other metabolic alterations are attributed to this 
weight loss67' 115• 379. A direct effect of the tumour, or potentially the secretion of 
humoral factors including cytokines, hormones or other mediators, may also act to 
induce hypermetabolism 178 . 
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Changes in carbohydrate, lipid and protein metabolism have been documented in 
tumour-bearing hosts, with cancer cachexia being characterised by a shift in nutrient 
use to immune response and disease resistant processes, rather than muscle growth 
and maintenance135. Typically BCM, body fat and FFM are reduced, and the 
extracellular-intracellular water ratio is altered in cachexia cancer patients357' 381 . 
BCM is of great importance, since it comprises the body compartment containing 
most of the tissues vital to normal functioning and thus accounts for 95% of the 
body's metabolic activity27' 362 . While patients may survive a body weight loss of 
up to 50%, a 30% loss in body weight is almost always fatal390. 
Tisdale (1997)390 reported evidence suggesting that unlike starvation, where more 
than 75% of weight is attributed to body fat loss, the weight loss in cancer patients 
arises equally from muscle and fat loss. This evidence was further supported by 
others noting that "cancer cachexia may be characterised by a disproportionate loss 
of lean tissue, suggesting a failure of the normal regulatory processes which conserve 
skeletal muscle and visceral organs during periods of undernutrition, uncomplicated 
by disease"177. However, this is not a general consensus as others have reported that 
fat loss still accounts for the majority of weight loss occurring in cancer cachexia274 . 
While there is consistent evidence in the HIV population demonstrating a 
disproportionate loss of lean tissue and relative sparing of fat with loss of body 
weight252 , evidence has also indicated that the baseline fat content determines the 
level of fat loss. That is, those who begin with a greater fat mass will lose a higher 
level of fat, in comparison to a significantly greater proportion of lean body mass 
loss in those who have a baseline fat content of less than 15%. As the energy 
balance becomes more negative, the proportion of weight lost as lean body mass 
mcreases. 
In relation to cancer patients, it has been noted that depletion of skeletal muscle 
exceeds that of visceral mass in cancer cachexia390. Theories have been proposed 
suggesting that a tumour/host competition for nutrients exists, with the aggressive 
tumour succeeding at the expense of the host. However, some patients with large 
tumours show no signs of cachexia, while others with relatively small tumours 
exhibit significant cachexia, making these theories unlikely90• 
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Carbohydrate, fat and muscle metabolism abnormalities have also been reported in 
cancer patients274' 390. The production of lactic acid associated with some tumours 
leads to an elevation in the conversion of lactate to glucose by the liver. This is an 
energy-consuming process and studies have found a correlation between increased 
Cori cycle activity and weight loss. These findings have been supported in animal 
investigations reported by Ogilvie (1998)274 . Tumours preferentially metabolise 
glucose for energy by anaerobic glycolysis forming lactate as an end product. 
Therefore, energy is required to convert lactate to glucose via the Cori cycle, 
resulting in a net energy gain by the tumour, and a corresponding energy loss by the 
host. 
Given that fat loss accounts for a substantial proportion of weight loss, it is not 
surprising that cancer patients experience lipid metabolism abnormalities274. An 
increased glycerol and fatty acid turnover has been observed in some cancer patients 
when compared with healthy subjects390 . Ogilvie (1998i74 reported evidence 
demonstrating that the increased levels of free fatty acids, very low density 
lipoproteins, triglycerides, plasma lipoproteins and hormone-dependent lipoprotein 
lipase activity, and decreased levels of endothelial-derived lipoprotein lipase, are a 
result of the decreased lipogenesis and increased lipolysis observed in cancer 
patients. 
Decreased muscle mass, reduced skeletal protein synthesis and altered nitrogen 
balance in conjunction with concurrent elevations in skeletal protein breakdown, 
liver protein synthesis and whole body protein synthesis have also been shown in 
studies with cancer patients274' 390• Tumours preferentially utilise protein for energy, 
and certain amino acids for gluconeogenesis, unfortunately at the expense of the 
host. Additionally, total skeletal muscle mass decreases during cachexia have been 
shown, and white or phasic muscle experiences faster losses when compared with red 
or tonic muscles390. Increased muscle catabolism, decreased protein synthesis or a 
combination of the two, may contribute to the peripheral muscle wasting observed in 
some cancer patients252' 390. The use of amino acids for energy by the tumour 
becomes clinically important when protein synthesis is exceeded by the loss. At this 
time, immune response, gastrointestinal function and wound healing are some of the 
bodily functions adversely influenced274. 
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Thirty per cent of newly-diagnosed lung cancer patients studied demonstrated a 
weight loss of 10% or more from their preillness stable weight372 . A combination of 
elevated REB and reduced dietary intake were reasons given for the weight loss. An 
investigation on patients with pancreatic cancer showed that on average patients had 
lost 18% of their preillness weight with part of this loss being reflected by significant 
reductions in FFM and BCMll5. Finally, an investigation performed on 42 children 
between the ages of 1.3-17.1 years, undergoing either an autologous or allogeneic 
BMT illustrated that muscle protein reserves were significantly reduced (11 %) 
during the first month post-transplant, and it could take approximately six months for 
patients to reach pre-BMT levels385 . While weight was gained during periods of 
parenteral nutrition, there was a simultaneous loss of skeletal muscle protein reserve. 
In summary, energy deficits resulting in a loss of both FM and FFM occur when EE 
exceeds El. Body composition of the patient, the relative size of the energy deficit 
and the effect of the disease will influence the partitioning between FFM and FM 
during weight loss123 • 
Although a reduction in body weight has been given much of the attention, cancer, 
treatment and/or psychosocial problems have the potential to increase body weight. 
Between 50-96% of early-stage breast cancer patients experience a significant weight 
gain of 2.5-6.2kg, with up to 10kg not uncommon96. Treatment-induced premature 
menopause, hormone treatment, changes in endocrine functioning, reduction in 
physical activity, elevations in energy intake and emotional reactions to cancer, are 
all plausible reasons for weight gain295 . At present there is debate regarding the 
influence of body weight on prognosis377, although a consensus exists that an 
increase in body weight adversely effects women's self-esteem, feelings of 
inadequacy, insecurity, loneliness and social rejection. Additionally, the tendency 
toward weight gain consisted ofboth an increase in fat tissue and a loss in lean body 
tissue, thus contributing to a reduced functional capacity. Others have also reported 
a reduction in lean body mass (mean loss of 0.8kg) with a corresponding increase in 
percentage body fat (1.3%), in premenopausal and perimenopausal patients being 
treated with chemotherapy and radiotherapy for breast cancer198 . 
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An investigation studying the effects of medroxyprogesterone on food intake and 
body composition in patients with advanced, nonhormone-sensitive cancer, found 
that the drug induced a positive influence on appetite and led to a significant increase 
in energy, protein, fat and carbohydrate consumption. This increase in food intake 
led to the reversal of ongoing fat loss, however it failed to improve the functionally 
important body component, lean tissue362 . These data have been supported by other 
studies which found that sedentary patients on total parental nutrition may synthesise 
fat rather than lean tissue in contrast to those who exercise108. A further investigation 
performed on oral cancer patients demonstrated similar findings for weight gain26 . 
Following treatment, patients experienced a mean weight loss of 1 0.8%, and more 
than three years post-treatment, 10 out of 25 patients had not returned to pre-
treatment 'usual' weights. However, according to body mass index, 24 patients were 
either at or above the 'normal' level. Importantly, a change in weight distribution 
was found, with a greater proportion of body fat and lower proportion of FFM 
evident when compared with age- and sex-matched controls. The results suggested 
that regained weight is laid down predominantly as fat rather than lean tissue. 
Although an important cause of weight loss is undoubtedly low caloric intake, the 
aetiology of wasting is more complex and multifactorial135. It is becoming evident 
that although adequate energy intake has the potential to slow, stop or even reverse 
body weight loss, an adequate food intake fails to correct or prevent loss of muscle 
mass that is associated with cancer and its treatment331 . 
4.1.3 Impact of exercise on body weight and body composition 
The muscle atrophy and decrements in muscular strength caused by unloading is 
widely recognised297 • Evidence provided above shows that nitrogen wasting caused 
by malnutrition, side effects of the disease and/or immobilisation, cannot be easily 
reversed by food alone. One area of potential optimism is the use of exercise in 
improving body composition status. 
The effects of exercise on body composition in the 'healthy population' have been 
well documented300. While aerobic exercise is known for its role in reducing body 
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fat and maintaining lean tissue, resistance training is generally considered to be 
associated with improving lean tissue status. 
Moderate exercise training has the capacity to increase the efficacy of dietary protein 
utilisation 57 . Nitrogen balance is maintained with normal protein intake. However, 
when protein intake is marginal, the rate of nitrogen retention is elevated when 
exercise of an intensity of 40-50% V02 max is added. An exercise intensity higher 
than this, however, can lead to a negative nitrogen balance, illustrating the 
importance of maintaining a moderate exercise intensity for cancer patients. 
Animal research reported by Hicks (1990)161 found that protein synthesis may be 
enhanced through exercise, even in the presence of malignancy. Protein turnover can 
be significantly altered by the presence of tumour in rats, to a greater extent than that 
caused by food restriction. Endurance exercise for seven weeks was shown to retard 
both muscle mass depletion and tumour growth. 
An investigation with HIV -patients was conducted to study the effects of an anabolic 
steroid treatment in conjunction with a resistive exercise program on body 
composition. All study participants received the drug and were randomised to either 
a progressive resistance exercise group or control group. Unfortunately the study did 
not include an exercise-only group. Nevertheless, the results showed that by the end 
of the first month, six control subjects gained 1.9% of entry weight, one subject lost 
weight, and two lost BCM. In contrast, seven subjects in the exercise group 
demonstrated a 3.2% increase of entry weight and no subject within the exercise 
group showed any declines323. In another study with HIV -1 patients (Spence et al, 
1990 in Lox et al, 1996222), following a six week progressive resistance training 
program, muscular strength for the regions of the legs, chest, shoulder and arms, 
significantly improved pre- to post-program for those in the exercise group. The 
exercising patients at post-program also experienced significantly higher levels of 
muscular strength when compared with the control group. Of particular interest, for 
those in the control group, muscular strength was either unchanged or declined 
following the six week period. In addition, body weight and girth measurements 
increased for the experimental group, while the control group showed significant 
decreases for these variables. 
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In yet another HIV -1 and AIDS investigation (Rigsby et al, 1992 in Lox et al, 
1996222), it was shown that improved cardiovascular and anthropometrical status can 
occur with the integration of both aerobic and strength exercises. The experimental 
participants demonstrated a 30% improvement in muscular strength following a 12-
week program. In contrast, no significant changes were found for the control 
participants. 
Lastly, an investigation studying the effects of an aerobic-only, a strength training 
program-only and a stretching control group on body composition and fitness was 
undertaken on HIV -1 males222 and provided supporting evidence for the above 
studies. The aerobic-only group demonstrated the highest fitness changes, and the 
strength training group demonstrated the highest muscular strength gains. Both 
groups demonstrated losses in fat mass and gains in FFM, with the aerobic group 
illustrating the higher fat mass losses and the strength group higher FFM gains. 
While these results demonstrate the principle of training specificity, the results 
observed also illustrate that a certain level of 'crossover' can occur. That is, those in 
the exercise group also showed partial improvements in leg strength, and the weight 
training group showed partial improvements in cardiovascular training. As was 
expected, the changes in body composition mirrored the changes observed in 
muscular strength. Importantly, these results also demonstrated the notion that 
inactivity is associated with physiological declines, as was evidenced by the decline 
in fitness and muscular strength in the control group. The collaborative results of the 
above investigations provide important evidence for the potential for exercise to be 
used to correct or combat the wasting process associated with disease and treatment. 
Furthermore, exercise can also have the alternative effect in weight maintenance, 
whereby weight gain and muscle wasting can be reduced through exercise226 . · 
Weight stabilisation, and improved weight and skinfold thickness have been shown 
in exercising breast cancer patients following a ten week cycle ergometry protocot226, 
and an eight week aerobic protocol429, respectively. A later investigation 
demonstrated that exercising breast cancer patients (patients exercised 20-30 
minutes, three times per week for 10-12 weeks) experienced a reduction in 
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percentage body fat and an increase in lean body mass, even though both control and 
exercising patients attained a slight increase in total body mass428 . 
4.1.4 Use of body composition assessment methods 
The above research clearly demonstrates the importance of assessmg body 
composition, rather than just body weight changes in the clinical setting. However, 
for body composition to become a commonly measured variable throughout the 
cancer continuum, practical assessment techniques need to be identified. 
Unfortunately, numerous difficulties exist in accurately monitoring body 
composition changes in cancer patients177. An increase in hydration and changes in 
potassium concentration observed in these patients have the capacity to invalidate 
many of the classical methods used to determine body composition177• It has been 
suggested (Cohn et al, 1981 in Reilly and Workman, 1994316) that the wasting 
associated with many cancer states leads to a higher than expected water content of 
the FFM, due to the loss of BCM with a relative expansion of the extracellular fluid. 
In addition, measurement of total body potassium to determine body composition is 
problematic in cancer patients experiencing muscle wasting, since muscle is 
relatively rich in potassium. Of specific relevance to this investigation are PBST 
patients, and it has been reported that bone marrow transplant patients frequently 
experience fluid weight shifts post-transplant68 . 
Two methods, bioelectrical impedance analysis (BIA) and skinfolds, are available for 
use within the clinical setting to assess body composition, and are based on a two 
compartment model comprising FM and FFM364. It was identified in two 
investigations with both normal and underweight cancer patients that the single-
frequency BIA parameter ht2/R, maintains a high correlation with total body water as 
assessed via deuterium dilution363' 364 . However, an important problem identified 
was that the BIA systematically overestimated total body water in underweight 
patients when a prediction formula,. developed from normal-weight subjects, was 
applied364. 
The second technique, the use of skinfolds is relatively inexpensive and is considered 
to be accessible and precise, when implemented using a trained observer316 . Apart 
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from tester skill, reliability of this technique is also dependent on the standardisation 
of the skinfold calipers and the use of appropriate age- and sex -specific equations301 . 
However, one source of potential error that specifically relates to its use within the 
cancer population is that the method depends on the relationship between 
subcutaneous adiposity and total body fat being similar to that in the original healthy 
population upon which the predictive equations are based316• It is plausible that in a 
number of oncology populations fat distribution may be altered, as may the 
relationship between subcutaneous fat and total body fat. The practical significance 
of this error source is as yet unknown and future research in this area is required. To 
date, no work could be identified throughout the literature that compared the 
calculation of percentage body fat using various techniques in the oncology setting. 
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4.2 Methodology 
Chapter 3 provided a detailed outline of the methodological procedures that relate to 
subject recruitment, the testing phases and the intervention program implemented. In 
summary, 12 patients, with 6 patients in each group were recruited. Of these, only 7 
patients were recruited at PI, while the remaining subjects entered the investigation at 
PII. Outlined below are the methodological procedures which relate specifically to 
the aims of this section of the investigation and involve anthropometric, body 
composition, energy expenditure and food frequency intake measures. 
4.2.1 Height, weight and body mass index 
Height and weight were measured to the nearest O.lcm and O.Olkg, respectively. 
The variables were assessed with the subjects barefoot and were measured using a 
wall mounted Harpenden stadiometer™ (Holtain Ltd, Crymych, Dyfed) and a 
calibrated digital electric scale, Wedderburn Scales™ (Tanita BWB-600). Body 
mass index (BMI) was calculated from the formula, weight(kg)lheighr(m2). 
4.2.2 Body composition 
A number of factors limit the accuracy of measuring body composition in patients 
with cancer177• Therefore, 2 techniques, the skinfold method and singly labeled 
water method, were employed to assess %BF, FM and FFM in order to improve the 
reliability of the data. 
4.2.2.1 Singly labelled water technique 
The calculation of body composition is often derived from the measurement of total 
body water (TBW). One method of assessing TBW is through the use of the 
deuterium dilution technique. 
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The calculation of the total body water volume is based on the following simplified 
relationship27 : 
or 
where: cl =initial concentration of ingested or injected tracer 
V1 =initial volume of ingested or injected tracer 
C2 =final concentration of tracer in blood or urine 
v2 =volume of total body water 
In order to minimise error associated with dosing, a 10% stock dose solution was 
made and then autoclaved (EA-652 Bench Type Autoclave, Medical & Surgical 
Requisites Pty Ltd, Brisbane, Australia). A 5ml sample was then taken from the 
autoclaved dose for calibration and frozen until required. Each subject received a 
dose of 0.5glkg body weight following collection of a pre-dose urine sample. The 
pre-dose urine sample was used to assess background levels of isotopic enrichment, 
and it was assumed that these levels remained constant throughout the study period 
of four to six hours. Following ingestion of the dose, the bottle was then reweighed 
to the nearest O.OOlg, to ensure that the exact dose ingested could be calculated. 
Between 4-6 hours post-dose ingestion, the subject was required to provide a second 
urine sample and to record the exact time the sample was taken. The two urine 
samples were then kept frozen until required for assessment. 
The isotope enrichment of the pre-dose urine sample, the post-dose urine sample, 
local tap water and a sample of the dose given, were measured in triplicate samples 
by using a gas isotope ratio mass spectrometer (Hydra PDZ Europa Scientific, Crew, 
UK). When using deuterium dilution, two approaches can be implemented to 
calculate TBW and include either the plateau or back-extrapolation method. Both 
methods have previously been examined and have been found to yield similar 
results90 • The plateau method, which involves calculating the dilution space by 
subtracting the pre-dose urine sample enrichment from the four to six hour post-dose 
enrichment, was applied in this investigation. The enrichment then represents the 
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concentration of the administered tracer in the body, and by taking into· account the 
weight of the dose given, can be used to determine the volume of the dilution space. 
The equation used to calculate the dilution space (N) is as follows: 
Where: A= 
a= 
T= 
Ea= 
Et= 
Ep= 
Es= 
N = TA*(Ea-Et) 
a*(Es-Ep) 
isotope in grams for mass spectrometer analysis, 
the portion of the dose in grams retained for mass spectrometer 
analysis, 
the amount of tap water in which the portion of a is diluted before 
analysis, 
isotopic enrichment in delta units of the portion of the dose 
isotopic enrichment in delta units of the tap water used 
isotopic enrichment in delta units of the pre-dose urine sample 
isotopic enrichment in delta units of the post-dose urine sample 
Delta units express isotopic enrichment relative to a standard, standard mean ocean 
water (SMOW). The dilution space assessed exceeds TBW due to the exchange of 
the tracer with non-aqueous hydrogen atoms within the body. The difference in 
humans is believed to be 3-4%90 and hence, the 2H dilution space can be converted to 
TBW by dividing TBW by 1.04. 
When using this method, FFM is calculated by dividing the measured TBW by 0.73, 
the assumed hydration coefficient of the FFM in normal-weight healthy individuals. 
FM is subsequently calculated by subtracting FFM from body weight. While limited 
data is available on the hydration coefficient of the FFM in normal-weight or 
underweight cancer patients, Simons and colleagues (1998)362 reported unpublished 
laboratory work demonstrating that, through the use of deuterium dilution and 
DEXA-scanning, the hydration coefficient of lung carcinoma patients (mean BMI, 
20.8) was 0.73±0.03 (range = 0.68-0.79). Therefore, to extrapolate to body 
composition, the following formula was applied: 
FFM = TBW (litres)/0.73 
Thus, 
FM =BW-FFM. 
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4.2.2.2 Skinfold technique 
Jackson and Pollock (1985)174 have simplified the calculation of %BF by providing 
tabulated percentage body fatness values for different skinfold thicknesses across 
various age groups305 . All that is required for %BF and thus FM and FFM to be 
determined is the sum of skinfolds (SOS). The same qualified tester (accredited at 
Level 1 Anthropometry) assessed six standard skinfolds (triceps, biceps, subscapular, 
abdominal, supraspinale and medial calf) at each of the three testing periods, in order 
to ensure that the procedure was standardised and implemented with reliability and 
objectivity. The specific details relating to the assessment of each skinfold site has 
been provided in Appendix V. Each skinfold site was assessed twice and the 
technical error of measurement (TEM) followed by the relative TEM (% TEM) was 
calculated and recorded at less than 5%. The procedure used to calculate the 
absolute and relative TEM has been described by Norton & Olds (1996i71 . The 
mean of the two skinfold scores for each site was used in the SOS calculation, which 
was derived from the addition of all six skinfolds sites. Tabulated data allowed the 
calculation of %BF from the SOS and the patient's age. Body weight and %BF were 
then used to calculate FM and FFM. 
4.2.3 Energy expenditure- doubly labelled water technique 
The premise of the doubly labeled water (DL W) method is that 0 atoms in expired 
CO have isotopically equilibrated with the 0 atoms in body water. Thus, following a 
loading dose of 2H and 180 water, the 2H is eliminated from the body as water, 
mainly as urine, while the 180 is eliminated as water and C02, in an exponential 
fashion. The rapid equilibration of oxygen between water and carbon dioxide leads 
to the elimination via carbon dioxide. The difference between the elimination rates 
from the body water pool, after adjusting for isotopic fractionation, is therefore 
proportional to C02 production and hence energy expenditure can be calculated74' 273 ' 
341
. A primary underlying assumption of the technique is that the hydrogen and 
oxygen of water are only lost from the body water pool as water and carbon 
dioxide313 . Error will be introduced in the calculation ofrC02, if any other exchange 
or transformation in the body occurs. An example would be if deuterium is 
incorporated into protein or fat during reductive biosynthesis which would cause an 
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overestimate of water flux and an underestimate of the difference between 2H and 
180 fluxes, and thus an underestimate of rC02. A review of the literature performed 
by Haggarty (1988) and reported by Ravussin (1991)313 found that the maximum 
error on rates of C02 due to fat synthesis was 5%. 
The doubly-labelled water technique is considered a valid tool for assessing energy 
expenditure in various populations including infants, young adults, healthy adults, 
and patients with gastrointestinal disorders, and subjects under metabolic ward 
conditions340• The accuracy (1-2% with a relative standard deviation of 3-9%) and 
precision (approximately 4%) of the technique have also previously been shown90. 
A mixed dose containing 0.125glkg 100% H2180 and 0.05glkg 100% 2H20 was 
given orally to each subject following the collection of a pre-dose urine sample. In 
each case the weight of the dose ingested in grams was determined to three decimal 
places through the use of Mettler Todedo PB3002 scales™ (Switzerland). Urine 
specimens were then collected 4-6 hours post-dose and thereafter at daily intervals 
for 14 days. The time of each urine sample was accurately recorded on data sheets 
provided to the patients, and the patients noted whether they had experienced any 
vomiting or diarrhoea on any day. Urine samples were stored in the freezer 
(collection tubes and container bags were provided) and the samples were collected 
at the end of the 14 days by the researcher. While 16 samples were collected, 
triplicate samples were only assessed for the pre- and post dose-samples and day 1, 
2, 3, 11, 12, 13 and 14 samples. 
Isotopic enrichment of the urine samples was measured relative to local standards by 
isotope ratio mass spectrometry (Hydra PDZ Europa Scientific, Crew, UK). The 
sensitivity of isotope ratio mass spectrometer measurements is achieved by 
comparing the isotopic abundance of the sample to that of a reference gas under 
identical measurement conditions. Results are expressed in delta units or as o/oo (per 
mil) enrichment relative to SMOW. Thus, 
8 enrichment = [ (RsfRr) - 1] * 103 
Where: Rs =the ratio of isotopes in the sample, ie 2H/1H, 
Rr= is the ratio of isotope in the reference (SMOW) 
eH = o.ooo15595, 180 = o.oo2oo5) 
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Linear regression equations were obtained from the log transforms of measured 
enrichments of 2H and 180 across time minus the predose. The regression 
coefficients are therefore the disappearance rates, kJ and ko of 2H and 180, 
respectively. The dilution space of each isotope (N0 , Nd) at the beginning of the 
study period is calculated as: 
N= TA * ;Eg -E1 
a Es 
Where: N0 the 180 dilution space, and 
Nd the deuterium dilution space, 
A the dose of isotope given, 
a a portion of the dose diluted for mass-spectrometric analysis, in a mass, 
T oftap water. 
N, T and A are in grams. 
E. emichment of the portion, 
Et enrichment of tap water, 
Es the antilog of the intercept of the regression line. 
Output rates of carbon dioxide, rCOz (mole/day) corrected for fractionation effects 
were calculated using a constant value for the proportion of water fractionated (x) 
and values for the fractionation of 2H and 180 (f1 and f2) in water vapour and 180 (f3) 
in C02. The value of x used in the present study was 0.25 and the values for ft, f2, 
and f3 were 0.941, 0.993 and 1.040, respectivel/0. 
Carbon dioxide production rate was calculated as, 
rCOz NQkQ - Ngk;g{l±_(f2 - f1ill 
2f3 
Assuming a respiratory quotient of 0.85, total energy expenditure was calculated 
using Weir's formula418. 
4.2.4 Dietary assessment 
A food frequency questionnaire (Table 4.1) was designed and administered by the 
investigator, to evaluate the number of servings of vegetables, fruits, breads and 
cereals, meat products, dairy products, snacks and beverages consumed per day, over 
the past week. Detailed dietary analysis was considered beyond the scope and intent 
of this thesis and thus the dietary assessment was initiated merely to obtain a broad 
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indication of food intake. Therefore, in the design of the questionnaire, no attempt 
was made to classify the size of the servings or the number of calories consumed per 
day, nor was the questionnaire validated. The questionnaire required the subject to 
circle a response relating to specific food groups, that best represents their nutritional 
habits at the time of completing the questionnaire. 
Table 4.1 Dietary intake questionnaire 
servmgs, servmgs, Rarely 
4-6 x week <4 x week 
Fruit- 1 serving = >2 1-2 At least 2 At least 2 
a piece of any fruit servmgs servings servmgs, servings, Rarely 
4-6 x week <4x week 
Breads cereals At least 2 At least 2 
- 1 serving= 2 .. servings servings servings, servmgs, Rarely 
slices of bread or a per day per day 4-6 x week <4x week 
>2 1-2 At least 2 At least 2 
servings servings servmgs, servings, Rarely 
per day per day 4-6 x week <4x week 
or 
Dairyproducts-1 
serving = a glass of >2 1-2 At least 2 At least 2 
milk, a tub of servings servmgs servings, servings, Rarely 
yo@mrt, 2slices of per day per day 4-6 x week <4x week 
cheese etc 
Snack foods 
including cakes, >2per 1-2 per At least 1, At least 1, 
sweets, lollies, day day 4-6 x week <4x week Rarely 
chocolates, chips, 
etc 
Niunberof >6per 4-6 per 2-3 per day one per day <1 per 
beverages day day day 
4.2.5 Statistical analysis 
Data for total energy expenditure, body composition and food intake frequency were 
collected at each of the three testing phases, and TEE and body composition data 
were analysed according to the statistical procedures outlined in Chapter 3. Food 
81 
Chapter Four, Study One 
frequency data was assessed by reporting the number of patients within the study 
group at PI and PII, and the control and exercise groups at PI, PII and PHI, who 
consumed a specific number of servings per food group. In this manner, changes in 
food frequency consumption across the testing phases could be observed. 
Finally, a Pearson's product moment was used to determine the relationship between 
%BF calculated via the use of the skinfold and SL W technique, while the Bland 
Altman technique40 was employed to calculate the agreement between the two 
methods. This technique required several calculations: 
>- calculating the difference between %BF recorded for the two techniques 
(skinfold and SLW) (a); 
>- calculating the mean of%BF recorded for the two techniques (b); 
>- plotting a (y axis) against b (x axis); 
>- calculating the mean of the differences (x) and SD of the differences (s); 
>- and, provided the differences lie within x±2s, the limits of agreement can be 
calculated: 
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4.3 Results 
The changes in body composition and energy expenditure for patients undergoing a 
PBST are presented in Table 4.2. The treatment is associated with significant 
decreases in weight (p<0.01) and BMI (p<0.01) (Figure 4.2 and 4.3). Although there 
was no significant change in %BF by use of the skinfold technique, significant 
decreases in FM (p<0.05) and FFM (p<0.01) were shown. When body composition 
was assessed via the deuterium dilution technique, FFM decreased (p<0.05). No 
significant decrease was observed between the pre- and post-transplant testing phases 
for energy expenditure. 
Table 4.2 Body composition and energy expenditure measures at PI and PII for 
the study group (mean±SE) 
S#!~Y'Gioup.•· .. P;JI;, .'n~;'-,12. .· .. :t'value: 
·~-"' ··~ ·Ni~~'~i> ;, ,';~;x'?,, ,';:: ,'; ', :''', ~',; . variaoie· ~SE v~ ,':~"? ;,;;f,~:~':,'(: v ,,',,! 
l 
Wt (kg) 87.6 1.4 79.5 0.9 0.000** 
BMI (wtlht2) 29.9 0.5 27.2 0.3 0.000** 
Skinfold technique: 
BF(%) 27.9 0.8 26.2 0.5 0.085 
FM (kg) 22.4 0.8 20.1 0.5 0.030* 
FFM (kg) 55.7 0.7 52.5 0.4 0.003** 
Singly-labelled water 
technique: 
BF(%) 34.3 1.5 33.6 1.1 0.736 
FM (kg) 32.1 1.9 28.5 1.4 0.142 
FFM(kg) 54.8 1.3 51.1 0.9 0.036* 
TEE (kcal/day)/FFM(kg)0·3 284 (n=4) 84.6 260 (n=4) 84.6 0.104 
* p<0.05, ** p<0.01 
The high levels of body fat found in certain patients prevented the repeatable 
measurement of %BF, FM and FFM, via the use of the skinfold technique for these 
particular patients. Consequently, there were greater missing data derived from the 
skinfold technique, when compared with the SL W technique. That is, repeatable 
measurements for body composition were collected from 12 patients using the 
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deuterium dilution method, compared with only 8 patients when using the skinfold 
technique. Further data analysis and reporting of results therefore only relates to the 
data collected via the SL W technique. 
Table 4.3 shows body composition changes across the testing phases for the control 
group. The patients in the control group showed significant changes in weight 
(p<0.05) and BMI (p<0.05) between pre- and post-treatment. Three-months post-
transplant, weight and BMI remained significantly lower (p<0.05) than pre-transplant 
measures. Mean changes were observed in %BF, FM or FFM across the testing 
phases, however these were not statistically significant. 
Table 4.3 Body composition measures across the testing phases for the control 
group (mean±SE) 
Variable Phase Mean SE Compaiisons . pvaluei 
Wt (kg) I 78.6 2.2 PI- PII 0.017* 
II 71.8 1.4 PI- PIII 0.041 * 
III 72.8 1.6 PII- PIII 0.573 
BMI (wt/ht2) I 27.7 0.8 PI- PII 0.013* 
II 25.3 0.5 PI- PIII 0.032* 
III 25.7 0.6 PII- PIII 0.540 
%BF I 33.7 2.5 PI- PII 0.687 
II 32.4 1.6 PI- PIII 0.628 
III 32.1 1.8 PII- PIII 0.876 
FM (kg) I 27.2 3.1 PI-PII 0.318 
II 24.8 1.9 PI- Pili 0.416 
III 25.1 2.2 PII- PIII 0.867 
FFM (kg) I 51.5 2.1 PI- PII 0.145 
II 47.0 1.3 PI- PIII 0.213 
III 47.0 1.8 PII- PIII 0.996 
n =PI- 3; PII- 6; PHI- 5 
* p<0.05 
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Table 4.4 demonstrates changes in body composition and EE observed across the 
testing phases for the exercising group. Weight, BMI and FM were significantly 
lower at Pili (p<0.05) when compared with pre-transplant data. Following the 
exercise intervention program, FFM significantly increased (p<0.01) while %BF 
significantly decreased (p<0.05). Additionally, by three months post-transplant, 
exercising patients were expending a significantly greater (p<0.01) amount of energy 
when compared with pre- and immediately post-treatment. 
Table 4.4 Body composition and energy expenditure measures across the testing 
phases for the exercise group (mean±SE) 
Variable '; Phase Mean, '1SE': ; ;';~ ~0mpansons, 
' . . :· . : 
0, ;;;<;ip0[va:Iuej 
Wt (kg) I 96.7 1.8 PI-PII 0.007** 
II 87.4 1.4 PI- Pili 0.028* 
III 89.7 1.4 PII- Pili 0.315 
BMI (wt/ht2) I 32.3 0.6 PI- PII 0.010* 
II 29.2 0.5 PI- Pili 0.033* 
III 29.9 0.5 PII- Pili 0.369 
%BF I 34.9 1.8 PI- PII 0.980 
II 34.8 1.6 PI- Pili 0.051 
III 29.5 1.6 PII- Pili 0.041 * 
FM (kg) I 37.0 2.2 PI- PII 0.201 
II 32.2 1.9 PI- Pili 0.032* 
III 28.2 1.9 PII- Pili 0.245 
FFM (kg) I 58.4 1.5 PI-PII 0.140 
II 55.1 1.3 PI- Pili 0.152 
III 61.6 1.3 PII- Pili 0.008** 
TEE I 284 11 PI- PII 0.185 
(kcaVday)/FFM(kg)0·5 II 260 11 PI- Pili 0.004** 
III 356 11 PII- Pili 0.001 ** 
n =PI- 4; PII- 6; Pili - 6 
* p<0.05, ** p<0.01 
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Changes in weight and body composition across the testing phases for both groups 
are presented in Figure 4.2a, b, c and d. Individual changes ofFFM for the subjects 
in the control and exercise groups are presented in Figure 4.2e. A mean reduction in 
weight (Figure 4.2a), %BF (Figure 4.2b ), FM (Figure 4.2c) and FFM (Figure 4.2d) 
are observed following the transplant. However, only the changes detected in weight 
. and FFM during the pre- and post-transplant period were significant (p<0.01 and 
p<0.05, respectively). Weight remained (p<0.05) lower for both the control and 
exercising patients at three months post-treatment. Mean decreases in %BF (p<0.05) 
and FM, and a significant increase (p<0.01) in FFM, were also detected following 
participation in the exercise intervention program. All subjects in the exercise group 
displayed a similar trend for change in FFM across the testing phases (Figure 4.2e). 
As is also shown in Figure 4.2e, 4 out of 5 subjects in the control group displayed 
either no change or a mean increase in FFM during the 3-months post-transplant, 
while 1 patient demonstrated a mean loss ofFFM. 
Figure 4.2 Changes in weight and body composition for the study group (PI & 
PII), and the control and exercise groups (PI, PII & Pili) (mean±SE) 
(a) Changes in weight 
IIJ PI 1iJ PII [] Pili 
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* p<0.05, ** p<0.01 
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(b) Changes in percentage body fat 
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(c) Changes in fat mass 
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(d) Changes in fat free mass 
II PI Ill PII [iJ Pili 
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(e) Individual changes in FFM across the testing phases {PI, PII & Pili) 
for subjects in the control and exercise group 
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Figure 4.3 displays the TEE results recorded from four subjects in the EG. A 
Pearson correlation performed on FFM and TEE data (R=0.60, p<0.05) indicated that 
the level of FFM measured influenced TEE. Since the FFM of the subjects altered 
across the three testing phases, it was deemed crucial to appropriately adjust TEE 
with regard to these FFM fluctuations. A common method of adjusting for FFM 
changes is by dividing TEE by FFM. However, a second negative correlation 
(R=-0.56, p<0.05) applied to TEE/FFM and FFM indicated that a ratio of TEE and 
FFM may not adequately account for FFM changes. In order to find an appropriate 
method of adjusting for FFM changes, TEE and FFM values were log-transformed 
and analysed by linear regression. The coefficient calculated in this case, is the 
power to which FFM must be raised to completely adjust TEE for FFM. Since the 
linear regression coefficient was within 2 standard errors of either 0.5 or 1, TEE can 
be adjusted for FFM by expressing TEE per FFM (kg)0·5 or alternatively, 
TEE/vfFFM(kg)89• 
Across the sampling periods there were no incidences of vomiting or diarrhoea, 
which could have potentially influenced the results. No change was observed in TEE 
as a consequence of undertaking a PBST. However, TEE significantly increased 
(p<O.Ol) by three months post-PBST. Results for TEE at Pill was also significantly 
higher (p<O.Ol) than that measured at PI. 
Figure 4.3 Changes in TEE for four subjects in the exercise group across the 
testing phases (TEE at each phase for each subject) 
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A Pearson correlation performed on %BF data Table 4.5) recorded by the use of 
skinfolds and SL W demonstrated that the two techniques were significantly related 
(R=0.885; p=O.OOO). 
Table 4.5 Pearson correlation of percentage body fat techniques 
%BF(SLW) 29.9 9.5 
** p<O.Ol 
However, the skinfold technique consistently recorded significantly lower values for 
%BF, when compared with the values recorded using SLW. Thus, a high correlation 
does not necessarily mean agreement between the two methods. In order to calculate 
the agreement between the two methods the Bland Altman technique was 
employed40. Figure 4.4 illustrates that the limits of agreement lie between 21.56% 
and -30.26%. 
Figure 4.4 Bland Altman Plot displaying the limits of agreement between the 
skinfold and SL W technique 
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Table 4.6 displays the change in the frequency of food group consumption per day 
following a PBST and a three-month intervention period post-transplant. Data 
collected from the entire study group (SG) is presented for PI and PII, while Pili data 
has been presented for both the control and exercising group. No statistical 
procedure was employed to analyse the changes in the frequency of food group 
consumption per day, across the phases. 
Undertaking a PBST was associated with a reduction in the number of patients who 
reported eating more than one serving of each food type assessed (vegetables: PI=5 
patients, 72%; PII=6 patients, 50%; fruit: PI=4 patients, 57%; PII=5 patients, 42%; 
bread: PI=7 patients, 1 00%; PII=8 patients, 67%; dairy products: PI=6 patients, 89%; 
PII=5 patients, 42%; and meat: PI=5 patients, 72%; PII=3 patients, 25%). Fewer 
patients were also snacking and consuming fluids. By three-months post-transplant, 
patients in both the control and exercising group demonstrated an increase in the 
number of food servings ingested per day. In the CG, 80%, 40%, 80%, 60%, and 
40% of patients ate greater than one serving of vegetable, fruit, bread, dairy and meat 
products, respectively, per day. In the EG, 83%, 66%, 88%, 83% and 33% of 
patients ate more than one serving of vegetable, fruit, bread, dairy and meat products 
per day. 
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Table 4.6 The number of patients consuming a certain quantity of major food 
group servings per day over the past week 
Group and 
Phases 
Number of patients within the 
number of ~,r,.,in<~~ 
>2 1-2 
servings/ 
SGPI 7 3 
SG PII 12 1 
CG Pili 5 3 
EG Pili 6 4 
servings/ 
4 
8 
2 
2 
who have consumed a certain 
week 
Rarely 
3 
SG = study group; CG control group; EG = exercise group 
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4.4 Discussion 
The results of this investigation demonstrated that TEE and body composition altered 
following a PBST and participation in a three-month exercise intervention program. 
Adverse changes in body composition were associated with a PBST, as was evident 
by the losses observed in both BW and FFM at PII. Only those patients who 
participated in the exercise intervention were able to regain FFM by three months 
post-transplant. While participation in the exercise program increased TEE to levels 
higher than that experienced pre-transplant, body composition was not adversely 
influenced. 
4.4.1 Body composition and total energy expenditure 
Significant fluctuations in body weight experienced by the study group highlighted 
the presence of an energy imbalance between PI and PII. The TEE recorded from 
four patients during this same period decreased, however the reduction was not 
significant. Three months post-treatment, body weight remained significantly lower 
than pre-transplant levels. During this same period, TEE recorded by PHI had 
significantly increased and was statistically higher than pre-transplant levels. 
Similar changes in TEE identified here were also found by the use of the labelled 
bicarbonate-urea technique in small cell lung cancer patients177 . Following 
treatment, TEE decreased as a consequence of an elevation in REE in conjunction 
with a decrease in spontaneous activity, when compared to matched controls. 
Through the use of heart rate recordings, TEE and physical activity levels have also 
been assessed in long-term survivors of childhood malignancies410 . Reductions in 
TEE, when compared with healthy siblings and as explained by reduced patterns of 
physical activity, were found. This continued decline in TEE adversely influenced 
body composition. Taken together, the results indicated that unless patients actively 
work towards readjusting TEE following cancer treatment, the energy imbalance has 
the potential to produce longer-term adverse consequences. In contrast to the 
reduction in TEE observed following treatment, an increase in TEE has also been 
reported following radiation and chemotherapy treatment for breast cancer201 . 
However, these increases were considered 'slight and insignificant'. 
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While a relationship between REE and FFM has been previously shown, with the 
results indicating that the lower the FFM, the lower the REE195, studies of patients 
with unresectable pancreatic cancer have shown that body weight losses can also 
occur in the presence of increases in REE 115• Therefore, although patients in this 
investigation showed a reduction in body weight and FFM following the PBST, it 
cannot be assumed that REE also declined. Decreases in REE are not consistent 
findings, with the literature reporting increased, decreased and normal states 
following cancer treatment. Factors including the type of tumour, the type of 
treatment and the intensity of treatment50, as well as changes in BW and FFM331 
maintain the potential to influence changes in REE measured in patients with cancer. 
As previously noted, limited data are available that directly assess the TEF in cancer 
patients. Yet many studies maintain the assumption that the TEF accounts for 10% 
of the TEE. Unforturlately, when dealing with the cancer population, this assumption 
may be violated as conventional treatment regimes may lead to the presence of side 
effects including mucositis, nausea, vomiting and diarrhoea. The presence of these 
side effects has the potential to alter food intake and thus TEF. Patients who have 
undergone a PBST are commonly readmitted to hospital following the procedure due 
to the presence of mucositis and the need for pain relief. Informal interviews with 
patients during the treatment period highlighted the adverse effect of treatment on 
appetite and food intake. This was further supported by the responses to the food 
frequency questionnaire. The results demonstrated a reduction in the percentage of 
patients who reported eating more than one serving of each food type assessed, 
between PI and PII (vegetables: PI=72%, PII=50%; fruit: PI=57%, PII=42%; bread: 
PI=l 00%, PII=67%; dairy products: PI=89%, PII=42%; and meat: PI=72%, 
PII=25%). Fewer patients were also snacking and consuming fluids. The declines 
were unfortunately greater in food types that yield a higher energy value such as 
bread, dairy and meat products when compared with food groups yielding a lower 
energy value, such as vegetables and fruit. The number of patients consuming more 
than one serving per day of bread, dairy and meat products decreased by 33%, 47% 
and 47%, respectively. In contrast, the number of subjects consuming more than one 
serving/day of vegetable and fruit decreased by 22% and 15%, respectively. The 
observed reduction in the number of servings of food per day would have 
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implications on both the TEF and energy balance, and be an accounting factor for the 
decrease in BW observed at PII. 
Recommendations have been made for energy intake requirements during treatment. 
However, given the lack of evidence with regard to changes in TEE as a consequence 
of treatment, these recommendations are difficult to support. It is crucial to 
determine how treatment effects TEE, before it is possible to comment on the energy 
requirements during this treatment period. The results presented by this investigation 
demonstrate that no significant change in TEE occurs following a PBST. 
Consequently, the energy intake requirements during the treatment process should 
also not change. 
By Pili, patients in both the control and exercising group demonstrated increases in 
the number of food servings ingested per day. In the CG, 80%, 40%, 80%, 60%, and 
40% of patients ate more than one serving of vegetable, fruit, bread, dairy and meat 
products, respectively, per day. In contrast, the EG demonstrated a slightly higher 
percentage of patients eating more than one serving of vegetable, fruit, bread, and 
dairy products per day .(83%, 66%, 88%, and 83%), with the exception of meat 
product consumption (33%). While the exercising subjects demonstrated a higher 
serving consumption for the majority of the food groups assessed, this was m 
conjunction with positive body composition changes, as will be discussed later. It 
seems evident that participation in an exercise program has a positive result on 
appetite and energy intake. It also seems plausible to suggest that the elevation in 
energy intake observed by an increase in the number of servings consumed would 
lead to an elevation in the TEF, accounting for a small portion of the increase 
observed in TEE by PHI. 
While participation in physical activity may have a positive influence on total energy 
intake, the type of foods consumed could be improved. In the exercising group, 83% 
and 67% of subjects consumed less than the Australian daily recommendations for 
the number of servings for vegetables and fruit407 . Fifty per cent of patients in the 
EG also failed to include an appropriate number of bread and cereal product servings 
per day in their diet, while 84% of patients needed to include a greater number of 
dairy products. An evaluation of the data collected from the CG provided similar 
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results. This work supports previous findings which were based on responses to a 
'health behaviour and readiness to pursue life-style changes' questionnaire95 . The 
results from the survey highlighted that 55% of cancer respondents ate fewer than 
five daily servings of fruit and vegetables per dal5, with prostate cancer respondents 
eating significantly fewer servings when compared with breast cancer patients. 
While a correction in EI following treatment is considered important and beneficial 
for cancer patients, it is crucial to begin to further investigate the influence of long-
term changes in EI, in conjunction withEE alterations. A significant increase in EI 
relative to REE was observed in lung cancer patients at twelve months post-
treatment123. The elevation in the EIIREE ratio led to a positive energy balance and 
in turn, an average gain of 3.8kg in FM. Future research should attempt to determine 
whether EI corrections are matched with EE corrections. The following data on 
energy expended via physical activity indicates that a correction in TEE is unlikely 
without any structured intervention. 
Although the extent of the data regarding the energy expended on physical activity 
during or following cancer treatment is limited, a decline in energy spent on this 
component of TEE has been observed95' 177 . The PBST hospitalisation period can 
last up to one month, with patients spending the majority of this time in a supine 
position. For those patients undergoing more than one transplant, the inpatient 
period is increased and thus the period of reduced physical activity is further 
prolonged. During the inpatient period, 'bed' or 'hallway' exercises are needed to 
maintain the energy spent on physical activity. However, it is not common practice 
to prescribe exercise to PBST patients in the hospital setting, and unless the patient 
has an intrinsic motivation to maintain physical activity, energy spent on physical 
activity during the treatment period is likely to decline. Unfortunately, it could be 
suggested that many carers and even health professionals see this drop in physical 
activity as crucial in maintaining an energy balance. When patients are experiencing 
an 'unwanted' weight loss during treatment, and with participation in physical 
activity related to an increase in energy expenditure, activity may therefore seem 
contraindicated. However, evidence provided by this investigation contradicts these 
beliefs. 
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The primary aim of implementing an exercise program in the rehabilitation phase of 
cancer patients is to facilitate recovery and thus allow the patient to perform normal 
daily activities without undue fatigue. It has previously been reported that TEE is 
'robust' and can remain relatively stable when challenged by such stimuli as an 
exercise intervention 142' 177• This lack of net TEE change is considered a 
consequence of one component of TEE compensating for changes in another. For 
example, given that an exercise intervention causes an increase in the energy spent 
on physical activity, people may correspondingly decrease the energy spent on daily 
tasks and spend more time during the day 'resting'. This would be considered an 
adverse consequence of physical activity in the cancer population given the objective 
of an exercise intervention. It was identified in this investigation that TEE did not 
remain stable, but was higher at Pili when compared with PI. These data suggest 
that the patients were able to maintain their participation in normal daily tasks, in 
conjunction with expending additional energy during their exercise sessions. 
The reduction in BW observed by PII indicated the presence of a negative energy 
imbalance during the period of PI to PII. Since there was no statistically significant 
change in TEE during this period and given the mean change was in the negative 
direction, EI must have substantially decreased between PI and PII. Unfortunately, 
the significant drop observed in BW (p<0.05) can be characterised by a 
disproportionate loss of FFM, as indicated by an insignificant loss in FM, in 
conjunction with a 6% significant decline in FFM (p<0.05). As can be seen in 
Figures 4.2e, · all 7 patients investigated between PI and PII demonstrated a loss of 
lean tissue. The decline in functional tissue observed in this investigation supports 
previous findings demonstrating that children between the ages of 1.3-17.1 years 
experienced an 11% reduction in muscle protein reserves during the first month post-
autologous or allogeneic BMT385 . 
A similar disproportionate loss of FFM observed in the PBST patients within this 
research, has consistently been shown in studies investigating body composition 
changes in HN patients252 . However, evidence within the cancer population is 
inconsistent. Data derived from the cancer population has shown equal FM and FFM 
losses390, greater FM losses when compared with FFM losses274 and greater FFM 
losses when compared with FM losses177 . FFM losses have also been demonstrated 
97 
Chapter Four, Study One 
in patients who are gaining weight201 ' 385 • However, of relevance to all findings is 
that BW changes can be at least partly accounted for by FFM losses, or in simple 
terms, functional tissue losses. These are the losses that are clinically important to 
prevent, minimise and/ or correct. 
Significant improvements in body composition were evident by Pili for the exercise 
group, with all 6 patients gaining lean tissue. While body weight remained stable 
between PII and Pili, percentage BF declined (p<0.05) in conjunction with an 
increase in FFM (p<0.05). The subjects in the EG at Pili maintained an average 
%BF of 29.5±.1.6%, and therefore the loss in FM observed by PHI was neither 
detrimental to their energy reserves or their health. In summary, participation in the 
exercise program was associated with an elevation in TEE, weight and functional 
tissue, and a decrease in non-functional tissue. By contrast, the adverse changes in 
body composition experienced by the patients in the CG as a consequence of 
treatment were not corrected by three-months post-transplant. The data suggest that 
unless patients participate in a regular exercise program, body composition will 
continue to deteriorate and therefore adversely influence functional capacity. This 
statement can be supported by the failure to regain lost FFM, with a concomitant 
mean increase in FM observed by PHI in the non-exercising patients. Additionally, 1 
out of 5 patients in the control group, assessed at PHI, demonstrated a further loss of 
functional tissue by 3-months post-transplant. The adverse change in FFM of this 
subject highlighted the risk for continued declines in functional tissue following 
treatment cessation. 
Investigations involving breast cancer patients have also shown improvements in 
body composition through the use of an exercise intervention. Breast cancer patients 
have shown weight stabilisation226, and/or %BF improvements in conjunction with 
mcreases in FFM, even when BW increases428, through participation in aerobic 
exercise. 
The patient population studied in this investigation could be considered as 
overweight, as shown by BMI (mean = 31.85) or %BF (mean = 27.65) at PI. 
Therefore, for many patients, a loss in %BF as a consequence of the treatment might 
be considered beneficial. The continued loss in %BF demonstrated by the EG by 
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PHI might also be considered advantageous. However, it is a crucial factor for all 
patients, whether they were classified as overweight or underweight, that a loss of 
FFM at any stage is detrimental to functional capacity and quality of life. 
Unfortunately, if body weight changes are the only factor assessed across time, 
patients, carers and health professionals could falsely perceive the body weight 
changes as positive. Unless body composition is assessed during the treatment and 
rehabilitation phases of cancer patients, it is difficult to comment on whether body 
weight changes are ofbenefit or detriment to the patient. It is therefore important to 
begin to find appropriate clinical procedures that can be implemented to assess body 
composition, rather than just body weight. Consequently, this study assessed body 
composition via the skinfold technique and deuterium dilution method. 
The calculation of %BF via the use of skinfolds was highly correlated with that of 
deuterium dilution (R=0.89, p<O.Ol). Unfortunately, a high correlation does not 
indicate agreement between the two methods. A significant difference (p<O.Ol) 
existed between the two assessment techniques, with the skinfold method 
consistently underestimating %BF when compared with the deuterium dilution 
method. Since neither of the techniques should be considered more accurate when 
compared with the other, it could also be said that the deuterium dilution technique 
consistently overestimated %BF when compared with the skinfold technique. 
Furthermore, the limits of agreement were calculated between -30.26% and 
+21.56%, which is clinically unacceptable. Nevertheless, both techniques are able to 
detect changes across time, and the value of this information should not be 
underestimated. While limitations exist for both techniques and either or both of the 
techniques may not be accurate, they are repeatable and therefore could be used in 
clinical practice. It seems plausible that the availability and cost associated with the 
skinfold technique might make its application within the clinical setting more 
appropriate 
4.4.2 Limitations of research and directions for future research 
This investigation provides important information regarding changes in the TEE and 
body composition of cancer patients across the cancer continuum. However, to 
confirm the results derived from this investigation, more work is required with 
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additional subject numbers. Further, research should begin to examine changes in 
the energy expended on the specific components of TEE including REE, TEF and the 
energy cost of physical activity. Recommendations for food intake and participation 
in physical activity during treatment and recovery periods will continue to be limited 
until more research is performed within the area. 
Finally, as previously mentioned, a number of factors such as hydration and 
potassium concentration changes may influence the accuracy of calculating %BF by 
using conventional methods. Therefore, further studies are required before %BF 
calculations derived from techniques such as the use of skinfolds or singly labeled 
water are considered accurate. Nevertheless the repeatability of these techniques has 
been demonstrated and therefore, changes in body composition measured by these 
techniques, either as a result of treatment or an intervention, can be considered 
accurate. 
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4.5 Conclusion 
Undergoing a PBST led to adverse changes in body weight and fat free mass. While 
the change in body weight highlighted an energy imbalance during the treatment 
period, the results of this investigation demonstrated that changes in EI were the 
likely cause of the imbalance rather than changes in TEE. The adverse changes in 
body composition associated with the treatment were maintained by the CG during 
the three month recovery period. In comparison, the EG demonstrated that 
participation in the regular aerobic and resistance training program led to 
improvements in body composition, specifically elevations in FFM. Exercise has a 
functionally important role in preserving and increasing skeletal mass in the 
rehabilitation phase of cancer patients. The results also indicated that while 
participation in the exercise program led to a significant increase in TEE, this was 
not at the expense of lean tissue. Physical activity is an important rehabilitation 
strategy that can be used to increase the functional tissue of cancer patients following 
treatment. 
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Changes in aerobic capacity and muscular 
strength following a PBST and participation in 
• an exercise program 
" .... if patients can sit in a chair, do not let them lie in bed; if they can 
walk, do not let them sit" Winningham (1991/25 
Chapter Five, Study Two 
List of abbreviations specific to Chapter five 
ATP 
BMT 
BP 
BW 
CG 
ECG 
EG 
FFM 
HR 
MET 
PBST 
PI 
PII 
Pili 
RER 
SG 
VAS 
VE 
V02 max 
WAIT 
Adenosine triphosphate 
Bone marrow transplant 
Blood pressure 
Body weight 
Control group 
Electrocardiography 
Exercise group 
Fat free mass 
Heart rate 
Metabolic equivalents 
Peripheral blood stem cell transplant 
Phase I 
Phase II 
Phase III 
Respiratory exchange ratio 
Study group 
Visual analogue scale 
Ventilation 
Aerobic capacity 
Winningham aerobic interval training protocol 
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5. Changes in aerobic capacity and muscular strength following a 
PBST and participation in an exercise program 
5.0 Introduction 
Cancer, and its associated treatment and sedentary condition, induces a number of 
adverse physical and functional effects on patients. Interestingly, findings as early as 
1978 estimated that at least one third of the functional decline observed in cancer 
patients, can be attributed to hypokinetic conditions that develop as a result of 
prolonged inactivitl27 . The adverse physical conditions may include diminished 
cardiovascular function, reduced lean body tissue and muscular strength, impaired 
pulmonary function and weight changes77• These detrimental changes lead to a 
reduction in work capacity, and in turn, patients require a greater degree of effort to 
perform any given task. It is therefore not surprising to find that tiredness and 
fatigue are associated with performing normal daily activities105 following cancer 
treatment. 
To avoid fatigue, patients may decrease their level of activity, and thereby induce 
further muscular and cardiorespiratory losses. Unfortunately, the creation of a self-
perpetuating condition of 'diminished activity which leads to easy fatigability and 
vice versa', is not uncommon 105• General progressive debilitation not only fosters 
the sense of disability, but also elevates the risk of injury and excessive fatigue for 
those individuals who attempt physical activitl26 . It is therefore of primary 
importance to determine the level of physical activity that promotes functional 
capacity recovery, without the negative consequences of fatigue, muscular weakness 
and injurl26 . 
Of specific relevance to this investigation is the physical status of PBST patients. 
Reduced physical performance and fatigue constitute universal concerns for BMT 
patients101 . Following hospital discharge, the majority of patients find it difficult to 
undertake normal daily tasks and it may take patients months to years to regain their 
pre-treatment fitness level105 • It has been estimated that 40% of BMT patients 
require a full year for recovery of physical functioning, while approximately 30% of 
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patients are unable to return to work during the first two years following BMT105 • In 
addition, feelings of tiredness, weakness and compromised ability to engage in 
vigorous physical activity have been reported in 78%, 42% and 76% of patients, 
respectively13 . 
5.0.1 Purpose 
Objective 1: To investigate changes between pre- and post-PBST measures of . 
aerobic capacity and muscular strength. 
Research hypothesis for objective 1: 
Aerobic capacity and muscular strength will be adversely affected following a 
PBST (as determined by pre- and post-transplant measures). 
Objective 2: To investigate the role of a three-month duration, moderate intensity, 
mixed type exercise program on aerobic capacity and muscular strength, post-PBST. 
Research hypothesis for objective 2: 
Exercising PBST patients will demonstrate a faster recovery of aerobic capacity 
and muscular strength during the three-month post-.transplant period, when 
compared with control patients (as determined by pre- and post-intervention 
measurement). 
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5.1 Literature Review 
The following review of the literature outlines the cardiovascular, pulmonary and 
muscular changes that are induced by cancer and its associated treatments, and the 
role of exercise in correcting these adverse consequences. 
Cancer patients are often deconditioned as a result of their surgery and prolonged 
medical therapl29• However, in addition to the adverse changes in aerobic capacity 
associated with cancer and treatment, is the impact of prolonged inactivity. 
Inactivity leads to a reduction in the oxidative capacity of skeletal muscle. 
Consequently, more oxygen is required by deconditioned skeletal muscle for the 
performance of comparable work, when compared with conditioned muscles, which 
in turn contributes to fatigue and reduced endurance227 . Additionally, orthostatic 
intolerance, ataxia, reduction in stroke rate and increased pulse rate are well 
documented consequences of prolonged inactivity, influencing aerobic capacity161 . 
Aerobic capacity is influenced by the ability to utilise and metabolise carbohydrates 
and fats to resynthesise adenosine triphosphate (ATP) for energy. The synthesis of 
ATP for sustained activity is dependent on oxygen, and thus oxygen uptake and 
delivery must match the demand of the working muscles. This relies on an effective 
integrated response of the cardiovascular and pulmonary systems, as well as the 
oxygen-extraction ability of muscle cells. Disease and treatment have the potential 
to inhibit the oxygen transport system at any one of several points. However, all 
points are compromised in a deconditioned state226• 
A number of side effects from cancer and its associated treatment also maintain the 
potential to adversely influence pulmonary capacity41 ' 413 . Common abnormalities 
identified by pulmonary function testing include a reduction in inspiratory and 
expiratory lung volumes such as forced vital capacity, an elevation in arterial carbon 
dioxide and a reduction in arterial oxygen levels. 
Intrapulmonary inflammation may occur as a consequence of radiation, and result in 
alveolar wall thickening in response to an increased release of surfactant. A further 
chronic reaction to treatment such as radiation exposure to the lungs, is pulmonary 
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fibrosis, where the fibrosis may develop as a result of the healing process of 
pneumonitis. The process of fibrosis consists of collagen replacing the alveolar 
membrane, thus impairing gas exchange and compliance, with an increase in 
physiologic dead space. Other pulmonary side effects include pulmonary oedema 
and respiratory distress, which are potentially caused via changes in capillary 
permeability and an increase in interstitial lung water241 ' 413 . Finally, breathlessness 
is experienced by approximately 30% of advanced cancer patients, and is often 
described as the "subjective sensation of an uncomfortable awareness of breathing or 
difficult breathing"75. The effects of breathlessness have the potential to be 
extensive, adversely influencing quality of life, since they directly impact on the 
patient's ability to perform daily activities. Breathlessness can severely limit 
mobility, while intensifying feelings of anxiety, isolation and fear. 
In addition to the cardiovascular and cardiopulmonary effects induced by cancer, 
treatment and related inactivity, are changes to body composition and muscular 
strength121 ' 161 • Inadequate nutrition and protein intake during cancer treatment have 
the potential to exacerbate lean tissue losses, while side effects of therapy can 
contribute to excessive weight gains or losses. Drug therapy such as steroids may 
lead to myopathy and significant muscle atrophy, and peripheral neuropathies 
including sensory disturbances and weaknesses may be associated with the use of 
certain chemotherapeutic drugs such as vincristine and cisplatin. Interruption to 
nerves or muscles directly from the location of the tumour or alternately during 
surgical removal of the tumour, may also contribute to muscle strength losses. 
Finally, one of the earliest and most frequent decrements of inactivity occurs in the 
musculoskeletal system 121 , with muscle atrophy and decreases in muscular strength 
and endurance caused by unloading being widely recognised297' 429. 
Maintenance of adequate muscular performance is an essential consideration for the 
capacity of individuals to independently perform daily tasks 52. Every coordinated 
movement requires the application of muscular force, and the ability to produce this 
force is reflected by muscular strength. In order to move the body, the muscles must 
generate enough force to mobilise the bones, with the development of force being 
dependent on the number of motor units activated, type of motor units activated, 
initial muscular length upon activation, muscular size, joint angle, and the muscle's 
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speed of action422 . The force that an individual can apply to a task to produce work 
has also been explained as the ability to generate power435 • The greater the power 
generated, the more work able to be performed. As a consequence of muscular 
impairment due to injury or bed rest, the capacity to generate power is diminished, 
and is interpreted as 'loss of strength'. It has long been known that significant 
muscle atrophy and a corresponding loss of strength of approximately 3% per day, 
can occur within the first week of bed rest160. Thereafter, deterioration continues at a 
rate of strength loss of 1-1.5% per day45 . 
Finally, cancer, treatment and inactivity can influence the physical status of patients 
through the side effects imposed on mobility. Mobility or flexibility are terms used 
interchangeably to describe the ability to move a joint through a range of motion and 
is dependent on the distensibility of the joint capsule, muscle temperature and 
viscosity, flexibility of ligaments, gender, age, activity level, immobilisation and 
body type3' 338 . Mobility contributes to total fitness since maintaining a functional 
range of motion at all joints of the musculoskeletal system is important to efficient 
body movement5. 
Compression of a nerve plexus or peripheral nerves, or interruption to the 
neuromuscular system as a result of ·cancer or certain treatment regimens, may 
adversely affect range of motion and thus the ability to perform daily activities161 . 
For example, increased stiffuess in periarticular structures and a reduction in 
cartilage integrity are likely to occur when a patient undergoes prolonged rest in a 
cast. Radiotherapy, or radiotherapy in conjunction with chemotherapy maintains the 
potential to contribute to the presence of joint contractures. Additionally, patients 
who experience pain in certain positions may try to assume the most comfortable 
position. In turn, this may foster the development of flexion contractures and 
adversely affect range of motion. 
Inactivity can further exacerbate range of motion limitations caused by cancer and 
treatment. With prolonged inactivity, joint mobility is reduced by an increase in the 
density of supportive collagen tissues surrounding the joint428 . Contractures caused 
by the shortening of soft tissue structures surrounding a joint, in association with 
weakened muscles, further minimise flexibility26 . 
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5.1.1 Physical status of cancer patients 
Evidence supports the notion that cancer diagnosis, treatment and inactivity lead to a 
reduction in aerobic capacity and muscular strength. The initial exercise capacity of 
the cancer patient is within a range of 3-6 metabolic equivalents (MET) (i.e. 10.5-
20.5 ml/kg/min)3 . This range was derived from investigations assessing patients with 
breast cancer who had undertaken conventional treatment regimens. However, more 
recent published work investigating BMT patients, has shown that the initial exercise 
capacity of patients being treated with more intensive regimes also falls within this 
range. Maximal MET values of 4.7±1.2 were reported on average 30 days following 
a BMT procedure101 . 
While few studies exist that have assessed physical status immediately following 
cancer treatment, information regarding the cardiovascular and musculoskeletal 
status of patients can be found in work assessing patients who are considered long-
term survivors of cancer. Forty-three per cent of patients who had received 
anthracycline therapy for acute lymphoblastic leukaemia (ALL) demonstrated 
abnormalities during exercise testing which limited their starnina175. Twenty-five per 
cent and thirty-one per cent oflong-term survivors (1.5-16 years) of acute leukaemia 
failed to attain normal maximal aerobic capacity, and normal anaerobic threshold, 
respectivell8. An earlier investigation also found that children treated for ALL have 
a reduced maximal exercise capacity180, with the etiology of the results thought to be 
a combination of the effect of treatment modalities and low participation rates in 
physical activity. Moreover, psychological testing demonstrated that children treated 
for leukaemia perceive their exercise capacity as limited and therefore avoid exercise 
participation58 . 
Musculoskeletal disorders and gross motor disabilities have also been reported in 
children with ALL 440 . While the majority of children were able to perform basic 
motor skills, their levels of gross motor proficiency and performance on selected 
measures of musculoskeletal function were significantly poorer than those of school-
matched peers. In addition, reduced muscle strength, weakness and progressive 
osteopenia relating to poorer bone integrity was further identified. 
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Limited research involving long-term survivors of patients who have undergone a 
BMT exists. Sixty-three patients who had undergone a BMT, aged 18 years or less, 
were assessed to determine cardiac function and the prevalence of cardiac 
abnormalities, at one year post-transplant109. Forty-one per cent of patients had a 
cardiac abnormality with 21 out of 26 patients demonstrating the abnormality pre-
transplant. Furthermore, 16.4% showed abnormal resting electrocardiographs, three 
patients illustrated decreased left ventricular ejection fraction, and 23 out of 31 
patients who underwent an exercise test demonstrated a borderline or abnormal 
response. 
More recently, a long-term follow-up study assessing cardiopulmonary function and 
recovery was performed on 33 patients who had undergone a BMT between 1979 
and 1994166• While no significant episodes of arrhythmia or electrocardiographic 
evidence of ischaemia occurred during exercise testing, maximal cardiac index failed 
to improve over a median follow-up time of six years following BMT. This finding 
is indicative of a persistent impairment of the cardiovascular response to the 
metabolic demand of exercise. Subclinical cardiac dysfunction was also evident as a 
result of the combination of a low cardiac index and a normal peak HR, which 
demonstrated a low stroke volume. Although cardiovascular function was impaired, 
there was no deterioration over time. In tum, this suggested that the myocardial 
injury following BMT is persistent, but not progressive. Additionally, aerobic 
capacity via the measurement of oxygen consumption at peak exercise and at the 
ventilatory threshold was assessed. The study confirmed that both maximal aerobic 
capacity and aerobic capacity at ventilatory threshold were decreased in BMT 
patients, when compared with age- and sex-matched healthy controls. The aerobic 
capacity at ventilatory threshold also failed to improve across the study period, 
indicating impaired oxygen delivery. 
In summary, the above research shows that patients who have been treated with 
either conventional or intensive regimens report substandard physical and 
psychosocial status. Therefore, given that BMT patients often undertake 
conventional treatment options prior to the transplant, it is possible that their poor 
post-BMT status is a function of previous treatment rather than the BMT. 
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Unfortunately, information regarding the physical status of BMT recipients prior to 
BMT is limited14. Consequently, this also influences the ability to determine the 
exact impact of the BMT on physical status. To investigate this issue a prospective 
study assessed 28 adult BMT recipients prior to BMT and then again at 12-16 
months post-BMT14. Comparisons of mean scores for various physical and 
psychosocial status indices demonstrated few significant differences between pre-
and twelve month post-BMT scores. However, this was based on group findings and 
when individual results were considered, it became evident that many patients were 
unable to return to pre-BMT levels within the twelve-month period. The individual 
findings were of particular relevance to the older patients, indicating that the older 
the patient, the poorer post-BMT status. 
Research findings clearly demonstrate that the physical status of patients with cancer 
is adversely affected following conventional treatment or intensive treatment such as 
a BMT. Additionally, patients may remain at lower than 'normal' functioning levels 
for many years post-treatment. Bone marrow transplant patients are at risk of 
experiencing poor physical status prior to the BMT regimen, potentially due to the 
conventional treatment already undertaken. 
5.1.2 Fatigue 
The cardiorespiratory and musculoskeletal losses observed as a consequence of 
cancer, treatment and inactivity, have been regarded as substantial contributors430 , if 
not the primary causes104 of other common side effects, such as fatigue. Fatigue is 
one of the most common and pervasive physiological consequences associated with 
cancer, and is reported in 40-100% of patients343 . For certain diagnoses, 30-40% of 
patients may experience fatigue for years following treatment cessation367 . While the 
advent of new antiemetic regimens has advanced the management of symptoms such 
as nausea and vomiting, fatigue is one symptom that remains difficult to manage315 . 
Fatigue can be described as being multifactorial and multidimensional318 . There are 
biological, psychological, social and personal factors that have the potential to 
influence the onset, impact, expression, duration and severity of cancer-related 
fatigue318. Other potential fatigue mechanisms have been reported and include sleep 
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disturbances, biochemical changes secondary to disease and treatment, internal and 
external environmental conditions, activity levels, nutritional status and diverse 
inherent factors430. Fatigue can be initiated by radiation, surgery and chemotherapy, 
may increase over the course of treatment, and persist for months afterwards. 
Treatment-related fatigue is severe for many patients and imposes limitations on the 
ability to perform normal daily tasks105. Patients note that cancer treatment-related 
fatigue is very different from the fatigue often experienced prior to cancer diagnosis, 
as it is more intense, chronic, disruptive, and is unrelieved with rest342 • With the aim 
of reducing fatigue, physical activity levels are often down-regulated and the 
detrimental cycle of 'diminished activity which leads to easy fatigability and vice 
versa' is initiated105 . Eighty-four per cent of patients experiencing fatigue used 
resting and napping as a mechanism to overcome fatigue. However, one of the few 
tested interventions that has reliably demonstrated the ability to reduce fatigue levels 
in cancer patients is exercise246 . 
5.1.3 Aerobic exercise and cancer patients 
Given the low maximal METS experienced by patients following treatment, it is not 
surprising that participating in normal daily activities including walking, preparing 
meals, vacuuming and mowing, that have calculated MET values between 2.5-4.57, 
rapidly induce fatigue. These activities would require patients to work between 50-
100% of their maximal aerobic capacity. It therefore seems evident that if a patient's 
maximal aerobic capacity could be enhanced, their ability to function throughout the 
day would improve, and in tum quality of life would be positively influenced. 
Aerobic exercises including walking, cycling, swimming or any activity that uses 
large muscle groups have the potential to improve the oxidative capacity of skeletal 
muscles, stimulate the general adaptation of the aerobic biochemical system, and 
result in measurable increments of oxygen uptake227 . 
5.1.3.1 Aerobic exercise studies 
Exercising cancer patients have demonstrated improved work capacities, lower HR at 
a given power, increased maximum workloads and lengthened time to achieve peak 
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aerobic capacity (peak V02) when compared with non-exercising patient controls226' 
227
. Winningham and Mac Vicar (1988)427 further reported that exercising breast 
cancer patients demonstrated a 40% improvement in functional capacity after 
participating in a Winningham Aerobic Interval Training (WAIT) protocol, when 
compared with no significant change in the control and placebo groups. 
Additionally, following a ten week aerobic exercise intervention, patients with breast 
cancer experienced a 20.7% increase in V02 (1.37 -1.73 L/02), compared with a 
1.8% reduction in peak V02 (1.11 - 1.09 L/02) reported in non-exercising patients226 . 
The exercising cancer patients were also able to make comparable gains in functional 
capacity when compared with healthy age-matched exercising controls (where 
functional capacity increased by 17.4%). 
Mock and coworkers (1997i47 implemented a self-paced, progressive (20-30 
minutes) walking program for the duration of radiation treatment in breast cancer 
patients. Outcome measures evaluated included physical functioning (as assessed by 
the 12-minute walk test) and fatigue, anxiety, depression and difficulty sleeping. 
Eighty-six per cent of the experimental group maintained the active exercise program 
for the duration of the study. The exercise group was able to increase distance 
walked by 4% following treatment cessation, in contrast to the 5% decline 
demonstrated by the control group. While all participants reported fatigue as the 
most intense symptom, the exercise group experienced significantly lower levels of 
fatigue. Two of the most important findings derived from this research was that a 
self-paced walking program was tolerated by breast cancer patients, and that higher 
walking activity levels correlated with higher physical performance scores246 . 
A similar study involving women being treated for breast cancer provided supporting 
evidence343 . The intervention tested involved an eight week, home-based, low-to-
moderate intensity exercise program that allowed for a recovery period, and that 
accommodated individual cycles of chemotherapy by reducing the duration of 
exercise. Subjects were able to participate in any aerobic activity of their choice, 
given the exercise frequency was maintained at three to four times per week, for 
duration of 15-30 minutes. Participants who adopted the exercise program 
demonstrated a 10.4% increase in functional capacity as measured by the 12-minute 
walk test. In contrast, nonexercisers showed a 16% decline. Those women who 
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regularly exercised experienced less fatigue and increased vigour, in comparison to 
those women who did not exercise. However, it is important to note that this 
research also demonstrated a U-shaped relationship between high intensity and 
fatigue, whereby both nonexercisers and high-intensity or long-duration exercisers, 
reported elevated fatigue levels, in comparison to 'moderate' exercisers. 
Five patients diagnosed with var)'lng cancers and having undergone different 
treatment regimens, were recruited into an exercise intervention program on the basis 
of suffering from severe fatigue103• Fatigue for all five patients imposed significant 
limitations on daily activities, causing one patient to forgo school and another to 
leave university. The exercise intervention program implemented consisted of 
aerobic training on a treadmill for a period of six weeks, at an intensity relating to 
80±5% of maximum HR. Prior to participation in the study, these patients had been 
advised to seek periods of rest and to reduce their level of activity, in order to reduce 
their fatigue. The results of the investigation concluded that these well-meaning 
recommendations had worked paradoxically. Exercise could interrupt the 
detrimental cycle of lack of exercise, impaired performance and easy fatigability. 
By the end of the training program, subjects experienced improved physical 
performance as measured by distance walked, maximal METs, and HR and lactate 
levels at submaximal workloads. Feelings of fatigue also improved with two patients 
resuming studies, and the others able to participate in daily tasks without undue 
fatigue. 
Fourteen out of twenty patients undergoing either an allogeneic or autologous BMT 
were able to complete a six-week walking program101 • By the end of the training 
period, physical performance had increased for all fourteen patients, as was measured 
by training speed, maximal walking distance, maximal performance (measured via 
METs and km/hour walked), HR and lactate. Of clinical importance was the finding 
that all patients reached MET values high enough to perform tasks of daily living (as 
was classified as 5 METs ). The researchers commented that these physical gains led 
to improvements in emotional stability as was observed through an elevation in self-
confidence and reductions in depressed states. Additionally, no complications 
attributable to the training program occurred. Unfortunately, the interpretation of 
results was limited by the absence of a control group, and comments made on 
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emotional stability were subjective and not quantified via questionnaires. The 
investigation however, provided evidence illustrating that BMT patients can show 
improvements in functional capacity within weeks of discharge from the BMT unit. 
Promising results were also shown in an exercise intervention investigation 
performed with autologous BMT patients. Patients in the exercise group exhibited 
significant improvements in maximal performance following the completion of a six 
week, daily walking program, at 90% HRmax104• In contrast, 19% and 25% of the 
control group failed to show any improvements and were unable to reach MET 
values sufficient to perform daily activities, respectively. Additionally, 25% of the 
control group reported fatigue at the conclusion of the study and reported limitations 
in performing usual activities. These limitations were of no concern to the 
experimental group and only 6% of the exercise group failed to attain the minimum 
MET value. 
Finally, improvements in haemoglobin concentration, functional capacity, duration 
of neutropenia and thrombocytopenia, severity of diarrhoea and pain, and duration of 
hospitalisation have also been shown in exercising BMT patients80• 102• 104• 
5.1.4 Strength training and cancer patients 
While exercise intervention studies in cancer are relatively scarce, within the 
available studies, aerobic exercise has been given much of the attention. It is 
important to highlight that daily living activities repeatedly involve both isometric 
and isodynamic exercise404 • Therefore, it seems unreasonable to exclude resistance 
training from exercise programs prescribed for cancer patients. To date, no research 
could be identified that has implemented a resistance training program in the cancer 
population. Strength training prescription will therefore continue to be limited until 
such data are available. Pending further research, data from strength training 
intervention studies with other clinical populations may provide some insight to the 
potential benefits that participation in a strength training program could provide. 
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5.1.4.1 Strength training studies 
Improvements in muscular strength have been universally reported, following low to 
moderate isotonic, isokinetic and circuit resistive exercise training in the young, 
middle-aged, older individuals, and cardiac populations404• Studies performed with 
the 'healthy' population have shown that strength training maintains the potential to 
produce upper and lower body strength gains in the range of 20-50%, while studies 
recruiting the older population and cardiac population have demonstrated strength 
improvements between 9-227% and 20-40%, respectivell04• The wide range of 
strength gains is largely dependent upon the muscle groups studied and initial 
strength levels404• 
Assessing strength training intervention studies utilising HN patients may provide 
slightly more relevant information regarding the potential role of strength training for 
patients with cancer. An investigation with HIV -patients was conducted to study the 
effects on body composition of an anabolic steroid treatment in conjunction with a 
resistive exercise program. All study participants received the drug and were 
randomly assigned into either a progressive resistance exercise group or control 
group. The results showed that by the end of the first month, six control subjects 
gained 1.9% of entry weight, one subject lost weight, and two lost body cell mass. In 
contrast, seven subjects in the exercise group demonstrated a 3.2% increase of entry 
weight and no exercising subject demonstrated a body weight decline323 . In another 
HIV -1 study, significant gains were observed in muscular strength for the regions of 
the legs, chest, shoulder and arms following a six-week progressive resistance 
training program370• These patients at post-program experienced significantly higher 
levels of muscular strength when compared with the control group. Those in the 
control group, who performed no exercise during the six-week period, either showed 
no increase in muscle strength, or in some cases demonstrated losses. In addition, 
body weight and girth measures increased for the experimental group, while the 
control group showed significant decreases for these same variables. 
Improved cardiovascular and anthropometrical status has been shown in HIV -1 and 
AIDS patients following participation in both aerobic and strength exercises320. The 
experimental group participants demonstrated a 30% and 17% improvement in 
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muscular strength and cardiovascular and cardiorespiratory fitness (as measured by 
V02 peak), respectively, following a twelve-week program. In contrast, no changes 
were observed in the control participants for these measures. 
Lastly, an investigation studying the effects of an aerobic only, a strength training 
program only and a stretching control group on body composition and fitness was 
undertaken on HIV -1 males and demonstrated supporting evidence for the above 
studies222 . It was found that the aerobic-only group demonstrated the highest fitness 
changes, while the strength training group demonstrated the highest muscular 
strength gains. Both groups demonstrated losses in fat mass and gains in fat free 
mass, with the aerobic group illustrating the higher fat mass losses and the strength 
group higher fat free mass gains. While these results demonstrated the principle of 
training specificity, the results further illustrated that a certain level of 'crossover' 
can occur. Those in the aerobic group showed partial improvements in leg strength, 
and the weight training group showed partial improvements in cardiovascular fitness. 
Importantly, the results also demonstrated that inactivity is associated with 
physiological declines, as was evidenced by the decline in fitness and muscular 
strength seen in the control group. 
In summary, the results of the investigations involving HIV patients provide 
important evidence that supports the use of strength training to be used to correct or 
combat the wasting process of lean tissue, and thus the reduction in muscular 
strength, associated with disease and treatment. 
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5.2 Methodology 
Chapter 3 provided a detailed outline of the methodological procedures that relate to 
subject recruitment, the testing phases and the intervention program implemented. In 
summary, twelve patients, with six patients in each group were recruited. Of these, 
seven patients were recruited at PI, while the remaining subjects entered the 
investigation at PII. Outlined below are the methodological procedures that relate 
specifically to the aims of this section of the investigation and involve 
cardiorespiratory and muscular strength measures. 
5.2.1 Cardiorespiratory assessment 
Maximum oxygen consumption (V02 max) was assessed via a maximal graded 
treadmill exercise test (GXT). Originally, a testing protocol starting at a walking 
speed of 2.5 kmlh and a grade of 5%, with increments in speed and grade every two 
minutes was planned. However, on presentation of the subjects during the treadmill 
familiarisation session, it became clear that while this protocol was appropriate for 
some patients, for others it was either 'too hard' or 'too easy'. If this protocol were 
employed, some patients would have completed the test within five minutes while 
others would have required up to twenty minutes. It has been previously shown that 
incremental tests between 8-17 minutes are optimal when trying to measure V02 
max55 • In order to ensure patients reached their V02 max within this time span, it 
was evident that the treadmill protocol needed to be individually designed. 
Therefore, the treadmill speed began at a slower than 'normal' or 'comfortable' pace 
for each subject. The initial workload was set at a speed ranging between 1-4 kmlh 
and a grade of 0. Depending on HR and the Visual Analogue Scale (VAS) response, 
workload was increased every 1-2 minutes through the use of speed and/or grade. 
Details of the VAS have been provided in Appendix VI. 
For several patients (particularly those in the exercising group), a variation of the 
graded exercise test protocol employed at PI and PII was usually required for V02 
max assessment at Pill. This prevented comparison of HR and VAS at specific 
workloads, however it ensured that the time to reach V02 max was similar for all 
three testing phases. 
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Due to the predicted reduced fitness level of the patients and the lack of regular 
exercise participation during the prior months, only lower body stretches were 
performed during the warm-up. This was instead of the more common warm-up 
which involves a combination of aerobic exercise and stretching. For some patients, 
walking at the slowest available treadmill speed could induce fatigue. Therefore, to 
ensure that the patient was not fatigued prior to the test, and to maximise the ability 
to reach V02 max within the time period allocated, no warm-up was performed on 
the treadmill. Variables assessed throughout the test included gas analysis, 
e1ectrocardiography (ECG), HR, blood pressure and the VAS. 
A Quinton treadmill (Q65 Series 90), electrocardiogram (ECG - Q4500) and gas 
analysis machine (Q-Plex 1) were used to measure ECG, ventilation (VE), V02 
(mllkg/min), and the respiratory exchange ratio (RER). To configure the Q4500 for 
a GXT, an exercise test environment including the procedure and protocol to be 
implemented was established. Patient data and room conditions including dry 
temperature, barometric pressure, humidity and syringe volume (3L) were then 
entered and used for the calibration procedures. The Q-Plex 1 was calibrated using 
both high-cal (C02, 4.987±0.020% & 0 2, 18.14±0.02% in Nitrogen) and low-cal 
(C02, 3.986±0.020% & 0 2, 16.69±0.02% in Nitrogen) gas ranges and the volume 
and flow rates were calibrated with the use of a 3L calibration syringe (Hans Rudolf 
Inc. Model No. 5530). Following calibration, the patient was then prepared for the 
exercise test. 
During the familiarisation session, and once again prior to subject preparation for the 
exercise test, a thorough explanation of the testing procedure was given to the 
patient. At this time, the patient was also given instructions on how to assess their 
perceived effort using the VAS. Once the patient understood the process they were 
prepared for the testing procedure. This included preparation and placement of 
electrodes for ECG, followed by preparation for gas analysis and blood pressure (BP) 
assessment. Preparation for gas analysis involved attachment of the nose clip, 
mouthpiece and appropriate headgear. . Finally, the sphygmomanometer cuff was 
applied to the left arm in order to assess BP. In addition to the use of the VAS, the 
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patient was instructed to use hand signals including the 'thumbs up' or thumbs down' 
signal, to communicate feelings during the testing procedure. 
Medical supervision was present at all testing sessions, and ECG was continually 
monitored throughout the testing protocol. HR was measured and recorded every 
minute, while BP and VAS were assessed every two minutes. During the final stages 
of the test, a more regular assessment (every 30 seconds) of the VAS was performed. 
V02 max is classically defined as the greatest amount of oxygen that can be utilised 
under the most exhaustive exercise, and is traditionally measured as the point where 
oxygen consumption levels off even when work rates continue to rise. However, this 
measurement endpoint, known as plateauing, is no longer universally accepted for a 
number of reasons mentioned throughout the literature302 . Plateauing is also difficult 
to reproduce and is highly dependent on sampling methods. Therefore, several 
investigators have referred to the highest oxygen consumption attained for a given 
presumed maximum exercise effort as peak V02• The following criteria were 
implemented within this study to determine test cessation and peak VOz: 
~ when V02 reaches a plateau, that is, a rise in oxygen uptake of less than 
0.15L.min-1 or less than 2ml.kg-1.min-1 with an increase in power output 
~ if the subject grabs the handrails and is unable to maintain work output 
~ when the subject scores 10 on the VAS 
~ if the subject feels dizzy, has an unsteady gait, or expresses unusual sensations of 
discomfort 
~ if the RER is greater than 1.1 
~ loss ofECG monitoring or the occurrence of any serious ECG abnormality 
~ if systolic BP (SBP) is greater than 250mmHg and/or diastolic BP is greater than 
120mrn!Hg 
~ if SBP falls greater than 20mmHg with increased power output. 
On presentation of any of these criteria, the treadmill speed was reduced to a 
comfortable speed as judged by the patient, at a 0% grade. The nose clip and 
mouthpiece were removed, however continual recordings of HR, BP and ECG 
occurred until HR was below 1 OObpm. Peak V02 was measured in mVkg/min, and 
body weight (BW) and fat free mass (FFM) levels evaluated in Chapter 4 were used 
to express peak V02 in Llmin, and ml!FFM/min. 
120 
Chapter Five, Study Two 
5.2.2 Muscular strength assessment 
The strength measures were selected for this study on the basis of their relationship 
to normal functional tasks. It was concluded that both isometric and isodynamic 
assessments should be used since they are utilised repeatedly during daily tasks. · 
Therefore, the following tests were implemented to assess muscular strength: 
~ an isometric handgrip strength test - the prevalence of isometric tasks is greater 
for the hand than for any other biomechanical component435 , and is associated 
with tasks such as opening jars and bottles and turning on tight taps; 
~ 15 repetition maximum (RM) bench press- which assesses general upper body 
strength; and 
~ 15RM leg press test -which assesses general lower body strength. 
Strength usually refers to a maximum single muscular contraction and is sometimes 
assessed via a 1RM. However, assessing 1RM on a population which has 
experienced excessive strength losses or who may be at risk of low skeletal strength 
due to side effects of the disease and its associated treatment, may be 
contraindicated. When more than one contraction can be performed against a 
specific resistance, pure strength is no longer being assessed338 . However, an 
individual maintains good muscular strength when they possess good high resistive 
endurance338 . For this reason, assessing a 15RM has been regarded as a muscular 
strength test since an indication of strength status is provided. By having subjects 
use the greatest resistance possible to complete 15 repetitions, a low-repetition and 
high-resistance regimen was avoided and the risk of musculoskeletal injury reduced. 
The specific procedures implemented for the muscular strength tests are presented in 
Appendix VII. 
5.2.3 Statistical analysis 
Data for the peak ventilation, peak aerobic capacity, peak HR, peak RER and 
muscular strength were collected at each of the three testing phases and were 
analysed according to the statistical procedures outlined in Chapter 3. 
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Strength results were adjusted for changes in FFM as a consequence of the following 
statistical procedures. When strength values were correlated with FFM, a significant 
(p<0.05 for BP & HGR, and p<0.01 for LP) positive correlation (r = 0.402 - BP; 
0.372 - HGR; 0.505 - LP) was identified. Since the FFM of the subjects tested 
altered across the 3 testing phases, it was deemed crucial to appropriately adjust 
strength results with regard to these FFM fluctuations. Fat free mass changes across 
time were appropriately adjusted by dividing upper body (BP) and lower body (LP) 
strength values by FFM values. However, when this calculation was performed with 
handgrip (HGR) strength values, a second negative (R=-0.369, p<0.05) correlation 
for HGR/FFM and FFM was identified. In order to find an appropriate method of 
adjusting for FFM changes, HGR strength values and FFM values were log-
transformed and analysed by a linear regression91 • The linear regression coefficient 
was 0.761 and the standard error was 0.194. The coefficient in this case is the power 
to which FFM must be raised to completely adjust HGR for FFM. It should be noted 
that the coefficient was within 2 standard errors of either 0.5 or 1, demonstrating that 
the data can be adjusted by either dividing by FFM, which is in effect FFM1, or 
dividing by FFM(o.s). Given the data had already been calculated by dividing by 
FFM, results for HGR strength values were expressed as a ratio ofFFM. 
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5.3 Results 
Although 7 subjects were recruited at PI, equipment problems during one patient's 
testing session reduced the accuracy of the aerobic capacity data collected and the 
data was therefore not included in the analysis. As shown in Table 5.1, mean values 
for peak ventilation, aerobic capacity and strength were reduced following the 
transplant. However, differences between pre- and post-transplant data were only 
significant (p<0.05) for upper body strength. No change was evident in the mean 
peak HR and RER attained during the GXT tests. 
Table 5.1 Aerobic capacity and strength measures at PI and PII for the study 
group (mean±SE) 
Peak V02 (L/min) 1.97 0.13 1.73 0.08 0.135 
Peak V02 (mllkg/min) 23.71 1.25 21.76 0.79 0.211 
Peak V02 (ml/FFM/min) 35.85 2.40 33.20 1.50 0.367 
Peak HR (b/min) 165 3 164 2 0.725 
PeakRER 1.09 0.04 1.10 0.02 0.564 
Handgrip strength (Handgrip 
Right (units)/FFM(kg)) 0.81 0.07 0.76 0.05 0.47 
Upper body strength (log [Bench 
Press (kg)/FFM(kg)]) -0.46 0.06 -0.61 0.04 0.049* 
Lower body strength (Leg Press 
(kg)/FFM(kg)) 1.17 0.08 1.06 0.06 0.450 
n = 6 at PI for VE, V02, HR and RER data, and 7 at PI for strength data; n = 12 at PII 
* p<0.05 
The control group showed little change in peak ventilation, peak aerobic capacity and 
muscular strength across the three testing phases (Table 5.2). Only the change 
identified for peak aerobic capacity (L/min), between pre- and post-transplant, was 
significant. 
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Table 5.2 Aerobic capacity and strength measures across the testing phases for 
the control group (mean±SE) 
Peak VE (Limin) I 62.22 5.55 PI- PII 
II 64.15 3.46 PI- Pili 
III 61.91 3.97 PII- Pili 
Peak V02 (Limin) I 1.76 0.19 PI- PII 0.042* 
II 1.44 0.16 PI- PHI 0.182 
III 1.56 0.13 PII- PHI 0.290 
Peak V02 (mllkg/min) I 23.68 1.79 PI- PII 0.090 
II 20.13 1.11 PI- PHI 0.304 
III 21.53 1.28 PII- Pili 0.359 
Peak V02 (ml/FFM/min) I 35.68 3.42 PI- PII 0.147 
II 29.85 2.13 PI- PHI 0.397 
III 32.23 2.44 PII- Pili 0.431 
Peak HR (b/min) I 158 4 PI-PII 0.509 
II 155 3 PI- Pili 0.816 
III 157 3 PII- PHI 0.606 
PeakRER I 1.05 0.05 PI- PII 0.383 
II 1.10 0.03 PI- Pili 0.211 
III 1.15 0.04 PII- Pili 0.105 
Handgrip strength I 0.86 0.08 PI- PII 0.625 
Handgrip right II 0.79 0.05 PI- PHI 0.319 
(units)/FFM(kg) III 0.72 0.06 PII- PHI 0.442 
Upper body strength I -0.43 0.09 PI- PII 0.178 
log [Bench press II -0.61 0.06 PI- PHI 0.245 
(kg)/FFM(kg)] III -0.59 0.06 PII- PHI 0.882 
Lower body strength I 1.21 0.16 PI- PII 0.464 
Leg press (kg)/FFM(kg) II 1.03 0.10 PI- PHI 0.401 
III 0.98 0.12 PII- PHI 0.812 
n =PI- 3, PII- 6, Pili- 5 
* p<0.05 
The trend for change was similar for all measures assessed in the exercising group 
(Table 5.3), and demonstrated that participation in an exercise program led to 
significant improvements in peak ventilation (p<0.01), peak aerobic capacity 
(p<0.05) and upper and lower body strength (p<0.01). Additionally, results recorded 
following the 3-month intervention period were significantly higher than pre-
treatment levels, for peak aerobic capacity (Limin, p<0.05 and mllkg/min, p<0.01) 
and lower body strength (p<0.01). 
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Table 5.3 Aerobic capacity and strength measures across the testing phases for 
the exercise group (mean±SE) 
Peak VE (L/min) 
Peak V02 (Limin) 
Peak VOz (mllkg/min) 
Peak VOz (ml!FFM/min) 
Peak HR (b/min) 
PeakRER 
Handgrip strength 
Handgrip right 
(units)/FFM(kg) 
Upper body strength 
log [Bench press 
(kg)/FFM(kg)] 
Lower body strength 
Leg press (kg)/FFM(kg) 
n =PI- 3, PII- 6, Pili - 6 
* p<0.05, ** p<0.01 
I 80.08 5.47 PI- PII 0.874 
II 78.82 3.46 PI- PHI 0.012* 
III 105.82 3.46 PII- Pili 0.002** 
I 2.19 0.18 PI-PII 0.557 
II 2.02 0.16 PI- Pili 0.034* 
III 2.90 0.16 PII- Pili 0.004** 
I 23.73 1.76 PI- PII 0.885 
II 23.38 1.11 PI- Pili 0.007** 
III 32.55 1.11 PII- Pili 0.001** 
I 36.03 3.37 PI- PII 0.908 
II 36.55 2.13 PI- Pili 0.051 
III 46.37 2.13 PII- Pili 0.021 * 
I 172 4 PI- PII 0.884 
II 173 3 PI- Pili 0.808 
III 174 3 PII- Pili 0.898 
I 1.12 0.04 PI- Pli 0.767 
II 1.10 0.03 PI- Pili 0.417 
III 1.15 0.03 PII- Pili 0.683 
I 0.75 0.07 PI- PII 0.621 
II 0.72 0.05 PI- Pili 0.875 
III 0.76 0.05 PII- Pili 0.450 
I -0.49 0.17 PI-PII 0.181 
II -0.61 0.06 PI- Pili 0.068 
III -0.32 0.06 PII- Pili 0.003** 
I 1.12 0.13 PI- PII 0.897 
II 1.10 0.10 PI-Pili 0.001** 
III 1.81 0.10 PII- Pili 0.000** 
Figure 5.3a and b displays individual changes in aerobic capacity (mllkg/min) and 
muscular strength (lower body strength adjusted for FFM changes) across the testing 
phases, for subjects in the control and exercise group. With the exception of 1 
subject, the pattern and magnitude of change was similar for all subjects in these 
measures between PI and PII. By 3-months post-transplant, greater gains in aerobic 
capacity and muscular strength were evident in all 6 patients participating in the 
intervention program, when compared with the 5 subjects in the control group. In 
addition, all exercising subjects showed improvements, while subjects within the 
control group displayed slight mean gains, no change or mean losses in these 
measures. 
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Figure 5.3 Individual changes in peak aerobic capacity and lower body strength 
across the testing phases (PI, PII and Pili) 
(a) Peak aerobic capacity 
--- CG subjects EG subjects 
60~--------------------------------------------~ 
50 
40 
30 
20 
10 
04---------------~--------------~--------------~ 
PI PII Pili 
Testing Phases 
(b) Lower body strength 
,.-.. 
OJ) --- CG Subjects EG Subjects 
c 2.5 ~ 
f.;l:.; 
~ 2.0 ,.-.. 
OJ) 
~ 
'-" 
>£1 1.5 
OJ) 
~ 
Cl) 
.b 1.0 <J) 
;::..... 
"'tj 
0 0.5 ..0 
:..... 
Cl) 
~ 
0 0.0 
-
PI PII Pili 
Testing Phases 
126 
Chapter Five, Study Two 
As shown in Table 5.4, following the 3-month intervention period, the exercising 
patients recorded higher mean fitness and strength values than the patients in the 
control group, with the differences between peak ventilation (p<0.05) and lower 
body strength (p<0.01) being significant. 
Table 5.4 Aerobic capacity and strength measures at Pili for the control and 
exercise group (mean±SE) 
Peak VE (Limin) 62.04 25.71 105.82 33.29 0.040* 
Peak V02 (Limin) 1.57 0.86 2.90 1.22 0.072 
Peak V02 (mllkg/min) 21.58 7.59 32.55 13.07 0.133 
Peak V02 (ml/FFM/min) 31.88 11.48 46.37 16.74 0.090 
Handgrip Right (units)/FFM(kg) 0.72 0.27 0.76 0.18 0.749 
Bench Press (kg)/FFM(kg) 0.29 0.17 0.55 0.33 0.096 
Leg Press (kg)/FFM(kg) 0.94 0.38 1.81 0.40 0.005** 
* p<0.05, ** p<0.01 
The magnitude of change between Pil and Pili was calculated for the CG and EG, 
for all variables assessed and is illustrated in Figures 5 .4a, b and c. The magnitude of 
change is significantly larger for the EG when compared with the controls, for peak 
VE (p<0.01), peak V02 (Limin and ml/kg/min, p<0.05)) and upper (p<0.05) and 
lower body (p<0.01) strength. A mean negative change for peak VE, handgrip 
strength and lower body strength, was observed for the CG between Pil and PilL 
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Figure 5.4 Magnitude of change between PII & Pili for the control and exercise 
group (mean±SD) 
(a) 
(b) 
(c) 
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Handgrip strength and peak V02 data collected within the study were compared with 
Australian normative data144 (Figures 5.5 and 5.6, respectively). These comparisons 
demonstrated that pre-transplant, patients experienced lower mean aerobic capacity, 
and similar handgrip strength, when compared with age- and sex-matched healthy 
controls. Undertaking a PBST was associated with declines in aerobic capacity and 
muscular strength, and by PII the study group was experiencing a significantly lower 
aerobic capacity when compared with normative data. 
Figure 5.5 Comparisons ofhandgrip strength (average scores between right 
and left) between the control and exercise group, and age- and sex-matched healthy 
controls (mean±SD) 
I SG DND 
PI PII 
ND =age- and sex-matched data 
n (SG) =PI- 7, PH- 12 
n (PIH) = CG- 5, EG- 6 
ICGICGND IEGQEGND 
PHI 
Figure 5.6 Comparisons of peak aerobic capacity (mllkg/min) between the 
control and exercise group, and age- and sex-matched healthy controls (mean±SD) 
I SGffiND I CG I CGND li! EG ffiEGND 
PI PII 
ND =age- and sex-matched data 
n (SG) =PI- 6, PH- 12 
n (PHI)= CG- 5, EG- 6 
** p<0.01 
Pill 
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5.4 Discussion 
The results of this investigation indicated that pre-transplant, the aerobic capacity of 
PBST patients was below age- and sex-matched healthy controls. Additionally, 
undertaking a PBST was associated with further aerobic capacity decline. While the 
change between PI and PII scores was not significant, the magnitude of change was 
such that patients recorded significantly lower aerobic capacity scores when 
compared with age- and sex-matched data immediately post-transplant. Undertaking 
a PBST was also associated with detrimental changes in muscular strength, as was 
evident by the significant change in upper body strength between pre- and post-
transplant. Participation in a regular exercise program for 3-months post-transplant 
has the potential to significantly improve peak ventilation, aerobic capacity and 
upper- and lower-body strength. Exercising patients demonstrated improvements in 
peak ventilation, aerobic capacity and lower body strength scores by Pill, to levels 
which were higher than that recorded at pre-transplant. Importantly, while the non-
exercising patients also showed mean improvements in certain variables following 
the intervention period, the magnitude of change between post-transplant and 3-
months post-transplant was significantly less for peak ventilation, aerobic capacity 
and upper and lower body strength, when compared with exercising patients. 
5.4.1 Testing procedures and expression of results 
Prior to the results being discussed in more detail, it is important to clarify the testing 
procedures implemented and the manner is which results were expressed. A 
maximal GXT is regarded as a valid methol of assessing aerobic capacity. However, 
when designing the project, concerns were raised regarding the appropriateness of 
the testing procedure for this clinical population. Previous cancer studies have 
implemented methods including the 12-minute walk test247• 342• 344, and symptom 
limited maximal exercise tests101 ' 102' 104' 428 to calculate aerobic fitness, and no 
contraindications have been reported. In support of these previous findings, no 
contraindications were associated with the use of a V02 max GXT for the assessment 
of peak aerobic capacity in this investigation. Continual ECG analysis performed 
throughout the entire duration of the exercise test demonstrated that there were no 
abnormalities present that would prevent exercise participation. In addition, the 
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patients were able to tolerate the maximal test, without experiencing extended 
periods of fatigue. 
Concern with respect to undue fatigue, was also raised with regards to the strength 
tests implemented. However, the study patients were able to perform the 15RM 
upper and lower body strength tests without any extended periods of muscular 
soreness or injury. 
The attainment of peak HR and RER greater than 1.1, during a maximal GXT are 
potential indicators of the ability to achieve peak V02. As in earlier studies102, no 
differences were detected in this investigation between peak HR attained during the 
maximal GXT throughout the testing phases. That is, regardless of the level of 
aerobic fitness measured, peak HR did not significantly alter throughout the testing 
sessions. In addition, the mean difference observed between peak HR achieved by 
the control and exercise group is reflective of the mean age difference between the 2 
groups. Peak RER attained also showed no change throughout the testing phases. 
Furthermore, mean peak RER was recorded at 1.1 or greater, with the exception of 
mean peak RER for the CG at PI (1.05). In summary, the attainment of peak HR 
(which was within 10% of the age-predicted maximum), RER of 1.1 or greater, and 
the same peak HR and RER achieved throughout all testing phases, were indicators 
ofthe achievement of peak vo2. 
Finally, it is also important to comment on the expressiOn of results. The 
relationship between V02 and BW is well recognised artd therefore peak V02 results 
are commonly expressed throughout the literature in mllkg/min. This is particularly 
important in a study such as this, when weight status changes. However, oxygen is 
transported within and utilised by lean tissue and thus when dealing with a 
population of changing FFM as well as BW, it is also important to adjust for FFM 
changes. To allow for comparisons with data in the literature, peak V02 was 
expressed m two ways: the absolute value (Limin), and by adjusting for BW 
(ml/kg/min). To appropriately adjust for changes in body composition, aerobic 
fitness was also expressed in ml!FFM/min. Irrespective of the manner in which the 
results were expressed, a similar trend for change across time was identified. 
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Strength is yet another variable that is influenced by both BW and FFM. Strength 
values recorded in this investigation were adjusted for FFM and thus expressed as a 
ratio of strength values (units or kg) and FFM (kg). 
5.4.2 Pre-transplant function 
Comparisons with Australian normative values144 indicated that PBST patients 
experienced a lower mean peak VOz (ml/kg/min), pre-transplant. While this mean 
difference was not significant, examining the aerobic capacity data on an individual 
basis, provided further support for the notion. Of the 6 subjects assessed at PI, 4 
recorded aerobic capacity levels that placed them below the 25th percentile for 
normative data. The remaining 2 patients recorded fitness scores above the 50th 
percentile. In contrast, individual handgrip strength values were between the 50th 
and 75th percentile for the majority of patients assessed at PI. 
As a consequence of the limited knowledge regarding pre-transplant aerobic capacity 
and muscular strength values, it is difficult to determine whether the poor physical 
condition reported in patients following a PBST is a function of the transplant or 
previous conventional treatment regimens often undertaken by these patients. The 
results of this study indicate that factors such as prior treatment, and/or cancer and 
treatment-related side effects such as physical inactivity may lead to a deterioration 
in aerobic capacity in patients who are about to undergo a PBST. These data also 
highlight the need for intervention programs following transplant to attain higher 
than pre-transplant function, rather than just a return to pre-transplant levels. 
5.4.3 Post-transplant function 
Undertaking a PBST was associated with declines in aerobic capacity and strength. 
Although the differences between pre- and post-transplant data were not significant 
for aerobic capacity, patients recorded significantly lower peak V02 (mllkg/min) 
results following the transplant, when compared with age- and sex-matched controls. 
Furthermore, 42% (5 patients) of the study group assessed at PII recorded fitness 
values below the 25th percentile and 50% (6 patients) recorded values below the 5th 
percentile for normative data. The patient experiencing the highest fitness at all 
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testing phases, dropped from above the 75th percentile to below the 50th percentile for 
normative data, following the PBST. Previous research has led the American 
College of Sports Medicine to conclude that the initial exercise capacity of the cancer 
patient is in the range of3-6 metabolic equivalents (METS) or 10.5-20.5 mllkg/min3. 
The peak V02 results provided by the PII analysis (21.76±9.02 mllkg/min) were 
supportive of this range. 
Research reported by the ACSM (1990)4 showed that significant losses in 
cardiorespiratory fitness occur following only 2 weeks of detraining and that a 50% 
reduction in aerobic capacity can occur after only 4-12 weeks of detraining. 
Following the treatment period, patients in this investigation, experienced 25%, 22% 
and 23% losses in aerobic capacity, when fitness was expressed as Llmin, mllkg/min 
and ml!FFM/min, respectively. 
All strength measures were reduced following the transplant, with significant 
changes being identified for upper body strength only. During the 2-4 weeks 
between pre- and post..,treatment tests, the study group lost 4%, 28% and 19% in 
handgrip, upper body and lower body strength, respectively. These rates of strength 
loss are in agreement with earlier research which demonstrated that strength losses 
can occur at a rate of 3% per day160 within the first week of bed rest, followed by 
losses of 1-1 Y2% per dal45 . The changes observed in strength measures in this 
investigation indicated that greater strength losses occur in muscles associated with 
the thigh and trunk, when compared with muscles of the hand. Between PI and PII, 
patients spent the majority of time in bed and were performing few movements that 
required upper and/or lower body strength. In contrast, any movement performed 
while in bed, such as eating, reading, and writing, would have predominantly 
required hand strength. It is possible that these arm and hand activities were able to 
minimise the strength losses observed for handgrip strength. 
One of the most common and pervasive physiological consequences of cancer and 
treatment is fatigue343 and a substantial contributor to cancer fatigue is low physical 
performance430 . Following PII, it became evident that the patients in this 
investigation would require at least 50% of their peak aerobic capacity to undertake 
normal daily tasks, which often have calculated MET values of 2.5-4.57• Moreover, 
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the decline observed by PII in handgrip, upper and lower body strength, highlights 
that both isometric and isodynamic strength is detrimentally affected and thus the 
ability to produce force for daily movements and tasks is adversely influenced. Loss 
of aerobic capacity and strength following a transplant may contribute to the 
presence of fatigue in this cancer population. 
Due to the relatively small subject numbers within this investigation, it is possible 
that large fluctuations in one individual could significantly influence the mean 
change. However, when individual changes in aerobic capacity and muscular 
strength (lower body strength) were assessed, all patients demonstrated a similar 
trend of change and magnitude of change, with the exception of one patient. One 
patient assessed between PI and PII demonstrated greater declines in aerobic capacity 
and muscular strength, when compared with the magnitude of change experienced by 
the remaining subjects. The subject was female, aged 56 years and was diagnosed 
with multiple myeloma. She underwent a one-transplant procedure and experienced 
a 4.5kg and lkg decline in weight and FFM, respectively, between PI and PIT. It is 
difficult to explain the level of change observed as a function of these characteristics, 
since they were also present in other patients and were representative of the larger 
group. In addition, other patients assessed were either older, or experienced greater 
weight and FFM losses during the same period, yet did not experience the same 
decline in aerobic capacity and strength. The primary difference between this subject 
and the remaining subjects was the initial weight and body mass index. The subject 
who demonstrated the greatest losses in aerobic capacity and strength reported the 
lowest BW (44kg) and body mass index (16.9) pre-transplant. Consequently, this 
subject also demonstrated the lowest peak vo2 and muscular strength when 
expressed in Llmin and absolute weight lifted, respectively, at PI. However, when 
BW and FFM were taken into account, peak aerobic capacity and muscular strength 
were close to the mean of the group 
5.4.4 The importance of a physical intervention program 
The differences observed between the exercising and non-exercising PBST patients, 
at 3-months post-treatment, highlight the importance and need to implement a 
physical intervention program during the recovery period. The exercising patients 
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recorded significant improvements in peak ventilation, peak aerobic capacity and 
muscular strength by 3-months post-transplant. In comparison, results for the same 
measures did not change between PII and Pili for the non-exercising patients. 
Following the 3-month intervention period the exerc1smg patients recorded 
significantly higher peak ventilation results in comparison with the control subjects. 
Furthermore, the exercising subjects had significantly higher peak ventilation results 
at Pill, when compared with immediately post-transplant and pre-transplant values. 
In contrast, the control participants displayed no significant change during the three 
testing phases. The significant difference detected between the magnitude of change 
experienced during PII and Pili by the control and exercising group further 
highlights the importance of an exercise program following treatment. While the 
exercising group demonstrated a mean peak ventilation improvement between PII 
and Pill, the control group experienced a mean decline. The results therefore 
indicate that participation in a regular aerobic and resistance training program has the 
potential to prevent further declines in peak ventilation following treatment. 
The change detected in aerobic fitness for the control and exercising patients during 
the intervention period was similar, regardless of how the results were expressed. 
When assessing peak V02 in absolute terms (Limin) or when accounting for BW 
changes across the phases (mllkg/min), the control group demonstrated mean 
improvements, although the changes were not significant. Additionally, following 
the intervention period, the mean peak aerobic capacity recorded for the control 
participants remained less than that recorded prior to the transplant. In contrast, 
patients in the exercising group displayed significant changes following the 3-month 
intervention period, with peak aerobic capacity levels that were significantly higher 
than post-transplant and pre-transplant measures. Between PII and Pili, the 
exercising group demonstrated a significantly higher magnitude of change, when 
compared with the non-exercising patients. Similar trends were observed when 
aerobic capacity results were adjusted for changes in FFM. Participation in an 
exercise program induced positive changes in peak V02, which enabled the 
exercising PBST subjects to achieve higher than pre-transplant values by Pill and 
significantly higher values when compared with PII. In comparison, no significant 
135 
Chapter Five, Study Two 
change was detected for the control group across the testing phases when aerobic 
capacity was measured in ml/FFM!kg. 
As previously indicated, maJor fluctuations by one subject could significantly 
influence the group mean, and in turn, potentially exaggerate the results. However, 
upon an analysis of individual changes between PIT and Pill, all exercise group 
subjects demonstrated an increase in peak aerobic capacity (mllkg/min). Somewhat 
surprisingly and in contrast with observations of healthy subjects, those with the 
lowest baseline fitness, did not necessarily experience the greatest gains. In addition, 
those with the highest initial fitness level also did not necessarily experience the 
smallest gains. While there were minor changes in peak aerobic capacity 
experienced by all control group subjects, 4 out of 5 subjects demonstrated an 
increase by approximately 2-4 ml/kg/min, while one subject demonstrated a loss of 
approximately 4 mllkg/min. This decline observed in peak aerobic capacity 
(ml/kg/min) was due to a decrease in aerobic capacity (Limin) in conjunction with a 
gain inBW. 
The intervention program required the exercise group to perform at least 2 sessions 
per week of walking on the treadmill for up to 20 minutes. It is possible that the 
higher familiarisation with treadmill walking experienced by the exercise group in 
comparison with the control group, contributed to the improvements observed in 
peak aerobic capacity for the former group. However, as previously noted, peak HR 
and RER achieved during each of the graded exercise treadmill tests did not change 
across the testing phases, indicating that all patients in both groups attained peak 
V02 at each testing session. In addition, the mean peak HR for both the control and 
exercise group at each testing phase was within 10% of the age-predicted maximum. 
Mean peak RER was 1.1 or greater, with the exception of the mean peak RER for the 
CG at PI. 
Patients with breast cancer have shown a 20.7% increase in V02 (1.37-1.73 Llmin) 
following participation in a 10-week aerobic-only exercise intervention226. In 
comparison, the control breast cancer participants demonstrated a 1.8% decline 
during the same period. In this investigation, the exercising PBST patients 
demonstrated a higher aerobic capacity (Limin) increase of 44%, while the control 
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group reported a mean increase of 8%. Differences in the outcomes of these studies 
may reflect factors such as the type of cancer, treatment regimen undertaken, initial 
fitness levels of the participants, the length of the intervention period implemented, 
and the type ofthe intervention program. 
When aerobic capacity results were analysed in mllkg/min, the exercising PBST 
patients showed a significant increase of 39% between PII and PilL No significant 
change was detected across the same period for the control participants. These 
results are supportive of previous findings. Following participation in a WAIT 
protocol, breast cancer patients demonstrated a 40% improvement, when compared 
with no significant change in the control groups427 . Higher gains in maximal METs 
(4.7-7.4) of 57%101 have been previously demonstrated in BMT patients following a 
6-week walking program. However, in a more recent investigation performed on 
BMT patients categorised with excessive fatigue, only 12% gains in maximal METs 
(4.9-5.5) were identified following the same intervention program103 . 
What is of primary importance is whether the improvements demonstrated by the 
exercising patients in this investigation are of sufficient magnitude to allow for 
participation in normal daily activities without undue fatigue. A maximal MET 
value of 5 (~17.5mllkg/min) is regarded as sufficient to adequately perform daily 
tasks101 . While all exercising PBST participants exceeded this level (range= 21-51 
mllkg/min), 40% of the control group failed to reach the minimum requirement 
(range = 11.8-32.2 mllkg/min). Similar findings have been previously reported in 
BMT patients. Following a 6-week walking program, Dimeo and colleagues 
(1996)101 found that all exercising BMT patients achieved the minimum MET value. 
A later investigation implementing the same 6-week walking program104, showed 
that 6% of the exercising patients, in comparison with 25% of the control group were 
unable to achieve the minimum functional requirement. Differences in the 
intervention duration and group characteristics may provide potential reasons for the 
slight variation in the results obtained between this investigation and the above 2 
experiments. 
Since the GXT employed per subject at each of the three testing phases was adapted 
to ensure the patient reached peak V02 within a set period, exact comparisons of 
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peak workloads, time to exhaustion and HR at given submaximal workloads were not 
possible. However, the ability of all exercising patients to progress across the 3-
months, in terms of aerobic exercise duration and intensity, and the ability to lift 
more weights and increase the number of exercises performed during the training 
session, is indicative of improvements within these areas. That is, for aerobic 
exercise, when HR at certain submaximal workloads began to decrease, workload 
was correspondingly increased to ensure that the patients maintained the desired 
exercise intensity. When patients could perform greater than 20 repetitions of a 
particular exercise without reaching failure, weight lifted was increased. The ability 
to work at a given submaximal workload with a lower HR is indicative of gains in 
stroke volume. In addition, since peak HR attained during each GXT test did not 
differ across the phases, gains observed in peak aerobic capacity were also indicative 
of improvements in stroke volume. The improvements observed for submaximal 
HR, maximal exercise duration, and peak workloads, have also been observed in 
exercising breast cancer patients226• 227 . 
Differences were detected for strength changes across the phases, between the 
exercising and control PBST patients. Handgrip strength values did not significantly 
alter across phases for either the control or exercising patients. However, while the 
control group demonstrated a mean loss between PII and Pili, the exercising 
participants showed a mean strength gain. Across the intervention period, the control 
group failed to show any significant change in upper- and lower-body strength, but 
again the mean change for lower-body strength was in the negative direction. In 
comparison, the exercising patients significantly improved upper- and lower-body 
strength across the same period. Lower-body strength of the exercising group was 
significantly higher at the end of the intervention period, when compared with pre-
transplant levels and lower-body strength results recorded by the control group at 
PilL The positive impact of the exercise program on strength is further highlighted 
by the results that demonstrate a significantly greater magnitude of change for upper-
and lower-body strength, between PII and Pili strength scores for the exercising 
patients, in comparison to the control patients. In addition, the subject who 
experienced the least muscular strength (lower body) at PII, demonstrated the highest 
strength gains, while the subject who reported the highest muscular strength, showed 
the smallest strength gains, following the intervention period. While these changes 
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indicated that initial strength levels could potentially influence the magnitude of 
gains achieved, this trend was not consistent throughout the exercise group. That is, 
when the exercising patients were ranked according to their initial lower body 
strength and the strength gains made following the intervention program, the subject 
with the 2nd lowest initial strength, also experienced the 2nd lowest magnitude of 
gains. 
As previously noted, daily tasks commonly involve isometric and isodynamic 
strength. Continued strength losses or alternatively, an inability to regain lost 
strength following the transplant will impact on the patient's ability to perform daily 
tasks. Furthermore, the negative magnitude of change experienced in handgrip and 
lower-body strength observed in the control group emphasises the risk of continued 
strength losses with failure to participate in physical activity following treatment 
cessation. Improvements in strength lead to greater muscular efficiency and a 
reduced effort in performing any given task. Consequently, it could be suggested 
that the exercise group would have a greater ability to perform normal daily activities 
without fatigue, when compared with the control group. 
The exercising group achieved average gains of 6%, 51%, and 65% in handgrip, 
upper-body, and lower-body strength between PII & PHI, respectively. In 
comparison the control group demonstrated a 3% mean improvement in upper-body 
strength, in conjunction with mean strength losses of 9% and 5% for handgrip and 
lower body strength, respectively. The range of gains observed by the exercising 
group (6-65%) are slightly higher than those previously reported for adult and 
cardiac populations (20-50% and 20-40%, respectively), but within the range for 
strength improvements reported in older populations (9-227%)404• 
Strength results presented within this investigation support the findings derived from 
studies integrating strength training within a HIV-1 population. Following a 6-week 
progressive resistance training program, muscular strength for the regions of the legs, 
chest, shoulder and arms, significantly improved pre- to post-program for those in 
the exercise group370• The exercising patients also experienced significantly higher 
levels of muscular strength when compared with the control group. These results are 
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comparable to the significantly higher lower body strength levels experienced by the 
exercising PBST group at Pili, when compared with the control group. 
The inability to regam strength losses without the integration of any structured 
intervention has previously been shown in 36 long-term ALL survivors440 . Reduced 
muscle strength and weakness were identified when the strength results derived from 
the children under investigation were matched with results from school peers. In 
turn, this reduced strength had a detrimental impact on the children's ability to 
perform basic motor skills and their level of gross motor proficiency and 
performance. 
5.4.5 Longer-term implications of PBST or BMT 
It has previously been reported that 40% of patients undertaking a BMT require a full 
year to regain pre-treatment fitness levels, while approximately 30% of patients are 
unable to return to work during the first 2 years following the transplant105. An 
investigation performed on 56 long-term survivors (1.5-16 years) of acute leukaemia 
demonstrated that 25% of patients had failed to attain 'normal' maximal aerobic 
capacit;?8. Of particular concern is that the rates of achieving normal peak V02 were 
the same regardless of whether less than, or more than, 8 years had elapsed since 
treatment cessation. A more recent investigation, which assessed the 
cardiopulmonary function and recovery rates of BMT patients at pre-transplant and 
then again at approximately 6 years post-transplant, concluded that cardiovascular 
impairment as a result of a transplant is persistent, but not progressive166. It seems 
evident from the above investigations that patients undergoing a BMT are at risk of 
persistent declines in aerobic capacity and strength as a consequence of a transplant. 
However, the results of this investigation demonstrate that adverse changes 
associated with. a transplant are potentially reversible. Those patients who 
participated in a regular exercise program were able to attain higher aerobic capacity 
and strength levels than those recorded pre-transplant, within a 3-month period. 
These results demonstrate that the inability to regain pre-treatment fitness and 
strength is potentially the inevitable consequence of lack of aerobic and/or strength 
exercises, rather than adverse treatment effects. 
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5.5 Conclusion 
Undertaking a PBST leads to decrements in aerobic capacity and muscular strength, 
which are clinically relevant. However, while the results of earlier work indicates 
that 40% of BMT patients require 12 months to regain pre-treatment fitness levels, 
the results from this investigation demonstrate that it can take as little as three 
months. Moreover, this investigation demonstrates that t~ough participation in an 
aerobic and strength training program, PBST patients can return to higher than pre-
treatment levels, and comparable to age- and sex-matched strength and fitness levels. 
Furthermore, failure to participate in an exercise program following treatment may 
exacerbate any physical functioning losses induced by the treatment process. 
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STUDY THREE 
Changes in immunological status and function 
following a PBST and participation in an 
• exercise program 
"The dogmas entrenched from the 1950s and '60s, of never do this 
and never do that, are pretty life threatening" 
Dr Urve Kuusk, in Kent (1996/94 
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List of abbreviations specific to Chapter six 
BMT 
CD3+ 
CD4+ 
CDS+ 
DMSO 
FCS 
FITC 
I1 
I2 
I3 
I4 
I5 
IFN 
IL 
MHC 
MTT 
NKC 
PBS 
PBST 
PE 
PerCP 
PHA 
PI 
PH 
PHI 
PWM 
RPMI 
SG 
TNF 
URTI 
V02 max 
WBC 
Bone marrow transplant 
T lymphocyte cells 
T lymphocyte helper cells 
T lymphocyte suppressor cells 
Dimethylsulfoxide 
Fetal calf serum 
Fluorescein isothiocyanate 
Intervention 1 (testing phase scheduled at 1-month post-PH) 
Intervention 2 (testing phase scheduled at 2-months post-PH) 
Intervention 3 (testing phase scheduled at 3-months post-PH) 
Intervention 4 (testing phase scheduled at 4-months post-PH) 
Intervention 5 (testing phase scheduled at 5-months post-PH) 
Interferon 
Interleukin 
Major histocompatibility complex 
3-( 4, 5 dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide 
Natural killer cells 
Phosphate buffered saline 
Peripheral blood stem cell transplant 
Phycoerythrin 
Peridin chlorophyll-a protein 
Phytohaemagglutinin 
Phase I 
Phase II 
Phase III 
Pokeweed mitogen 
Roswell Park Memorial Institute 
Study group 
Tumour necrosis factor 
Upper respiratory tract infections 
Maximal aerobic capacity 
White blood cells 
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6. Changes in immunological status and function following a PBST 
and participation in an exercise program 
6.0 Introduction 
Cytotoxicity, prolonged bleeding, suppression of immune function, susceptibility to 
secondary infection and general fatigue constitute some of the side effects associated 
with oncology treatment429 . Patients who have undergone extensive cancer treatment 
such as a PBST, are placed in an immunocompromised state for some time post-
transplant, with T cells taking the longest period to recover to baseline levels when 
compared with other immune cells. Since T cells are the primary immune cells in 
resisting the presence of illness, the risk for the development of infections and colds 
is elevated during this 'open window' period. Furthermore, the presence of such 
conditions maintains the potential to influence the functional capacity and quality of 
life ofPBST patients. 
Currently, there is growing recognition that both acute and chronic exercise can 
·modulate immune function354, with factors such as exercise intensity, duration, and 
mode of exercise influencing the type of change258 . The expanding body of evidence 
demonstrating the effects of exercise on immune status and function has raised the 
hope that a suitably graded exercise prescription might be a valuable adjunct to the 
treatment of cancer, not only by improving functional capacity, but by also 
counteracting immunological disturbances349• Within the limited research available 
in the area of exercise immunology and cancer, studies have predominantly assessed 
the role of exercise in enhancing tumour defense by the innate component of the 
immune system. Consequently, cells within the adaptive component of the immune 
system, such as T cells, have been given little attention. 
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6.0.1 Purpose 
Objective 1: To investigate changes between pre- and post-PBST measures ofT cell 
numbers and function. 
Research hypothesis for objective 1: 
T cell numbers and function will be adversely affected following a PBST (as 
determined by pre- and post-transplant measures). 
Objective 2: To investigate the role of a three-month duration, moderate intensity, 
mixed type exercise program on T cell numbers and function, post-PBST. 
Research hypothesis for objective 2: 
Participation in the exercise program will lead to a faster recovery ofT cell 
numbers and function, when compared with the recovery ofT cell numbers and 
function of non-exercising PBST patients (as determined by pre- and post-
intervention measures). 
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6.1 Literature Review 
The human immune system has the ability to distinguish foreign substances from 
those of our body, become activated and subsequently neutralise and remove 
potential pathogens, while coordinating tissue repair and to finally return to a 
surveillance condition146. The immune system has been defined as consisting ofboth 
specific and nonspecific defenses against foreign materials, where the innate and 
adaptive or acquired components represent the specific mechanisms354' 368• The 
innate defense mechanism is always ready for action and contains various cellular 
elements including natural killer cells and numerous types of phagocytes 
(neutrophils, eosinophils, basophils, monocytes and macrophages), together with 
important soluble factors: acute phase proteins, complement, lysozymes, and 
interferons. The ability to acquire a response to specific antigens arises from the 
adaptive system. This component of the immune system consists of specific cells, T 
and B lymphocytes and soluble factors, immunoglobulins. In order to understand the 
potential role exercise may play on the immune system of patients with cancer, it is 
important to first understand the role of specific immune cells and the 
interrelationships between the immune and endocrine systems. 
The innate immune cells that have been given much of the attention throughout the 
literature are monocytes, natural killer cells and. neutrophils. Monocytes are 
immature macrophages that are produced in the bone marrow, and released into 
circulation in response to several cytokines, where they function as phagocytic cells, 
cytokine producers, presenter of antigens and as blood-clotting regulators436• Once 
monocytes reach their destination to fixed sites along specialised vessels, they 
mature into macrophages. 
The activated macrophage plays a dominant role in first-line immune defense against 
tumour cells436' 438 , as an initial phagocytic agent, an antigen-presenting cell, and an 
initial source of interleukin-1 (IL-l), interferon (IFN) and various stimulating 
factors165 . Their function requires several capacities including adherence, 
chemotaxis, phagocytosis, and a respiratory burst and release of toxic products, 
which ultimately leads to death of the ingested organism. In addition, macrophages 
maintain a role in coordinating tissue repair in an injured muscle. Interleukin-1, IFN-
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gamma, tumour necrosis factor-alpha (TNF-alpha), and macrophage-activating factor 
regulate the anti tumour activities of the macrophages. 
Lymphocytes that lack identifying surface markers comprise null cells, with one 
particularly important subgroup of null cells being the natural killer cells (NKC)47. 
Natural killer cells account for 10-15% of all circulating mononuclear cells. The 
cells provide an important nonspecific first line of defense against many types of 
tumour cells with the rate of metastasis being inversely proportional to the level of 
NKC function. Furthermore, NKC demolish some virus-infected cells and act in the 
repair process of injured muscle289' 355• Natural killer cells maintain the capacity to 
function without needing to recognise cell-surface associated major 
histocompatibility complex (MHC) molecules277 and can influence the behaviour of 
target cells including tumours, by the production of cytokines165 . 
Neutrophils are one of the body's most efficient phagoctyes of many microbial, 
bacterial and viral pathogens, act as a first line of defense against infectious agents, 
and constitute about 60% of circulating leucocytes259' 308' 439 . Additionally, 
neutrophils are involved in the synthesis and release of immunomodulatory cytokines 
that influence T and B cell activities308 . Tumour cells can be destroyed by 
neutrophils through their production of peroxides and free radicals265 . 
The 2 specific adaptive immune cells important to note are the T and B cells. T cells 
(CD3+) are lymphocytes that are coded in the thymus in response to both specific 
allergens and nonspecific mitogens44• They comprise cells that have a distinguishing 
antigen- helper cells (CD4+) and suppressor (CD8+) cells. Foreign antigens, in the 
context of Class II MHC molecules, expressed on the surface of antigen-presenting 
cells are recognised by helper T cells355 . For example, macrophages release IL-l, 
which is a signal for the activation ofT helper cells. In turn, IL-2 is produced by the 
activated T cells and can synergise with interferons to further elevate T cell activity. 
Additionally, IL-2 has the ability to stimulate the secretion of another lymphokine 
(IL-3) by the helper T cell. The dispatch of a signal to cytotoxic or suppressor T 
cells is initiated potentially by this latter substance. The cytotoxic T cells act by 
destroying abnormal cells that are recognised by foreign surface constituents. B cells 
are activated by the helper T cells, proliferate and differentiate into plasma cells, with 
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a resultant antibody release, while the helper T cell action is controlled by the 
suppressor T cell via a negative feedback mechanism. It has been noted that the ratio 
of helper to suppressor cells is a critical variable, where susceptibility to infections 
may be elevated if the ratio falls below 1.5191 . 
6.1.1 Immune system status 
The status of the immune system is associated with the endocrine system. The 
endocrine system has a distinct role of signalling a network of hormones and 
neurotransmitters that act to regulate cell function throughout the bodl76• 
Catecholamines are known to exert a significant effect on various cellular 
components of the immune system, including mediation of leucocytosis, functional 
changes in leucocyte subsets and modulation of NKC number and activity08 . 
Catecholamines facilitate leucocytosis by reducing adhesion of leucocytes to the 
endothelial cells that line vessel walls416 . Furthermore, CD3+, CD4+ and CDS+ 
lymphocytes are functionally enhanced by catecholamines through alpha-adrenergic 
stimulation. However, beta-adrenergic impulses inhibit CD4+ and CDS+ 
proliferation through catecholamine blood levels, and also by the number of beta-
adrenoceptors on lymphocytes416 . 
Other hormones known to influence the immune system are cortisol, growth 
hormone and insulin. Cortisol is considered to be a 'broad-spectrum' 
immunosuppressive agent that affects the activity of several types of immune cells 
and may reduce circulating lymphocytes by the action of re-trafficking them to 
peripheral tissues256• Growth hormone (a neuropeptide) is essential for the 
development and maintenance of immunocompetence and the enhancement of 
lymphocyte proliferation, T lymphocyte and NKC cytotoxicity. Additionally, 
growth hormone primes the microbicidal activity of the macrophage cell308. Finally, 
insulin maintains a primary role in immune cell metabolism. The insulin-mediated 
glucose influx, for which the interaction between insulin and its receptors and the 
activation of glucose transporters are responsible, supports the energy demand of 
immune cells416 . The uptake of amino acids and protein metabolism in lymphocytes 
is further facilitated by insulin416 . 
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As a consequence of the relationship between the endocrine and immune system, any 
event of a psychological or physical nature that leads to a change in certain hormone 
levels, maintains the ability to influence the status of the immune system. Elevated 
stress hormone levels, accompanied by an increase in the activation of the 
sympathetic nervous system or the hypothalamic pituitary adrenocortical system, 
have been associated with certain life stressors such as bereavement, loneliness, 
divorce, and unemployment. Additionally, the presence of these stressors has also 
been shown to yield a negative impact on the immune system204 . Furthermore, 
affective states such as anxiety and depression have been associated with declines in 
NKC cytotoxicity, mitogen responsiveness, T cell ratios and T lymphocyte 
numbers448 • 
Cohen and associates (1991)71 tested the link between the endocrine and immune 
system by assessing degrees of psychological stress via questionnaires, followed by 
dosing 394 healthy subjects with nasal drops containing one of five respiratory 
viruses. An additional 26 subjects were given saline nasal drops. The results 
demonstrated that the rates of both respiratory infection and clinical colds 
significantly increased in a dose-response manner with increases in the degree of 
psychological stress. Controlling for age, sex, education, allergic status, weight, the 
season, personality traits and other various factors did not alter these results. 
Research findings have also linked bereaved spouses with elevated cortisol and 
decreased NKC lysis173, and lonelier medical students with lower levels of NKC 
activity196• 
Furthermore, enhancement of the immune system has been demonstrated VIa a 
behavioural stress reduction intervention197 . On completion of the 4-week relaxation 
training program, the NKC activity of older adults significantly increased in 
conjunction with a decrease in distress-related symptomatology. In contrast, no 
significant differences were observed in these same measures for the control group or 
social contact only group. 
In summary, psychological stress may indirectly influence the immune system 
through the release of the immunomodulatory hormones. However, just as 
psychological stress has been related to the release of stress hormones, so too have 
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physical stress conditions such as exercise. Common to exercise are increases in 
plasma cortisol, epinephrine and norepinephrine concentrations286. 
The individual endocrine response to exercise is dependent on the nature, intensity 
and duration of the exercise session, and the initial fitness level of the participant308. 
Intense exercise (more than 60% V02max) will generally activate both the 
sympathoadrenal and pituitary-adrenocortical endocrine system, leading to an 
increase in the plasma concentration of catecholamine (epinephrine and 
norepinephrine) and glucocorticoid hormones (such as cortisol). The relationship of 
catecholamines and cortisol, and immune function has been summarised as follows. 
Following high-intensity exercise, a transient increase in the circulating lymphocyte 
count is caused by epinephrine, while the longer-acting cortisol quickly dominates 
events during recovery, causing marked and prolonged lymphocytopenia and 
neutrophilia256' 259. 
Physical activity can influence a person's psychological state by inducing either a 
calming or stressful effect. While an appropriate dose of exercise can correct a 
depressed mood state, an inappropriate dose can further deteriorate a negative mood. 
Exercise set at an intensity that a patient finds difficult to perform, may lead to 
feelings of helplessness and thus further contribute to a reduced self-perception and 
physical well-being149. As previously discussed, distress may increase the release of 
glucocorticoids and thus result in an immunosuppressive effect. Conversely, the 
potential benefits of an appropriate exercise prescription on psychological status 
have also been shown. The beneficial changes observed in mood states tend to be 
greater in an individual who initially has high stress, anxiety or depression levels, 
when compared with the person who is in a positive mental state349. The association 
between exercise, psychological status, the endocrine system and the immune system 
is illustrated in Figure 6.1. 
150 
Chapter Six, Study Three 
Figure 6.1 The link between exercise, psychological status, the endocrine system 
and the immune system 
Psychological Status 
Endocrine System Exercise 
6.1.2 Immune system status of patients with cancer 
The immune status of patients with cancer is potentially influenced by a number of 
factors including the psychological status of the patient, the cancer present and 
treatment regimens undertaken. Depression, worry, fear, and other negative 
psychological states are common characteristics known to exist in patients with 
cancer105 . The relationship between the presence of these psychological states, and 
the release of hormones that evoke immunomodulatory effects, has already been 
discussed. It has also been noted that patients with cancer who are experiencing 
prolonged anxiety may continually activate the hypothalamo-pituitary-adrenal axis, 
in conjunction with the sympatho-adrenomedullary axis. In tum, this may lead to 
immune suppression, an increase in susceptibility to infection and slow reconstitution 
of immune function following treatment, while enhancing the risk of cancer 
recurrence12 . 
In addition to the effect of psychological status on immune function, is the influence 
that the cancer and its associated treatment might impose. Impaired immune 
function has been considered a 'hallmark of malignant disorders'356 . Various studies 
reported in Brittenden et al (1996i3 have shown that peripheral blood natural 
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cytotoxicity (NK.C cytotoxic function) is significantly reduced in patients with 
familial and nonfamilial melanoma, head and neck, lung, ovarian, cervical, bladder, 
prostatic, hepatocellular, pancreatic, oesophageal, breast and various combined 
cancers, when compared to non-cancerous controls. However, others have 
documented that the natural cytotoxicity does not change in patients with colorectal, 
pharyngeal and breast cancer, irrespective of the stage of disease. Brittenden et al 
(1996)53 further noted that a wide biological variation exists in the NKC number and 
activity of healthy controls. Therefore, interpreting studies on natural cytotoxicity in 
patients with cancer is difficult. Overall, however, a trend for reduced NKC activity 
in certain cancers is emerging. 
T lymphocyte subsets and lymphocyte reactivity m the peripheral blood from 
patients with various types ofurological cancer, compared with age-matched controls 
have also been studied190. A depression in immune competence was found in the 
group of male patients with infiltrating bladder cancer. In more than 50% of these 
patients, CD4+ cell numbers were reduced with a corresponding inversion of the 
CD4+/CD8+ ratio and an impairment of T cell function. In contrast, the patients 
with superficial bladder carcinoma and those with renal cell carcinoma demonstrated 
a similar immune profile to that of the control group. Lastly, the group diagnosed 
with prostatic carcinoma had reduced CDS+ cells and thus reported higher mean 
CD4+/CD8+ ratios when compared with controls. 
The relationship between stage of disease and cytotoxicity has not been well 
defined 53. While some investigations have reported a reduction in cytotoxicity with 
disease progression84' 360• 391 , others have not found the same correlation244' 374. With 
regard to the T lymphocyte response, a poorer proliferative response of peripheral 
blood mononuclear cells in response to phytohaemagglutinin (PHA) in breast cancer 
patients has been reported, with the degree of defect being directly correlated to stage 
of disease, including tumour size and lymph node status423 . 
Anti-cancer treatments including surgery, radiotherapy and chemotherapy also have 
the potential to influence natural cytotoxicit~3 . In regards to surgery, a post-
operative immunosuppression has predominantly been observed, with the onset of 
impaired immune function being dependent on various factors including pre-
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medication and anaesthetic agents used, type of surgery performed and peri-operative 
blood transfusions53 . 
Most chemotherapeutic agents produce a cytotoxic effect in a wide variety of normal 
tissues53 . Neutropenia is often a complication of chemotherapy, increasing the 
patient's risk of susceptibility to infection, colds or flus161 . It is these cytopathic 
effects of myelosuppression, lymphopenia and bone marrow reserve depletion, that 
provide potential limitations for the use of many current cancer therapies to combat 
any residual disease51 • Animal studies have shown that drugs such as 
cyclophosphamide, vinblastine and methotrexate inhibit NKC activity, whereas 
vincristine has been shown to elevate NKC activitY3. 
The effect of radiotherapy on NKC counts and activity may ultimately depend on the 
extent of the underlying disease, the dosage delivered and the area of tissue 
irradiated 53. For example, intra-operative radiotherapy such as that used in the 
treatment of pancreatic cancer, utilises a small radiation field and consequently does 
not inhibit NKC activity443 . In contrast, radiation to areas such as the chest or pelvic 
region has been shown to influence blood lymphocyte populations and NKC activity. 
Patients with breast cancer have demonstrated a significantly reduced NKC 
activitl3, while patients with lung cancer have shown a reduction in the number of 
circulating lymphocytes, following radiotherapy393 . 
Of specific relevance to this investigation is the impact of a PBST on immune 
function. As a consequence of the high-dose treatment received as part of a PBST, 
immune function is significantly impaired following transplantation and infectious 
complications are common249 . 
An imbalance in the CD4+/CD8+ ratio, impairment in T cell function, a reduction in 
IL-2 production and/or a failure to respond to endogenous IL-2, have been 
demonstrated following PBST and BMT384. Additionally, diminished B cell 
function, cytokine production and/or levels of soluble cytokine and T cell receptor 
levels in the serum have been noted. The speed at which the immune system 
recovers following a transplant is in part determined by whether a PBST or BMT has 
been undertaken. In general, the recovery of the immune system tends to be faster in 
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patients who have undergone a PBST216 . Monocyte and NKC counts have usually 
recovered within the first month post-transplantation, while recovery ofT cell counts 
generally occurs within 6 months post-transplant. Although T cell counts may take 
up to 6 months to fully recover, the CD4+/CDS+ ratio tends to be markedly 
decreased for a longer period post-transplane84. Others have also reported that T cell 
subsets display an increase in CDS+ frequency within the first 3-months post-
transplant in conjunction with a decrease in CD4+ cells and the CD4+/CDS+ ratio 
(mean ratio of 0.3±0.2)158 • Furthermore, the ratio failed to return to normal with 4-6 
months post-transplant. T cell function has also been shown to adversely change 
following transplantation. It was suggested that high levels of suppressor cell 
activity following the transplant may provide, in part, the origin of the decreased 
total T cell function384. 
In summary, immune cell recovery following a transplant usually occurs in the order 
of neutrophils, monocytes and NKC first, followed by CDS+ cells, B cells and then 
lastly CD4+ cells384• It thus seems plausible that patients may experience an "open 
window" period to infections and colds, up to a period of 6 months following a 
PBST. Therefore, methods that have the ability to initiate faster immune cell 
recovery post-treatment could potentially influence the patient's presence of illness 
post-transplant and thus their state ofhealth and quality of life. 
Evidence demonstrates that participation in exercise can influence the state of the 
immune system. It is the relationship between the immune system and physical 
activity that has attracted the attention of clinicians concerned with either the 
prevention or treatment of cancer, autoimmune diseases, HIV infections and 
transplant rej ections355 • 
6.1.3 Exercise and the immune system 
In order to understand the role exercise might play in influencing either cancer 
prevention or recovery of the immune system following cancer and treatment, it is 
crucial to first understand the immune defenses against tumour cells. Once a tumour 
has been developed, the basic processes of immunoprotection include a slowing of its 
growth rate (cytostasis) and destruction of the abnormal cell (cytolysis). Tumour 
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promoters include factors that suppress immune function, while factors that enhance 
immune function could be regarded as inhibitors. The initial step in cytolysis is the 
presentation of tumour antigens to T and B cells via antigen-presenting cells, 
macrophages and monocytes. Secretions of various cytokines through the resulting 
activation of the CD4+ (T helper) cells stimulate the cytolytic activity ofT cells, 
NKC, macrophages and neutrophils. The process of cytolysis involves an adhesion 
between the immune cell and the tumour target, the insertion of pores into the 
membrane of the tumour cell and the injection of cell-specific molecules through 
these pores, which ultimately rupture the tumour cell membrane. Antibodies 
produced by the B cells aim to counter the tumour antigens, and certain cytokines 
including both IFN and TNF may exert a cytotoxic or cytostatic effect in their own 
right31 . It is therefore important to determine what type of physical activity leads to 
an enhancement of the immune system, and could thus potentially influence cancer 
development or progression. Moreover, an evaluation of the literature examining the 
exercise response of specific immune cells is required. 
Several investigators240' 266 have reported an increase in peripheral venous leucocyte 
count roughly proportional to the intensity and duration of the exercise bout. 
However, leucocyte counts may reduce prior to the termination of exercise if the 
activity bout is of a prolonged duration 127. Taking these two factors into 
consideration, it seems plausible that leucocyte counts may increase with increasing 
duration up to a certain time point, however they may reduce prior to the end of the 
exercise bout, once the particular time point has been reached. Determining exactly 
when this time point occurs requires further research. 
The acute response of macrophages to exercise has been examined extensively by 
experimental studies. The macrophage and monocyte counts in peripheral blood are 
increased transiently by a given exercise bout (irrespective of duration or intensity). 
However, normal values are obtained within minutes, or at most, hours of 
recoverl36. Counts are often unaffected by training, but seven days of exhausting 
training has been found to decrease the macrophage response. Woods et al (1999)439 
reported extensive evidence linking acute and moderate, and acute and exhaustive 
exercise with enhanced macrophage activity by increasing their enzyme content, 
phagocytic and cytotoxic activity, chemotaxis and adherence. Other researchers 
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maintain that while macrophage function is enhanced with moderate exercise, it is 
impaired with heavy exercise. 
Of all the lymphocyte subsets, the most responsive to exercise stress are NKC439. An 
increase in NKC number and activity during exercise has been demonstrated in a 
number of studies, with a transient fall of number and/or activity post-exercise259• 264• 
287
• 
289
• 
352
• 
354
• 
392
. However, the suppression in NKC numbers was not observed 
following intensities of 25% and 50% V02max392 . The increase in NKC number 
with exercise has been attributed to an increase in NKC activation and potentially an 
elevation of recycled NKC223. Additionally, Shephard (1994)351 ' 355 reported research 
demonstrating that a catecholamine-mediated decrease of cell margination may 
potentially induce the rise in NKC. The fall in NKC activity post-exercise or during 
prolonged exercise may be attributable to an increased prostaglandin release by the 
monocytes289 or serum cortisollevels351 ' 355. However, restoration of normal resting 
levels of NKC function occurs within a few hours post-exercise, and there is often a 
partial compensation even for the immediate suppression of the NKC by a favourable 
change in the T -helper/T -suppressor ratio. 
As a result of the catecholamine-mediated demargination of cells from endothelial 
tissues and bone marrow, or as part of the phagocytic and inflammatory response to 
exercise-induced tissue damage, the circulating number of neutrophils increases with 
exercise308 • Neutrophils undergo adherence, phagocytosis of bacteria or tissue 
fragments, degranulation of cytoplasmic granules, and ultimately activation of the 
respiratory burst following mobilisation into the circulation and migration into 
tissues308• Evidence also indicates that the production of peroxides and free radicals 
is increased for as long as 6 hours following an acute exercise bout, thereby 
increasing the killing capacity per cell353 • It is possible to tentatively conclude that 
exercise acts to recruit inactive cells into a pool that are able to respond to stimuli, 
and leads to a relatively small elevation in cell activitl17 . However, only moderate 
exercise is associated with a prolonged improvement in the killing capacity of these 
cells, while exhaustive exercise has the opposite effect259 • 
The impact of exercise on T cells has been demonstrated in studies assessing 
lymphocytes. The effect of high- versus moderate-intensity exercise on lymphocyte 
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changes has been investigated, with findings demonstrating that greater 
lymphocytosis, represented by T and NKC counts, was associated with high-intensity 
exercise263 • Following exercise, lymphocytopenia was documented for both 
intensities, but was greater following high-intensity exercise when compared to 
moderate-intensity exercise. Others have identified changes in the T cell ratios with 
suppressor cells increasing from 33-36%, a reduction in helper T cells from 54-43% 
and a corresponding ratio drop from 1.94 to 1.36 following exercise28 . Similar T cell 
ratio drops following a bout of maximal or exhaustive exercise have been identified 
in more recent investigations164' 215 . However, an investigation assessing T cells 
following endurance running did not find any change in the T cell ratio265 . 
Acute exercise has also been shown to influence the release of cytokines. Exercise 
typically increases the production of IL-l and resting levels are sometimes enhanced 
by training110' 352• The effect of acute exercise on IL-2 is commonly a depression of 
plasma levels317• However, the effect is not always a depression of function, since 
sustained moderate exercise that elevates core temperatures may expand plasma 
levels of IL-2, and the substantial up-regulation of IL-2 beta receptors may further 
enhance the IL-2 response289. Following training, rises in the NKC count may be 
responsible for the particularly large gains of IL-2 beta-receptor activity seen. The 
impact of exercise and training upon IFN levels has been relatively inadequately 
studied. However, an increase following a moderate exercise bout of 60 minutes 
duration has been reported110 and elevated levels of TNF-alpha have also been 
detected following moderate exercise229• 
In summary, participation in exercise is most likely to influence the protection 
against cancer through the exercise-induced rise in the number and/or activity of 
macrophages, NKC and their regulating cytokines353 . Since most of the immediate 
immune responses to exercise are relatively short in duration, susceptibility to cancer 
is more likely to be affected by training-induced changes in resting function of the 
immune system than by immediate responses to an exercise bout. Simon (1987)361 
supported this view by commenting that since the acute exercise response is usually 
quite transient in nature, impact upon the normal defense against bacteria, viruses 
and neoplastic cells is likely to be minor. It was also noted that depending on the 
type, intensity and duration of exercise undertaken, the immune response to the 
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exercise bout may vary from day-to-day with an enhanced response on one occasion 
and a suppressed response on another191 . 
Information required for determining the immune response to continuous and regular 
training can be obtained by evaluating cross-sectional investigations. 
Granulocytosis, lymphocytosis and an increase in antibody-dependent cytotoxic and 
NKC activity, are the most consistently observed features in resting athletes265• 288 . 
Investigations reported by Nieman and colleagues (1993f64 have illustrated that 
NKC activity was enhanced in physically active Japanese men compared with their 
sedentary counterparts, highly conditioned elderly women versus sedentary elderly 
women, and in elite cyclists relative to untrained subjects. 
A cross-sectional survey examined whether habitual endurance exercisers retained a 
higher level of T cell function when compared with sedentary age-matched 
controls358 . Immune senescence was also assessed by comparing the sedentary and 
exercising elderly groups with young healthy controls. Results observed included a 
lower circulating CD3+ and CD8+ cell count in conjunction with a trend toward a 
higher CD4+/CD8+ ratio in the elderly, when compared with the young. 
Furthermore, higher percentages of activated CD3+ and 'memory' CD4+ and CD8+ 
cells were also found. While comparison between the exercising and sedentary 
group demonstrated no differences in circulating counts of immunocompetent cells, 
the active elderly subjects showed a significantly greater T cell proliferative response 
and related cytokine production. 
In comparison, other cross-sectional investigations have reported poorer immune 
function in exercising subjects compared with sedentary controls. McCarthy and 
Dale (1988)240 demonstrated that at any given absolute work-rate, the sedentary 
subjects experienced a higher level of leucocytosis when compared with athletes. 
Phagocytic activity has been shown to be poorer in athletes, and lower lymphocyte, T 
helper, T ratio and NKC counts were observed in athletes undergoing controlled 
intensity training when compared with healthy untrained men355• 
Others have reported no significant differences in baseline immunocompetence as a 
result of regular training260' 317. Natural killer cell and T cell function of highly 
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trained runners and cyclists were compared with sedentary controls, and no 
differences were found. It was also noted that NKC activity and T cell function were 
unrelated to aerobic capacity. Furthermore, a comparable leucocytosis has been 
observed when the two groups were exercised maximally. 
As a consequence of the available evidence regarding the effect of acute and chronic 
exercise on immune status, many researchers217' 224' 235' 254' 308' 417' 438 claim that 
moderate exercise enhances immunity, while more strenuous exercise and prolonged 
training appear to suppress it. Nieman (1994)259 modelled this theory by describing 
the relationship between exercise and upper respiratory tract infections (URTI) in the 
form of a 'J' curve. The model suggests that participation in moderate exercise 
training may reduce the risk of URTI, while participation in periods of excessive 
amounts of high-intensity exercise may elevate the risk. However, other 
investigators224' 225 have not demonstrated consistent support for such a model. 
Attempts to compare resting immune function in athletes and non-athletes have been 
unable to provide crucial evidence that links clinically important immune changes 
with athletic endeavour267• 
Investigations analysing the clinical significance of changes in immune function with 
exercise are scarce. Furthermore, in the few studies identified, the clinical changes 
identified have been in the presence of adverse, no change or improved immune 
system status. 
An investigation performed on elite swimmers undertaking intensive training found 
that swimmers had significantly lower neutrophil oxidative activity at rest when 
compared with matched controls309. However, while oxidative activity was lower, 
URTI rates did not differ between the swimmers and controls. Others have shown 
that near-daily brisk walking, compared with inactivity, reduced the number of 
sickness days by half over a 12- to 15-week period262' 265 . However, this change 
occurred without a change in resting immune function. Finally, it has been 
demonstrated that elderly women classified as 'aerobically sedentary' experienced 
the highest incidence of URTI, while the highly conditioned subjects maintained the 
lowest incidence262 . In association with these findings, NKC and T cell function 
were most superior in the highly conditioned elderly women. Taken together, these 
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results suggest that higher NKC and T cell function is associated with a reduction in 
the presence ofURTI. 
It seems evident that while the clinical significance of the effect of exercise on the 
immune system remains unclear, it is widely accepted that exercise can influence the 
status of the immune system, with the type of change being dependent on the nature 
of the exercise. It is this relationship between exercise and the immune system that 
; 
has led to investigations assessing the effect of exercise on patients with a 
compromised immune system, such as those with cancer. 
6.1.4 Exercise, cancer and the immune system 
The potential benefits and detriments that exercise may have on the immune system 
has been discussed above. The state of the immune system following neoplasia and 
cancer treatment has also been highlighted and is generally regarded as 
suppressed359. Therefore, it is of great interest to determine whether exercise can 
play a positive role in enhancing an already suppressed immune system in patients 
with cancer. Concurrently, there is concern that exercise may further deteriorate the 
immune system, placing the patient at an even greater risk of infection. 
Unfortunately, evidence describing the role of exercise in immune cell recovery post-
cancer and treatment is scarce and thus neither view can as yet, be accepted. 
Animal investigations have been performed to further define the relationship 
between cancer, the immune system and exercise. Results derived from these studies 
have been inconsistent due to methodological differences210' 437 . Nevertheless, these 
investigations have generally shown that the resistance of animals to experimentally-
induced tumours is enhanced through participation in an exercise program353 , and 
that tumour growth rate is slowed when animals are trained 1-8 weeks prior to 
tumour induction165 . Woods et al (1994)437 found that moderate exercise training in 
rats increased the phagocytic capacity of intratumoural phagocytic cells, when 
compared with those of the exhaustive training or control group. However, these 
changes had no apparent effect on tumour incidence or progression. 
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Unfortunately, little data regarding changes in immune cell number and function in 
exercising cancer patients are available. The investigations available have 
predominantly assessed NKC number and activity, since this is the immune 
surveillance cell for the first-line defense against cancer446• 
Resting NKC activity was enhanced in women with breast cancer after participating 
in a 7 -month moderate exercise program292 . Baseline NKC activity levels in patients 
with breast cancer were lower (18.9% lysis) when compared to healthy subjects (30-
35% lysis). However, following the exercise intervention, cytotoxic activity was 
enhanced by 28.3%. The changes in NKC activity occurred in the absence of 
changes in cell number and percentage. Natural killer cell number and percentage of 
the breast cancer group were within normal range and were comparable with values 
of healthy athletes at each testing time point. A further study, again investigating 
breast cancer patients293 , identified that following 7-months of moderate exercise 
training there were significant leucocyte subpopulation changes and that granulocyte 
concentration was significantly enhanced. In contrast to the rise observed in 
granulocytes, the percentage of lymphocytes and monocytes decreased. Two tests 
were implemented to assess monocyte function and demonstrated that monocyte 
phagocytotic capacity was improved against receptor-destroying, enzyme-treated 
sheep red blood cells following training, but was unchanged against Anti-D loaded 
human erythrocytes. 
Immune changes of breast cancer patients who had undergone surgery, 
chemotherapy and/or radiotherapy, following an 8-week exercise intervention have 
also been assessed261 • It was found that the exercise program induced no significant 
effect over NKC activity, and concentrations ofT cell and NKC counts. However, it 
was also identified that those patients who had been diagnosed and treated for an 
average of three years, maintained NKC activity levels similar to healthy controls. 
The effect of a 14-day moderated exercise program, utilising an arm and bicycle 
ergometer, on NKC cytotoxic activity has been studied among stomach cancer 
patients446 . The study suggested that early moderate exercise has a beneficial effect 
on the function of in vitro NKC activity in patients with stomach cancer following 
curative surgery. This conclusion was based on findings that demonstrated a drop in 
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NKC activity until postoperative day 7 for both the control and exercising group, 
followed by an increase in the mean NKC activity of the exercise group, and a 
continued decrease in the control group, by day 14. At day 14, the exercise group 
was demonstrating significantly higher NKC activity levels when compared with that 
of the control group. It could be suggested that these are clinically significant 
findings since others have reported that disease-free treated patients with high 
peripheral blood NKC activity have demonstrated a significantly longer metastasis-
free survival time than those with low NKC activity07 • 
Changes in immune parameters associated with a 12-week aerobic training 
intervention were assessed on 6 children aged between 13-14 years of age, 
successfully treated for acute lymphoblastic leukaemia and other types of 
neoplasms359. Three out of six of these children fully completed the 12-week 
program and were receiving chemotherapy during the course of the study. While all 
six children participated in the initial and final exercise tests, only the results from 
the 3 exercising children were presented and compared with the results from the 
control participants. The investigation found that those children who had been 
diagnosed with cancer were experiencing a suppressed immune system when 
compared with healthy matched controls, evidenced by the low leucocyte, 
lymphocyte, monocyte and granulocyte counts during the initial testing phase. It 
also appeared that participation in the exercise program led to a continued decline in 
certain aspects of immune effectiveness, as could be identified by the change in T 
cell counts and the helper/suppressor ratio. CD3+, CD4+, CD8+ and the 
CD4+/CD8+ ratio was reduced from 0.51±0.17, 0.31±0.12, 0.27±0.07, and 1.1±0.2, 
respectively, at the initial testing phase, to 0.28±0.07, 0.13±0.03, 0.20±0.19, and 
0.9±0.3, respectively, during the final testing session. In addition, spontaneous, and 
IL-2 induced cytolytic activity, and PHA- & PWM- (pokeweed mitogen) induced 
proliferation were also reduced. However, it was noted that major increases in 
susceptibility to either infection or spontaneous neoplasia are unlikely while the 
CD4+ counts exceed 200 cells x 106 cells/Land the CD4+/CD8+ ratio exceeds 0.2. 
Therefore, it was believed that the observed changes in the immune system remained 
insufficient to cause concern for health. Unfortunately, since the data from the 3 
children who failed to complete the exercise program were not shown, it is difficult 
to accept exercise as the primary cause of the continued immune system decline. 
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Previous research has demonstrated that chemotherapy treatment is associated with 
adverse immune changes and it was unclear in this investigation which subjects were 
still receiving chemotherapy treatment. 
Finally, duration of neutropenia and thrombopenia were assessed in patients with 
cancer receiving high-dose chemotherapy followed by a PBST. Thirty-three patients 
participated in a daily aerobic exercise program during the hospitalisation period. 
The results demonstrated that the exercising patients experienced shorter durations of 
neutropenia (p<0.01) and thrombocytopenia (p<0.06) when compared with the 
controls102. 
Exercise immunology and cancer research has predominantly assessed the innate 
component of the immune system, specifically NKC. However, this study has an · 
emphasis on determining the role of exercise on the adaptive component of the 
immune system, and particularly T cells. More information regarding the role of 
exercise and T cells can be found by analysing studies that have investigated patients 
withHIV. 
6.1.5 Exercise, HIV and the immune system 
Shephard and others (1991)355 commented on an investigation performed with HIV+ 
patients that found 4 weeks of endurance exercise increased T helper cells and 
elevated the T helper/suppressor cell ratio, in comparison with a reduced T cell ratio 
in the control subjects. These findings were supported by others, who found that T-
lymphocyte levels in moderately-exercising AIDS patients can return to levels 
comparable to patients with AIDS who are taking treatment drugs such as AZT276 . 
However, research reported by Ullum and associates (1994)396 showed that moderate 
exercise training of HIV -seropositive patients may either increase, or induce no 
change in resting CD4+ cell counts. 
Others have investigated not only the exercise response ofT cells counts in HIV 
patients, but have also examined the NKC response204 . The investigators showed 
that exercising patients demonstrated improvements in cardiovascular fitness, 
maintenance of NKC numbers and unaffected distress levels, in comparison to an 
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increase in anxiety and depression, and a corresponding drop in NKC numbers in the 
non-exercising patients. Increases in T helper cell counts were also observed in the 
exercising patients. This is a clinically important finding since a reduction in this 
cell type has been related to worsening immune function and an elevated disease 
progression. Furthermore, additional evidence of immune normalisation was 
measured by an improved ability of the exercising patients to ward off latent viruses. 
An earlier investigation reported similar findings with no change in NKC counts in 
the exercising HN groups, while the control group demonstrated non-significant 
declines203 • However, it was also reported that cell cytotoxicity remained unchanged 
in both groups. 
CD4+ counts ranging from 9-804J-LL and CD4+/CD8+ ratios ranging from extremely 
low values of0.02 to normal limits of>l.5, have been shown in HN subjects319• It 
was also found that the disease stage was not statistically related to training-induced 
changes of T cell counts, and that gains in aerobic fitness were achieved in the 
absence of changes in totalleucocytes, lymphocytes, or CD4+ and CDS+ subsets. 
A literature review on changes in CD4+ enumeration in HIV -1 patients following 
aerobic exercise training has recently been performed205 . The results were 
summarised as follows: regardless of the disease stage, symptomatology, or level of 
CD4+ cells, no decline in CD4+ counts have been observed and there is a trend 
toward an increase in the number of CD4+ cells in all but one investigation 
identified, with the more significant increases being observed in patients at an earlier 
stage of the disease. Possible mechanisms were related to the role exercise may play 
in stress management and thus the ability of exercise to have a buffering on 
suppressive stressor effects, thereby facilitating a return to normal CD4+ counts. 
Collectively, the studies reviewed provided supportive evidence for HN patients to 
start regularly exercising, particularly within the early stages of the disease. 
However, others have noted that to date no convincing data exist that link moderate 
exercise training with improved T helper cell counts267 . While this may be true, the . 
potential role for exercise in maintaining cell counts rather than improving counts, 
should not go urmoticed or undervalued. 
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In summary, cross-sectional and epidemiological evidence now exists that 
demonstrates single acute exercise bouts and prolonged training can produce changes 
in the distribution and function of particular immune system components308• Despite 
some conflicting evidence, data collection to date has led to an extension of 
Nieman's J-shaped curve, to the development of the "inverted 'U' theory" that 
illustrates moderate exercise enhances immune function, while heavy or lack of 
exercise may attenuate the immune response308' 438 . The development of this theory 
has raised the hope that a suitably graded exercise program might be a valuable 
adjunct to the prevention or treatment of cancer. Therefore, exercise and cancer 
studies have predominantly investigated the role of exercise in enhancing the innate 
immune system or the first line of defense. 
In comparison, studies involving patients with HIV have predominantly assessed the 
role of exercise in enhancing T cells and have shown promising results. 
Furthermore, the beneficial immune changes observed have been related to an 
improved ability of the exercising patients to ward off latent viruses. It is known that 
for patients undergoing a PBST, T cells are usually the last cells to recover, often 
taking up to 6 months to return to 'normal' levels. It is also known that the risk of 
colds and infections is high among this patient population. Therefore, it seems 
plausible that if exercise could improve immune cell recovery following a PBST, in 
particular T cell recovery, the risk and presence of colds and infection could reduce 
during the recovery period. 
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6.2 Methodology 
Chapter 3 provides a detailed outline of the methodological procedures that relate to 
subject recruitment, the testing phases and the intervention program implemented. In 
summary, 12 patients, with 6 patients in each group were recruited. Of these, only 7 
patients were recruited at PI, while the remaining subjects entered the investigation at 
PH. Outlined below are the methodological procedures, which relate specifically to 
the aims of this section of the investigation and involve the assessment of T cell 
number and function. 
Unlike the previous 2 study chapters that involved 3 testing phases, this study 
assesses T cell number and function at more frequent intervals and includes an 
additional 2 testing phases. These 2 testing phases are implemented at the end of the 
first and second month of the intervention period (Il and I2, respectively). 
Therefore, T cell number and function are assessed at PI (pre-transplant), PH (post-
transplant), I1 (1-month post-PH), I2 (2-months post-PH) and PHI (3-months post-
PH). 
6.2.1 T cell number and function 
Blood sampling 
Because lymphocytes exhibit a circadian rhythm 446, blood sampling was set for all 
patients between 8-1 Oam. In addition, since an acute bout of exercise can influence 
blood counts349, patients refrained from exercise participation for 24-hours prior to 
blood sampling. 
A 1 Oml sample of blood was collected from the ante-cubital vein of the forearm 
during each of the 5 testing phases, using a winged cannula attached to an ethylene 
diaminetetra-acetic acid treated vacutainer. A commercial pathology service (S&N 
Laboratories) collected the blood samples for the study during routine blood tests, 
and was therefore able to provide full blood count data. 
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Cryopreservation of the cells 
For convenience of data analysis, the blood samples were cryopreserved prior to 
developing the assays and performing lymphocyte subset counts. Cryopreservation 
involved the separation of mononuclear cells from whole blood by "Ficoll-Hypaque" 
density centrifugation, which were then washed and suspended at room temperature 
in RPMI (Roswell Park Memorial Institute) 1640 supplemented with 20% heat-
inactivated fetal calf serum. An equal volume of freezing medium (complete RPMI 
1640 plus 15% dimethylsulfoxide (DMSO)) was added dropwise. This yielded a 
final freezing suspension of complete RPMI 1640 plus 10% foetal calf serum (FCS) 
plus 7.5% DMSO. This mixture was pipetted into ampoules and was then transferred 
to a controlled-rate freezer at -70°C. The cells remained in the freezing medium for 
minimal time prior to being frozen. 
At the time when the cells were required for the development of the proliferation 
assays, the cryopreserved cells were removed from the freezer and immediately and 
rapidly thawed by shaking in a 37°C-water bath. Prior to the last ice crystal being 
melted, the vial was removed from the water bath. With a 1ml pipette, the contents 
of the vial were transferred to a 15ml round tube by gently adding the cells down the 
side of the tube. The tube was then placed at room temperature and the dilution 
procedure to remove the DMSO was initiated. By using RPMI and human AB 
serum, the procedure began by gently adding 1 drop of complete medium down the 
side of the round-bottom tube. The addition was then repeated, doubling the volume 
each time (that is, 2, 4, 8, 16, 32 drops, etc) until a DMSO concentration of 4% was 
achieved. Following each addition, the cells and medium were gently mixed. The 
round-bottom tube was filled to a 15ml volume with medium, and then centrifuged at 
200g for 10 minutes. Aspiration of the medium followed. The cells were then 
resuspended in complete RPMI with 10% foetal calf serum, at a concentration of 8 x 
105 ce1Lrrir1. 
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Lymphocyte proliferation assays 
Aliquots of 200!-t1 were added to round-bottomed microtitre 96-well plates at a final 
concentration of 201-1gmr1. Eight replicates of cultures with mitogen (positive wells) 
and eight replicates of cultures with phosphate buffered saline (PBS) added instead 
of mitogen (controls/blank wells), were then incubated at 37°C in a 5% C02 
humidified atmosphere for 64 hours. Following incubation, the culture media was 
carefully removed with a multi-channel pipette, ensuring that the cells were not 
disturbed from the bottom of the plate. The culture was then replaced with fresh, 
serum-free RPMI (1 001-11 per well). 
Colorimetric detection methods were utilised to quantify cell number and 
proliferation rates of human T cells. To each well, 101-11 of MTT (3-(4,5 
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) at 5mg/ml in PBS was 
added and incubated for 4-6 hours (37°C in 5% C02). MTT is converted to intensely 
coloured (blue) formazan products by mitochondrial enzymes. These products can 
be detected spectrometrically at an absorbance of 540nm. Following the incubation 
period, 150!-11 of acid isopropanol (3.32ml concentrated HCl in 1 litre isopropyl 
alcohol- 0.04M HCl) was also then added and the plate was left at room temperature 
for approximately 60 minutes to assist the crystals to dissolve. Each well was then 
mixed by pipetting up and down with a multi-channel pipette. Finally absorbance 
was read at 540nm, and adjusted for background absorbance, which was read at 
630nm. 
Throughout the literature the quantification of cell function occurs in two ways: 
);> Method 1: positive minus the blank (unproliferative cells) - the absorbance 
obtained from the blank wells is taken away from the absorbance obtained from 
the positive wells. 
);> Method 2: positive - this method involves the measurement of the absorbance 
obtained from the positive wells only and ignores the absorbance obtained from 
the blank wells. 
Previous research has demonstrated that there is no difference between the results 
obtained from both methods70. Therefore, as a consequence of dealing with low cell 
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counts in this investigation, method 2 was implemented. That is, during some of the 
testing phases, particularly at PII, the number of cells available for the assay enabled 
the development of positive wells only. During these testing phases, the latter 
method enabled the attainment of results, even when cell numbers were low. 
Furthermore, since mitogens are known to stimulate specific lymphocyte subsets70, it 
has previously been suggested that mitogen responses should be expressed on a per 
cell basis of the major respondent subset. In the case of the mitogen used for this 
assay, that subset is T lymphocytes (CD3+ cells). Moreover, it is generally accepted 
that it is the T helper cells (CD4+ cells) which respond to the mitogen, rather than the 
CD8+ cells. Therefore, once function was quantified, the data were adjusted 
according to the number of CD3+, and also according to the number of CD4+ cells, 
present within the well. Total blood counts and lymphocyte subset counts were 
therefore required. 
Lymphocyte subset counts and total blood counts 
Following lymphocyte suspension at a concentration of 8 x 105 cell.mr1, and prior to 
the development of the assay, 50J.LL of cells was mixed with 5J.!L of a cocktail of 
selected monoclonal antibodies conjugated with fluorescein isothiocyanate (FITC), 
phycoerythrin (PE), and peridin chlorophyll-a protein (PerCP) in the following 
combinations: CD3 monoclonal were conjugated with PerCP, CD4 monoclonal with 
FITC, and CD8 monoclonal with PE. Monoclonal antibodies were purchased from 
Becton-Dickinson, San Jose, CA, USA. Following a 30-minute incubation period in 
the dark, cells were then washed with PBS, then resuspended in 200J.!L of 2% 
paraformaldehyde solution. Stained cells were passed through a Becton Dickinson 
F ACScan flow cytometer and were specifically gated. The same forward- and side-
scatter parameters were used for each trial as established for human peripheral 
leucocytes. Standard gating procedures were used to select mainly lymphocytes and 
to differentiate between labelled and unlabelled cells. The natural fluorescence of 
unstained preparation and its contribution to the fluorescence channels was 
determined using an unstained proportion of the cell suspension. Once the CD3+ 
cells were gated, the CD4+ and CD8+ subsets were then gated from this identified 
CD3+ population. Full blood counts (provided by S&N Laboratories) taken at the 
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same time as the blood sample, were then used in conjunction with the data collected 
via the use of the FACScan, to determine absolute CD3+, CD4+ and CDS+ counts. 
Therefore, data were obtained for: 
>- leucocyte and lymphocyte counts, 
>- T cells (CD3+) and T cell subset counts (CD4+ and CDS+ counts), 
);;> and T cell function, which was expressed in three ways:-
>- positive (positive response to mitogen only); 
>- positive/absolute number of CD3+ cells; 
>- and, positive/absolute number of CD4+ cells. 
6.2.2 Statistical analysis 
Data for T cell numbers and function were analysed according to the statistical 
procedures outlined in Chapter 3. 
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6.3 Results 
As shown in Figure 6.2, undertaking a PBST is associated with adverse effects on T 
cell subsets, with CD4+ cells and the CD4+/CD8+ ratio illustrating significant 
declines. 
Figure 6.2 T cell subset measures at PI and PII for the study group (mean±SE) 
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Figures 6.3a and b, depict the change in T cell function caused by the PBST. 
While the mean total T cell function (total positive response, Figure 6.3a) declined, 
function per CD3+ cell and per CD4+ cell (Figure 6.3b) increased. However, the 
changes were not significant. 
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Figure 6.3 T cell function at PI and PII for the study group (mean±SE) 
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Statistical analysis revealed that exercise had no effect on T cell count recovery 
following the transplant. This was evident by the p values calculated in the analysis 
of the group interaction for CD3+, CD4+ and CD8+ counts (p = 0.948, 0.777 and 
0.870, respectively). Therefore, the CG and EG data were pooled for all testing 
phases and the means, standard deviations and standard errors, have been calculated 
for the entire group. Figure 6.4 illustrates that the white blood cell (WBC) counts 
significantly decreased following the transplant (p<0.05), but returned to pre-
transplant and 'normal' age-matched levels by the end of the first-month post-
transplant. Lymphocyte counts also declined significantly (p<0.05) by PH but 
significantly increased during the 1st month post-transplant (p<0.01). By Il, 
lymphocyte counts were similar to pre-transplant and age-matched levels. 
Figure 6.4 WBC and lymphocyte counts across the phases for the study group 
(mean±SD) 
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Figure 6.5a displays the changes in CD3+, CD4+, and CDS+ cell counts and the T 
cell ratio, across the phases. Also shown in Figure 6.5a are the comparable age-
matched data for T cell subsets and ratios. Pre-transplant, CD3+ cell counts were 
significantly lower than age-matched healthy counts (p<0.01), and reduced further 
following the transplant. However, by 1-month post-transplant, CD3+ counts had 
significantly increased (p<0.05) and were similar to healthy matched controls. 
Counts remained at 'normal levels' for another month, but by 3-months post-
transplant, declined to levels that were again significantly lower (p<0.01) than age-
matched data. 
CD4+ counts declined (p<0.01) by PII, and showed little improvement throughout 
the testing phases. As can be seen by Figure 6.5a, CD4+ counts were significantly 
lower than age-matched data at all testing phases. 
At PI, absolute numbers of suppressor T cells (CDS+) were lower (p<0.01) than age-
matched data and undertaking the transplant was associated with a further mean 
decline. However by Il, counts had increased (p<0.05) to levels that were similar to 
normative data. Although suppressor counts illustrated a decline between I1 and 
Pili, counts remained similar to normative values. 
The ratio between the helper to suppressor cells dropped following the transplant 
(p<0.01) and continued to decline until the end of the first-month post-transplant. At 
Il, the ratio was significantly less than pre-transplant and 'normal' levels (p-:=::0.01). 
While the ratio showed a mean increase between I1 and Pili, at the end of the 
intervention period, the ratio remained lower than pre-transplant and normal (p<0.01) 
levels. Individual T cell ratio measures across the testing phases for 2 subjects are 
displayed in Figure 6.5b. These 2 patients were followed for a longer period post-
transplant, and demonstrated that at 4-months post-transplant the ratio remained low 
(0.45 for one patient, and 0.15 for the other). Additionally, one subject was followed 
for another one-month and reported a ratio of0.16 at 5-months post-transplant. 
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Figure 6.5(a) T cell subset and T cell ratio measures across the phases for the 
study group, and comparisons with normative data (mean±SE) 
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Figure 6.5(b) Individual T cell ratio measures across the phases for 2 subjects at PI, 
PII, Il, I2, I3 (3-months post-PH), I4 (4-months post-PII) and IS (5-months post-PI!) 
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Figure 6.6 illustrates the changes in T cell subset percentages across the phases and 
compares study group data with age-matched normative data. The percentage of 
CD3+ cells remained relatively stable up until the 3rd -month post-transplant (Pill). 
Until this time, the percentage of lymphocytes that were CD3+ cells was close to 
normative data. However, by Pili, the percentage of CD3+ cells was lower (p<0.05) 
than age-matched data. The percentage of CD4+ cells decreased (p<0.05) following 
the transplant and continued to decline until Il. The percentage of CD4+ cells was 
significantly lower at Il, I2 and Pill when compared with pre-transplant (p<0.01) 
and age-matched data (p<0.01). Furthermore, %CD8+ cells increased between PI 
and PII (p<0.05) and continued to increase until I1 (p<0.01). At Il, the percentage of 
suppressor cells was higher than pre-transplant levels (p<0.01) and normative data 
(p<0.01) and remained at those levels until the end of the intervention period. 
Figure 6.6 T cell percentages across the testing phases for the study group, and 
comparisons with normative data (mean±SD) 
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Statistical analysis revealed that the intervention program had no effect on T cell 
function recovery following the transplant. This was evident by the p values 
calculated in the analysis of the group interaction forT cell function, expressed as the 
positive response to the mitogen, positive response adjusted for CD3+ cells and the 
positive response adjusted for CD4+ cells (p = 0.861, 0.200 and 0.135, respectively). 
Therefore the subject data from the control and exercise group were pooled. Figure 
6.7 depicts the changes in T cell function, expressed as the total positive response 
only (Figure 6.7a), positive response per CD3+ cell (Figure 6.7b), and positive 
response per CD4+ cell (Figure 6.7b), across the testing phases. T cell function was 
significantly higher at 3-months post-transplant, when compared with immediately 
post-transplant, when expressed as the total positive response. However, no other 
changes in function across the phases were significant, regardless of how function 
was expressed. 
Figure 6.7 
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6.4 Discussion 
The results of this investigation demonstrated that while the absolute WBC count, 
percentages of CD3+, CD4+ and CD8+ cells and the CD4+/CD8+ ratio were 
considered normal pre-transplant, the absolute counts of lymphocytes and T cell 
subsets were below age-matched controls. Therefore, patients were already 
immunocompromised prior to undertaking a PBST. Following the transplant, 
adverse changes were observed for total leucocyte, lymphocyte, CD3+, CD4+, and 
CD8+ counts, and the helper/suppressor ratio. Regardless of whether an exercise 
program was initiated post-transplant, more than 3-months was required for total 
lymphocyte and T cell subset counts to return to 'normal' levels. Additionally, T cell 
function was adversely affected following the transplant but showed a mean 
improvement during the 3-months post-transplant. However, these changes were not 
statistically significant. 
6.4.1 Pre-transplant immune parameters 
Until now, little data have been available regarding pre-PBST immune function, and 
it was therefore difficult to determine the exact impact of undertaking a PBST on 
immune parameters. Additionally, immunological measurement pre-transplant 
allows the quantification of immune status in cancer patients who are likely to have 
undergone previous conventional treatment regimens. Previous research has 
associated a deterioration in immune status and function with cancer51 ' 190' 356 and its 
associated treatment53' 393 . Therefore, the patients investigated within this study were 
considered 'at risk' of maintaining poor immune status, even prior to undertaking a 
PBST. 
While the percentage of lymphocytes that were T cells, and the percentage ofT cells 
that were CD4+ and CD8+ cells at PI, were similar to normative data, absolute 
counts for T cells, helper T cells and suppressor T cells were below 'normal' 
(p<O.Ol). In addition, although the mean helper/suppressor ratio for the study group 
was considered normal, an analysis of individual ratios demonstrated that 2 out of 7 
patients assessed pre-transplant, were experiencing below 'normal' ratios. 
Furthermore, total lymphocyte counts were also below normative ranges and can be 
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used to explain how the percentage of CD3+ cells were considered normal while the 
absolute count was not. Although total leucocytes were slightly less than age-
matched normative data, the difference was not significant. Through the analysis of 
the full blood counts, it was determined that leucocytes other than lymphocytes, such 
as neutrophils, monocytes, eosinophils and basophils, were able to recover following 
previous treatment to levels which enabled the total WBC count to reach near normal 
levels. 
As discussed earlier, T cell function was determined in three ways. Firstly, via 
quantification of the positive response to the mitogen, secondly by dividing the 
positive mitogen response by the absolute number of CD3+ cells, and finally, by 
dividing the positive mitogen response by the absolute CD4+ cell count. When it is 
assumed that CD4+ cells are predominantly proliferating in response to a mitogen, 
then expression of function per CD4+ cell would be considered the most appropriate. 
However, if it were assumed that both CD4+ and CDS+ cells show a proliferative 
response in the presence of a mitogen, than expression per CD3+ cell would be 
considered the most appropriate method. More work is required before either of 
these assumptions can be fully accepted. Nevertheless, regardless of how function 
was expressed, mitogen response observed at PI, compared with the mitogen 
response observed by other work performed on cells from 'healthy' subjects within 
the QUT laboratories, was not significant. These comparisons indicate that the 
lymphocytes were functioning at below 'optimal' levels pre-transplant, with the 
results providing support for the statement, that "lowered T cell function has been 
considered a hallmark of malignant disorders"356 . 
The quantification of these immune parameters indicates that cancer, prior treatment 
or factors associated with cancer diagnosis and treatment - such as treatment-related 
physical inactivity, psychological stress, or a change in food intake - have led to a 
deterioration in lymphocyte and specifically T cell counts, and T cell function. That 
is, the adaptive component of the immune system, which has a primary role in 
preventing the presence of illness or infection, is compromised pre-transplant. 
Further, any negative impact that the transplant is likely to impose will exacerbate 
cancer patients' already 'poor' immune status. 
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6.4.2 The impact of a PBST on T cell number and function 
Irradiation and some cytostatic drugs elicit a steep dosage-versus-antitumour effect 
relationship, with a correlation existing between the higher the dose, the more 
effective eradication of the malignant cell. However, due to the toxicity of normal 
tissues such as the bone marrow or gastrointestinal epithelium, dosage escalations 
above 150-250% of the conventionally used dosages of drugs are prevented, and 
therefore CT doses are often insufficient to cure specific cancers250' 397 . Failure to 
find exploitable differences between malignant and normal cells have frustrated the 
attempts to develop more effective agents that would allow the highly selective 
therapy required for tumour eradication. However, the inability to use drugs to 
eradicate the tumour without being lethal to the patient has led to the development of 
PBST. The transplantation process begins with an intensive course of high-dose CT, 
called the 'conditioning regimen'. Following high-dose CT, patients are 'rescued' 
from the lethal effects of the treatment with their previously collected pluripotent 
stem cells126• These stem cells are able to migrate to the bone marrow and 
immediately begin their role of generating one or more subsets of mature cells that 
eventually evolve into erythrocytes, leucocytes or platelets. Following this 
conditioning regimen, a period of profound pancytopenia 371 is inevitable. 
As was expected, the patients in the study demonstrated a mean decrease in 
leucocytes, T cells and suppressor cells, in addition to a significant decrease in the 
total lymphocyte count, CD4+ cell count, and the helper/suppressor cell ratio. By 
PII, leucocyte, lymphoctye, CD3+, CD4+ and CDS+ cell absolute counts were lower 
than age-matched normative data. In contrast, the mean ratio of helper to suppressor 
cells was similar to age-matched data during this same testing phase. However, 
unlike the other immune parameters measured, the helper/suppressor ratio was on 
average higher than age-matched data at PI. Additionally, an analysis of individual 
ratios showed that only half of the group assessed at PII reported ratios similar to 
age-matched controls, while the remaining 5 subjects reported below normal ratios. 
The mean leucocyte and lymphocyte counts at PII were 5.46±2.47 and 0.38+0.47 103 
x cells/J..LL, respectively. While the leucocyte counts of the PBST patients were 
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similar to stage I and II breast cancer patients (5.25+2.08 x 103 cells/f..LLi93 , the 
lymphocyte counts were much lower (1.49+0.69 x 103 cells/f..LLi93 . 
Additionally, a PBST leads to a reduction in the mean total positive response to the 
mitogen. In contrast, the mean function per CD3+ cell and per CD4+ cell is 
elevated. When these results are considered concurrently they indicate that while 
function per CD3+ and CD4+ cell was enhanced, total function was reduced. 
Irrespective of the manner in which function was expressed, the changes were not 
significant and therefore the results indicated that undergoing a PBST had no impact 
on an already below optimal T cell function. In comparison, previous research has 
demonstrated impairment in T cell function following a PBST or BMT transplant384. 
The results indicate that a patient who has undergone a PBST is in an 
immunocompromised state immediately post-transplant, with both the innate and 
adaptive components of the immune system being adversely effected. Consequently, 
these patients are considered to be at an elevated risk of infection post-transplant371 . 
Therefore, PBST patients are often advised to avoid public places or environments 
with crowds or children and are also given recommendations regarding safe food 
preparation. Patients are expected to follow these guidelines until their immune 
system has fully recovered and yet previous research has demonstrated that T cells 
can take up to 6 months to recover384• Unfortunately, these guidelines may have 
· certain social and psychological ramifications for the patient which, in turn, could 
potentially lead to the release of immunomodulatory hormones. What is unknown at 
this stage, but is of clinical interest, is the difference between infection rates of 
patients who do and do not comply with these recommendations. 
6.4.3 Changes in immune parameters post-transplant 
Statistical analysis revealed that there was no group-by-phase interaction, indicating 
that the exercise intervention did not influence the recovery of cells post-transplant. 
Therefore, the results obtained from the CG and EG were pooled. 
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While leucocyte counts were below normal following the transplant, by I1 counts 
had significantly increased and had returned to what were considered normal levels. 
Additionally, lymphocyte counts during this same period also showed a significant 
increase by I1, and reached numbers similar to age-matched data. The increase in 
lymphocyte counts during PII to I1 can account for some of the elevation in WBC 
counts during the same period. However, by 1-month post-transplant, the full blood 
count analysis revealed that neutrophils and monocytes had also fully recovered for 
all patients. Therefore the increase in neutrophils, monocytes and lymphocytes all 
attributed to the elevation in total leucocyte counts by Il. Previous research has also 
demonstrated that neutrophils371 , monocytes384 and NKC337' 384 are able to recover 
within 1-month following a PBST. 
While leucocyte counts showed a mean decrease by I2, followed by a corresponding 
mean increase by 3-months post-transplant, the fluctuations were not significant and 
values remained within normal ranges. Lymphocyte counts demonstrated the same 
trend between I1 and I~, but again the changes were not significant. However, in 
contrast to WBC, following I2, a mean decline in lymphocyte counts was observed. 
By 3-months post-transplant, although the mean lymphocyte count was significantly 
higher than that measured at PII, counts remained significantly lower than age-
matched data. The results indicate that more than 3-months is required for total 
lymphocytes to fully recover following a PBST. An analysis of change across time 
for specific lymphocyte subsets (CD3+) provided more detail regarding the factors 
contributing to these changes. 
The trend across time for the mean change in CD3+ counts is similar to that observed 
for the total lymphocyte count, in that CD3+ counts significantly increased during 
the first month post-transplant and reached levels considered normal. However, 
during this same period, the %CD3+ population demonstrated a mean decrease. By 
taking into account changes in lymphocyte and T cell percentage and absolute 
numbers, the results indicated that NKC experienced a faster recovery following the 
transplant, when compared with the recovery rates of T cells. Again, these results 
support those previously reported384. Between the 1st_ and 2nd -month post-transplant, 
a mean decline in absolute CD3+ counts was observed, followed by a further decline 
by the 3rd -month post-transplant. At Pili, T cell counts had returned to levels that 
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were significantly less than age-matched counts. It seems plausible to suggest that 
the change in the mean absolute CD3+ count following the transplant could account 
for some of the change observed in the mean total lymphocyte counts during the 
recovery period. In addition to these results, by Pili, the %CD3+ cell population was 
lower than pre-transplant, post-transplant and normative percentages. In order to 
explain these results, an analysis of CD4+ and CDS+ data are required. 
The percentage of T cells that were CD4+ cells and CDS+ cells, significantly 
decreased and increased, respectively, between Piland Il. A mean increase and thus 
a corresponding mean decrease, for the percentages of helper and suppressor cells, 
respectively, were observed between I1 and Pili. By Pili, the percentage helper cell 
population was significantly less than normal, while the percentage suppressor cell 
population was significantly higher than normal. It is therefore likely that the drop 
observed in the %CD3+ population between I2 and Pili, was a consequence of the 
significantly lower than normal %CD4+ cell population during this same period. 
The suppressor cells recovered at a faster rate than the helper cells, as can be seen by 
the significant increase in CDS+ cells between Pil and Il. The CDS+ counts then 
demonstrated a mean decline from 1-month to 3-months post-transplant, but during 
this period remained similar to age-matched controls. Further, by 3-months post-
transplant, CDS+ counts were also similar to pre- and immediately post-transplant 
measures. These results are supportive of previous research findings 158' 384 that 
demonstrated high levels of suppressor cell activity following transplant, which then 
returned to pre-transplant levels by day 100. 
As previously mentioned, CD4+ counts declined significantly following the 
transplant and remained significantly lower than pre-transplant and normative data at 
3-months post-treatment. Furthermore, the results obtained from 1 patient followed 
for 4-months post-transplant, and another followed for 5-months post-transplant, 
demonstrated that the CD4+ cell population was still unable to recover by 4-5 
months post-transplant. Previous investigations have also found that CD4+ cell 
counts may take up to 6 months to fully recover post-transplant158' 384. 
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T cell ratio changes are a direct consequence of the CD4+ and CDS+ cell count 
changes. However, unlike the other immune parameters assessed within this 
investigation, the mean helper/suppressor ratio for the group, did not fall below 
normal until 1-month following the transplant. This trend was evident in over half of 
the subjects within the study group. However, 2 subjects demonstrated below 
normal ratios at PI, and maintained a low ratio throughout all testing phases. While 
this mean group ratio showed a slight increase from I1 to Pill, 3-months post-
transplant the ratio (0.42±0.26) remained significantly lower than pre-transplant and 
age-matched values. Furthermore, the 2 subjects followed for an additional! month, 
and 2 months post-transplantation demonstrated the continued maintenance of below 
normal helper/suppressor ratios. Others have also reported a mean helper/suppressor 
ratio of 0.3±0.2 within the first 3-months post-transplant158. The low ratio relates to 
an imbalance of the adaptive component of the immune system, which can 
potentially lead to adverse implications for the cytokine cascade that activates other 
immune cells349• In particular, NKC cytotoxicity is potentially reduced as a 
consequence of a deficiency in interleukin-1 and interferon-gamma, and/or the 
activation of suppressor mechanisms. 
Major increases in susceptibility to either infection or spontaneous neoplasia are 
considered unlikely while the ratio exceeds 0.234. However, others have noted that 
susceptibility to infection is elevated if the ratio falls below 1.5191 . Normative values 
for the CD4+/CD8+ ratio for the 18-70 year age group have been reported as 1.2152. 
Therefore, while the patient population presented in this investigation maintained 
ratio values above 0.2, the mean ratio by 3-months post-transplant was 
approximately one third of age-matched 'normal' ratios and approximately one 
quarter of 1.5. Without comparing infection rates post-transplant to healthy matched 
controls, it is inappropriate to suggest that these patients, by nature of the low 
helper/suppressor ratio, were at an elevated risk of infection. It seems evident that 
the clinical significance of the helper-to-suppressor ratio needs further investigation 
before a specific ratio value becomes accepted as the critical level for elevated risk of 
infection. Additionally, when evaluating risk of infection, it is also relevant to 
consider changes in cell function, along with changes in cell counts. 
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In general, small and insignificant changes were observed in function during the 
recovery period. Nevertheless, by 3-months post-transplant, the mean function 
(regardless of how it was expressed) was higher than function measured immediately 
following the transplant. Furthermore, the change between the total T cell function 
at PIT and PIII was significant. However, at the end of the testing phases, function 
was similar to pre-transplant measures, and as has already been discussed, pre-
transplant function was considered below normal. These results provide support for 
previous work, which has demonstrated an impairment in T cell function in patients 
who have undertaken PBST or BMT384. 
6.4.4 The role of exercise in immune system recovery 
It was an objective of this investigation to assess the chronic exercise effect on 
immune parameters rather than the acute effect. The results of this study 
demonstrated that 3-months of regular exercise following a PBST, had no influence 
on immune cell recovery. Others have also shown that an 8-week exercise program 
failed to significantly enhance the NKC function, or NKC and T cell counts of 
patients with breast cancer261 • In contrast, improved NKC activity has been 
demonstrated in breast cancer patients following participation in a 7 -month exercise 
intervention program292. It therefore seems plausible that a longer intervention may 
be required to observe differences in immune status and function, between exercising 
and control patients. However, others have shown significantly higher NKC activity 
levels in exercising patients with stomach cancer following a 14-day moderated 
exercise program when compared with controls. Variations in the cancer populations 
studied, the treatments regimens undertaken, the timing of the intervention, the 
exercise programs implemented, and initial immune parameters are likely factors that 
have contributed to the results observed in the above studies, and make comparisons 
between the studies difficult. Nevertheless, it is evident that work regarding the 
chronic exercise effect on immune parameters in cancer patients is limited and 
preliminary, and requires further research. 
It could also be suggested that the exercise intervention implemented in this study 
was not of sufficient magnitude to induce an effect. However, the previous chapters 
have clearly outlined the benefits attained in body composition, energy expenditure, 
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aerobic capacity and muscular strength by the exercising subjects. Gains in aerobic 
fitness, in the absence of changes in total leucocytes, lymphocytes, or CD4+ and 
CDS+ subsets, have also been found in patients with HIV319. These results indicate 
that while certain physiological improvements can be observed within 3-months, 
other physiological components may require a longer period. 
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6.5 Conclusion 
In summary, the PBST patients were already immunocompromised pnor to 
undertaking the transplant and the transplant procedure imposed further adverse 
changes to WBC and lymphocyte counts. Participation in the exercise program had 
no impact on immunological changes following treatment. White blood cell and 
CDS+ cell counts returned to normal within 3-months post-transplant, however the 
lymphocyte, CD3+, and CD4+ cell counts demonstrated a delayed recovery for both 
exercising and non-exercising patients. Although participation in the exercise 
program had no influence on immune cell recovery following a PBST, importantly 
immune recovery was not adversely effected, demonstrating that exercise 
participation was of no detriment to immune status and function for these patients. 
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Changes in bone turnover following a PBST 
and participation in an exercise program 
"Bone is laid down where needed and resorbed where not needed" 
Wolff's Law (1892) 
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List of abbreviations specific to Chapter seven 
4-NPO 
4-NPP 
BMC 
BMD 
BMT 
CG 
DXA 
EG 
GVHD 
PBM 
PBST 
PI 
PICP 
PII 
Pill 
sAP 
SD 
SG 
uDPyr/Cr 
uHP/Cr 
4-nitrophenoxide 
4-nitrophenylphosphate 
Bone mineral content 
Bone mineral density 
Bone marrow transplant 
Control group 
Dual energy x-ray absorptiometry 
Exercise group 
Graft versus host disease 
Peak bone mass 
Peripheral blood stern cell transplant 
Phase I 
carboxyl-terminal propeptide of type I procollagen 
Phase II 
Phase III 
Serum alkaline phosphatase 
Standard deviation 
Study group 
Urinary deoxypyridinoline/creatinine 
Urinary hydroxyproline/creatinine 
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7. Changes in bone turnover following a PBST and participation in 
an exercise program 
7.0 Introduction 
As medical technology has advanced, outcomes have improved for many 
malignancies, and thus survival rates for those diagnosed with cancer are 
progressively increasing each year. Further, as survival rates continue to rise, there 
is an increasing concern over the quality oflife of these patients16. Many of the side 
effects associated with cancer and treatment arise in the relatively early stages of the 
cancer continuum, and their immediate effects on physical function and quality of 
life are evident. However, certain side effects also exist, which may not influence 
function or quality of life until later in life. Bone turnover change induced by cancer, 
or treatment, inadequate nutrition or physical inactivity associated with cancer, is one 
such side effect that maintains the potential to influence function and quality of life 
in the longer term. 
Bone turnover changes observed in patients with cancer relate to an elevation in bone 
loss and a corresponding increase in the risk of osteoporosis. The incidence of 
osteoporosis and consequential hip fractures is associated with high personal and 
community costs, particularly in developed countries. Mortality following hip 
fracture is in the order of5-15%, while almost 50% of individuals become dependent 
following fracture218 . 
Participation in weight-bearing physical activity and resistance training has been 
shown to improve bone mineral density and reverse bone loss. However, the role of 
exercise on bone turnover in patients with cancer, has not been investigated. The 
recovery of cancer patients post-treatment should involve both the return to normal 
functioning and quality of life, as well as the prevention of conditions that could lead 
to an adverse effect on functional capacity and quality of life at a later stage. It 
seems plausible that participation in an aerobic and resistance training program 
throughout the cancer continuum could influence the rate of bone loss during 
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treatment and the ability to reverse bone loss following treatment. In turn, 
participation in exercise may therefore provide an important means of reducing the 
risk of osteoporosis, and therefore ultimately influence functional capacity and 
quality of life in the longer term. 
7.0.1 Purpose 
Objective 1: To investigate changes between pre- and post-PBST measures of bone 
turnover. 
Research hypothesis for objective 1: 
Bone turnover will increase following a PBST (as determined by pre~ and post-
transplant measures). 
Objective 2: To investigate the role of a three-month duration, moderate intensity, 
mixed type exercise program on bone turnover, post-PBST. 
Research hypothesis for objective 2: 
Participation in the exercise program will lead to a beneficial effect on bone 
turnover, characterised by decreased resorption and increased bone formation 
activity (as determined by pre- and post-intervention measures). 
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7.1 Literature Review 
Key determinants of skeletal status and the potential for fracture include peak bone 
mass (PBM) and the rate of bone loss282 . The greater the PBM, the longer the period 
ofbone loss that is required before the fracture threshold is reached116. Further, the 
maintenance of bone mass between the ages of 20 and 50 years is crucial to long-
term skeletal health and can also influence the time at which the fracture threshold is 
reached82• Therefore, while most osteoporotic fractures occur in the elderll, early 
life events which affect acquisition of PBM, length of time PBM is maintained, or 
rate of bone loss, can significantly influence the risk of osteoporosis in later life. 
Although the essential morphology and biological processes of bone are 
predominantly genetically determined (60-80%)60, environmental and hormonal 
factors66' 198' 409, nutrition (specifically calcium intake)116' 236' 332 and physical 
activity' 184' 298 also play an integral role and maintain the potential to alter the 
individual expression of this genetic potential60. However, prior to evaluating the 
effect of these factors on skeletal health, it is first important to understand how 
skeletal status is assessed. 
7.1.1 Assessment of skeletal status 
Two opposing activities, bone formation by osteoblasts and bone degradation by 
osteoclasts, characterise bone metabolism93 . The tightly-coupled activity in time and 
space, in a sequence of events, defines a given remodelling unit112 . Overall bone 
mass is dependent on the balance between degradation and formation within a 
remodelling unit and on the number of remodelling units which are activated within a 
given period of time in a specific area of bone93 . Skeletal status can be assessed by 
either measuring bone mass (bone mineral content and bone mineral density) or by 
assessing the activity of osteoblasts or osteoclasts. Bone mass is assessed via the use 
of imaging techniques such as computed tomography, magnetic resonance imaging 
and more commonly, via the use of dual energy X-ray absorptiometry (DXA). The 
accuraci00' 408 and repeatabiliti38 of using DXA to determine bone mineral content 
(BMC) and bone mineral density (BMD) make this a valid technique for assessing 
skeletal status. However, the ability to observe changes in BMC or BMD within a 
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relatively short period of time (less than 12 weeks) using DXA, or other imaging 
techniques, is limited due to the time required for the completion of a remodelling 
cycle (up to 200 days)113 . 
Osteoblast and osteoclast activity can be measured with biochemical markers. These 
markers are commonly categorised as markers of bone formation or resorption 
(Table 7.1). 
Table 7.1 Biochemical markers ofbone turnover 
Formation Markers: Resorption·Markers: 
Osteocalcin (Gla protein ofbone) Pyridinoline and deoxypyridinoline 
(collagen and phosphatase crosslinks) Total and dialysable hydroxyproline 
Total and bone-specific alkaline Tartrate-resistant acid phosphatase 
phosphatase Hydroxylysine glycoside 
Procollagen I extension peptide Free y-carboxyglutamic acid 
Noncollagen protein fragments 
A combination of markers can be implemented during the same period, making it 
possible to assess formation and resorption, and cell activity and matrix components, 
simultaneously. While the potential application of these markers is significant, 
limitations also exist. Technical problems include issues with storage life, precision, 
accuracy and sensitivity of the markers at low turnover rates of bone, and daily 
physiological fluctuations in the measurements being assessed. In addition, the 
markers are unable to distinguish between cell/tissue abnormalities and between 
trabecular, endosteal and cortical tissue sheaths378 . While an ideal marker for bone 
formation and/or resorption does not exist93 , these markers and combinations of 
markers have been extensively employed in bone turnover studies and have provided 
useful information. 
The extent of new formation and bone degradation influences the biochemical 
parameters of bone metabolism. Bone stability occurs when equilibrium between 
formation and resorption exists378 . This balance can be shifted in either direction, 
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favouring formation or resorption, depending on the environment or disease 
processes present. 
7.1.2 Factors influencing skeletal status and risk of osteoporosis 
Osteoporosis has been defined as a "disease of the skeleton in which bone mass or 
density is reduced, accompanied by microarchitectural damage, such that there is an 
increase in the risk of fracture even in the absence of significant trauma'.21 8. It 
represents a class of bone pathology where there exists an uncoupling of the 
processes ofbone resorption and formation. 
Osteoporosis usually develops with age, both as a result of the age-related decline of 
bone density (approximately 1 %/year) coupled with the abrupt elevation in bone loss 
in females of up to 8% per year at the menopause60. Evidence stemming from 
investigations involving humans, primates and rodents has indicated that following 
loss of ovarian function, rate of bone resorption and formation elevate, with the 
former exceeding the latter230. In contrast, loss of bone that is specifically related to 
age is most likely a result of a reduction in the supply of osteoblasts in proportion to 
the demand for them. Age and postmenopausal bone loss also differ with respect to 
the skeletal sites affected. While postmenopausal bone loss predominantly occurs 
within trabecular bone, aging-associated bone loss primarily occurs in cortical 
bone230 . 
Other causes of bone loss exist and have been differentiated into categories relating 
to disease and drug therapy, diet and disuse 279. The following review of the 
literature discusses the impact of each of these categories on skeletal status, and the 
presence of these factors in patients with cancer. 
7.1.2.1 Disease- and drug-related bone loss 
Numerous types of chronic diseases have been related to bone loss279, in particular 
those that require a patient to participate in the long-term use of specific drugs which 
induce bone loss as a side effect. Cancer is one such disease state and its treatment 
often involves the administration of drugs such as heparin, methotrexate, 
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cyclosporin, ifosfamide, and other steroids, which maintain the potential to adversely 
influence bone turnover. Unfortunately, the exact mechanisms of specific drugs are 
difficult to determine due to the disease process itself, and to the combination of 
several drugs implemented during the same period15. 
Although the exact mechanism by which methotrexate influences bone turnover is 
unknown, an elevated urinary calcium excretion suggests that bone loss results from 
an increased bone resorption and excretion, rather than diminished bone 
formation188. With regard to corticosteroid treatment, osteoblast activity is reduced, 
as is the active life span of the osteoblasts15. The association between corticosteroid 
treatment and loss of bone is significant since fractures have been known to occur 
within weeks ofthe start ofhigh-dose steroid therapy84• 
A longitudinal investigation performed on children diagnosed with various cancers, 
including acute lymphocytic leukaemia, solid tumour, Ewing's sarcoma, 
rhabdomysosarcoma and neuroblastoma, demonstrated the effect of the disease 
process and the associated treatments on BMD157. The BMD analysis showed an 
already diminished BMD (below 1 standard deviation for the BMD at the hip or 
spine) at the start of treatment in 46% of the patients. These results suggested that 
the disease process itself may predispose patients to a reduced BMC. Twenty-five 
per cent of patients showed a drop of at least 0.5 standard deviation (SD) during 
chemotherapy (20% demonstrated a BMD decline of at least 1SD). Moreover, the 
investigation followed the children for at least 1-year and there was no consistent 
'catch-up' response observed in BMD following treatment. 
Additionally, age at diagnosis may have the potential to influence the ability to attain 
PBM, or the ability to maintain peak bone mass, prior to the 'normal' age-associated 
decline. Paediatric cancer and its treatments can have both direct (chemotherapeutic 
agents, glucocorticoids) and indirect (sex hormone deficiency, growth hormone 
deficiency, thyroid hormone treatment) effects on the skeleton that would be 
predicted to interfere with normal bone accretion8, while those diagnosed with cancer 
between the ages of20-50 years are at risk of initiating bone loss at an early age. 
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Longitudinal changes in BMD, bone turnover and bone hormonal metabolism have 
been evaluated in children newly diagnosed with ALL or solid tumour17• The 
children were assessed at diagnosis and 1 year post-diagnosis. During the year, 
femoral BMD and apparent volumetric density significantly decreased in the patient 
group, while the age- and sex-matched controls demonstrated annual increments. 
Markers of bone formation (type I collagen carboxyl terminal propeptide and serum 
osteocalcin) were significantly lower at diagnosis among the children with cancer 
than controls, with these results indicating that the disease process impairs skeletal 
status. By 1 year post-diagnosis, although the bone formation marker had 
normalised, the bone resorption marker was significantly increased. It was 
concluded that the deficient accumulation of bone mass may lead to an impaired 
development of PBM and thus may predispose the children to increased osteoporosis 
risk and skeletal fractures later in life17• These conclusions support those of others 
who have assessed the relationship between childhood cancers and skeletal status 
(BMD) via the use ofBMD measurements. 
The BMD of the lumbar spine, femoral neck, and total body was assessed using 
DXA, while single-photon absorptiometry was used to determine the BMD of the 
distal radius among 40 long-term survivors of childhood cancers (including solid 
tumours, lymphoma or acute leukaemia)8. Mean age at diagnosis was 12.7 years, 
and the mean age at time of assessment was 25.8 years. When compared with 
controls, the mean BMD for the patients was significantly reduced at the distal 
radius, femoral neck and total body, but not at the lumbar spine. Since the patients 
studied were at an age that coincided with the normal age of attainment of PBM, and 
that PBM is a primary determinant of BMD later in life, the risk for osteoporosis and 
fractures in the future was elevated. 
Others who have compared the BMD of children with cancer to normative data have 
found similar results and drawn the same conclusions15' 156' 159' 402 . Following the 
assessment of the BMD of the lumbar spine in 97 long-term survivors of childhood 
cancer (5-23 years post-diagnosis), it was found that approximately 13% and 32% of 
participants were characterised with a BMD SD score of below -2 and -1 to -2, 
respectively159 . These results indicated that 45% of participants experienced below 
normal BMD levels. Height for age at follow-up and increasing doses of cranial 
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irradiation were inversely correlated with BMD SD scores. Other paediatric studies 
have reported similar results with 19-23% of patients recording greater than 2 SD 
below age-matched controls97' 138. Slightly lower rates were found in an 
investigation of 60 patients aged 5.5-20.1 years, who had been disease-free for 1.0-
14.5 years156• It was reported that only 8% of these patients were more than 2 SD 
below age-matched normal BMD. 
Previous studies have also assessed the risk of bone loss in adults diagnosed with 
cancer. Women diagnosed with breast cancer are at a considerable risk for the 
development of osteoporosis as a consequence of the early induced menopause that 
is commonly related to breast cancer treatment201 ' 219 . The majority of these 
investigations have assessed the impact of tamoxifen treatment on BMD changes. 
Tamoxifen is an anti-oestrogen agent and since oestrogen receptors have been 
identified on osteoblasts, it was feared that tamoxifen would induce BMD loss. 
However, following extensive research, the effects of tamoxifen on bone remains 
controversial, with some investigations illustrating no effect, while others 
demonstrating a deleterious effect on bone214' 221 ' 255, 306. 
Investigations involving BMD changes in patients treated with L-thyroxine have also 
been conducted. This thyroid hormone stimulates the remodelling of both trabecular 
and cortical bone, with the release of excessive amounts of the hormone being 
characterised by an uncoupling between bone resorption and formation, leading to 
reduced BMD140' 141 . The resulting osteoporosis has been illustrated in hypothyroid 
patients taking replacement therapy, in adult hyperthyroid patients and in patients on 
L-thyroxine treatment to suppress thyroid stimulating hormone secretion for various 
diseases. In an investigation performed on patients who had undergone total 
thyroidectomy due to non-medullary thyroid carcinoma, and who were being treated 
with thyroid-suppressive doses of L-thyroxine, it was demonstrated that values of 
bone alkaline phosphatase and urinary excretion of hydroxyproline were elevated136• 
These results indicated an increased bone turnover and bone resorption. However, 
others have noted that therapeutic doses of thyroxine do not have a significant impact 
on BMD, and patients receiving sophisticated thyroxine therapy for the treatment of 
differentiated thyroid carcinoma are not at risk of developing osteoporosis140. 
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Changes in the BMC of children and adolescent females being treated with high 
doses of L-thyroxine have also been studied311 . Results showed a significant 
reduction in the BMC of the proximal two-thirds of the forearm, but not in the distal 
one third. Since cortical bone is more susceptible to thyroid hormones, and the 
proximal site is more representative of cortical bone, the results are in accordance 
with the literature. 
The potential for inducing bone loss in patients with cancer is further elevated when 
combination treatment, involving the concurrent use of radiation and chemotherapy, 
or the combination of several bone-influencing chemotherapeutic agents, is 
administered82• Treatment options such as BMT and PBST involve the use of this 
combination treatment and, as such, reduced BMD is a common finding in patients 
following BMT433 . 
The pre-transplant myeloablative therapy in autologous and allogenic patients has 
been associated with changes in biochemical markers of bone metabolism in the 
initial 12 weeks post-transplant and has suggested a reduction in bone formation and 
an elevation in resorption61 . The inhibitory effect of glucocorticosteroids upon bone 
formation, the damage to osteoprogenitor cells by the myeloablative therapy and the 
inhibition of osteoblast function by locally-secreted cytokines were given as potential 
reasons for the shown effect. Another investigation performed on 27 women aged 
16-49 years who received either an allogenic or autologous transplant assessed 
biochemical markers of bone formation and resorption, and evaluated the presence of 
osteopenia and osteoporosis by DXA64 . According to the World Health Organisation 
criteria, 33% and 18% were diagnosed as osteopenic and osteoporotic, respectively. 
Osteocalcin bone Gla-protein was elevated in 6 out of 20 analysed cases, while 
procollagen type I carboxyterminal pro peptide was increased in 10 out of 19 cases, 
indicating an accelerated bone formation. Bone resorption markers also indicated an 
accelerated bone turnover, with 95% of patients demonstrating an elevation in the 
hydroxyproline/ creatinine ratio. 
Stem and associates (1996)375 investigated changes in BMD in patients with clinical 
extensive chronic graft-versus-host disease (GVHD), and who were receiving 
treatment with prednisone and cyclosporin A. The researchers followed bone 
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turnover and density parameters over 9-months, during the treatment for chronic 
GVHD. Despite an adequate dietary calcium intake, biochemical parameters 
revealed increased bone turnover. Urinary calcium and hydroxyproline excretion 
were initially elevated and remained high throughout the course of the investigation. 
Additionally, dual photon absorptiometry revealed that significant osteopenia of the 
lumbar spine had developed in six out of eight of the patients investigated. The 
female patients were at an elevated risk compared to males, and males who 
experienced greater post-transplant complications were at an increased risk when 
compared to those that had fewer complications. 
Withold et al (1996)433 measured serum bone alkaline phosphatase and unnary 
pyridinium cross-links in 21 bone marrow transplant patients (18 patients received an 
allogenic transplant, while 3 underwent an autologous transplant) approximately 281 
days post-transplant. All participants recorded an elevation in the urinary excretion 
values of pyridinium cross-links, while only the female subjects displayed 
significantly higher serum bone alkaline phosphatase values when compared with 
age- and sex-adjusted controls. The increase in bone formation for the females 
potentially reflected primary ovarian failure and an enhancement of bone resorption, 
possibly mediated by circulating interleukin-6. 
Another investigation performed on allogenic BMT patients, not only studied bone 
loss and turnover following transplant, but also assessed whether bone loss could be 
prevented by administration of calcium with or without calcitonin398 . Dual energy 
X-ray absorptiometry was used to assess BMD, while several biochemical markers 
were employed to assess bone turnover. Calcium with or without calcitonin had no 
effect on bone loss or bone markers, and BMD reduced in the lumbar spine and 
femoral sites. Markers of bone formation reduced during the initial weeks, but then 
returned to baseline by 6 months. This was in conjunction with elevations in the 
bone resorption marker (serum type I collagen carboxyterminal telopeptide) which 
stayed above normal throughout the entire observation period. At the end of the 
study, 58% of patients had osteopenia at least in the femoral neck. However it is 
important to note that the majority of the patients were experiencing a reduced bone 
mass even at the beginning of the study. 
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A change in bone mass of one SD (of the normal population) elevates fracture risk by 
an estimated 100%218. Additionally, a reduction in femoral neck BMD by one SD 
from the age-adjusted mean has been shown to increase the risk of hip fracture by a 
factor of 2.6 in women over the age of 65 years83 . These data highlight the 
significance of findings demonstrating adverse changes in bone turnover and bone 
mineral density. 
Not all investigations regarding the effect of BMT on skeletal status have found 
adverse results. Keilholz and colleagues (1997) 193 investigated the endocrine 
function and bone metabolism of 29 patients who had successfully undergone an 
autologous BMT or PBST and did not show any significant late effects on these 
factors. Others have assessed BMD changes in patients with multiple myeloma 
treated either by conventional chemotherapy or high-dose chemotherapy and/or 
radiotherapy, followed by autologous PBST233 . Following treatment, a 4.1% and 
3.9% increase in lumbar BMD was demonstrated in patients with a partial or 
complete response, and patients with refractory disease, respectively. These results 
were consistent with a previous investigation performed by the same investigators on 
a similar population, which demonstrated that lumbar BMD increased by 
approximately 8% in males, but did not show any change in females234• However, in 
comparison with the elevation in lumbar BMD, total body BMD data decreased and 
were related to a reduction of the appendicular BMD. 
In summary, substantial evidence associates cancer and oncology treatment with an 
adverse effect on skeletal status. Furthermore, an inadequate diet and/or extensive 
periods of hospitalisation and bed rest can also contribute to the elevated risk of bone 
loss in patients with cancer. 
7.1.2.2 Dietary-related bone loss 
Dietary-related bone loss may be caused by chronic dietary deficiencies of calcium, 
protein, vitamin D, which regulates calcium deposition, and/or vitamin C, which is 
an essential cofactor in collagen metabolism189. Therefore any condition or disease 
process which influences total food intake or the ability to digest food and absorb 
nutrients has the potential to influence bone turnover. 
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Certain types of cancer, such as gastrointestinal cancer, will influence the ability to 
digest and absorb food420, while certain treatment regimens induce side effects that 
will influence total dietary intake. Many chemotherapeutic agents, including 
dactinomycin, bleomycin, cyclophosphamide, 5-fluorouracil, methotrexate and 
vincristine, can lead to side effects including constipation, nausea, vomiting, 
diarrhoea, dry mouth and mouth sores, which in turn reduce food intake67• Patients 
who have received high-dose chemotherapy and/or radiotherapy, such as PBST 
patients, are at a particularly high risk of experiencing these symptoms68. 
However, research demonstrates that bone loss may be unavoidable even in the 
presence of an adequate diet. An investigation performed on allogenic BMT patients 
experiencing chronic GVHD found that despite an adequate diet intake, biochemical 
parameters still revealed an increased bone turnover375. A more recent investigation 
also performed on allogenic BMT patients demonstrated supportive findings398. 
Bone loss experienced by these patients could not be prevented by administration of 
calcium with or without calcitonin. Therefore, while an inadequate diet is a potential 
contributing factor to bone loss, an adequate diet may be unable to prevent bone loss 
in patients with cancer. Consequently, other bone loss prevention strategies need to 
be investigated. 
7.1.2.3 Disuse-related bone loss 
Reduced levels of physical activity or bed rest are additional contributing factors for 
bone loss. Prolonged periods of disease and treatment are related to hospitalisation, 
and hospitalisation periods are associated with reduced levels of physical activity17 • 
Osteoporosis caused predominantly by disuse occurs as a consequence of alterations 
in bone mass in response to the changing environmental stimuli. In order to match 
the mechanical demands applied to bone, bone maintains the ability to remodel by 
altering its size, shape and structure269 . Wolffs Law (1892), "bone is laid down 
where needed and resorbed where not needed", summarises the phenomenon in 
which cancellous and/or cortical bone is gained or lost as a consequence of the 
demands applied269 . Later investigations regarding the effects of physical activity or 
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disuse have continually substantiated this theory, which was proposed over 100 years 
ago. 
Reduction in physical activity and associated bone loss 
Evidence exists from as early as 1921 that immobilisation, disuse, bed rest and 
weightlessness can elicit deleterious effects on bone structures167' 253 • If, due to 
partial or total immobilisation, bone does not undergo the usual mechanical stresses, 
then periosteal and subperiosteal bone is resorbed with a consequent reduction in 
strength and stiffuess and increase in risk of osteoporosis269. Additionally, it has 
been reported that neither endocrine nor dietary intervention can compensate for 
bone loss associated with inactivity39. 
Research investigating the relationship between immobilisation and bone 
remodelling has been undertaken by studying animals, patients with casted limbs, 
amputees and space flight subjects. These studies suggest that following 
immobilisation periods as short as 2 weeks, systemic and local changes may 
influence BMD153' 176' 312' 441 . An increased number of osteoclasts, an increased bone 
resorption activity, and a decreased rate of bone formation have been observed 
morphologically after both short-term and long-term bed rest19. However, the ratio 
between calcified and noncalcified matrix, as well as the chemical composition of 
bone, remain essentially unchanged186. 
Biochemical markers of bone turnover display rapid alterations following bed rest 
with urinary markers of bone resorption such as the hydroxyproline/creatinine, 
calcium/creatinine, and deoxypyridinoline/creatinine ratios increasing within the first 
week399. Similarly, serum markers ofbone resorption such as tartrate-resistant acid 
phosphatase and cross-linked carboxyl-terminal telopeptide of collagen type I also 
increase a few days after commencing bed rest. The carboxyl-terminal propeptide of 
type I procollagen (PICP), which reflects the synthesis of type I collagen, has been 
shown to gradually reduce after bed rest commences285 . Simultaneously, the level of 
urinary deoxypyridinoline/creatinine (uDPyr/Cr) has been shown to increase. It was 
therefore suggested that by using uDPyr/Cr and PICP as biochemical markers of 
bone turnover, there is an apparent uncoupling of bone resorption and formation 
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within the first few days of bed rest285 . Studies of premenopausal women have 
shown that serum osteocalcin and serum alkaline phosphatase decreases and 
uDPyr/Cr increases with immobilisation285 . 
Since osteocalcin is a direct product of osteoblasts and is known to reflect the 
activity of the mineralisation phase of the newly-formed bone matrix, osteocalcin has 
been used to investigate the impact of immobilisation on bone185. Following the 
immobilisation of rats for three weeks, the immunoreactivity of osteocalcin was 
markedly decreased or was completely absent in all the patella areas studied. 
Normally these areas show intense reaction as a sign of mineralisation of the newly-
formed bone. 
LeBlanc and colleagues (1995i08 showed in their investigation on males that urine 
and faecal calcium increase and a negative calcium balance arises with bed rest. A 
reduction in true calcium absorption of 22% from baseline, and a 17% decrease in 
vitamin D accompany these changes. Additionally, the cross-links pyridinium and 
deoxypyridinium were elevated (32-37% above baseline) during bed rest, indicating 
that resorption was increased. However, it was further suggested that bone loss was 
related to an increase in bone resorption rather than a decrease in bone formation. 
The maintenance of alkaline phosphatase and osteocalcin levels during the bed rest 
period indicated that bone formation did not decrease208 • 
Furthermore, studies that have assessed the effect of weightlessness on humans 
during space travel have demonstrated detrimental changes in bone turnover. A 
negative calcium balance, an increase in urinary and faecal calcium excretion, and 
loss of calcium and phosphorus have been shown following periods of 
weightlessness92' 380' 382 . 
Studies assessing changes in BMC and BMD with bed rest or immobilisation have 
reported similar findings to those investigations assessing changes in biochemical 
markers. An immobilisation study on growing chicks caused a reduced gain in bone 
mass and length, reduced bone curvature and, in some cases, reversed bone 
curvature32 . The 14% reduction in bone length found in the immobilised chicks was 
similar to that observed for children with congenitally paralysed limbs32 . 
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A 29% reduction in the trabecular volume of sheep's hind legs was observed 
following a 12-week immobilisation period387. Similar findings were also found in 
an investigation assessing both immobilisation and partial immobilisation on sheep 
calcaneus365. Partial immobilisation was classified as immobilisation of the 
calcaneus with periods of remobilisation set at 'normal' walking speeds for 20 
minutes/day. It was identified that the BMC of both the total and partial 
immobilisation group, was significantly reduced by 22% and 21%, respectively. The 
significant loss in the partially-immobilised group seemed unusual, since by 
definition it is the bone's normal strain environment which prevents disuse-
associated bone loss365. However, it was previously hypothesised that the main 
osteoregulatory stimulus to the skeleton is derived from unusual strains engendered 
by the inevitable loading 'accidents', and not from the normal strains of controlled 
functional acti vit~02 • 
Finally, space flight investigations have also shown detriments in BMC and BMD. 
Rats subjected to periods of weightlessness have shown that cortical and trabecular 
bone mass, mineral content, osteocalcin production, periosteal bone formation, 
growth hormone secretion, bone growth turnover and vertebral apatite crystal 
size/perfection are significantly reduced442• Humeral flexural rigidity, elastic 
modulus, load at the proportional limit, tensile stress and maximum load were all 
significantly greater in control rats than in spaceflight rats. 
The evidence demonstrating the relationship between reductions in weight-bearing 
physical activity and an elevated risk of bone loss is compelling. Unfortunately, 
cancer patients are at risk of experiencing significant reductions in physical activity 
following diagnosis and treatment. An observational design investigation classified 
patients with cancer as having 'low' levels of physical activity and found that 24% of 
BMT patients failed to perform any activity throughout the day, including walking, 
during periods ofhospitalisation80. Of those who were considered 'active', the mean 
duration of walking and stationary cycling fell short of 8 minutes per day. 
Additionally, children who had received treatment for acute lymphoblastic leukaemia 
maintained low participation rates in physical activity, when compared with age- and 
sex-matched controls411 • 
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Physical activity and associated bone gain 
Just as declines in weight-bearing physical activity have been associated with bone 
loss, loading has been related to bone gain. Weight-bearing athletes have a greater 
BMD when compared with the 'general population'268 , and 'physically active' 
children have a significantly higher BMD when compared with 'less physically 
active' children366. Additionally, young army recruits have demonstrated increases 
in BMD following a 3-month weight-bearing physical activity intervention 
program232, while the majority of studies implementing physical activity as an 
intervention for osteoporosis have shown a reduction in the rate of bone loss in 
elderly patients87 . Studies demonstrating a 35% greater bone mass in the dominant 
arm of tennis players compared with the non-dominant arm182 and runners 
illustrating an elevation in bone mass in the calcaneun421 , highlight that the effect of 
exercise on bone mass, is site-specific. 
Benefits to BMD are not just derived from participation in weight-bearing physical 
activity, as studies assessing the influence of resistance training on BMD have also 
shown positive results. Improvements in femoral neck BMD following a heavy 
resistance training program in older men has been previously reported330. A more 
recent investigation regarding resistive training and BMD has shown that strength 
training maintains BMD in conjunction with improving muscular strength in 
postmenopausal women. The ability to improve muscular strength in conjunction 
with maintaining BMD has the potential to reduce the incidence of falls and thus 
osteoporotic fractures329• 
The evidence relating participation in weight-bearing physical activity and resistance 
training with bone gain provides hope for the role of physical activity as an 
intervention for patients at risk of bone loss. However, periods of bone loss 
associated with disuse are divided into phases, and the ability of any intervention to 
influence bone loss may ultimately depend upon the phase at which the intervention 
was initiated. 
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7.1.3 Phases of bone loss 
Disuse osteoporosis has been described as comprising an active and inactive phase, 
with the active phase consisting of an initial period of rapid loss, a recovery period, 
and finally a period of slower more lasting bone loss395. Following the initial period 
of bone loss, which tends to reach a maximum at the end of 6 weeks, bone mass may 
then improve. The inversion of the bone balance following the phase of rapid loss 
has been explained by the osteoblastic response to the relatively increased strain 
exerted on thinner and/or less trabecular bone387. The final period of the active phase 
ofbone loss, is characterised by a stabilisation in bone mass at values 30-50% below 
the initial value. During this latter phase, the absence of mechanical force results in 
diminished bone formation and leaves the bone resorption activity temporarily 
unopposed. While the exact extent ofboth processes is yet to be fully determined, it 
was estimated that approximately 30% of total immobilisation-induced bone loss in 
experimental rats is caused by increased bone resorption, and about 70% by reduced 
bone formation185 . 
A steady state is reached when bone formation restores equilibrium of resorption, 
most likely after the first 5-6 months. The inactive phase of disuse osteoporosis 
starts at approximately this time. It is during this stage that bone loss nadir and less 
bone mass is maintained45' 167. Research indicates that reversal of bone loss is 
dependent on the time of remobilisation. That is, whether mobilisation is established 
in the active phase, prior to the establishment of long-term bone loss. Factors 
including age and the particular bone involved will also influence the ability to 
recover lost bone419 • 
7.1.4 Remobilisation 
Reconstruction of bone is a much slower process than its resorption167 . It was 
identified that the first radiographic signs of bone organisation did not appear until 
three to four weeks after plaster immobilisation in rabbits, whereas bone resorption 
was evident at the end of the second week of immobilisation. A period of 8 weeks 
free remobilisation following a period of 3 weeks immobilisation is not sufficient to 
return the patellar expression of osteocalcin in rats to normal185 . 
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The greatest recovery in bone mass in immobilised dog limbs occurred when 
remobilisation was initiated during the active phase of disuse osteoporosis176. 
Further, long-term immobilisation could lead to losses in bone mass that may never 
be recovered. Even following 5 years of remobilisation, the os calcis BMC of the 
nine crew members of a Skylab experiment remained lower than preflight values389. 
Another investigation demonstrated that BMD values of a previously immobilised 
limb (cast-treated tibial shaft fracture) were 4-11% lower than those in the 
contralateral limb, even after 10 years ofremobilisation186. 
While the potential for recovery of an immobilised bone is a controversial issue, it 
seems that recovery is possible if the remobilisation and follow-up time are long 
enough, and if the immobilisation period has not exceeded 5-6 months - the time 
limit between the active and inactive phases of immobilisation induced osteopenia. 
What is certain is that time needed for recovery is longer than the time needed to 
produce osteopenic changes 186. 
In summary, much data have been presented that highlight the elevated risk and 
presence of bone loss in patients with cancer. The roles of weight-bearing exercise 
and strength training in preventing or reversing bone loss have also been previously 
proven in numerous populations. However, limited data exist to describe the 
importance ofremobilisation during and/or following cancer treatment, for improved 
long-term skeletal status. Only one investigation could be identified that assessed the 
relationship between physical activity levels and skeletal status. Higher levels of 
physical activity were associated with improved BMC in children with acute 
lymphoblastic leukaemia412 . Although information is limited, it has been recently 
recommended that patients with cancer should resume weight-bearing exercise as 
soon as possible in order to avoid or reduce bone loss398. However, more research is 
required within the area to determine the influence of physical activity in preventing 
bone loss, reducing the rate of bone loss, or reversing bone loss associated with 
cancer patients. 
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7.2 Methodology 
Chapter 3 provides a detailed outline of the methodological procedures relating to 
subject recruitment, the testing phases and the intervention program implemented. In 
summary, 12 patients, with 6 patients in each group were recruited. Of these, only 7 
patients were recruited at PI, while the remaining subjects entered the investigation at 
PII. Outlined below are the methodological procedures which relate specifically to 
the aims of this section of the investigation and involve the biochemical assessment 
of two markers of bone turnover, urinary hydroxyproline and serum alkaline 
phosphatase. 
7.2.1 Biochemical markers of bone turnover 
As previously discussed, a number of biochemical markers are used to routinely 
determine bone turnover. The markers used in this experiment were selected on the 
basis ofthe value of the information to be derived from the marker, cost, and ease of 
implementation. While the markers chosen (serum alkaline phosphatase and urinary 
hydroxyproline) are not specific indicators of bone metabolism, they have previously 
been used to provide information in bone metabolism research and in clinical 
situations321 • For example, the measurement of urinary hydroxyproline values, 
together with alkaline phosphatase, has proven useful in detecting accelerated bone 
loss in postmenopausal women112• 
Qualified laboratory technicians in Queensland Medical Laboratories performed the 
assessment of both markers, and a summary of the experimental procedures 
implemented is outlined below. 
7.2.2 Marker of bone resorption- urinary hydroxyproline/creatinine 
Measurement of urinary hydroxyproline, corrected for creatinine, has provided 
information with regards to bone catabolism. The concentration of hydroxyproline 
in the urine corresponds to the collagen content in tissue and is therefore a good 
indicator of collagen metabolism. Since half of human collagen resides in bone, 
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where its turnover is potentially faster than in soft tissues, hydroxyproline excretion 
in urine is regarded as an effective marker of bone resorption93 . During bone 
turnover, there is also an increased release of hydroxyproline from the bone matrix, 
which is excreted by the kidney and subsequently, urinary hydroxyproline levels 
mcrease. 
A 24-hour urine sample was collected in an acid-preserved (25ml of 6M 
hydrochloric acid) container for the assessment of urinary hydroxyproline (uHP). An 
accurate 24-hour collection is essential for uHP determination, as there is diurnal 
rhythm of excretion, which is maximal between midnight and 8.00 am434 . Dietary 
collagen is catabolised and, in part, excreted as hydroxyproline peptides. Therefore, 
patients were instructed to follow a low-collagen diet during the 24-hour collection 
period and for the 24-hours prior to collection. Meat, fish, meat extracts and all 
gelatine-containing foods such as jellies, canned foods, processed meat, chocolates, 
ice-cream and cream biscuits were avoided. 
Bound hydroxyproline present in the 24-hour sample was converted into free form 
by acid hydrolysis, and resin and charcoal were used to remove any contaminants434. 
The neutralised hydrolysate was oxidised with chloramine-T and decarboxylated to 
produce a pyrrole - which then reacted with Ehrlich's reagent and was detected 
spectrophotometrically at 560nm. Most methods rely on hydrolysis and oxidation of 
hydroxyproline and subsequent colour production. Standards are also used to limit 
interference by similarly reacting compounds. In summary, the steps implemented to 
obtain results included hydrolysis, preparation of fresh reagents, removal of 
interfering compounds, neutralisation, oxidisation, colour reaction and finally, 
absorbance was read434 . The uHP result was reported to the nearest 5 J..LmoV24hr and 
was then adjusted for urinary creatinine according to the formula: 
uHP/Creatinine Ratio = uHP (!J11loV24 h) 
Urinary Creatinine (mmoV24h) 
The uHP/creatinine (uHP/Cr) ratio was reported to the nearest whole number in 
J..LmoVmmol. 
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7.2.3 Marker of bone formation -serum alkaline phosphatase 
Total alkaline phosphatase has been correlated with osteoblast activity and is used to 
provide a measure of bone formation378. Determination of total activity provides 
critical information for bone turnover, however differentiation between sources 
(tissue-nonspecific including bone, liver, kidneys, intestinal and placental) is not 
possible310. Additionally, substances such as bilirubin, phosphate, bile acids, urea, 
glucose and certain drugs can interfere with these measurements. While these factors 
are known limitations to the measurement of bone formation activity, previous 
findings296 have failed to demonstrate a clear superiority of bone-specific versus total 
alkaline phosphatase measurement. 
The assessment of serum alkaline phosphatase (sAP) required the collection of 10ml 
of blood in a heparin tube, which was then stored at room temperature until it 
reached the pathology testing laboratories. The methodology used to measure sAP 
was based on the recommendations of the International Federation of Clinical 
Chemistry, and utilised 4-nitrophenylphosphate (4-NPP) as the substrate and 2-
amino-2-methyl-1-propanol as the buffer310. Under the optimised conditions, sAP 
present in the sample catalysed the following transphosphorylation reaction: 
sAP 
4-NPO+ phosphate 
Mg/alkaline pH 
At the pH of the reaction, 4-nitrophenoxide ( 4-NPO) has an intense yellow colour. 
The reagent also contains a metal ion buffer system to ensure that optimal 
concentrations of zinc and magnesium are maintained. The metal ion buffer also 
chelates other potentially inhibitory ions which may be present. The reaction was 
monitored by measuring the rate of increase in absorbance (Abs) at 405nrn which is 
proportional to the activity of sAP in the serum. 
210 
Chapter Seven, Study Four 
A clinical chemistry analyser (Technicon Dax System, Bayer) capable of maintaining 
constant temperature (37°C) was used to measure sAP activity in units per litre 
(U/L): 
Activity in U/L = Mbslmin x Factor, 
Factor = TV x 1000 
18.8xSVxP 
where 
TV = total reaction volume in ml 
SV = sample volume in ml 
18.8 =millimolar absorption coefficient of 
4-nitroplzenol at 405nm 
P = cuvette patlzlengtlz in em 
Circadian rhythms can be observed in nearly all markers of bone metabolism and can 
range from 10-15%378. The time of testing was therefore standardised for all 
patients, with blood tests being performed between 8.00am and lO.OOam, and the 
urine sample was commenced on awakening and continued until the same time the 
following morning. 
7.2.4 Statistical Analysis 
Bone turnover data were collected at each of the three testing phases and were 
analysed according to the statistical procedures outlined in Chapter 3. Additionally, 
the relationship between bone formation and resorption activity was assessed for the 
SG at PI and PII, and the CG and EG at Pill via the use of a Pearson correlation. 
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7.3 Results 
Changes in bone resorption and formation following the transplant are presented in 
Table 7.2. Pre-transplant, the range for uHP/Cr and sAP was 12-40 ~mol!mmol and 
56-115 U/L, respectively. The mean for the bone resorption marker was outside the 
normal range at PI, while the mean formation marker was well within the usual 
range. All individual values for sAP levels at PI were within the normal range. 
Following the PBST, the rate of bone turnover increased, with a significant change 
(p<0.05) being detected in the bone resorption marker (range at PII = 8-
60~mollmmol). In addition, only 33% of patients at PII recorded uHP/Cr levels 
within the normal range. Mean bone formation also increased (range = 48-185U/L), 
however, only 25% of patients recorded sAP levels outside the normal age- and sex-
matched range. 
Table 7.2 Bone turnover measures at PI and PII for the study group (mean±SE) 
uHP/Cr (~mollmmol) 5-25 
sAP (U/L) 30-115 
25.42 2.50 33.58 1.80 
80.88 13.07 92.50 9.38 
NR =Age- and sex-matched normal range 
* p<0.05 
0.482 
The change in bone turnover across the testing phases for the control group is 
presented in Table 7.3. While no significant differences were observed in markers 
across the phases, the mean change demonstrated a trend towards an elevation in 
bone turnover following the transplant, and a reduction in bone turnover during the 
recovery period. Undertaking a PBST led to an elevation in bone resorption, shifting 
uHP/Cr levels to outside the normal range. By 3-months post-transplant, levels had 
returned to just within the normal range (5-25) but remained above pre-transplant 
levels. At Pill, 40% of patients were still recording uHP/Cr levels outside the 
normal range, with an additional patient recording uHP/Cr levels at 25umol/mmol. 
Mean bone formation was within the normal range for all three phases, with only 2 
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patients at PII recording individual levels above the range. However, a mean 
increase in sAP was observed by PII, with a corresponding reduction in activity by 
PIII. Three-months post-transplant, bone formation was lower than PI levels, in 
contrast to the higher mean bone resorption activity at PIII, when compared with PI. 
Table 7.3 Bone turnover measures across the testing phases for the control 
group (mean±SE) 
uHP/Cr (J.lmollmmol) I 3 23.29 4.08 PI-PII 
II 6 30.50 2.54 PII-PIII 0.186 
III 5 24.92 2.92 PI-Pili 0.757 
sAP (U/L) I 3 78.22 21.31 PI-PII 0.536 
II 6 96.50 13.27 PII-PIII 0.349 
III 5 73.73 15.22 PI-PIII 0.887 
Table 7.4 demonstrates the change in bone turnover across the testing phases for the 
exercise group. The mean uHP/Cr activity levels at pre-treatment were outside the 
normal range and demonstrated a further significant increase by PII. At conclusion 
of the exercise intervention, levels at PIII had fallen significantly to within the 
normal range. The range varied at each phase and was recorded at 12-40 
J.lmollmmol, 20-60 J.lmollmmol and 13-34 J.Lmollmmol, at PI, PII and Pill, 
respectively. Serum alkaline phosphatase was elevated as a result of the transplant, 
and remained higher than pre-transplant and similar to PII levels, at PIII. Across the 
testing phases only 1 patient at PII, and 1 patient at PIII, recorded sAP levels outside 
the normal range (145 and 120, respectively). 
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Table 7.4 Bone turnover measures across the testing phases for the exercise 
group (mean±SE) 
uHP/Cr (J.Lmollmmol) I 4 27.55 2.90 PI-PII 0.046* 
II 6 36.67 2.54 PII-PIII 0.010* 
III 6 24.83 2.54 PI-PIII 0.508 
sAP (U/L) I 4 83.54 15.15 PI-PII 0.793 
II 6 88.50 13.27 PII-PIII 0.983 
III 5 88.10 15.15 PI-PIII 0.823 
* p<O.OS 
With respect to bone apposition, there were few variations in individual changes, in 
contrast to the marked intra-group differences in bone resorption (Figure 7.1). The 
subjects in the exercise group demonstrated the same trend of change between each 
of the testing phases. While the majority of subjects in the control group 
demonstrated a slight reduction in resorption activity post-transplant, one subject 
displayed an increase in activity. 
Figure 7.1 Individual changes in urinary hydroxyproline/creatinine across the 
phases for the subjects in the control and exercise group 
--- CG Subjects -+- EG Subjects 
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Following a PBST, a significant positive correlation between bone resorption and 
bone formation activity was found (Table 7.5). By 3-months post-transplant, a 
positive relationship between the biochemical markers of bone turnover remained 
evident in the control group subjects, however, the reduction in data points reduced 
power and therefore the ability to detect significant differences. In contrast, by Pili, 
no relationship between the markers was identified for the EG. 
Table 7.5 Correlations of the bone turnover measures 
SG PI Pearson Correlation -0.198 
Sig. (2-tailed) 0.639 
n 7 
SG Pil Pearson Correlation 0.611 * 
Sig. (2-tailed) 0.035 
n 12 
CG Pili Pearson Correlation 0.485 
Sig. (2-tailed) 0.407 
n 5 
EG Pili Pearson Correlation -0.023 
Sig. (2-tailed) 0.971 
n 6 
* p<0.05, ** p<0.01 
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7.4 Discussion 
Biochemical markers used to assess bone turnover demonstrated that bone resorption 
was elevated pre-PBST and continued to increase post-transplant, as was indicated 
by the significant change in uHP/Cr between PI and PII. A PBST was also 
associated with an elevation in bone formation, however the mean change was not 
significant. Bone resorption significantly reduced to mean levels that were lower 
than that recorded at pre-transplant, following participation in the 3-month aerobic 
and resistance training program. Additionally, by Pill, mean bone formation of the 
exercising patients was higher than pre-transplant values. In contrast, the non-
exercising patients demonstrated a mean reduction in bone formation to below pre-
transplant levels within 3-months post-transplant. However, the changes observed in 
the bone formation marker were not significant for either the exercising or control 
group. 
7.4.1 Impact of the transplant on bone turnover 
Bone resorption increased by 32% following the transplant and reached activity 
levels outside the normative range. The average increase for bone formation was 
14%, but this was not a significant change. Therefore, while bone turnover is 
elevated immediately post-transplant, the results suggest an uncoupling of bone 
resorption and formation, favouring resorption. A similar trend towards an elevation 
in bone turnover, where both resorption and formation elevate, with the former 
exceeding the latter, has been reported following loss of ovarian function230 . 
Additionally, the significant change detected in the uHP/Cr ratio between PI and PII 
of this study supports previous findings which have demonstrated that with bed rest, 
urinary markers of bone resorption such as uHP/Cr, calcium/creatinine and 
deoxypyridinoline/creatinine ratios can increase within the first week19' 399 
Additionally, the results of this investigation are similar to earlier findings which 
have shown an elevation in urinary calcium and uHP excretion following allogenic 
transplane75, and an elevation in the uHP/Cr ratio following either an allogenic or 
autologous transplant64. 
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The significant change in bone resorption detected between the pre- and post-
transplant phases could be explained by the influence of certain chemotherapeutic 
drugs, such as glucocorticoids and methotrexate, on bone turnover. Glucocorticoids 
appear to be the primary cause of the uncoupling of reduced bone formation and 
increased resorption398, while methotrexate influences bone turnover by increasing 
bone resorption 188 . 
In addition to the treatment effect on bone resorption, is the influence of a reduction 
in physical activity levels during the treatment period. The PBST transplant process 
induces a period of hospitalisation lasting approximately 1-week. Additionally, 92% 
of the study sample were readmitted for a period that ranged between 1-3 weeks, 
following the transplant due to the presence of certain side effects. The 
hospitalisation period was further lengthened (approximately 12 weeks) for those 
patients who were required to undertake 3 consecutive PBST (n=3). The response 
of bone to immobilisation or bed rest has been well documented, and if devoid of 
normal mechanical stresses, bone strength and stiffness are reduced269 . Following 
long-term and short-term bed rest, an elevation in the number of osteoclasts, an 
increased bone resorption activity, and a reduction in bone formation rate have been 
morphologically observed19• Therefore, it can be suggested that both the treatment 
administered and the period of bed rest experienced, were contributing factors to the 
elevation in bone resorption observed. 
Finally, results from the administration of a food frequency questionnaire (details are 
provided in Chapter 4) demonstrated that pre-transplant, 89% of the subject 
population were ingesting at least 1 serving of dairy products daily, with only 11% 
consuming 2 or more servings per day. Therefore, at pre-transplant, the majority of 
patients were consuming less than the minimum daily recommendation for dairy 
product consumption189. However, following the transplant, the intake of dairy 
products further declined, with only 33% of the subjects consuming 1-2 servings per 
day and 58% of the subjects failing to consume at least 1 serving daily. When 
calcium intake is below the recommended levels, the body draws on the calcium 
reserves in the bone to replace the deficit189. Therefore, given that dairy products 
provide one of the highest sources of calcium189, the decline observed in dairy 
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product consumption in this investigation, is another potential contributing factor for 
the elevation in bone turnover and bone resorption measured. 
Changes in the bone formation marker post-treatment during this investigation 
support previous work that has reported either no change or an elevation in bone 
formation markers during periods of bed rest or treatment. While there was little 
change in the bone formation markers, sAP and osteocalcin, during a 4-month bed 
rest period208, elevated levels of bone alkaline phosphatase have been shown in 
patients being treated for non-medullary thyroid carcinoma, with thyroid suppressive 
doses of L-thyroxine136. Two other investigations involving allogenic and 
autologous transplant patients have demonstrated an elevation in serum bone alkaline 
phosphatase 281 days post-transplant433 and an increase in osteocalcin bone Gla-
protein, 7-158 months post-transplant64. The elevation in the bone formation 
markers observed in the above investigations were attributed to an increase in bone 
turnover, and were also associated with increases in the bone resorption markers 
measured. 
The attainment of PBM, the maintenance of PBM during the ages of 20-50 years, 
and the rate of bone loss are critical factors in the prevention of osteoporosis82 . 
Regardless of the patient's age, undertaking a PBST may induce adverse effects on 
bone turnover including an inability to attain PBM, the initiation of bone loss at an 
early age, and an accelerated rate of bone loss. Determining intervention strategies 
to reverse these detrimental effects is crucial in minimising the risk of the 
osteoporosis in later life. 
7.4.2 The effect of the intervention program on bone turnover 
Participation in weight-bearing physical activity and resistance training has 
previously been shown to induce positive changes in bone turnover and BMD. 
Remobilisation following periods of hospitalisation or bed rest is also critical for 
reversing any bone loss. While the effectiveness of activity has been evaluated in a 
number of population groups including postmenopausal and elderly groups87' 329' 330, 
this is the first investigation that has assessed the importance of activity for skeletal 
health in cancer patients. The results of this investigation demonstrated that 
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participation in the aerobic and strength training program following a PBST was 
associated with beneficial changes in bone turnover, in particular bone resorption. 
Following the exercise intervention period, the EG demonstrated a significant decline 
(33%) in the mean bone resorption activity, with all exercising patients displaying a 
reduction in bone resorption activity, in conjunction with a marginal mean decline of 
0.5% for bone formation. These results indicated that an uncoupling of bone 
resorption and formation existed during the intervention period for the exercising 
patients, with the uncoupling favouring formation. 
While both bone resorption and bone formation markers decreased for the control 
group during the intervention period, mean uHP/Cr was higher, while mean sAP was 
lower, at Pill when compared with pre-treatment levels. However, the differences 
between the PI and Pili marker activities, were not significant. It could be suggested 
that although the bone turnover markers followed the same trend post-transplant, 
bone turnover activity for the CG, may have favoured resorption. That is, greater 
increments were observed in uHP/Cr between PI and PII and lower decrements 
between PII and Pill, when compared with the formation marker. 
Following the 3-month intervention period, the CG and EG recorded similar mean 
uHP/Cr levels (24.92 and 24.83umol/mmol, respectively). However, the exercising 
participants demonstrated higher mean sAP levels (88.1 U/L) when compared with 
the non-exercising subjects (73.73U/L). Although these differences were not 
significant, the change in the markers suggests that participation in an aerobic and 
resistance training program, has the potential to reduce the rate of bone resorption, 
while maintaining or increasing the rate of bone formation. In tum, the beneficial 
effects on bone turnover following the transplant could potentially lead to an 
improved skeletal status in the future, and a reduction in the risk of osteoporosis. 
Differences in the direction of the relationship of the bone turnover markers 
measured in this investigation were observed. Prior to the transplant, no relationship 
was detected between bone resorption and formation activity. However, following 
the transplant, a significant positive relationship between the 2 bone turnover 
markers was identified, whereby the higher the resorption activity, the higher the 
formation activity. This positive relationship was maintained by the CG up to 3-
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months post-transplant, however the reduction in data points at Pili reduced 
statistical power, and therefore the results were not found to be significant. In 
contrast, undertaking the aerobic and resistance training program was associated with 
a change in the relationship of the two markers, so that again, no relationship was 
identified between the formation and resorption activity. These results indicate that 
formation activity was maintained while resorption activity reduced, in the exercising 
patients 
It should however be noted that inconsistencies also exist throughout the literature 
regarding the relationship between bone formation and resorption markers. While 
significant correlations between resorption and formation markers have been 
reported in primary45 or secondary hyperparathyroidism431 , bone metastases432, and 
in patients with breast cancer-induced osteolysis46, previous work in patients with 
cancer following BMT has found that the resorption and formation activity are 
unrelated433 . 
Regardless of whether the patients in this investigation were exercising or control 
participants, the uHP/Cr levels returned to within the normal range by 3-months post-
transplant. These results are in contrast to earlier investigations of bone turnover 
following BMT. Elevated levels of uHP for a period of 9-months post-transplant 
have been shown in patients who had undergone an allogenic transplant375 . 
However, the patients were receiving treatment for extensive GVHD throughout the 
9-month period, which may explain the continued elevation in bone resorption. 
Nevertheless, an investigation following patients for a 12-week period post-
autologous or allogenic-transplant also demonstrated an elevation in bone resorption, 
in conjunction with a reduction in bone formation activity. The inhibitory effect of 
glucocorticosteroids upon bone formation, the damage to osteoprogenitor cells by the 
myeloablative therapy, and the inhibition of osteoblast function by locally secreted 
cytokines were given as potential reasons for the elevated resorption. 
It is possible that the differences between the calcium intake of the control and 
exercise groups following the transplant may have contributed to the changes 
observed in bone turnover in this investigation. Results from the food-frequency 
questionnaire demonstrated that 40% of the control group, compared with only 17% 
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of the exercising group, did not consume dairy products daily. However, findings 
from previous analyses regarding the role of calcium intake in preventing or 
reversing bone loss following a BMT, suggest otherwise. An investigation on 
allogenic transplant patients found that, despite an adequate calcium intake, an 
elevation in bone turnover continued post-transplane75. Further, calcium intake, with 
or without calcitonin, had no influence on bone loss in a more recent investigation 
utilising allogenic tran~plant patients398 . It therefore seems likely that dietary 
interventions have limited effect on bone turnover and BMD during or following a 
BMT. 
Finally, although preliminary and limited by subject numbers, the changes detected 
in the biochemical markers should not be underestimated. Future research including 
longer intervention periods, greater subject numbers and the inclusion of BMD 
measurement, will be important to confirm the findings of this investigation and to 
determine their clinical and long-term significance. 
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7.5 Conclusion 
In summary, bone resorption was significantly elevated following the transplant, 
indicating that autologous PBST patients are at risk of bone loss during and after the 
treatment period. It is crucial for long-term skeletal integrity and health that the bone 
turnover and BMD of these patients be monitored following a transplant. It is also 
important to implement intervention strategies that will work towards preventing, 
minimising and/or reversing the bone loss experienced by patients with cancer. 
Physical activity is one such potential intervention strategy. The exercising PBST 
patients demonstrated that regular participation in weight-bearing exercise and 
resistance training led to a significant decrease in bone resorption activity, in 
conjunction with the maintenance of higher than pre-transplant bone formation 
activity. This is in contrast to the mean decrease in both resorption and formation 
activity by 3-months post-transplant for the control group. The control group also 
experienced mean resorption activity above, and mean formation activity below pre-
treatment levels. Therefore, results indicate that participation in an aerobic and 
resistance training program stimulated bone metabolism, through the uncoupling of 
bone turnover, favouring bone formation. 
222 
CHAPTER EIGHT 
STUDY FIVE 
Changes in QoL following a PBST and 
participation in an exercise program 
... .. .[Among the Greeks] eminent physicians say to a patient who come 
to them with bad eyes, that they cannot cure his eyes by themselves, but 
that if his eyes are to be cured, his head must be treated; and then again 
they say that to think of curing his head alone, and not the rest of the 
body also, is the height of folly. And arguing in this way they apply these 
methods to the whole body, and try to treat and heal the whole and the 
part together .... 
[The physicians for Thrace, however, criticize this and say that 
they are right as far as they go, but} that as you ought not to attempt to 
cure the eyes without the head, or the head without the eyes, neither 
ought to attempt to cure the body without the soul; and this ... is the 
reason why the cure of so many diseases is unknown to the physicians of 
Hellas because they are ignorant of the whole, which ought to be studied 
also; for the part can never be well unless the whole is well. 
PLATO, Charmides (Jowett translation) 
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List of abbreviations specific to Chapter eight 
ADL Activities of daily living 
AS Average severity 
BMT 
CARES 
CG 
EG 
EP 
FLIC 
HRQoL 
HOF 
KPS 
MQoL 
MIQoL 
ND 
PBST 
PQoL 
PSQoL 
QLI 
QoL 
Rec Act 
SG 
SQoL 
ss 
TQoL 
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Bone marrow transplant 
Cancer rehabilitation evaluation system 
Control group 
Exercise group 
Endorsed problems 
Functional living index-cancer 
Health-related QoL 
Higher order factors 
Kamofsky performance scale 
Marital QoL 
Medical interaction QoL 
Normative data derived from a cancer population 
Peripheral blood stem cell transplant 
Physical QoL 
Psychosocial QoL 
Quality of life index 
Quality of life 
Recreational Activities 
Study group 
Sexual QoL 
Subscales under the physical domain 
Total QoL- which has been derived from the 5 QoL domains 
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8. Changes in QoL following a PBST and participation in an 
exercise program 
8.0 Introduction 
As a consequence of continuous progress in medical science, numerous previously 
fatal diseases are now curable and the severity of others has been effectively 
reduced172. With respect to cancer, the most recent estimate of the 5-year relative 
survival rate is now recognised to be 59%148. Unfortunately, medicine and science 
have failed to prevent the prolonged or permanent disabilities, which may arise from 
these conditions and their associated treatments. 
Mortality and survival rates have commonly reflected the impact of new therapies on 
the disease process. However, as treatment modalities improve and the emphasis on 
humanising health care increases, these blunt and inadequate indicators are being 
replaced with quality oflife (QoL) measures21 ' 171 ' 406. The belief that QoL is just as 
important as quantity of life is now widely accepted65 . "Quality of life always 
matters to the patient and therefore, health care providers must always be concerned 
with the impact of their ministrations on the QoL in addition to the effect of the 
disease"73 . 
Cancer diagnosis and its associated treatments are associated with numerous physical 
and psychological side effects. The increased risk of late physical effects, 
psychological sequelae and social consequences have been identified as significant 
issues adversely influencing QoL272 . Therefore, a strong need exists, for intervention 
strategies to assist in mitigating the adverse effects of cancer and its treatment on 
QoL, and/or hasten recovery following treatment. Physical exercise has been 
associated with numerous physiological and psychological health benefits within the 
healthy population. Exercise has also been shown to provide physical and 
psychological benefits during the rehabilitation process of patients with chronic 
diseases including cardiovascular diseases, rheumatic disease, diabetes mellitus and 
renal diseases. It is therefore possible to suggest that participation in a physical 
exercise program throughout the cancer continuum could address a broad range of 
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physical and psychological issues associated with diagnosis and treatment. Research 
to date regarding the role of exercise in the rehabilitation of cancer patients has been 
regarded as "positive but preliminary"78 . There exists a need to replicate and extend 
the current research within the domain of cancer, exercise and QoL. 
8.0.1 Purpose 
Objective 1: To investigate changes between pre- and post-PBST measures of QoL. 
Research hypothesis for objective 1: 
Adverse changes will occurin QoL following aPBST (as determined by pre-
and post-transplant measures). 
Objective 2: To investigate the role of a three-month duration, moderate intensity, 
mixed type exercise program on QoL, post-PBST. 
Research hypothesis for objective 2: 
Participation in the exercise program will be associated with positive changes in 
QoL. That is, exercising patients will experience a faster QoL recovery when 
compared with non-exercising patients (as determined by pre- and post-
intervention measures). 
"The main point of using global QoL measures is that the more narrowly-defined 
objective (e.g. cardiovascular endurance) or subjective changes (e.g. anxiety) in 
functioning that may result from exercise following cancer diagnosis need ultimately 
to be reflected in the broad dimensions of QoL, or they may not have the practical 
benefit that is assumed"77 . This thesis provides an excellent framework whereby 
physiological changes can be compared with QoL changes. 
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Objective 3: To investigate the relationship between functional capacity and QoL. 
Research hypothesis for objective 3: 
Functional capacity will be highly related to QoL. That is, those who experience 
the highest functional capacity will also experience the highest QoL. 
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8.1 Literature Review 
The voluminous and growing body of scientific literature on QoL reflects the recent 
focus of interest on the integration of QoL end points in clinical trials of cancer 
therapies 145. A consensus exists that QoL is a multidimensional construct, including 
a minimum of physical, social, and psychological domains in addition to disease- and 
treatment-related symptoms such as pain, shortness of breath, nausea, alopecia, 
anxiety or depression130' 131 ' 325 . Existential concerns, sexual functioning, body 
image, and health care satisfaction are other important considerations when assessing 
QoL in cancer patients130. However, universal acceptance of one definition for QoL 
is lacking. 
Quality of life has been defined as "subjective well-being'm, as "the subjective 
evaluation of life as a whole", and "refers to patients' appraisal of, and satisfaction 
with, their current level of functioning compared to what they perceive to be possible 
or ideal"130• "Conceptually, QoL has to do with the sense of satisfaction and well-
being that an individual feels about his or her life, and qualities such as the degree to 
which an individual succeeds in accomplishing his desires and the extent to which a 
person's hopes and ambitions are matched and fulfilled by experience"278• Recently, 
a World Health Organisation group proposed that "QoL can be defined as the 
individual's perception of his/her position in life in the context of the culture and 
value systems in which he/she lives and in relation to his/her goals, expectations, 
standards and concerns"- highlighting the emphasis on an individual's judgemene73 . 
Health related quality of life (HRQoL) is commonly defined as the "subjective 
experience of the impact of the disease on the quality of one's life" 400 . This 
definition aims to provide a description of how the patient experiences their disease. 
Health-related QoL "describes the beliefs and behaviours of daily life which are 
governed by the degree of good or ill health that an individual, group or population 
experiences", with the typical domains of HRQoL a~sessment including well-being, 
pain and discomfort, body image, sexuality, mobility and the ability to perform daily 
activities172 . However, Avis and colleagues (1996i1 noted that HRQoL generally 
denotes the aspects of life most likely to be influenced by health, including physical 
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and mental health; physical, social and cognitive functioning; intimacy or sexual 
functioning; and productivity. 
During use in cancer clinical trials, QoL has been defined as "the ability to perform 
everyday activities which reflect physical, psychological and social well-being; and 
patient satisfaction with levels of functioning and control of disease and/or treatment-
related symptoms"145 . Similarly, it was stated that "QoL is a state of well-being 
which is a composite of two components including the ability to perform everyday 
activities which reflect physical, psychological and social well-being; and patient 
satisfaction with levels of functioning and control of disease and treatment-related 
symptoms" 118 • 
Assessment of QoL provides valuable and relevant data that are useful for patients, 
clinicians, researchers and health policy makers25 . These tools can prove useful in 
determining needs, developing intervention strategies and evaluating intervention 
outcomes213 • Quality of life assessment can also identifY patients' needs, monitor the 
impact of treatment and assist in determining the need for specific services. The use 
of QoL tools as an outcome measure is a relatively new concept. However, it is 
commonly used in describing the nature and degree of the patient's functional and 
psychosocial problems, in establishing norms of psychosocial morbidity, in 
monitoring the delivered quality of care, in evaluating intervention strategies, and in 
screening patients for the need for intervention strategies59. 
Numerous HRQoL assessment tools exist and include global assessment, multi-
attribute utility scales and multidimensional scales, which may be generic or disease-
specific instruments169• 172' 213 • The QoL tools that are disease-specific have the 
capacity to capture the unique problems and concerns in a particular population, and 
are extremely sensitive to small changes in QoL56• 132 . A list of questionnaires 
specifically designed for use with cancer patients has been provided in Table 8.1. 
Although these questionnaires have been designated as cancer-specific, some of the 
measures could be, and at times have been, applied in other diseased populations65 . 
Examination of the item content in some of these tools revealed that several of the 
concepts measured are generic rather than cancer-specific. A detailed review of each 
questionnaire has been provided elsewhere65 • 
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Table 8.1 Cancer-related QoL questionnaires 
Psychometric··mea5tires&il1clude::.: 
> Fun~tional Livingtilaex.:cancer(Etrcr 
> ·cane:er.Rehabilitation·E:Va!uatio~rSystem~(Cl\JffiS} 
> McGill questionnaire 
)> Spitzer Quality of Life Index 
'~ ' ' ' ' ' / 
);> Ferrans and·P<JV{ersQuality~of-I;ifeindex 
> Kamofs}(yg~rf()~~ce Ss@e {KPs). 
)> European Organisation forReseru:chand Treatment ofCancer Qualit:y-()f-Life 
Qu~s~iormaire - Core 
);> Functional :Assessment ofCancer 'therapy 
> Linear-Analogue Self-Assessment scale 
)> Rand 36-:item survey 1.0 
Utility1vfeasures inclu<}e:'7 .··• 
> Quality-of~Well-BemgScale 
)> 
When deciding upon the most appropriate QoL questionnaire to use, factors relating 
to the patient population should be taken into consideration. As described in detail in 
Chapter 3, the subject group for this investigation included patients with a range of 
cancer diagnoses, who had been administered and/or were about to undergo a vast 
range of treatment options including surgery, chemotherapy and radiotherapy. As a 
consequence of the cancer and treatment undertaken, the patient group was at risk of 
numerous short- and longer-term side effects. It has also been recommended in the 
literature that the QoL measure should include questions that are relevant and simple 
to comprehend, while being sufficiently sensitive to changes in symptomatology or 
QoL 65 . Following careful consideration of these factors, the CARES questionnaire 
was deemed to be an effective and useful tool for use in this investigation. 
The CARES is a standardised, comprehensive rehabilitation and QoL questionnaire 
designed specifically for use with cancer patients131 • It has been administered to 
greater than 1100 cancer patients who have been diagnosed with various forms of 
cancer and who have undergone a diverse range of treatment regimens334. The 
theoretical background, item and scale development of the instrument have been 
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previously described in the literature334. The tool provides a global QoL score and 
global scores for 5 QoL domains, which are referred to as higher order factors 
(HOF). The 5 HOF are physical, psychosocial, medical interaction, marital and 
sexual. For each of these categories, further information is provided regarding the 
number of identified problems (which are referred to as endorsed problems) and the 
average severity rating of these identified problems. 
Reliability studies335' 336 performed on the CARES have demonstrated that the tool 
has excellent test-retest reliability. The initial reliability investigation calculated the 
Pearson product-moment correlation on three of the CARES summary scores and 
reported the r value to be greater than 0.84. Subsequent testing of the tool supported 
previous results, with all correlations being above 0.82. Between 84-88% of the 
time, the patients' second ratings agreed with their first ratings in determining 
whether a problem existed. Research on the content validity of the instrument has 
suggested that it is comprehensive and represents problems experienced by cancer 
patients336. Concurrent validity has also been assessed, and it was found that the 
CARES is measuring what it purports to measure336. Moreover, the CARES has 
been compared with the Dyadic Adjustment Scale, the KPS, a global measure of 
QoL using a 1 0-centimetre visual analogue scale and the FLIC. These investigations 
have demonstrated expected correlations and provide evidence of the concurrent and 
construct validity of the CARES334. 
The CARES presents a detailed assessment of rehabilitation concerns, which makes 
it an ideal tool in research and clinical settings132 • It is also capable of discriminating 
between different surgery techniques, as is evidenced by the segmental mastectomy 
breast cancer group scoring fewer problems than the modified radical mastectomy 
group132 . Finally and importantly, the questionnaire is readily accepted by patients. 
This was determined through patient interviews, whereby the patients reported that 
the instrument was reflective of the cancer experience, was not offensive, was simple 
to comprehend and complete334 . 
In summary, the CARES meets a number of criteria for being a generic measure of 
QoL in cancer patients132 • The global CARES score is sensitive enough to identify 
stage-related differences in cancer sites and cancer site differences for patients who 
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are at the same phase of disease. Furthermore, the summary scales of the CARES 
provide additional insight into the specific dimensions of QoL that reflect variations 
in known disease-specific problems132 . 
8.1.1 Quality of life of patients with cancer 
The majority of the population tends to equate cancer with death, and thus cancer is 
perceived as the worst illness of all medical conditions322. However, previous 
investigations reviewed by Ringdal et al (1994)322 have compared the QoL of cancer 
populations to other diseased populations and to healthy subjects, and found 
contrasting results. Few studies were identified that were able to demonstrate that 
one or more QoL dimensions were substantially lower in the cancer population when 
compared with other clinical patient groups and healthy subjects. Some 
investigations reported that cancer patients were more satisfied with the care they 
received from their partner and 'significant others', and reported more positive and 
fewer negative social experiences, when compared with healthy persons. This was 
explained by changes in the way cancer patients value life and experiences. 
Although, it was also cautioned that patients may lower their aspirations and be 
satisfied despite their life being impaired. 
There have also been differing results reported36' 383 • Responses to 2 validated 
questionnaires assessing self-reported satisfaction with life and physical health, 
conducted among 204 long-term survivors of head and neck cancer, were compared 
with those responses from 766 matched controls36. It was found that, compared with 
the controls, cancer patients rated significantly lower satisfaction with life and 
physical health. Additionally, a QoL evaluation based on a number of questions 
covering general body symptoms, mood level and functional limitations, 
demonstrated that patients with gastric cancer reported more neurasthenic complaints 
such as reduced sexual interest, insomnia and poor appetite, in conjunction with a 
lower mood when compared with the general population383 . 
Comparisons between different cancer patient groups have also been made. The 
CARES QoL tool was utilised to investigate the QoL of patients with colorectal, 
breast, lung and prostate cancer132 . A relationship between the global CARES score 
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and the extent of disease was found for the colorectal and lung cancer patients, 
whereby those patients experiencing the most extensive disease, maintained the least 
favourable global score. fu this same patient group, the relationship described above 
was also found for the five HOF and extent of disease. The only exception was for 
the marital interaction summary scale in the lung cancer patient group. Similar 
results were reported in an investigation that compared the QoL of patients 
considered to have a good prognosis, with that of patients considered to have a 
medium or poor prognosis322 . Patients with a good prognosis scored significantly 
higher on the general QoL-scale and on physical aspects of the QoL. futerestingly 
though, only marginal differences existed among the prognosis groups for the social 
and psychological aspects of QoL, such as emotional functioning (anxiety and 
depression). 
A cross-sectional designed study was employed to assess the QoL in patients with 
lung, colon and prostate cancer, and who represented short-, intermediate- and long-
term survivors333 . While length of survival was not a critical factor in QoL ratings 
for the lung cancer patients, a clear positive association for length of survival and 
QoL was observed for colon cancer patients. Quality of life failed to improve with 
longer survival times in the prostate cancer group, with the survivors reporting 
poorer QoL globally. Additionally, functional status was a significant factor in QoL 
ratings for each of the cancers. 
Differences between patients at the same phase of disease with colorectal, lung and 
prostate cancer have also been assessed132 . For the patients with no evidence of 
disease, no significant difference was found between each of the different types of 
cancer groups. However, for the localised disease patients, patients with prostate 
cancer rated a higher QoL when compared with lung cancer patients. fu the 
extensive disease patients, patients with prostate cancer scored a higher QoL than 
lung and colorectal cancer patients. fu support of these findings, patients with 
advanced-stage lung cancer documented more physical functioning, psychosocial 
functioning and marital interaction problems and a lower global QoL when compared 
to patients with advanced-stage prostate cancer248 . 
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Common factors listed by patients which influence QoL include diminished 
cardiovascular function, reduced strength and deterioration of lean body tissue, body 
composition changes, fatigue, pain, weakness, insomnia, gastrointestinal problems, 
shortness of breath, sweating and anorexia72' 77 • Some of the more common 
psychological emotional sequelae of the cancer experience known to influence QoL 
include depression, anxiety, stress, reduced self-esteem, loss of sense of control and 
diminished psychological and emotional well-being77• 
Anxiety and depression have been detected in many patients with a variety of 
malignancies who are receiving radiotherapy, both prior to treatment and 3-4 months 
post treatment69. • With specific reference to breast cancer patients, evidence 
demonstrates that multiple factors including disturbances in body image and self-
concept; social, sexual and family relationship disruptions; emotional distress; and 
the inability to maintain or resume normal daily activities - adversely influence 
QoL246• Psychosocial difficulties such as peer relationship problems, depression and 
altered self-concept and body image perceptions, are known factors influencing the 
QoL of adolescents following cancer diagnosis and treatment192• Exacerbating these 
issues are the presence of physical and functional problems such as reduced 
cardiovascular and pulmonary function, reduced exercise tolerance and changes in 
body composition. A number of specific factors likely to compromise post-BMT 
QoL include fatigue, weakness, occupational disability, sleep difficulties and sexual 
relationships and functioning13 . 
Impaired social functioning, physical functioning and work-related problems were 
reported in 20%, 33% and 20% of BMT patients, respectivell24• Additionally, 
problems relating to physical, emotional, occupational and cognitive functioning 
have been associated specifically with allogenic transplant patients11 . BMT patients 
reported more negative changes regarding physical health, when compared with 
changes to relationship and psychological status85 . Allogenic transplant patients 
report poorer QoL when compared with autologous transplant patients, and greater 
age at BMT, lower education level and more advanced disease are also known risk 
factors for poorer QoL13 . Finally, while some BMT recipients rated 'normal' QoL, 
the majority indicated a compromised QoL when compared to their premorbid 
status13 • 
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More recent work has assessed the QoL in women with breast cancer undergoing 
autologous PBST206• Nine women, aged between 23-58 years completed two 
questionnaires - the Sickness hnpact Profile and the Swedish HRQoL questionnaire -
pre- and immediately post-transplant, and 7-15 weeks following the transplant. The 
results demonstrated that the women were adversely affected by the treatment in 
various dimensions of daily life. Undergoing the transplant particularly affected 
their self-rated health and function, and physical health status was perceived to be 
lowest at time of discharge, when compared with pre- and 7-15 weeks post-
transplant. The emotional status for the breast cancer patients was also considered to 
be poor throughout the entire study period, when compared with matched controls. 
Evidence clearly demonstrates that QoL is detrimentally affected as a consequence of 
cancer diagnosis and treatment. Cancer care should therefore include intervention 
strategies that have the potential to prevent, minimise and/or reverse these adverse 
effects. 
8.1.2 Exercise and quality of life 
"Physical exercise is a fundamental aspect of quality of life"38 . hnpairment of 
physical fitness is a significant contributor to decrements in QoL in cancer patients105 
during and following conventional levels of cancer therapies77• It has been suggested 
that participation in a regular exercise intervention program may simultaneously 
influence many dimensions of QoL, or alternatively it may directly influence one 
dimension, which in turn has a 'domino effect' among other wellness domains445 . 
The physiological benefits of participation in regular exercise have been extensively 
reported in the previous chapters. Of specific importance to this investigation are the 
benefits derived though exercise participation, both physiological and psychological, 
that will lead to positive changes in QoL. Following a review of24 empirical studies 
published between 1980 and 1997 regarding exercise, QoL and cancer, it was 
reported that studies have consistently demonstrated that physical exercise has a 
positive effect on QoL following cancer diagnosis77 . hnportantly, exercise was 
shown to induce a positive effect on physical, functional, psychological, emotional, 
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and social well-being. All these aspects lead to an overall improvement in global 
QoL. 
A decrease in total mood disturbance226, sleep disturbance, depression, fatigue and 
nausea
246
, and an enhanced perceived internal locus of control124, self-esteem, self-
confidence257, life satisfaction 78 and overall QoL 445, have been reported among 
exerc1smg cancer patients. Patients perceive exercise as a stress-controlling 
mechanism that assists them in coping with the disease426. It also allows patients to 
maintain a sense of control over their lives, including the maintenance or 
enhancement of fitness426. 
The majority of work in the area of exercise, QoL and cancer has investigated 
patients with breast cancer. Following a 10-week cycle ergometry protocol of 3 
sessions per week, breast cancer patients experienced reduced levels of nausea, 
anxiety and depression226. The exercising patients demonstrated a reduction in 
fatigue in conjunction with elevated feelings of vigour, while the control group 
showed a worsening of mood states226. Others have reported that exercise may 
induce positive mood changes, body image, self-esteem, confidence, personal worth, 
self-acceptance, and control, while reducing depression, tension, anxiety, anger, 
helplessness, hostility and pessimism246' 369. Women with breast cancer have 
demonstrated that those who exercise regularly experience a significantly higher 
QoL when compared with matched controls445 and that the improvement in quality of 
life is proportional to the amount of exercise undertaken291 . 
Others have investigated the role of exercise (a self-paced, progressive walking 
program) during radiation treatment and have also found positive results247 . 
Outcome measures evaluated included physical functioning (as assessed by the 12-
minute walk test) and fatigue, anxiety, depression and difficulty sleeping. Eighty-six 
per cent of the experimental group maintained the active exercise program 
throughout the entire duration of treatment. While anxiety, depression and difficulty 
sleeping were common symptoms for both groups, the control group experienced 
greater symptom intensity. Additionally, while both groups reported high levels of 
dissatisfaction with their body, the symptom was correlated with fatigue, anxiety, 
depression and difficulty sleeping. 
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The potential for physical activity to address QoL issues in adolescents with cancer 
has only recently been investigated192. Those adolescents who maintained their 
organised sport participation throughout the entire cancer experience (diagnosis, 
treatment and post-treatment) reported physical benefits and also noted better general 
self-concept, physical abilities, as well as parental, same-sex and opposite-sex 
relationships192• hnportantly, these are some of the primary psychosocial outcomes 
compromised in adolescents following cancer diagnosis. It was further suggested 
that participation in organised sport may provide adolescents with invaluable 
opportunities for normalising physical, functional, social and psychological well-
being. 
There have been only a few recent studies regarding the role of exercise in patients 
undertaking a BMT. Participation in exercise by BMT patients during 
hospitalisation has been significantly correlated with all QoL indices, except 
emotional and social well-being80. The most consistent relationships were identified 
for physical well-being, depression, anxiety and psychological well-being. 
Significantly fewer medical complications, including duration of neutropenia and 
thrombocytopenia, and severity of diarrhoea and pain - all of which may relate to 
improved QoL - have also been found in exercising BMT patients102 . 
An aerobic exercise program implemented in patients receiVmg high-dose 
chemotherapy followed by autologous PBST, showed that there can be positive 
effects on the mental status of cancer patients and that the effects of physical activity 
are not limited to improved physical performance alone105• Patients in Dimeo et al's 
study (1995)105 were divided into a control and training group, with the training 
program consisting of daily, discontinuous duration of exercise using a bed 
ergometer at an intensity of at least 50% cardiac reserve, for the duration of their 
hospital stay. hnprovements in the training group were shown in several indicators 
of psychological distress including depression, fear, anger/hostility, interpersonal 
sensitivity and phobic anxiety in the training group105. While several psychological 
distress scores were reduced in a number of areas for the exercising patients, the 
control group showed no improvement in mood state. In addition, unlike the training 
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group, the control group demonstrated a significant rise in fatigue and somatisation 
scores by the time of hospital discharge. 
The importance of the above findings are highlighted further when it is taken into 
account that depressed mood, functional QoL and mental adjustment have been 
previously linked to survival in BMT patients and other cancer patient groups12. An 
attitude toward cancer characterised by 'anxious preoccupation', in addition to 
poorer functional QoL, have each been associated with poorer post-BMT survival. 
Better functional QoL was related to longer survival. 
8.1.3 Relationship between functional capacity and quality of life 
The effectiveness of common intervention strategies currently available for patients 
with cancer such as relaxation training, meditation, professional support/counselling, 
social support and alternative treatments such as music therapy, in improving QoL, 
was assessed via a meta-analysis 77 . While the treatment categories were considered 
to be equally effective, they illustrated the weakest effect for functional QoL. The 
results of this investigation are particularly significant when the results of other 
research are also taken into account. A negative change in physical health has the 
greatest impact on overall QoL, when compared with changes in the other QoL 
domains22' 78 . This overlapping nature of health and functional status is commonly 
observed when individuals define their state of health by stating what they are 
capable and not capable of performing22. Importantly, while the functional and 
physical domain of _QoL has been reported to be the most important QoL dimension 
underlying overall satisfaction with life, it is often the least possessed78 . 
The strong relationship between physical QoL and global QoL underscores the 
potential inadequacies of current QoL interventions that fail to practically address the 
physical concerns of the patient80. 
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8.2 Methodology 
Chapter 3 provides a detailed outline of the methodological procedures that relate to 
subject recruitment, the testing phases and the intervention program implemented. In 
summary, 12 patients, with 6 patients in each group were recruited. Of these, only 7 
patients were recruited at PI, while the remaining subjects entered the investigation at 
PIT. Outlined below are the methodological procedures, which relate specifically to 
the aims of this section of the investigation and involve the assessment of total QoL 
and 5 QoL domains. 
8.2.1 Quality of life assessment 
The Cancer rehabilitation evaluation system (CARES) (Appendix VIII) was used to 
assess QoL. The CARES consists of 139 'problem statements' (which are referred to 
as items), 88 ofwhich are completed by all patients, while the remaining 51 items are 
only completed by patients when relevant. In total, a minimum of 93 items, and a 
maximum of 132 items may apply to any one patient. Patients completing the 
questionnaire are required to read each statement and provide a rating regarding how 
much the statement applies to them. The CARES utilises a 5-point rating scale, 
ranging from 0 (the statement does not apply at all) to 4 (the statement applies very 
much) during the past month. Due to the nature of the scoring system, a lower score 
corresponds with a higher QoL rating. 
The CARES can be scored in several ways, with the most detailed level of scoring 
consisting of 31 subscales and 7 remaining miscellaneous items. A broader 
overview scoring consists of a global QoL rating and global ratings for the 5 higher 
order factors or summary scales, including physical, psychosocial, medical 
interaction, marital and sexual. 
The level of scoring is represented in Figure 8.1, while a summary of the items which 
comprise the 5 summary scales (or QoL domains) has been presented in Appendix 
IX. 
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Figure 8.1 Scoring the CARES 
5 Summary scales 
31 Subscales 
139 Individual items 
Five types of scores (presented below) can be calculated in the three top levels of the 
pyramid. Obviously, the more scores that are calculated, the greater the detail 
obtained. 
1) The severity rating which represents a summation of all items within a scale 
rated between 1 and 4. 
2) The number (#) of potential problems which represents the number of items that 
maintains the potential of applying to a particular patient for each scale. 
3) The number (#) of endorsed problems (EP) which represents the number of 
items that have the potential of applying to a particular patient and has received a 
rating between 1 and 4. 
These three scores were then used to generate the average severity rating (AS) and 
the global score (QoL score). 
4) Average severity rating = severity rating 
# of endorsed problems 
5) Global score = severity rating 
# of potential problems 
The patients' responses between 1 and 4 in the CARES booklet were transferred to 
the CARES Score and Profile Sheet (appendix X). The three preliminary scores 
(Severity Rating, # of Endorsed Problems, and # of Potential Problems) were 
calculated for each summary scale and transferred to the bottom right comer on the 
score sheet, where the final calculations were made. The average severity rating and 
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the global score were then calculated. Following the computation of the raw scores, 
the data were then converted to T scores using the tables provided in the CARES 
manuaf6, and were then used in the statistical analysis. The T scores allowed for the 
comparison of data with 'normative' cancer population data, again provided in the 
CARES manual76 . The normative data were derived from 1047 American 
outpatients and included patients of various ages, socioeconomic status, marital 
status, ethnicity, disease diagnosis, and treatment regimens undertaken. 
In summary a global score, number of endorsed problem score and average severity 
score were calculated for total QoL, and physical, psychosocial, medical interaction, 
marital and sexual QoL. The number of endorsed problems and average severity 
rating were also calculated for the 7 subscales within the physical QoL domain. 
8.2.2 Statistical analysis 
QoL data were collected at each of the three testing phases and were analysed 
according to the statistical procedures outlined in Chapter 3. Additionally, the 
relationship between functional capacity and QoL was assessed by correlating 
(Pearson correlation) aerobic capacity (measured in ml/FFM/min as outlined in 
Chapter 5) and QoL measures at PI, PII and PHI. The QoL measures included in the 
analysis were total and physical QoL, number of endorsed problems relating to total 
and physical QoL, and average severity of endorsed problems relating to total and 
physical QoL. Psychosocial, medical interaction, marital and sexual QoL were also 
included in the correlations. 
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8.3 Results 
Significant adverse changes in total QoL (p<0.05) were associated with undergoing 
an autologous PBST (Table 8.2). Physical, psychosocial, medical interaction and 
sexual QoL domains were also affected, however the changes were not significant. 
With the exception of the sexual QoL domain, an elevation in the mean number of 
endorsed problems, as well as an increase in the mean average severity of the 
problem, contributed to these poorer global scores. Contributing to the mean change 
observed in the sexual global score was an increase in the number of endorsed 
problems, in addition to a significant reduction (p<0.05) in the average severity of 
the problems. 
Table 8.2 QoL measures at PI and PII for the study group (mean±SE) 
Total QoL (TQoL) 54.17 1.21 57.75 0.74 0.024* 
EP 56.64 1.43 57.92 0.87 0.457 
AS 51.31 3.03 54.92 1.86 0.326 
QoLDomains 
Physical QoL (PQoL) 56.42 2.09 61.17 1.28 0.071 
Physical EP 58.25 2.16 61.58 1.33 0.209 
Phlsical AS 54.14 1.88 58.50 1.15 0.066 
Psychosocial QoL (PSQoL) 51.50 1.41 54.50 0.87 0.090 
Psychosocial EP 54.56 1.78 55.67 1.09 0.603 
Psychosocial AS 48.25 1.73 . 51.58 1.06 0.121 
Medical Interaction QoL (MIQoL) 51.63 1.40 53.83 0.86 0.202 
Medical Interaction EP 52.33 1.21 55.00 0.74 0.080 
Medical Interaction AS 53.42 1.31 54.83 0.80 0.372 
Marital QoL (MQoL) 53.11 1.23 53.25 0.75 0.924 
Marital EP 54.19 0.89 53.33 0.54 0.420 
Marital AS 50.86 1.42 52.33 0.87 0.393 
Sexual QoL (SQoL) 54.75 1.32 57.50 0.81 0.097 
Sexual EP 53.17 1.87 57.00 1.14 0.100 
Sexual AS 60.89 1.70 56.33 1.04 0.037* 
* p<0.05 
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Undergoing a PBST was also associated with adverse changes in the number of 
endorsed problems and average severity of the problems in the physical subscales 
(Table 8.3). With the exception of pain and difficulty working, the mean number of 
endorsed problems increased following the transplant, with significant changes 
observed in the subscale of weight loss (p<0.05). Unlike the other subscales, the 
number of endorsed problems regarding difficulty working was significantly lower at 
PII (p<0.05), when compared with PI. The average severity of the endorsed 
problems also increased following the transplant, with the exception of the pain 
subscale. The change was significant for the subscales of ambulation (p<0.05), 
weight loss (p<0.05) and difficulty working (p<0.01). 
Table 8.3 Physical subscale measures at PI and PII for the study group 
(mean±SE) 
Physical subscales: 
Ambulation EP 3.31 0.27 3.42 0.17 0.731 
Ambulation AS 2.09 0.23 2.74 0.14 0.030* 
Activities of daily living EP 1.94 0.25 2.42 0.15 0.122 
Activities of dail~ living AS 1.20 0.29 1.88 0.18 0.065 
Weight loss EP 1.97 0.46 3.17 0.21 0.031 * 
Weight loss AS 0.88 0.38 1.93 0.17 0.024* 
Recreational activities EP 2.94 0.42 3.00 0.25 0.911 
Recreational activities AS 2.04 0.31 2.38 0.19 0.376 
PainEP 2.17 0.45 1.33 0.27 0.130 
Pain AS 1.22 0.37 1.04 0.22 0.694 
Difficulty working EP 3.17 0.46 1.67 0.28 0.013* 
Difficulty working AS 1.89 0.35 3.25 0.22 0.005** 
Clothing EP 1.11 0.27 1.33 0.16 0.485 
Clothins; AS 0.90 0.37 1.26 0.22 0.414 
* p<0.05, ** p<0.01 
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As shown in Table 8.4, both the EG and CG demonstrated a similar mean change 
across the phases for total QoL. Undertaking a transplant was associated with a 
reduction in total QoL, and a 3-month recovery period was associated with 
significant improvements in QoL (p<O.Ol). As is evident in Figure 8.2, the changes 
in the group mean are representative of individual changes. That is, all patients in 
both the CG and EG demonstrated the same trend of change between PI and PII, and 
PII and Pill. Both groups recorded mean QoL scores at Pili that were lower than PI, 
however, the difference was only significant for the EG (p<0.01). Although little 
change existed between the mean number of endorsed problems and average severity 
of the problems across the phases for the CG, the exercising patients demonstrated 
significant improvements (p<0.01) by 3-months post-transplant. Following the 
intervention period, significantly fewer endorsed problems (p<0.01) and less severe 
endorsed problems (p<0.01) were reported by the EG when compared with pre- and 
immediately post-transplant. 
Table 8.4 Total QoL measures across the testing phases for the control and 
exercise group (mean±SE) 
CG 
TQoL I 55.33 2.19 PI-PII 0.131 
II 58.33 1.05 PI- Pill 0.445 
III 53.83 1.21 Pill- PII 0.009** 
TQoLEP I 60.28 2.53 PI-PII 0.571 
II 59.67 1.24 PI- Pill 0.133 
III 58.31 1.43 Pili- PII 0.097 
TQoLAS I 50.44 5.46 PI-PII 0.328 
II 54.33 2.62 PI- Pill 0.678 
III 48.72 3.03 Pili- PII 0.065 
EG 
TQoL I 53.00 1.05 PI- PII 0.032* 
II 57.17 1.05 PI- Pill 0.000** 
III 40.33 1.05 Pill- PII 0.000** 
TQoLEP I 53.00 1.24 PI- PII 0.162 
II 56.17 1.24 PI- Pili 0.000** 
III 42.00 1.24 PIII-PII 0.000** 
TQoLAS I 52.17 2.62 PI- PII 0.453 
II 55.50 2.62 PI- Pili 0.007** 
III 37.67 2.62 PIII-PII 0.002** 
n = CG: PI-3, PII-6, PIII-5; EG: PI-4, PII-6, PIII-6 
* p<0.05, ** p<0.01 
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Figure 8.2 Individual changes in total QoL across the testing phases for the 
subjects in the control and exercise groups 
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Although the CG and EG demonstrated similar changes across the testing phases for 
physical QoL, the changes were only significant for the exercising patients (Table 
8.5). The 3-month exercise intervention period was associated with significant 
improvements in physical QoL (p<O.Ol), endorsed problems (p<O.Ol) and average 
severity of the problems (p<O.Ol). Further, scores for all 3 variables were 
significantly lower (p<O.Ol) at PHI, when compared with PI, for the exercising 
patients. 
The changes observed in physical QoL can be attributed to changes in the physical 
subscales. Across the phases, little change was observed in the number of endorsed 
problems and average severity of the problems for the CG (Figures 8.3a, 8.4a), with 
the exception of difficulty working. At PHI, the CG scored a significantly lower 
average severity of problems in the difficulty working subscale (p<0.05). In 
comparison, significant improvements in the number of endorsed problems and 
average severity of the problems in the physical subscales were observed for the 
exercising patients (Figure 8.3b, 8.4b ). Following the exercise program, patients 
rated significantly fewer problems for ambulation (p<0.05), activities of daily living 
(ADL) (p<0.05), weight loss (p<O.Ol), recreational activities (Rec Act) (p<O.Ol), 
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difficulty working (p<0.05) and clothing (p<0.05). By Pili scores were significantly 
lower when compared with PI, for the ambulation (p<0.05), weight loss (p<0.01), 
recreational activities (p<0.05), and difficulty working (p<0.01) subscales. The 
average severity of the problems in the subscales of ambulation, weight loss, 
recreational activities, difficulty working and clothing was also significantly lower 
by PHI (p<0.05, except for the clothing subscale where p<0.01). Finally, exercising 
patients perceived the average severity of their endorsed problems to be significantly 
less than PI for the subscales of ambulation (p<0.01), recreational activities (p<0.05) 
and difficulty working (p<0.01). 
Table 8.5 Physical QoL measures across the testing phases for the control and 
exercise group (mean±SE) 
Phx~iqal~~onrctom~rr'''· .'f£lia[e;:;~~~¢§rl~~ ~!!!SE~i, $~7":~1 ~~,~ cJ~mJiim'[<:in' ·• •• 'C ~;£i'x~file: 
CG 
PQoL I 59.83 3.76 PI- PIT 0.401 
II 64.50 1.81 PI- Pili 0.842 
III 58.67 2.09 PIII-PII 0.143 
PQoLEP I 63.00 3.90 PI-PII 0.507 
II 66.17 1.87 PI- Pili 0.857 
III 62.08 2.16 PIII-PII 0.223 
PQoLAS I 56.28 3.39 PI- PII 0.390 
II 60.33 1.63 PI- Pili 0.668 
III 54.14 1.88 PIII-PII 0.082 
EG 
PQoL I 53.00 1.81 PI- PII 0.055 
II 57.83 1.81 PI- PHI 0.001 ** 
III 42.83 1.81 PIII-PII 0.000** 
PQoLEP I 53.50 1.87 PI- PII 0.210 
II 57.00 1.87 PI- Pili 0.004** 
III 43.67 1.87 PIII-PII 0.000** 
PQoLAS I 52.00 1.63 PI- PIT 0.051 
II 56.67 1.63 PI- PHI 0.003** 
III 43.83 1.63 PIII-PII 0.000** 
n = CG: PI-3, PII-6, PIII-5; EG: PI-4, PII-6, PIII-6 
** p<O.Ol 
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Figure 8.3 Number of endorsed problems in the physical subscales, across the 
testing phases (mean±SE) 
(a) Control group data (n = PI-3, Pil-6, Pili-5) 
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Figure 8.4 Average severity of the endorsed problems in the physical subscales, 
across the testing phases (mean±SE) 
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As shown in Table 8.6, undertaking a PBST was associated with adverse changes in 
the global, EP and AS scores for the psychosocial domain, while a 3-month recovery 
period was associated with improvements in these scores. However, following the 
transplant, changes were only significant for the exercising patients (p<O.Ol). 
Further, following the 3-month intervention program, the exercising patients rated a 
significantly improved global (p<O.Ol), EP (p<O.Ol) and AS score (p<O.Ol), when 
compared with pre-transplant scores. 
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Table 8.6 Psychosocial QoL measures across the testing phases for the control 
and exercise group (mean±SE) 
CG 
PSQoL 
PSQoLEP 
PSQoLAS 
EG 
PSQoL 
PSQoLEP 
PSQoLAS 
I 
II 
III 
I 
II 
III 
I 
II 
III 
I 
II 
III 
I 
II 
III 
I 
II 
III 
49.33 
54.00 
52.67 
56.61 
57.17 
55.22 
42.83 
49.67 
48.25 
53.67 
55.00 
42.00 
52.50 
54.17 
43.50 
53.67 
53.50 
45.17 
2.55 
1.22 
1.41 
3.22 
1.55 
1.78 
3.12 
1.50 
1.73 
1.22 
1.22 
1.22 
1.55 
1.55 
1.55 
1.50 
1.50 
1.50 
n = CG: PI-3, PII-6, PIII-5; EG: PI-4, PII-6, PIII-6 
* p<0.05, ** p<0.01 
~@oU:iB;:lliJs~n~" i\P"~IL!i~ 
PI- PII 0.036* 
PI- PHI 0.120 
PIII-PII 0.272 
PI- PII 0.796 
PI- Pili 0.558 
PHI- PII 0.208 
PI- PII 0.364 
PI- Pili 0.105 
PIII-PII 0.434 
PI- PII 0.519 
PI- Pili 0.000** 
PIII-PII 0.000** 
PI- PII 0.524 
PI- PHI 0.005** 
PIII-PII 0.002** 
PI- PII 0.945 
PI- Pili 0.005** 
PIII-PII 0.005** 
Medical interaction QoL (Figure 8.5a, band c) and marital QoL (Figure 8.6a, b and 
c) showed few changes for both groups across the testing phases. Significant 
differences were only observed between the number of endorsed problems for 
medical interaction QoL at PI and Pili for the CG (p<0.05), and between the average 
severity of marital problems for the exercising patients at PII and Pili (p<0.05). 
Mean changes in sexual QoL were similar across the phases for both the exercising 
and non-exercising subjects (Figure 8.7a, b & c). The global sexual QoL score 
significantly improved following 3-months post-transplant for the CG (p<0.01) and 
EG (p<0.01). Additionally, the exercising patients rated significantly fewer 
problems following the intervention period when compared with the ratings recorded 
at PII (p<0.05). Although the CG demonstrated an improved average severity of the 
problems by Pili when compared with PI (p<0.05), the exercising patients rated a 
significantly lower average score at Pili when compared with both pre- (p<0.05) and 
immediately post- transplant scores (p<0.05). 
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Figure 8.5 Medical interaction QoL measures for the study group (PI & PII) and 
the control and exercise group (PI, PII & Pili) (mean±SE) 
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Figure 8.6 Marital QoL measures for the study group (PI & PH) and the 
control and exercise group (PI, PII & Pili) (mean±SE) 
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Figure 8. 7 Sexual QoL measures for the study group (PI & PIT) and the 
control and exercise group (PI, PII & Pill) (mean±SE) 
(a) 
(b) 
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Following the 3-month intervention program, those patients who participated in the 
exercise program reported a higher total QoL (p<0.05) and fewer endorsed problems 
(p<0.05) when compared with non-exercising participants (Table 8.7). Additionally, 
participation in the exercise intervention was also associated with higher physical 
QoL (p<O.Ol) and psychosocial QoL (p<0.05). Significantly fewer physical 
problems were endorsed (p<O.Ol) and the average severity of the endorsed problems 
was lower (p<0.05) for those in the EG when compared with the CG, by Pili. More 
specifically, in the physical domain the exercising patients demonstrated on average, 
fewer endorsed problems and less severe problems for all of the physical subscales 
(Table 8.8). These differences were significant (p<0.05), with the exception of 
ambulation EP, activities of daily living AS, weight loss AS, pain EP, and difficulty 
workingEP. 
Table 8. 7 Comparisons between the control and exercise group at Pili, for total 
QoL and QoL domain measures (mean±SE) 
CARES Global 53.83 1.21 40.33 1.05 0.025* 
CARESEP 58.31 1.43 42.00 1.24 0.036* 
CARES AS 48.72 3.03 37.67 2.62 0.080 
Physical Global 58.67 2.09 42.83 1.81 0.004** 
Physical EP 62.08 2.16 43.67 1.87 0.001 ** 
Ph~sical AS 54.14 1.88 43.83 1.63 0.037* 
Psychosocial Global 52.67 1.41 42.00 1.22 0.028* 
Psychosocial EP 55.22 1.78 43.50 1.55 0.059 
Ps~chosocial AS 48.25 1.73 45.17 1.50 0.309 
Medical interaction Global 54.06 1.40 51.83 1.21 0.250 
Medical interaction EP 57.58 1.21 53.33 1.05 0.232 
Medical interaction AS 53.33 1.05 53.00 1.14 0.662 
Marital Global 53.28 1.23 49.50 1.06 0.620 
Marital EP 56.19 0.89 49.83 0.77 0.456 
Marital AS 52.53 1.43 48.00 1.24 0.271 
Sexual Global 52.25 1.32 52.17 1.15 0.735 
Sexual EP 55.58 1.87 50.33 1.62 0.491 
Sexual AS 52.14 1.70 52.00 1.47 0.816 
* p<0.05 
** p<O~Ol 
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Table 8.8 Comparison between the control and exercise group at Pill for the 
physical subscale measures (mean±SE) 
Ambulation EP 3.72 0.27 1.83 0.23 0.066 
Ambulation AS 2.46 0.23 0.79 0.20 0.016* 
Activities of daily living EP 2.86 0.25 0.67 0.21 0.006** 
Activities of dailJ:: living AS 1.51 0.29 0.67 0.25 0.111 
Weight loss EP 2.03 0.35 0.17 0.30 0.005** 
Weight loss AS 1.44 0.29 0.33 0.24 0.099 
Recreational activities EP 3.53 0.42 0.67 0.36 0.000** 
Recreational activities AS 2.13 0.31 0.67 0.27 0.011 * 
PainEP 1.78 0.44 0.67 0.38 0.188 
Pain As 1.39 0.43 0.50 0.31 0.040* 
Difficulty working EP 2.00 0.46 0.83 0.39 0.156 
DifficultJ:: working AS 2.14 0.35 0.83 0.31 0.042* 
Clothing EP 1.86 0.27 0.00 0.23 0.000** 
Clothing AS 1.38 0.37 0.00 0.32 0.000** 
* p<0.05 
** p<0.01 
The PII and Pill QoL scores derived from the subject sample of this investigation 
were compared with normative data derived from a cancer patient population (Figure 
8.8, 8.9a and b). At PII, PBST patients were, on average, experiencing a lower total 
QoL, and a significantly lower physical QoL, when compared with other cancer 
patients (Figure 8.8). 
By 3-months post-transplant, the mean scores attained by the CG for total QoL, 
physical QoL, and psychosocial QoL remained higher than the normative cancer 
data, however the differences were not significant (Figure 8.9a). In comparison, the 
exercising transplant patients scored lower total QoL and QoL domain ratings than 
the normative cancer group, with significant differences being observed for total 
QoL and the QoL domains, physical, psychosocial and medical interaction (Figure 
8.9b). 
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Figure 8.8 Comparisons of total QoL and QoL domain measures at PII between 
the study group and normative cancer data (mean±SD) 
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Figure 8.9 Comparisons of total QoL and QoL domain measures at Pili 
between the control and exercise group, and normative cancer data (mean±SD) 
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Finally, it was an objective of this investigation to determine the relationship 
between functional capacity (as measured by aerobic capacity) and QoL, and 
changes in functional capacity and QoL experienced between PI and PII. Aerobic 
capacity measurements and changes across phases have been described in detail in 
Chapter 5. The results presented in Table 8.9 demonstrate that those who were 
experiencing a higher level of fitness were more likely to experience a higher QoL, 
. 
endorse fewer problems and rate less severe QoL problems, when compared with 
those experiencing poorer fitness. Further, those who were experiencing higher 
fitness levels were also more likely to experience a higher physical QoL, and fewer 
endorsed and less severe physical problems. Higher fitness levels were also related 
to improved psychosocial, medical interaction, marital and sexual QoL, however 
only the relationship between fitness and medical interaction and sexual QoL at PII, 
reached statistical significance. 
Table 8.9 Relationship between functional capacity (aerobic capacity m 
ml/FFM/min) and QoL measures of the study group at PI, PII and Pili 
-0.641 * 
0.025 
-0.281 -0.403 -0.630* 
0.647 0.194 0.038 
-0.676 -0.708** -0.273 
0.211 0.010 0.417 
-0.762 -0.750** -0.751 ** 
0.135 0.005 0.008 
-0.384 -0.634* -0.735* 
0.523 0.027 0.010 
-0.861 -0.792** -0.656* 
0.061 0.002 0.028 
-0.176 -0.201 -0.495 
0.778 0.532 0.121 
-0.036 -0.609* -0.435 
0.954 0.036 0.181 
-0.524 -0.484 -0.403 
0.365 0.111 0.219 
Pearson Correlation -0.666 -0.653* -0.481 
Sig. (2-tailed) 0.220 0.021 0.134 
* p<0.05 
** p<0.01 
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While the results presented in Table 8.10 demonstrate a trend towards a relationship 
between the level of change experienced in aerobic capacity and the level of change 
experienced in QoL, the relationship was not statistically significant. 
Table 8.10 Relationship between the level of change in functional capacity (aerobic 
capacity in ml/FFM/min) and QoL measures between PII and Pill 
Pearson Correlation 
, .............. , • Sig. (2-tailed) 
e•IHv:+'··"' :>.>•.;&; N 
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8.4 Discussion 
Undergoing a PBST was associated with a negative impact on QoL, together with 
mean increases in the number of endorsed problems and the average severity of those 
problems. However, significant improvements were observed in total QoL and a 
number of QoL domains when patients participated in the 3-month exercise program 
following treatment. Further, exercising patients demonstrated a significantly 
improved QoL when compared with pre-transplant ratings, non-exercising transplant 
patients and patients with cancer who have undergone more conventional treatment 
regimens. Moreover, fitness and QoL are related, with those experiencing higher 
fitness levels, also experiencing a superior QoL. 
8.4.1 Effect of undertaking a PBST on quality of life 
Undertaking intensive chemotherapy followed by a PBST had a detrimental impact 
on total QoL, with adverse changes in the mean physical, psychosocial, medical 
interaction, and sexual QoL ratings, contributing to this overall QoL effect. With the 
exception of the sexual QoL score, a mean increase in the number of endorsed 
problems, as well as a mean increase in the average severity of the problems, were 
associated with the reduced total QoL and QoL domain ratings. 
An impaired physical QoL dimension, in conjunction with a greater number of 
physical problems endorsed and an elevation in physical problem severity following 
a transplant, may not seem surprising. Many physiological decrements and their 
corresponding impact on physical function have been outlined in detail in the 
previous chapters of this investigation. However, an examination of the change 
recorded in many of the physical subscales between PI and PII provided further 
explanation to the mean changes observed in physical QoL. A mean increase in the 
number of endorsed problems relating to ambulation, activities of daily living, 
weight loss (p<0.05), recreational activities, difficulty working (p<0.05) and 
clothing, contributed to the poorer physical QoL rating following the transplant. In 
contrast, the average number of endorsed problems and average severity for the pain 
subscale improved by PII, potentially indicating that pain control and relief 
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throughout the treatment process was effective or that these patients were not 
experiencing pain. The number of endorsed problems for difficulty working 
(p<0.05) also improved by PIT, however the average severity of the problems was 
higher (p<O.Ol). These results indicated that the ability to work at PIT may not be an 
issue for some patients. However, for those who were considering or attempting to 
work, the severity of the endorsed problems became more pronounced. 
Previous studies have also documented the impact of cancer treatment on physical 
QoL. Adverse physiological changes such as a reduction in cardiovascular and 
pulmonary function, poorer exercise tolerance and changes in body composition, 
which in tum lead to an inability to maintain or resume normal daily activities has 
been reported in breast cancer patients155' 246, adolescents with cancer192, and BMT 
patients1L 105 . 
The mean changes observed in psychosocial QoL following the transplant were also 
supportive of previous findings. The items represented in the psychosocial 
component of the CARES questionnaire covered topics including body image, 
psychological distress, cognitive problems, communication and interactive issues, 
anxiety, worry and work concerns. Although the changes in psychosocial QoL 
following the PBST were not significant, on average, patients in this investigation 
rated a lower psychosocial QoL, endorsed a greater number of psychosocial 
problems and rated the average severity of these problems higher, when compared 
with pre-transplant reports. Disturbances in body image and self-concept and an 
elevation in emotional distress have also been reported following breast cancer 
treatment246• Adolescents with cancer have demonstrated depression and altered 
self-concept and body image perception following treatment192 . Social, 
psychological and emotional impairments have been reported following BMT11 ' 206' 
424 
The component of the CARES questionnaire that is relevant to medical interaction 
QoL includes items relating to problems obtaining information from the medical 
team, difficulty communicating with the medical team and inability to control the 
medical team. Although the mean global score following the transplant indicated a 
lower medical interaction QoL, the change was not significant. It was evident during 
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informal interviews that while some patients maintained an effective relationship 
with medical staff, others found that certain treatment side effects influenced the 
ability to communicate with the medical team. For example, fatigue or weakness, or 
sleeping during times medical staff were present, prevented patients from asking 
questions regarding cancer issues. Fears associated with the disease or treatment, or 
simply an inability to understand medical terminology, were other potential factors 
that influenced communication. 
The marital QoL domain relates to the ability to communicate with a partner, the 
ability to show affection and interact with a partner, and whether the patient is 
feeling overprotected or neglected by their partner. In this investigative sample the 
transplant had little effect within the marital QoL domain, indicating that the 
transplant process was neither advantageous nor disadvantageous to marital 
relationships. Previous investigations regarding changes to personal relationships 
with cancer treatment have presented inconsistent results. While a positive effect on 
relationships has been shown in BMT patients85, peer relationship problems and 
disruption to family relationships have been reported in adolescents with cancer192 
and women with breast cancer155. 
The sexual domain relates to sexual interest and sexual dysfunction issues. Sexual 
problems may arise as a result of fatigue, poor body image, and muscular 
weakness50. Economic worries, changes in anatomy and physiology due to surgery 
and/or treatment, and other psychological concerns are other factors that may 
contribute to sexual problems. Although changes were not significant, the mean 
adverse change observed in sexual QoL following the PBST was supportive of 
previous findings in both breast cancer155 and BMT patients13 . 
Finally, the PBST patients experienced similar total QoL, and psychosocial, sexual, 
medical interaction and marital QoL, to those who had undertaken more 
conventional treatment regimens for cancer76 • However, physical QoL was poorer 
when compared with normative cancer data, indicating that intensive treatment 
imposes a greater impact on physical health, when compared with more conventional· 
treatment. This finding is in contrast to previous physiological results presented in 
Chapter 5, which demonstrated that the aerobic capacity (which is a common 
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measure of functional capacity) of the PBST patients at PII, was similar to the initial 
exercise capacity of cancer patients3 who have undergone conventional treatment for 
breast cancer. One potential reason for the confounding results is that the QoL data 
were compared with normative data derived from a range of cancer patients, while 
the physiological data were compared with data derived from breast cancer patients 
only. 
When comparing this study sample to the normative cancer data derived from over 
1000 patients, it is also important to compare group characteristics. As is similar to 
the investigative sample, the normative sample includes patients who have been 
diagnosed with a variety of malignancies and who have undergone a variety of 
treatment regimes. Additionally, the majority of the normative group has at least 
completed secondary education and is married. The mean and range for age is 
64.05 years (21-99 years) and 56.83 years (21-87 years) for the male and female 
patients, respectively. Therefore, the normative cancer data has been derived from a 
slightly older population. A potential implication of the difference in age between 
the two groups, could be a poorer QoL in the older group. However, as is evident 
from the results of the QoL comparisons, this investigative sample experienced a 
similar QoL and QoL domains to the normative group, with the exception of physical 
QoL. Consequently, it could be suggested that treatment intensity may have a 
greater impact on QoL, when compared with age. 
In summary, evidence demonstrates that cancer treatment is associated with a 
reduced QoL. Consequently, it is becoming more important to investigate 
intervention strategies that could prevent, minimise or reverse the adverse QoL 
changes experienced by the cancer patient. 
8.4.2 Effect of a 3-month recovery period on quality of life 
"The ability to maintain or resume one's pattern of life activities is an undisputed 
aspect of quality of life"226 . When resumption of normal roles is prevented by 
impaired functional capacity, the patient and family are confronted with demands of 
illness and disability. The psychological reactions to disease and treatment can be 
intensified as a consequence of dependence on others, or fear of being dependent on 
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others for basic needs. Interventions which can influence the ability and capacity to 
perform daily activities, in turn, influence QoL 430. The physiological and 
psychological health benefits derived through participation in regular exercise, by 
healthy subjects and certain diseased populations, have been extensively reported 
throughout the literature. However, research to date regarding the role of exercise in 
the cancer domain has been relatively scarce. 
Both non-exercising and exercising PBST patients demonstrated similar changes 
across the testing phases, with regards to total QoL, and individual changes of the 
subjects were representative of the mean group changes reported. Three-months 
post-transplant, QoL ratings had significantly improved for both the control and 
exercising subjects. However, the exercising subjects also demonstrated significant 
improvements in the number of endorsed problems and the average severity of these 
problems. Additionally, the EG participants were able to achieve a higher QoL, 
fewer number of endorsed problems and less severe QoL problems at Pili, when 
compared with pre-transplant. Moreover, by Pili, the exercising patients reported a 
higher QoL when compared with non-exercising PBST patients, and patients who 
have undergone conventional treatment regimes. Taken together, these results 
indicate that although improvements in QoL can be attained by 3-months following 
treatment, QoL . could be further improved through participation in an exercise 
program. 
A review performed on 24 studies regarding exercise, QoL and cancer, found that 
participation in physical exercise consistently demonstrated a positive effect on QoL 
following cancer diagnosis77• Others have reported that exercising breast cancer 
patients experience an enhanced life satisfaction, and that the improvement observed 
in QoL is proportional to the amount of exercise undertaken291 . 
Greater insight regarding the role of exercise on QoL, can be attained by analysing 
changes to the specific QoL domains during the recovery period. 
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8.4.2.1 Physical QoL 
Exercising patients demonstrated significant improvements in physical QoL, and the 
number of endorsed physical problems and the average severity of those problems, 
by 3-months post-transplant. Although the non-exercising patients showed mean 
improvements in physical QoL, the changes were not significant. Furthermore, 
physical QoL at Pill was higher than at PI for the EG, indicating that patients 
maintained the ability to return to higher than pre-transplant physical QoL within a 
period as short as 3-months. Following the intervention program, exercising patients 
also scored a significantly higher physical QoL when compared with the CG and 
normative cancer group, and reported significantly fewer and less severe physical 
problems, when compared with the CG. 
Variations in the physical subscales can explain the changes observed in the physical 
domain for the CG and EG. While the general trend for the CG following a 
transplant was a reduction in the number of endorsed problems and average severity 
of these problems by Pili, only the changes detected for the average severity of the 
problems related to difficulty working were of significance. Importantly, although 
the average severity of the problems for 'difficulty working' significantly decreased, 
the number of endorsed problems during the same period, increased. In comparison, 
the exercising patients displayed numerous significant and beneficial changes 
between immediately post-transplant and 3-months post-transplant. These were 
within the subscales of ambulation, activities of daily living, weight loss, recreational 
activities, difficulty working and clothing. The exercising group endorsed fewer 
problems and rated the severity of the problems lower for all of the physical 
subscales at Pill, when compared with the CG. Differences were significant with the 
exception of the number of endorsed problems relating to ambulation, pain and 
difficulty working, and the average severity of problems within the subscales of 
activities of daily living and weight loss. Finally, following 3-months participation 
in a regular aerobic and resistance training program, exercising patients demonstrated 
significantly fewer and less severe endorsed problems relating to ambulation, 
recreational activities, and difficulty working, when compared with pre-transplant 
levels. Similar physical benefits have also been shown in exercising patients with 
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breast cancer247' 445, exerctsmg adolescents with cancer192 and exerctsmg BMT 
patients104. 
With regard to the pain subscale, while the mean number of endorsed problems 
relating to pain gradually decreased across the phases for the non-exercising subjects, 
the mean average severity increased. In contrast, both the mean number and severity 
of pain problems decreased gradually across the 3 testing phases for the exercising 
patients. By 3-months post-transplant, exercising PBST patients reported 
significantly less severe pain problems in comparison with the control group. These 
results are supportive of others who have also found that exercising BMT patients 
reported less severe pain102. 
8.4.2.2 Psychosocial QoL 
Little variation occurred in psychosocial QoL of non-exercising patients following a 
transplant. In comparison, those who exercised regularly demonstrated significant 
improvements in the global, number of endorsed problems and average severity 
score at PHI, when compared with immediately post-transplant. By 3-months post-
transplant, exercising PBST patients were able to achieve an improved psychosocial 
rating, and significantly fewer and less severe endorsed problems, when compared 
with pre-transplant levels and with non-exercising patients. Comparisons with 
normative cancer data also demonstrate that the EG experienced a significantly 
higher psychosocial QoL. Contributing to this enhanced psychosocial QoL for the 
exercising patients were reductions in psychological distress, worry, anxiety, body 
image concerns, work concerns, cognitive problems, difficulty communicating with 
friends and relatives and difficulty interacting with friends and relatives. 
A review performed on 24 studies in the area of exercise, cancer, and QoL found that 
exercise was shown to induce a positive effect on psychological, emotional and 
social well-being77 . The findings of this investigation support previous work that has 
reported a reduction in depression226' 246, anxiety226 and total mood disturbance226, 
and enhanced self esteem and confidence246' 257' 369 in exercising breast cancer 
patients. Additionally, an enhanced self-concept and improvement in family and 
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friend relationships have been previously reported in exercising adolescents with 
cancer192 . 
Results involving women with breast cancer indicated that while exercise 
participants demonstrated an enhanced mood status, non-exercising subjects 
displayed a worsening of mood states226. Others comparing exercising patients being 
treated with radiation for breast cancer, to non-exercising patients undertaking the 
same treatment regimen, noted that while factors such as anxiety and depression 
were common for both groups, the non-exercising patients experienced greater 
symptom intensity47 . 
Findings derived from previous investigations of BMT patients are also similar to 
those presented here. An improvement in self-confidence and depressed mood 
states, and an improved mental status, has been demonstrated in exercising BMT 
patients102 and exercising autologous PBST105. Additionally, although 
psychological distress scores including depression, fear, anger/hostility, interpersonal 
sensitivity and phobic anxiety, were reduced for the exercising autologous PBST 
subjects, the control group showed no improvement in mood state. Findings reported 
by others12 have linked depressed mood, functional QoL and mental adjustment with 
survival in BMT patients and other patient groups. These results highlight the 
importance for intervention programs to effectively influence these factors. 
8.4.2.3 Medical interaction QoL 
Little change was detected for medical interaction QoL across the phases for both 
exercising and non-exercising participants. While comparisons between the global, 
endorsed problems and average severity rating for the CG and EG at Pili, indicated 
that participation in an exercise program had little impact on this QoL domain, 
comparisons with normative cancer data suggest otherwise. By 3-months post-
transplant, exercising subjects reported significantly higher medical interaction 
global scores in comparison to normative cancer data, while the differences between 
the CG and normative data were not significant. Classifying the area of 'medical 
interaction' as a component of QoL is unique. to the CARES questionnaire. 
Consequently, a paucity of data exists regarding changes in patient's ability to 
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control or communicate with the medical team across the cancer continuum. 
Nevertheless, the results of this investigation indicate an improved medical 
interaction QoL with participation in an exercise program. It is possible that the 
physical or psychosocial benefits sustained through exercise participation - such as 
enhanced energy, reduced fatigue or weakness, enhanced self-confidence and/or an 
improved ability to communicate - could lead to an improved ability to interact with 
the medical team. 
8.4.2.4 Marital QoL 
No change was observed across the phases for either non-exercising or exercising 
patients in marital QoL. By 3-months post-transplant, the global, endorsed problem 
and average severity ratings for both the CG and EG were similar, indicating that the 
exercise program had little influence over marital issues relating to communication, 
affection and interaction with a significant other. 
8.4.2.5 Sexual QoL 
Similar changes were observed across the phases for both non-exerc1smg and 
exercising patients with regards to sexual QoL, and the number of endorsed problems 
and average severity of the problems, relating to the sexual domain. It was found 
that the transplant process was associated with adverse changes, and the 3-month 
recovery period was associated with improvements. While the positive changes 
observed during the recovery period were significant for both the CG and EG, the 
improvements in the number of endorsed problems were only significant for the 
exercising patients. Little difference existed between the global scores reported at 
Pill for exercising and non-exercising patients, and normative cancer data. These 
results indicate that exercise participation has little influence over changes in this 
domain, and therefore factors other than physical changes, body image perception, 
anxiety and depression, must influence sexual QoL. 
In summary, mean QoL, endorsed problems and average severity scores indicated 
that the exercising patients reported higher total QoL and QoL domains, when 
compared with non-exercising patients, 3-months post-treatment. These differences 
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were significant for total QoL, and physical and psychosocial QoL. The results 
therefore suggest that a physical intervention program has the potential to induce 
more than just physiological changes. 
8.4.3 Relationship between functional capacity and quality of life 
While impairment in physical fitness is a substantial contributor to reduced QoL in 
cancer patients105, this investigation has demonstrated that functional capacity is 
associated with QoL. Correlations performed on QoL data with aerobic capacity 
data (details described in Chapter 5) indicated that those who were experiencing a 
higher level of fitness were more likely to also experience a higher QoL (p<0.05), 
and fewer (p<0.05) and less severe (p<O.Ol) QoL problems. Not surprisingly, those 
who demonstrated higher fitness levels also demonstrated a more favourable physical 
QoL (p>O.Ol), and fewer (p<0.05) and less severe physical problems (p<O.Ol). 
Although the relationship between the level of change experienced in aerobic 
capacity and QoL, between Pil and Pili, was not significant, the results suggest that 
those subjects who showed the greatest improvement in aerobic fitness following 
treatment also showed the greatest improvement in QoL. 
Moreover, it has been previously suggested that participation in a regular exercise 
intervention program, may simultaneously influence many dimensions of QoL, or 
alternatively, it may directly influence one dimension, which in tum has a 'domino 
effect amongst other wellness domains445 . The results of this investigation support 
this statement as physical fitness was also found to be highly correlated with medical 
interaction (p<0.05) and sexual QoL (p<0.05), and correlated, but not significantly, 
with psychosocial and marital QoL. It should be noted that the significant 
correlations were found during the analysis ofPil and/or Pili data, where the number 
of data points were maximised (n=12 and 13, respectively). Although a relationship 
was also detected between QoL and certain QoL dimensions, and aerobic capacity at 
PI, only 6 six data points were available for the analysis, and in tum, the ability to 
detect a significant relationship between the variables was reduced. 
While the functional capacity as measured by aerobic capacity is linked with QoL, it 
has also been found that functional QoL is associated with post-BMT survival12• 
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Those who experience a lower functional QoL are associated with poorer post-BMT 
survival and those who demonstrate a higher functional QoL evidence a trend toward 
longer survival. These results indicate that physical fitness has the potential to 
influence both the quantity and quality of life, and highlight both the importance of 
functional well-being in cancer patients, and the potential inadequacy of QoL 
interventions that fail to address physical concems77. 
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8.5 Conclusion 
Significant adverse changes in QoL were associated with undergoing high-intensity 
chemotherapy treatment followed by a PBST. While total QoL significantly 
improved over time without an intervention program, further improvements were 
attained through participation in the aerobic and resistance training exercise program. 
This was evident by the exercising patients rating a significantly higher QoL when 
compared with non-exercising patients. Moreover, unlike the non-exercising 
patients, the exercising patients attained a higher QoL within 3-months post-
transplant, when compared with pre-transplant ratings. 
Further, improvements in functional capacity were significantly related to physical 
QoL. However, the effect of the intervention was not just limited to better 
physiological function. Indeed, the improvements in physical status positively 
influenced numerous factors relevant to psychosocial, marital, medical interaction, 
and sexual QoL. In summary, the degree of functional capacity improvements 
derived through exercise participation was highly related to improvements in total 
QoL and certain QoL domains. That is, patients experiencing a higher aerobic 
capacity were more likely to experience a higher QoL than those patients less 
physically fit. Finally, these results provide crucial evidence demonstrating the need 
for patients to participate in a physical intervention program following cancer 
treatment. 
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"It (the exercise intervention program) was certainly a very positive 
experience in a year that was very difficult health-wise. I guess we were 
focused on doing something of great benefit to ourselves- to be in 
control of our bodies, of our lives, again, and this is really important. " 
EG participant (2000) 
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9. Summary and Conclusions 
9.0 Summary 
As medical technology has advanced, outcomes have improved for many 
malignancies, and thus survival rates (defined as a relative combined 5-year statistic) 
of those diagnosed with cancer are progressively increasing each year. Survival rates 
for those undertaking a PBST have now reached approximately 50-80%, depending 
on the cancer diagnosis166. Given this improved outcome, it is essential to 
investigate the impact of cancer and its associated treatment, as well as addressing 
research issues such as facilitating recovery post-treatment and improving quality of 
life for cancer patients. 
This investigation was designed to assess changes in functional capacity and QoL 
following a PBST and participation in a 3-month aerobic and strength training 
program. Factors that directly or indirectly influence functional capacity were 
measured and included body composition, aerobic capacity, muscular strength, 
immunological status and function, and bone turnover. Outlined below are the 
primary objectives that were originally defined in Chapter one, followed by the 
findings of the investigation. 
Objective 1: 
To investigate changes between pre- and post-transplant measures of functional 
capacity and quality of life. 
Conclusions: 
> Functional capacity measures of body composition, aerobic capacity, 
muscular strength, immunological status and function, and bone turnover 
showed adverse changes following the PBST. 
)> Undertaking a PBST was associated with a reduction in total QoL. 
Significant losses in body weight, body mass index, and most importantly, lean tissue 
were observed following the transplant. These negative changes to body 
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composition occurred in the presence of decreasing energy· expenditure levels 
indicating the presence of an energy imbalance. Adverse changes to muscular 
strength, in particular upper body strength, were also evident, and were a likely 
consequence of the reduction in lean tissue measured during the same period. 
Aerobic capacity also showed a mean decline. Although the change between pre-
(PI) and post-transplant (PII) was not statistically significant, it could be considered 
clinically relevant, since aerobic capacity at PII was considered significantly lower 
than age- and sex-matched healthy controls. 
The measurement of certain immunological parameters at PI indicated that the 
patients were already immunocompromised prior to undergoing the transplant. 
While the absolute WBC count, percentages of CD3+, CD4+ and CDS+ cells and the 
CD4+/CDS+ ratio were considered normal at PI, the absolute counts of lymphocytes 
and T cell subsets, and T cell function, were considered below normal. The objective 
of a PBST is to destroy rapidly dividing cells, which include both malignant cells and 
cells within the bone marrow. Therefore, as was expected, further adverse changes 
were observed forT cell function, and total leucocyte, lymphocyte, CD3+, CD4+, 
and CDS+ counts, and the helper/suppressor ratio, following the transplant. 
These findings and additional adverse physiological effects may influence functional 
capacity and QoL, both in the short- and longer-term. For example, following the 
transplant the mean bone resorption and formation activity was elevated, indicating a 
rise in bone turnover. Bone resorption was significantly increased suggesting that an 
uncoupling of osteoblastic and osteoclastic function occurred post-transplant. 
Consequently the risk of bone loss in PBST patients was elevated following the 
transplant, which could influence the longer-term risk of osteoporosis unless 
arrested. 
It was also shown that undergoing a PBST was associated with negative changes to 
total QoL, as measured by the CARES QoL tool. Mean changes in the number of 
identified problems, and average severity of the problems in physical, psychosocial, 
medical interaction, marital and sexual QoL, contributed to the overall change 
observed in total QoL. These results, in conjunction with increasing survival rates, 
highlight the need for effective intervention strategies to assist patients in achieving 
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their optimal level of physical functioning and QoL following treatment. Further, 
there is a definitive need to 'bridge the gap' between treatment cessation and 
returning to a 'normal life'. 
Exercise has been shown to provide physical and psychological benefits during the 
rehabilitation process of patients with chronic diseases including cardiovascular 
disease, rheumatic disease, diabetes mellitus, and renal disease. Although evidence 
is limited and predominantly relates to patients with breast cancer, exercise 
intervention programs during or following cancer treatment have been associated 
with positive changes. This investigation was designed to extend our knowledge in 
this area and aimed to assess the role of exercise in the recovery ofPBST patients. 
To this end, following the transplant, patients were divided into an exercise 
intervention group or a stretching/control group for a period of 3-months. Exercising 
patients participated in an aerobic and strength program, 3 times/week, while those in 
the control group performed a flexibility/stretching regime, 3 times/week. The 
second primary objective as defined in Chapter 1, in conjunction with the results 
obtained through this investigative design, are outlined below. 
Objective 2: 
To investigate the role of a three-month duration, moderate intensity and mixed type 
exercise program in the recovery of functional capacity and quality of life, post-
PEST. 
Conclusions: 
);;. Recovery of body composition, aerobic capacity, muscular strength and QoL 
was faster for the exercising patients, when compared with the non-
exercising patients. 
? Participation in the exercise program failed to influence recovery rates of 
immunological factors. 
);;. While the results observed for changes in bone turnover were more 
favourable by three-months post-transplant for the exercising patients, in 
comparison with the non-exercising patients, it would be inappropriate to 
relate these preliminary results with improved skeletal status. 
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> Exercising patients reported higher total, physical and psychosocial QoL 
ratings when compared with non-exercising patients by 3-months post-
transplant. 
Participating in a regular progressive physical activity regimen led to a significant 
increase in energy expenditure, whereby total energy expenditure at 3-months post-
transplant was significantly higher than both immediately post-transplant and pre-
transplant levels. Exercising patients also demonstrated significant increases in lean 
tissue to levels that were higher than at pre-transplant. Body fat levels continued to 
reduce during the 3-month exercise period, and were significantly lower at Pili when 
compared with post-transplant levels. These changes in energy expenditure and 
body composition were accompanied by other important functional changes. Both 
fitness and muscular strength significantly improved by 3-months post-transplant, to 
levels that were clinically and/or statistically higher than those recorded pre-
transplant. Improvements in function were also detected by the use of the QoL tool 
with exercising patients rating their physical QoL at Pili significantly higher than 
their pre- and post-transplant ratings. 
In companson, non-exercising patients failed to demonstrate the same level of 
improvement throughout the 3-month period. While some measures demonstrated a 
mean improvement, others continued to show a mean decline during the 3-months 
post-transplant. Body composition was stable during this period, with little change 
being detected in body fat and lean tissue. However, of clinical and functional 
significance was the inability of this group to regain lean tissue lost during the 
transplant process. The maintenance of lower lean tissue mass was also reflected in 
strength results. While changes in strength measures between PII and Pili were not 
significant, the group mean for lower-body and hand-grip strength continued to 
deteriorate during the 3-months following the transplant. Finally, both aerobic 
capacity and physical QoL were other measures that failed to improve throughout the 
3-month recovery period. The findings from the control group indicated that more 
than 3-months might be required to recover pre-transplant function when regular 
exercise is not performed following the transplant. Additionally, patients who do not 
participate in regular exercise following treatment are at risk of experiencing further 
functional declines. 
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Participation in exercise had no impact on immunological changes across the testing 
phases. White blood cell and CDS+ cell counts returned to normal within 3-months 
post-transplant, however the lymphocyte, CD3+, and CD4+ cell counts demonstrated 
a delayed recovery for both exercising and non-exercising patients. Although 
participation in the exercise program had no influence on immune cell recovery 
following a PBST, importantly immune recovery was not adversely effected, 
demonstrating that exercise participation was of no detriment to immune status and 
function for these patients. 
Three-months post-transplant, the bone resorption activity of the exercising patients 
showed a significant decline. The changes observed in bone turnover between PII 
and Pili indicated an uncoupling of formation and resorption activity, favouring 
formation. In contrast, the control group demonstrated a mean reduction for both 
resorption and formation activity by Pili. During this same period, the non-
exercising patients experienced mean resorption activity above, and mean formation 
activity below, pre-treatment levels. Although preliminary, the results suggest that 
participation in an aerobic and resistance training program may have a favourable 
influence on bone metabolism. In tum, the development of longer-term skeletal 
conditions such as osteoporosis could be prevented through . participation m an 
intervention such as an aerobic and strength training program. 
A three-month recovery period following a PBST is associated with significant 
improvements in total QoL, regardless of whether patients perform regular physical 
activity. However, exercising patients were experiencing a higher QoL when 
compared with the control participants at Pili, with the results suggesting that further 
improvements in QoL can be sustained through regular exercise. Participation in an 
aerobic and resistance training program was also associated with significant 
improvements in the number of identified problems relating to total QoL and 
physical QoL, the average severity of these problems, and physical and psychosocial 
QoL. The exercise participants also demonstrated higher QoL ratings when 
compared with pre-transplant ratings, and ratings recorded by patients who had 
undergone more conventional treatment regimens. 
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In summary, exercise participation has the potential to reverse detrimental functional 
and QoL effects experienced as a result of cancer and its associated treatment, 
without initiating any adverse consequences. The third objective of this 
investigation, was to determine whether functional capacity is related to QoL. 
Objective 3: 
To investigate the relationship between functional capacity and quality of life of 
PBST patients. 
Conclusions: 
)> The effects of physical activity were not limited to better physi()logical . 
function. Functional capacity (as measured by aerobic capacity) was 
significantly related to total QoL and physical, psychosocial, marital; 
medical interaction, and sexual QoL. Those that experience a higher aerobic 
capacity were more likely to also experience a higher QoL. 
The experience and knowledge gained during the design and implementation of this 
investigation led to the attainment of the final general objective. 
Objective 4: 
To demonstrate that patients with cancer who are required to undergo intensive 
cancer treatment regimens such as PBST, are still able to participate and tolerate a 
planned regular exercise program. 
Conclusions: 
The intervention program highlighted that: 
)> PBST patients can safely participate in a regular exercise program of 
moderate intensity and mixed type, without any adverse consequences. 
)> PBST patients can tolerate a V02 max test and 15RM strength test. 
> The overload utilised in this investigation was appropriate for these patients 
as it ensured progression without inducing adverse effects such as undue · 
fatigue. 
> PBST patients should not be restricted to 'low' exercise intensities. 
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)> An exercising frequency of 3 times/week of up to 40 minutes duration for 
aerobic exercise, and twice/week of up to 6 exercises for strength training is 
sufficient to induce a significant training effect. 
)> In summary, PBST patients can participate in a regular exercise program 
safely and can tolerate overload and progression in both the aerobic and 
strength training components. 
The current research project used existing guidelines for exercise prescription and 
contraindications to exercise for cancer patients429 as a basis for the development of 
the intervention protocol implemented. However, in the conduct of this investigation 
and after consultation with both patients and medical supervisors, it became obvious 
that in some areas the current guidelines were inappropriate. For example, according 
to exercise guidelines426, platelet counts should be greater than 50 OOO/mm3, 
haemoglobin more than 1 Og/dL, WBC count greater than 3 000/mm3 and absolute 
granulocyte count higher than 2 500/mm3. However, only one out of six exercising 
patients progressed through the entire intervention period with all blood counts above 
these recommended levels. Haemoglobin, platelet and WBC counts were below 
'optimal' in 34%, 17% and 67% of patients, respectively, at some stage during the 
intervention period. The lowest counts recorded during the intervention period were 
77g/L for haemoglobin, 26 x 103/uL for platelets, and 0.9 x 103/uL for WBC. While 
counts were outside current guidelines, they were above the minimum requirements 
set for a previous investigation involving BMT patients104, where platelets counts 
needed to be greater than 20 x 1 09/L and leucocyte counts above 1.5 x 1 09/L. 
The nature of the program, including the prescriptive characteristics of type, 
intensity, duration and frequency of exercise, can determine the extent of the benefits 
attained3. Aerobic exercise such as walking, cycling and swimming, and dynamic 
lifting on weight machines have been recommended for cancer patients3. Intensity 
guidelines have recommended that patients should work within 50-85% V02 max or 
65-90% HR.max3. Additionally, it has been suggested that for those who are 
deconditioned following diagnosis and treatment, maintaining a HR intensity of 60% 
HR.max is sufficient425 . Caution is required when prescribing unsupervised programs 
and lower HR ranges of 40-65% of the estimated HRR426, or a working intensity 
corresponding to 60% vo2 max161 should be utilised. 
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While various protocols have been employed, the majority of studies have involved 
women during or after treatment with breast cancer, and have implemented aerobic 
only programs that work within the exercise guidelines recommended above. Only 
recently have exercise intervention programs been implemented among BMT or 
PBST patients during102• 105 and after treatment101 ' 104• These exercise programs were 
aerobic in nature and worked within the ACSM guidelines. The intervention 
assessed in this investigation was unique, as it involved a combination of aerobic and 
resistance exercise, for a duration of 12 weeks. While 12-week duration programs 
have been implemented in breast cancer populations, no other study could be 
identified that followed exercising PBST or BMT patients for this length of time. 
Furthermore, the exercise program of this investigation required patients to work at 
an initial intensity of 70% HRmax, which progressively increased over time to 90% 
HRmax. Exercise duration was initially 20 minutes, but progressed to no less than 
40 minutes by the end of the 12 weeks. The volume of work performed during the 
exercise sessions by the PBST patients is also unique to this investigation. 
9.0.1 Research or clinical implications of working with patients with cancer 
Inability to recruit adequate numbers of patients is a limitation in cancer research and 
has the potential to influence the success of a program. During the subject 
recruitment phase, it became evident that referral and encouragement by medical 
practitioners was crucial in attaining subjects. The importance of a doctor's belief in 
the benefit of a drug or in this instance an experimental program, to patient 
acceptance and/or participation has been discussed throughout the literature42• 
Willingness to participate during cancer treatment and its side effects, is no small 
endeavour for the patient. More specifically, recruiting patients prior to transplant is 
often at a time when patients are feeling depressed and have little energy to perform 
daily activities. Associated with these recruitment limitations is the influence of 
family and medical staff and their common recommendation that patients should 
'take it easy' and 'get plenty of rest' during and following treatment. While this 
investigation provides evidence that an exercise program should form a primary 
component of cancer rehabilitation, it also · highlights the need for medical 
practitioners' support. 
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Another important consideration for the success of an intervention program is 
program acceptance and adherence. Previous exercise intervention programs 
performed with BMT patients have reported a 90% acceptance rate101 and have 
suggested that patients perceive their 'active' role in the rehabilitation process, 
compared with their previously 'passive' role in the diagnostic procedure and 
treatment process, as a 'welcomed change'. The program acceptance and adherence 
rate of this investigation supports these findings. All patients within the exercise 
group adhered to the program, working at above the minimum intensity and duration 
of each exercise session. Additionally, only 2 patients failed to attend 1 week of the 
12-week program, due to illness. Comments regarding 'ownership' of the program, 
or 'personal control', were commonly stated by exercising patients during informal 
interviews, and it was felt that these feelings may have contributed to the program 
acceptance and adherence rate attained. The benefits achieved through exercise 
influence the ability to perform normal daily activities, and these benefits are often 
realised by the patient relatively quickly. This research indicates that patients can 
achieve 'normal' function within 3 months, and it is likely that these rapid 
improvements also contributed to the excellent adherence rates attained. Therefore it 
seems evident that, although difficulties are present during the recruitment phase, 
once patients have agreed to participate, program adherence is not problematic, at 
least for a 3-month program. 
The small number of subjects in this investigation reflects the recruitment difficulties 
faced when dealing with patients with cancer. The recruitment problems 
experienced are not unique to this investigation, and small sample sizes are not 
uncommon in cancer research. Recently, a group of Canadian researchers80 recruited 
from a major cancer hospital for 14 months, and were only able to initially enrol 39 
patients. The recruitment of the 12 subjects for this investigation occurred over a 
period of 15 months. Consequently, a primary limitation to this study, and many 
other studies investigating 'exercise and cancer' is sample size. This limitation 
highlights the importance of further research within the area that both replicates and 
extends current studies. Nevertheless, while the relatively small number of subjects 
investigated could be perceived as a potential study limitation, the statistical power 
was sufficient to detect many of the changes observed as statistically significant (at 
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two-tailed, alpha of 0.05). In addition, the assessment of individual change made 
throughout the thesis demonstrated that all subjects displayed a similar trend of 
change and magnitude of change. As such, the group mean change was 
representative of individual change. The results attained also supported results 
previously found in investigations using larger sample sizes. In turn, the similarities 
between study findings add credence to the validity of the results presented here. 
Initially, patients were to be randomly divided into two groups with age 
stratification, as they were recruited into the study. Unfortunately, the ability to 
attain matched control and experimental groups through randomisation was limited 
as a consequence of the slow recruitment rate, and thus low subject numbers. 
Therefore, the two groups were matched as closely as possible, taking into account 
all variables including cancer diagnosis, age, sex, treatment regimen to be 
undertaken, previous and current exercise habits, marriage status, weight and living 
distance from the hospital and exercise centre. Chapter 3 provides detailed 
information regarding group demographics a:Q.d demonstrates that while the groups 
t 
were not randomly created, they were closely matched. The ability to achieve 
closely matched groups further supports the findings that the positive responses may 
be attributed to the intervention program. 
Although limitations exist when working with patients with cancer, the available 
research has provided support for the role of exercise in cancer rehabilitation. Future 
research is, however, required to extend this current body of knowledge. 
9.0.2 Potential for future research 
In conformity with good research models, the results of this investigation highlighted 
areas in exercise and cancer which require further research. As a consequence of the 
nature of the intervention program implemented in this investigation, it was not 
possible to determine the contribution of the strength or aerobic program towards the 
functional and QoL changes measured. The inclusion of a greater number of 
experimental groups performing various exercise protocols, would provide greater 
insight into the benefit of specific types of exercise. 
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Additionally, this investigation evaluated the role of exercise following treatment for 
cancer and made no attempt to determine the role of exercise during the diagnosis to 
treatment period, or during the treatment period itself. Research demonstrates that 
participation in physical activity for cancer patients declines from point of cancer 
diagnosis80 and remains low throughout the treatment process, and following 
treatment. Therefore, the risk of decreased functional capacity elevates at the point 
of diagnosis as a consequence of the disease process itself, as well as a reduction in 
physical activity. Once treatment is initiated, this risk further escalates. Future 
research should investigate the optimum time throughout the cancer continuum that 
initiation of a physical intervention program will be of greatest benefit. It seems 
likely that those who exercise from point of diagnosis through to complete recovery, 
will maintain a higher functional capacity and thus QoL throughout the entire cancer 
continuum. 
Prior to this study, research has predominantly assessed functional capacity via the 
measurement of aerobic capacity. While this may be appropriate, future research 
should consider a greater range of physiological measures, which may influence 
function in both the short- and longer-term. Additionally, future research should 
begin to test the limits of exercise prescription guidelines available for patients with 
cancer. The list of questions provided below highlights potential areas in exercise 
prescription, for future research: 
);> What are the boundaries of exercise prescription for cancer patients? That is: 
);> While an exercising intensity equivalent to 60% HRmax has the potential to 
lead to benefits in deconditioned patients, can these patients work harder 
without inducing adverse effects? 
);> Is it necessary for patients to wait an extra day following an 'unwell' day 
before they return to their exercise program? If they are feeling 'well', why 
is it necessary to wait an additional day? 
);> Does an elevated pulse at 10 minutes post-exercise really indicate a need for 
reducing the exercise intensity of the following session, or is it an indication 
of an ineffective cool-down, or is it simply a side effect caused by certain 
medications? 
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);> Is it necessary to reduce exercising intensities during unsupervised sessions -
what are the potential risks to the patient? 
);> What are the lower limits for intensity, duration and frequency that are 
required to ensure benefits are sustained? 
);> Do greater duration, intensity, and frequency equate with greater benefits, or do 
benefits begin to plateau once a certain level is reached? 
);> Do interval, discontinuous, or ratio work provide the same benefits as continuous 
work? 
);> Do the type and location of the exercise influence the potential benefits? That is, 
is walking better than cycling, are group sessions better than individual sessions? 
Finally, the positive relationship between physical function and QoL in cancer 
patients has recently been recognised and demonstrates that an exercise program 
should be considered a primary component of rehabilitation. However, it is 
important to remember that exercise is just one component of cancer rehabilitation 
and should 'be used to complement other components rather than be used as an 
alternative strategy. In order to determine the level of emphasis that should be 
placed on exercise and other components of cancer rehabilitation programs, 
comparative studies examining the results of various intervention strategies are 
required. This would ensure that the relative merits of various interventions for a 
given outcome are realised. Further, these types of studies could also be used to 
assess whether QoL benefits attained with a combination of intervention strategies 
are greater than with any particular component alone. 
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9.1 Conclusion 
Cancer diagnosis and treatment are associated with side effects that adversely 
influence function, the ability to perform daily tasks and QoL. Diagnosis and 
treatment of cancer have also been associated with a reduction in physical activit/8• 
Interestingly and importantly, it has been estimated that at least one third of the 
functional decline observed in cancer patients, can be attributed to hypokinetic 
conditions that develop as a result of prolonged inactivity27 . Yet common advice 
still being given to cancer patients is to 'go home and take it easy', or 'get plenty of 
rest'. Unfortunately, the creation of a self-perpetuating condition of 'diminished 
activity, continued loss of physical function, easy fatigability when attempting daily 
tasks, followed by a further reduction in activity', is not uncommon in cancer 
patients105. This progressive physical debilitation fosters a sense of disability, and 
leads to negative changes in QoL and many QoL dimensions. 
The results of this investigation demonstrated that diminished physical activity 
throughout the cancer continuum and, more specifically, continued diminished 
activity following treatment, are not inevitable consequences of cancer and 
treatment. Participation in exercise can reverse the documented adverse cycle of 
reduced activity and function, and easy fatigability. This investigation demonstrated 
that exercising patients experienced a faster recovery oflean tissue, aerobic capacity, 
muscular strength and QoL, when compared with non-exercising patients. Not only 
were recovery rates faster for a number of physiological variables, but by 3-months 
post-transplant, exercising patients were experiencing significantly improved peak 
ventilation, lower-body strength, and QoL when compared with the non-exercising 
patients. The exercising patients also experienced more favourable percent body fat, 
lean tissue mass, aerobic capacity, hand-grip strength, and upper-body strength when 
compared with the non-exercising patients. Moreover, by 3-months post-treatment, 
exercising patients had improved body composition, aerobic capacity, peak 
ventilation, body strength and bone turnover when compared with pre-transplant 
measures. Finally, the mean aerobic capacity for the exercising group was also 
higher than the mean age- and sex-matched healthy controls. Therefore, although 
statistics illustrate that 40% ofBMT patients require 12 months to regain pre-
treatment fitness levels105, the results ofthis investigation demonstrated that patients 
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maintain the capacity to return to higher than pre-treatment function, in as little as 3 
months following treatment. 
The exercise intervention program implemented within this investigation consisted of 
a 3-month combined aerobic and resistance training program. Despite the exercise 
prescribed being of sufficient magnitude to induce positive changes in certain 
physiological variables, the type or length of the program administered, had no effect 
on the recovery of immunological variables. However, although the program did not 
facilitate immune cell recovery, neither was it hindered. Changes observed in bone 
turnover, the physiological measures that may influence function and QoL in the 
longer-term, indicated that participation in the aerobic and resistance training 
program exerted a favourable influence on bone metabolism through the uncoupling 
ofbone turnover, which favoured bone formation. However, more work is required 
in the area before these conclusions are definitive. 
The positive relationship between functional capacity and QoL was also evident from 
the results of this investigation. That is, those patients experiencing a higher aerobic 
capacity were more likely to experience a higher total QoL and higher QoL domains, 
than those patients less physically fit. Therefore, including wellness-oriented 
interventions such as physical exercise into the care plans of patients may facilitate a 
more comprehensive enhancement of the physical, functional, psychological, social 
and spiritual dimensions of QoL. 
In summary, more than 3 months is required for patients to return to pre-transplant 
function when exercise is not integrated into their care plan post-treatment. 
Additionally, failure to participate in physical activity following treatment could 
potentially lead to a further deterioration of function. Participation in exercise 
following cancer treatment facilitates the recovery of numerous physiological 
variables, which in turn influences functional capacity and QoL. This investigation 
provides evidence demonstrating that participation in an exercise program can 
'bridge the gap' between treatment cessation, and returning to a 'normal' lifestyle. 
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UNIVERSITY 
Miss Sandra Hayes 
School of Human Movement Studies 
OUT Kelvin Grove 
26 February, 1998 
Dear Miss Hayes 
I wish to advise that the University Research Ethics Committee has granted ethical approval for 
the human experimentation proposed in the project "The role of exercise in enhancing functional 
capacity and quality of life, in the rehabilitation phase of patients who have undergone an 
autologous blood stem cell transplant IAPBST)" {Ref No OUT 1349H). This approval is subject 
to: 
• the informed consent package being revised las the Committee felt that this was overly long 
and was not written in lay terms); 
• a qualified physician being present to monitor the ECG; and 
• an assurance that all body tissues/fluids will be handled in accordance with normal 
medical/hygiene standards. 
Please provide me with the revisions/additional information outlined above by 10 March 1998. 
Failure to aubmit this information by the date specified will result in withdrawal of approval for 
the project. 
This approval Is valid for the duration of the project or three years, whichever Ill earlier, 
commencing from 1 April 1998. 
Please note the following conditions of approval: 
• any departure from the protocol detailed In your application must be reported 
immediately to the Committee; 
• you are required to advise the Secretary if any complaints are made, or expressions of 
concern raised, in relation to the project; 
• you art required to report on the progress of the approved project at least aooually, or at · 
intervals determined by the Committee. The Committee may also choose to conduct a 
random audit of your research; 
• where a minor change to an approved protocol is proposed, you 1re required to submit 1 
request for approval of this change in writing to the Secretary. Minor changes will be 
usessed on a case by case basis and interim approval may be granted subject to 
ratification at the next meeting of the Committee; and 
• major changes to any 1pproved protocol require 1 naw application to ba submitted 1nd 
approved by the University Research Ethics Committee. 
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Please do not hesitate to contact me if you have any further queries in relation to this matter. 
Youra lincerllv 
Gary Allen 
Secretary, University Research Ethics Committee 
OUT Secretariat 
Telephone: (071 3864 2902 
Facsimile: (071 3864 1818 
Email:gx.allen@qut.edu.au 
cc Assoc Prof Peter Davies, School of Human Movement Studies, OUT Kelvin Grove 
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MATER ADULT HOSPITAL RESEARCH ETHICS COMMITTEE 
16July1998 
Miss Sandra Hayes 
19 Chinook Street 
Everton Hills QLD 4053 
Dear Miss Hayes 
At its 14 July 1998 meeting, the Mater Adult Hospital Research Ethics Committee 
considered your response to its queries in relation to the protocol "Exercise, 
functional capacity, quality of life, and cancer patients" (Ref No 115A). 
The Committee was satisfied that your response addressed its concerns, subject 
to clarification in the patient informaflon sheet that extra blood will be taken. The 
Director of Pathology requested that you liaise with the Department about the 
logistics of correcting the blood samples. Subject to the conditions above, the 
Committee resolved to approve this study. 
This approval is valid for the duration of the project, or three years, whichever is 
earlier. Please forward the revisions/additional information outlined above to the 
Coordinator of the Mater Research Secretariat by 30 July 1998. 
Please note the following conditions of approval. 
• Any departure from the protocol detailed in your proposal must be reported 
immediately to the Committee. 
• When you propose a change to an approved protocol, which you consider to 
be minor, you are required to submit a written request for approval to the 
Chairperson, through the Secretary. Such requests will be considered on a 
case by case basis and interim approval may be granted subject ratification at 
the next meeting of the Committee. 
• Where substantive changes to any approved protocol are proposed, you are 
required to submit a full, new proposal for consideration by the Research and 
Ethics Committee. 
• You are required to advise the Hospital Ethicist immediately if any complaints 
made, or expressions of concern raised, in relation to the study, or if any 
adverse events occur. 
• Under the NHMRC Statement on Human Experimentation and Supplementary 
Notes, research ethics committees are responsible for monitoring research to 
ensure continued compliance with ethical standards, and to determine the 
method of monitoring appropriate to each project. You are therefore required 
to provide written reports on the progress of the approved project at least 
annually. The Committee may also choose to conduct an interim audit of 
your research. 
L'\AP _DM~RRESPO\CORRJUL.DOC 
Mater 
Misericordi•• 
Hospitals 
Raymond Terrace 
South Brisbane 
Queensland 4101 
Australia 
Telephone 
07.3840 8111 
Facsimile 
07. 3840 1595 
Mater Res&a!Ch S8C!Utariat 
Room 204, Aubigny Piece 
Mater Hospitals C®lplex 
Raymond Terrace 
SOUTH BRISBANE QLD 4101 
Telephone: 3840 1585/1589 
FacsimDe: 3840 1840 
EmsH: 1dmesp@meter.OifJ.au 
or 2ep/ap@meter.Oifl.au 
Mater Adult Hospital 
Mater Children's Hospito. 
Mater Mothers· Hospital 
Mater Mothers· Private Hospital 
Mater Private Hospital 
CendvCIId by the Cofporttion 
ollheTrusteesoftheOrde~ 
oltlltSistersofMercy 
ln Oueensl~nd 
I would be grateful if you would confirm the commencement date of the project. 
(All correspondence should be directed to the Research Secretariat Coordinator, 
Room 204, Aubigny Place.) 
Yours sincerely 
~~ 
Mr Chris Coyne 
Chairperson, Mater Adult Hospital Research Ethics Committee 
LW' _OME'J,IAHICORRESPOICORRJUl.OOC 
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Wesley Private Hospital ethics 
approval 
27 August 1998 
Project No. 98/09 
Ms Sandi Hayes 
PhD Student 
Queensland University of Technology 
email: sc.hayes@student.qut.edu.au 
Dear Sandi 
RESEARCH PROPOSAL: The role of exercise in enhancing functional 
capacity and quality of life, in the rehabilitation phase of patients who 
have undergone an autologous peripheral blood stem cell transplant. 
I am pleased to advise that the abovenamed research proposal has 
been reviewed and was granted approval by the Multi-Disciplinary 
Ethics Committee of The Wesley Hospital Board at its meeting on 13 
August 1998. 
It is a strict condition of approval that any departure from the 
protocol detailed in the proposal submitted for approval be reported 
immediately to the Committee. If there is any change to the status of 
the project, this should be reported. 
Approval for the project is given subject to your agreement to The 
Wesley Hospital requirements for the monitoring of research, which 
have been based on the Australian Health Ethics Committee 
guidelines, a copy of which is enclosed. Please note the requirement 
to submit a report annually or at the completion of the project, as 
appropriate. 
With best wishes. 
Yours sincerely 
Douglas Killer MBBS FRACP 
Medical Superintendent 
Chairman, Multidisciplinary Ethics Committee 
encl. 
The Wesley Hospital Multidlacipllnary Ethics Committee is constituted and 
operates in accordance with the National Health and Medical Research 
Council's Statement on Human Experimentation and Supplementary !iotea. 
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Hello, my name is Sandi Hayes, and I am currently undertaking a research 
project entitled "Cancer, Functional Capacity, Quality of Life and 
Exercise". I have completed a Human Movement Studies university degree 
which specialises in prescribing exercise for particular populations. Throughout 
this degree I became extremely interested in the role of exercise for cancer pa-
tients. As my interest was developed and I began to study the area further, it 
was evident that research within this field is limited. 
Over the last couple of years, I have been involved with a number of cancer 
L.! rehabilitation programs available throughout Brisbane. During this time I spoke 
to patients about the importance of physical activity and the role that 
exercise can play in returning people back to their 'normal' functional capacity, 
that will allow them to return to work, or simply to perform daily activities with-
out becoming fatigued. My work as the Exercise Physiologist with a 
particular cancer rehabilitation program, allowed me to see patients that had 
undergone extensive treatment, improve their fitness, strength and mobility, 
whilst becoming less fatigued throughout their day. 
This study and work with cancer patients, has continued to stimulate my 
interest in the area. However, important documentation of these results is still 
not available. Therefore, I decided to enter into a PhD program, which is a 3 
year degree, researching a particular topic. I am writing to invite you to join me 
in my research endeavour to document exactly how exercise can improve 
patient's functional capacity and quality of life. Enclosed is a copy of a subject 
information package that describes what involvement within this project entails. 
It is quite heavy reading and I would be happy to go through the package with 
you personally. 
There are two hospitals (Wesley Private Hospital and Mater Adult Hospital) and 
the Queensland University of Technology involved with the implementation of 
this study. Dr Ian Bunce and Dr John Bashford (Wesley), and Dr Kerry Taylor 
(Mater) have assisted me in developing this project and can be spoken to if you 
have any concerns. I hope you will take the time to read the subject information 
package as I feel involvement within this research project will assist you in 
improving your functional capacity following your transplant. Again, I would 
love to personally speak with you about the project and can be contacted at any 
time. 
~·~· I look forward to speaking with you, 
Sandi Hayes (Hm: 3353 1687, Wk: 3864 5833, Mb: 0413 092 189) 
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Project Title: 
"Cancer, Functional Capacity, Quality of Life and Exercise" 
Miss Sandra Christine Hayes Principal lnvestigator:-
Qualifications:- Bachelor of Applied Science (Human Movement Studies) 
Contact No.: 3864 5833 
Project Supervisors:-
School/Centre (or Research: 
Associate Professor Peter Davies 
Contact No.: 3864 5830 
Professor Anthony Parker 
Contact No.: 3864 3282 
Queensland University of Technology 
Faculty of Health 
School of Human Movement Studies 
Kelvin Grove Campus 
Victoria Park Road 
KELVIN GROVE QLD 4059 
ph: 3864 3360 
Project Objectives and Rationale: 
Advances in medical technology is represented by increasing survival rates from those 
diagnosed with cancer. Unfortunately, significant side effects are still experienced as a 
result of cancer and its associated treatment and physical inactivity. Physical side effects 
that may be experienced include a reduced ability to participate in daily activities such as 
household chores and/or performing a days work. In addition, reduced self esteem, self 
confidence, and mood, may constitute some psychological side effects. 
Faculty of Health 
Queensland University of Technology 
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It is the primary purpose of this investigation, to demonstrate that participation in an 
appropriate and progressive exercise program has a significant role in improving functional 
capacity and ultimately quality of life, in patients who have undergone an autologous 
peripheral blood stem cell transplant. 
Experimental Procedures: 
Eligible subjects will be undergoing an autologous peripheral blood stem cell transplant, 
and will participate in a 5 month exercise intervention. Numerous types of exercise 
programs exist and it is therefore important to assess which form of exercise program is 
ideal in the rehabilitation phase of cancer. For this reason, subjects will be placed into one 
of two experimental groups: 
A. Group A will be involved in an aerobic exercise (walking, cycling, etc) and a resistance 
exercise (lifting light weights in a controlled fashion) program; 
B. and Group B will perform a stretching/mobility exercise program. 
In order to carry out the program properly, if you decide to participate in the program, 
you will not be able to choose which group you would like to participate in. As the 
investigator is notified that you are wanting to participate in the project, you will be placed 
into one of the groups in a randornised manner. 
1broughout the study, three testing sessions will be scheduled- pre-transplant, post-
transplant and following the 5 month intervention period. During these sessions, your T 
cell (an immune cell) number and function; bone turnover; body composition; muscular 
strength; flexibility; heart, lung and circulatory function; energy expenditure and quality of 
life; will be assessed in the following manner: 
Bone turnover (formation rate), and T ceU number and function:· 
Blood samples will be obtained at 7 different testing phases, which will be scheduled prior 
to the transplant, post transplant, and at the end of each month during the intervention 
period. These blood samples will be obtained during routine blood tests at the hospital 
and therefore you will not be required to undergo any extra blood tests. Blood obtained in 
the pre- and post-transplant period, and at the end of the 5 month intervention, will be 
used to assess bone formation rate. In addition, blood samples obtained at the 7 testing 
phases will be used to assess T cell number and function. 
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At the end of each day, for the duration of the study, you will be required to complete an 
illness questionnaire. It is a one page questionnaire, and will take little time to complete 
(expected duration of 30 seconds). The results of the questionnaire will be used to assess 
whether you are feeling ill or not on that particular day. In addition, we will be able to 
determine whether participation in exercise, has any influence over your feeling of 
wellness. 
Energy Expenditure and Bone turnover (resorption rate): 
In order to assess energy expenditure, two non-toxic isotopes of hydrogen and oxygen 
will be administered to you approximately 2 weeks prior to your transplant, as soon as 
possible following the transplant and 2 weeks prior to the completion of your 5 month 
intervention period. Prior to orally ingesting these isotopes, you will be asked to provide 
a urine sample which will be used to assess the resorption rate of bone. OD.ce the isotopes 
have been ingested, you will then be required to provide one urine sample per day, for 14 
days. These urine samples will be assessed to determine the difference between the 
elimination of the two isotopes, which reflects carbon dioxide production. By calculating 
carbon dioxide production, we are able to determine total energy expenditure. 
Body Composition:-
Body composition assessment requires the calculation of fat tissue and fat free tissue, and 
will be performed in 2 ways. Firstly, one of the urine samples obtained as outlined above, 
in the pre-transplant, post-transplant, and following the 5 month intervention preiod, will 
be used to assess fat and fat-free mass. Secondly, skinfolds at six sites across the body, 
will be taken. The taking of skinfolds is a painless technique which requires the 
investigator to lift a fold of skin and underlying fat tissue and to measure the size of this 
fold. 
Muscular strength:-
Muscular strength will be assessed by three methods and includes an isometric handgrip 
strength test, a 15 repetition maximum bench press, and 15 repetition maximum leg press. 
The handgrip test involves you to maximally grip a hand dynamometer which will assess 
gripping force (the test is similar to opening a tight jar lid). The bench press and leg press 
exercises, are two exercises which are commonly performed to improve upper and lower 
body strength, respectively. You will be instructed to perform the exercise 
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with the initial weight of the lift being dependent upon your estimated strength. The 
investigator will gradually add or reduce weight until a weight is achieved that you can lift 
exactly 15 times (not less than, or more than, 15 times). This part of the project is 
designed to evaluate the potential for participation in an exercise program to improve 
body composition (increase muscle mass particularly) and in turn to improve muscular 
strength (which will determine the ability to perform activities like opening a tight jar, 
carrying a bag full of groceries, lifting and moving objects). 
Flexibility:-
Range of motion will be assessed by 6 different mobility tests. These tests are 
implemented to assess the mobility of the joints and muscles which are particularly 
important for effective and efficient participation in normal daily activities such as bending 
over to tie up shoe laces, reaching for the seat belt, putting on underwear, and walking. 
That is, lower back, shoulder, ankle and hip mobility will be assessed. Each test will 
require you to move a specific joint through its maximum range of motion and to hold it at 
that position until the point has been measured. It is a non-invasive and painless 
procedure. 
Heart, lung and circulatory function:-
The assessment of this function will require you to participate in three graded exercise 
treadmill tests across the three usual testing periods. A graded treadmill exercise test, is 
an exercise test that begins at a light workload, but gradually increases in workload, until 
you are working maximally (as hard as you possibly can). Once it is noted that you are no 
longer able to perform more work, the test is ceased. Throughout the test, you will be 
required to breath through a mouth piece which is transporting expired air into a gas 
analyser. The test is able to assess maximal oxygen consumption and thus cardiovascular 
{heart and circulation) and cardiorespiratory (heart and lung) function. Additionally, 
electrocardiography - ECG (looking at the electrical activity of the heart), heart rate and 
blood pressure will be continually assessed, and a doctor will be present to analyse the 
ECG as the test progresses, to ensure the test is perform~d with maximal safety. This test 
will be able to measure the potential for exercise participation to improve cardiovascular 
and cardiorespiratory endurance (the ability to perform prolonged periods of work such as 
mowing the yard, vacuuming, performing a days work, etc). 
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Quality of Life:-
The 'CARES' is a quality of life questionnaire which has been specifically designed for 
assessing quality of life in cancer patients. Unfortunately, to obtain as much information 
as possible, it is a lengthy questionnaire and will take you approximately 30 minutes to 
complete. The questionnaire is a subjective analysis by you, and will be used to measure 
the impact of physical activity on your quality of life in all wellness areas including 
physical, social, spiritual, occupational, etc. 
Patient Commitment of Time and Expense: 
The primary commitment will be that of time. Unfortunately, present guidelines suggest 
that exercise intervention programs need to be scheduled for 5 months, in order to observe 
significant changes in physiological data. For this reason, you will be required to exercise 
3 times per week for a period of 5 months. Within this first month, it will be necessary for 
you to attend supervised exercise sessions at the QUT, Human Movement Clinic. Each 
session will last approximately 1 hour. Following this familiarisation period, if you would 
prefer to exercise in community centers, or where appropriate, within the home 
environment, arrangements will be made when possible. In addition to participation within 
these exercise sessions, you will be required to participate in the three testing dates, held 
within the laboratories at the QUT, School of Human Movement Studies. Approximately, 
1.5-2 hours will be required to complete all scheduled tests. Exercise and testing sessions 
will be scheduled at times which are convenient to you. 
Additionally, it is felt that the exercise sessions will be an enjoyable time when you are 
working towards attaining personal goals, and a time when you are able to socialise with 
other patients who have undergone similar experiences. 
Potentilll Complications offrocedures: 
Participation in physical activity programs, brings with it the risk of musculoskeletal injury. 
This risk will be minimised by ensuring that the exercise program developed is initiated at 
a level which is well tolerated, and will be progressed slowly to ensure that you are able to 
adapt to the increasing stimulus without risk of injury. As noted above, you will be asked 
to participate in three graded maximal treadmill exercise tests. At the end stages of this 
test, you will be working the heart, lungs, circulation and muscles maximally. Due to the 
high intensity of workload effon, it is likely that delayed muscle 
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soreness may occur following the test. This muscle soreness will be relieved with time, 
however, an appropriate warm-up and cool down will be undertaken before and after the 
test, respectively, to minimise this soreness. All exercise programs and testing procedures 
have been designed to ensure that the chance of developing a musculoskeletal injury is 
minimal. 
In the case of an injury occurring, the investigator is trained in first-aid and will therefore 
be able to initiate the appropriate primary treaunent immediately. Following primary 
treatment, arrangements will be made for you to see the appropriate health professional. 
Potential Benefits Derived (rom ParlicWation: 
.! The benefits of exercise may enhance your ability to cope with the rigors of cancer 
treatment, and will maximise your independence post-treatment . 
.! Involvement in an exercise program has the potential to minimise the loss of muscle 
mass and thus strength, it may stimulate appetite, and optimise your ability to perform 
daily activities . 
.! This research will assist in providing knowledge of the impact that undergoing an 
APBST has on the immune system, skeletal system, cardiovascular system and quality 
of life. It will also determine the potential of an exercise program in improving these 
systems back to pre-transplant levels. 
! This investigation will allow the energy cost of undergoing an APBST to be measured 
and therefore will assist medical professionals in determining the amount of energy 
intake needed to maintain you in a state of energy balance - meaning what amount of 
food intake is required for you to maintain a steady body weight. It will also allow the 
measurement cost of participating in an exercise program to ensure that the exercise 
being prescribed is beneficial to your health. 
! Long term benefits include the prevention of further debilitatiilg conditions including 
cardiovascular diseases, diabetes, and osteoporosis, to name a few. 
Confidentiality ofRecords mul Patient Information: 
Data obtained from all investigations will remain confidential so that the primary 
investigator will be the only individual who has access to the raw data. Additionally, data 
will be kept within a locked filing cabinet and locked room during times when it is being 
stored. Specialists or GPs will be able to gain access to the data only when 
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pennission has been granted by the relevant patient. When assessing, analysing and 
discussing results, each patient will be allocated a number, and that patient number will be 
used to discuss specific results if the need arises. Otherwise, results will be discussed 
according to the intervention groups, A and B. 
Voluntary Participation: 
You have been given this subject infonnation package, as you have met the appropriate 
inclusion criteria for the investigation. However, participation in this project is entirely 
voluntary. If you decide to participate, you are free to withdraw consent before or during 
the experiment, at any time. Your participation or withdrawal of consent will not 
influence your present and/or future involvement with Queensland University of 
Technology, Mater Hospital or the Wesley Hospital. 
Enquires: 
Questions concerning the procedures and/or rationale used in this investigation are 
welcome at any time. Please ask for clarification of any point you feel is not explained to 
your satisfaction. Your initial contact person is the investigator, Sandi Hayes, 
ph: 3864 5833. Subsequent enquires may be directed to the Principal Supervisor, Peter 
Davies, ph: 3864 5830. 
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The researcher conducting this investigation supports the principles governing the 
ethical conduct of research outlined by the National Health and Medical Research 
Council (NHMRC). Additionally, the protection of the subject's interests, comfort 
and safety will be upheld at all times. 
This form and the accompanying Subject Information Package are given to you for 
your own protection. A detailed outline of the experimental procedures, potential 
benefits and possible risks are clearly outlined within the Subject Information 
Package. Your signature below indicates the following: 
1. you have read the Subject Information Package; 
2. you have been given the opportunity to discuss its contents with either 
the researcher or her supervisor prior to commencing the experiment; 
3. you clearly understand these procedures and potential risks; 
4. you voluntarily agree to participate in this project; and 
5. you understand that your participation may be terminated at any point in 
time throughout the project, without jeopardising your involvement with 
the Queensland University of Technology, the Mater Hospital or the 
Wesley Hospital. 
Any enquires or further questions may be initially directed to the researcher, Sandi 
Hayes, on 3864 5833, or 3353 1687, or to the principal supervisor, Associate 
Professor Peter Davies, on 3864 5830. Any complaints regarding the conduct of 
the research may be directed to the Head of the School of Human Movement 
Studies, Professor Tony Parker or the Secretary of the University Research Ethics 
Committee, on 3864 2902. Additionally, Dr Kerry Taylor can be contacted if you 
are a Mater Patient, or Dr Ian Bunce, if you are a Wesley Patient. 
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I agree to participate in the experimental procedures outlined in the Subject 
Information Package. 
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The following six skinfolds were assessed using standard procedures, with calibrated 
Harpenden Skinfold Calipers for the calculation of the sum of skinfolds (SOS) and 
percentage body fat (%BF): 
+ Triceps: The vertical skinfold was raised with the left thumb and index finger 
such that the lateral surfaces of the thumb and finger are aligned with the 
intersection of the extended mid-acromiale-radiale line and the vertical line on 
the most posterior aspect of the arm, with the arm in the anatomical position. 
The caliper was applied such that the nearest edge of the caliper jaw is 1 em from 
the marked site. 
+ Biceps: The vertical skinfold was raised on the anterior surface of the arm at the 
intersection of the extended mid-acromiale-radiale line and the vertical line in the 
middle of the belly of the biceps muscle. The lateral surfaces of the thumb and 
finger are aligned with the point of intersection. The caliper was applied 1 em 
from the point of intersection. 
+ Subscapular: The inferior surface of the inferior angle of the scapula was 
palpated with the tip of the left thumb. A skinfold was raised below and lateral to 
the inferior angle of the scapula. The fold sloped downwards towards the side of 
the body. The caliper was applied 1 em from the thumb and index finger. 
+ Abdominal: The vertical skinfold was raised at a marked site on a horizontal line 
5 em to the right of the centre of the umbilicus. The lateral surfaces of the left 
thumb and index finger were aligned with the marked site. The caliper was 
applied 1 em below the marked site. 
+ Supraspinale: The iliospinale landmark was located first - the undersurface of 
the tip of the anterior superior iliac spine. It was located by palpating in a 
forward direction along the iliac crest. Then the supraspinale skinfold site was 
located. The anthropometric tape was positioned on a line from the anterior 
axillary fold to the iliospinale site. The point where the tape intersects with the 
imaginary horizontal line projected medially from the iliac crest was marked. 
The skinfold sloped downward in a medial direction and the caliper was applied 
1 em from the lateral surfaces of the left thumb and index finger. 
+ Medial Calf: This site was on the medial surface of the calf at the level of the 
greatest calf circumference. The subject was asked to stand on a box with feet 
slightly apart and body mass evenly distributed. The anthropometric tape was 
used to determine the level of maximum right calf circumference. With the tape 
around the calf, a horizontal mark was made just below the tape on the most 
medial surface of the calf. The subject was then asked to stand on the floor and 
place the right foot on a chair with the knee bent at 90°, calf relaxed. A skinfold 
was raised with the lateral surfaces of the left thumb and index finger aligned 
with the horizontal mark. The caliper was applied 1 em below the horizontal 
mark. 
Figure 4.1 provides an illustration of the anatomical location of each site. 
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Figure 4.1 Skinfold Sites 
Biceps ___ _ 
Mid-
abdominal---+----+++---
Medial 
--If----Calf 
Taken from Gore & Edwards (1992)144 
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the use of the visual analogue scale 
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The VAS is a technique used to assess the patient's perception of effort and is a 
continuum that ranges from 0- no exertion (smiley face), to 10- maximum exertion 
(hot/tired face) (shown in Figure 5.2). While it is similar to using the revised Borg's 
rating of perceived exertion scale (RPE) (shown in Figure 5.1 ), several differences 
exist. A graphical presentation of the revised RPE scale and the VAS is provided 
below. Use of the VAS requires the patient to observe a straight line with no 
divisions across the scale. When asked, the patient must move a marker along the 
line to the point that most closely represents their perceived level of exertion. On the 
tester's side of the VAS, the scaling is clearly marked in millimeters and therefore 
the positioning of the marker by the patient can be quantified without the patient 
knowing the exact score given. The implementation of this procedure assisted in 
minimising bias towards how the patient was feeling from one stage to the next. 
Once the patient reported their perceived exertion, the marker was returned to the 
beginning of the scale, '0', thereby limiting the ability of one score to influence the 
next. 
Figure 5.1 Visual analogue scale 
Patient observes this side: 
Tester observes this side: VAS Score= 5.5 
/ 
I 
1 
Figure 5.2 
I 
2 
I 
3 
I 
4 
I 
5 
I 
6 
I 
7 
Borg's 10 point RPE scale 
RPE -10 Point Scale 
0 Nothing at all 
0.5 Very, Very light 
1 Very light 
2 Light 
3 Moderate 
4 Somewhat Heavy 
5 Heavy 
6 
7 Very Heavy 
8 
9 
10 Very, Very Heavy 
Maximal 
I 
8 
I I 
9 10 
* The adapted version taken from Wilmore & Cos till (1994/22 
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Assessment of hand grip strength 
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Handgrip strength test (Smedley's Dynamo Meter TTM)142: 
• A verbal description and practical 
demonstration of the test was given; 
• the handgrip apparatus was adjusted to 
suit the patient's hand grip and the dial 
was set at zero; 
• the patient was then instructed to 
maximally grip the apparatus; 
• in order to standardise the procedure no 
encouragement was given; 
• and, the test was repeated three times for 
both the right and left hand. 
Appendices 
All patients were right hand dominant, and thus the best score achieved for the right 
hand was adjusted for FFM variances. The averaged score of the best right and left 
hand grip strength results were also recorded and used for comparison with 
normative data. These values were then used during statistical analysis. 
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Instructions 
Below is a list of Problem Statements that describe situations and experiences of 
individuals who have or have had cancer. Read each statement and circle the numbe 
that best describes HOW MUCH EACH STATEMENT APPLIES TO YOU during the PA 
MONTH, INCLUDING TODAY. Some sections will not apply to you. Please skip 
these sections and proceed to the next one as directed. 
Example 
1. I have difficulty walking ···································································0 G) 2 3 4 
2. I find that food tastes bad ................................................................. 0 1 2 3 @: 
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1. I have difficulty bending or lifting ..............•..............................•............ 0 1 2 3 4 
2. I have difficulty walking and/or moving around ..................................... 0 1 2 3 4 
3. I have difficulty doing physical activities such as running and 
playing sports ..................................................................•..................... 0 1 2 3 4 
4. I do not have the energy I used to .......................................................... 0 1 2 3 4 
5. I have difficulty driving .......................................................................... 0 1 2 3 4 
6. I have difficulty doing household chores ............................................... 0 1 2 3 4 
7. I have difficulty bathing, brushing my teeth, or grooming myself ........... 0 1 2 3 4 
8. I have difficulty preparing meals .......................................•.................... 0 1 2 3 4 
9. I am not interested in recreational activities like I used to be ................. 0 1 2 3 4 
10. I do not engage in the recreational activities that I used to ..................... 0 1 2 3 4 
11. I do not have enough enjoyable activities to fill the day ........................ 0 1 2 3 4 
12. I have difficulty planning activities because of the cancer or its 
treatments .............................................................................................. 0 1 2 3 4 
13. I cannot gain weight .............................................................................. 0 1 2 3 4 
14. I am continuing to lose weight. .............................................................. O 1 2 3 4 
15. I find food unappealing ......................................................................... 0 1 2 3 4 
16. I find that food tastes bad ....................................................................... 0 1 2 3 4 
17. I find it difficult to swallow .................................................................... 0 1 2 3 4 
18. I find that the cancer or its treatments keep me from working ................ 0 2 3 4 
19. I find that cancer or its treatments interfere with my ability to work ....... 0 1 2 3 4 
20. I frequently have pain ............................................................................ 0 1 2 3 4 
21. I have chronic pain from scars and surgery ............................................ 0 1 2 3 4 
22. I have pain that is not controlled by pain medication ............................ 0 1 2 3 4 
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23. I have pain that is controlled by pain medication .................................. 0 1 2 3 4 
24. I find that my clothes do not look good on me ....................................... O 1 2 3 4 
25. I find that my clothes do not fit .............................................................. 0 2 3 4 
26. I have difficulty finding clothes to fit ...................................................... 0 1 2 3 4 
27. I find that the medical team withholds information from me about 
the cancer ............................................................................................. 0 1 2 3 4 
28. I find that doctors don't explain what they are doing to me ................... 0 1 2 3 4 
29. I find that nurses don't explain what they are doing to me ..................... 0 1 2 3 4 
30. I have difficulty asking doctors questions ............................................... 0 1 2 3 4 
31. I have difficulty asking nurses questions ................................................ 0 1 2 3 4 
32. I have difficulty expressing my feelings to the doctors and nurses .......... 0 1 2 3 4 
33. I have difficulty telling my doctor about new symptoms ........................ 0 1 2 3 4 
34. I have difficulty understanding what the doctors tell me about the 
cancer or its treatments .......................................................................... 0 1 2 3 4 
35. I have difficulty understanding what the nurses tell me about the 
cancer or its treatments .......................................................................... 0 1 2 3 4 
36. I would like to have more control over what the doctors do to me ........ 0 1 2 3 4 
37. I would like to have more control over what the nurses do to me .......... 0 1 2 3 4 
38. I am embarrassed to show my body to others because of my illness ...... 0 1 2 3 4 
39. I am uncomfortable showing my scars to others .................................... 0 1 2 3 4 
40. I am uncomfortable with the changes in my body ................................. 0 1 2 3 4 
41. I frequently feel anxious ........................................................................ 0 1 2 3 4 
42. I frequently feel depressed ..................................................................... 0 1 2 3 4 
43. I frequently feel angry ............................................................................ 0 1 2 3 4 
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44. I frequently feel upset ............................................................................ 0 1 2 3 4 
45. I frequently feel overwhelmed by my emotions and feelings about 
the cancer ..............................•.............................................................. 0 2 3 4 
46. I have difficulty sleeping ........................................................................ 0 1 2 3 4 
47. I have difficulty concentrating ............................................................... 0 1 2 3 4 
48. I have difficulty remembering things ...................................................... 0 1 2 3 4 
49. I have difficulty thinking clearly ............................................................. 0 1 2 3 4 
50. I have difficulty telling my friends or relatives to come over less 
often ..................................... : ................................................................ 0 1 2 3 4 
51. I have difficulty telling my friends or relatives to leave when I do 
not feel well .......................................................................................... 0 1 2 3 4 
52. I have difficulty asking my friends or relatives to do something fun 
with me ................................................................................................. 0 1 2 3 4 
53. I do not know what to say to my friends or relatives .............................. 0 1 2 3 4 
54. I have difficulty asking friends or relatives to do things for me ............... 0 1 2 3 4 
55. I have difficulty telling my friends or relatives about the cancer ............. 0 1 2 3 4 
56. I have difficulty asking my friends or relatives to come over more 
often ...................................................................................................... 0 1 2 3 4 
57. I find that my friends or relatives tell me I'm looking well when 
I'm not ................................................................................................... o 1 2 3 4 
58. I find that my friends or relatives withhold information from me ............ 0 1 2 3 4 
59. I find that my friends or relatives avoid talking with me about 
the cancer ............................................................................................. 0 2 3 4 
60. I find that my friends or relatives do not visit often enough .................... 0 1 2 3 4 
61. I find that my friends or relatives do not call often enough ..................... 0 1 2 3 4 
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62. I find that my friends or relatives are uncomfortable when they 
visit me .................................................................................................. O 1 2 3 4 
63. I find that friends or relatives have difficulty talking with me 
about my illness .................................................................................... 0 1 2 3 4 
64. I feel uncomfortable when I see other patients getting treatments .......... 0 1 2 3 4 
65. I become nervous when I have to go to the hospital .............................. 0 1 2 3 4 
66. I become nervo~s when I am waiting to see the doctor ......................... 0 1 2 3 4 
67. I become nervous when I am waiting to find out the results of tests ....... 0 2 3 4 
68. I become nervous when I am having diagnostic tests ............................. 0 2 3 4 
69. I become nervous when I get my blood drawn ...................................... 0 1 2 3 4 
70. I worry about whether my treatments are working ................................. 0 1 2 3 4 
71. I worry about whether the cancer is progressing .................................... 0 1 2 3 4 
72. I worry about not being able to care for myself ...................................... 0 2 3 4 
73. I worry about how my family will manage if I die .................................. 0 2 3 4 
74. I do not feel sexually attractive .............................................................. 0 2 3 4 
75. I do not think my partner(s) finds me sexually attractive ......................... O 2 3 4 
76. I am not interested in having sex ........................................................... 0 1 2 3 4 
77. I do not think that my partner(s) is interested in having sex 
with me ................................................................................................. 0 1 2 3 4 
78. I sometimes don't show up for my doctor's appointment ....................... 0 1 2 3 4 
79. I sometimes don't show up for my treatments ........................................ 0 1 2 3 4 
80. I sometimes don't take my medication as prescribed ............................. 0 2 3 4 
81. I sometimes don't follow my doctor's instructions ................................. 0 2 3 4 
82. I have financial problems ...................................................................... 0 2 3 4 
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83. I have insurance problems ..................................................................... 0 1 2 3 4 
84. I have difficulty with transportation to and from my medical 
appointments and/or other places ..........................................•............... 0 1 2 3 4 
85. I am gaining too much weight ............................................................... 0 1 2 3 4 
86. I find some diagnostic procedures extremely painful ............................. 0 1 2 3 4 
87. I have frequent episodes of diarrhea ...................................................... 0 1 2 3 4 
88. I have times when I do not have control of my bladder ......................... 0 1 2 3 4 
89. I have difficulty taking care of the children and/or the grandchildren ..... 0 1 2 3 4 
90. I have difficulty helping my children cope with my illness ..................... O 1 2 3 4 
91. I have difficulty helping my children talk about my illness ..................... 0 1 2 3 4 
92. I have difficulty talking to my boss about the cancer .............................. 0 1 2 3 4 
93. I have difficulty talking to the people who work with me about 
the cancer ............................................................................................. 0 1 2 3 4 
94. I have difficulty telling my employer that I cannot do something 
because of my illness ............................................................................. 0 1 2 3 4 
95. I have difficulty asking for time off from work for medical treatments .... 0 2 3 4 
96. I am worried about being fired .............................................................. 0 1 2 3 4 
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97. I have difficulty finding a new job since I have had cancer ................. 0 1 2 3 4 
98. I find that employers are reluctant to hire people with a cancer 
history ...............................................•................................................. 0 1 2 3 4 
99. I find that the frequency of sexual activity has decreased .................... 0 1 2 3 4 
100. I have difficulty becoming sexually aroused ........................................ 0 2 3 4 
101a. I have difficulty getting or maintaining an erection (Males) ·················0 1 2 3 4 
b. I have difficulty getting lubricated (Females) 
102. I have difficulty reaching orgasm ........................................................ 0 1 2 3 4 
104. My partner and I have difficulty talking about our fears ....................... O 1 2 3 4 
1 OS. My partner and I have difficulty talking about what will happen 
after my death ..................................................................................... 0 1 2 3 4 
1 06. My partner and I have difficulty talking about our future ..................... 0 1 2 3 4 
107. My partner and I have difficulty talking about the cancer and what 
might happen ...................................................................................... o 1 2 3 4 
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108. My partner and I have difficulty talking about wills and financial 
arrangements ........................................................•............................. 0 1 2 3 4 
109. I do not feel like embracing, kissing, or caressing my partner .............. 0 1 2 3 4 
110. My partner does not feel like embracing, kissing or caressing me ....... 0 1 2 3 4 
111. I am not interested in touching my partner .......................................... 0 2 3 4 
112. My partner is not interested in touching me ........................................ 0 2 3 4 
113. My partner and I are not getting along as well as we usually do .......... O 1 2 3 4 
114. My partner and I are upset with each other more often than usual ...... 0 1 2 3 4 
115. My partner and I have so much time together that we get on each 
other's nerves ..................................................................................... 0 1 2 3 4 
116. My partner and I are more distant than usual ...................................... 0 2 3 4 
117. My partner won't let me do activities that I am capable of doing ........ 0 1 2 3 4 
118. My partner spends too much time taking care of me ........................... 0 1 2 3 4 
119. My partner does not take care of me enough ...................................... 0 1 2 3 4 
120. I have difficulty asking my partner to take care of me ......................... 0 1 2 3 4 
121. I have difficulty initiating contact with potential dates ........................ 0 2 3 4 
122. I have difficulty meeting potential dates .............................................. 0 1 2 3 4 
123. I am afraid to go to places that I used to visit to meet dates ................. 0 1 2 3 4 
124. I have difficulty telling a date about the cancer or its treatments ......... 0 1 2 3 4 
125. I am afraid to initiate a sexual relationship with someone .................. 0 1 2 3 4 
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126. I become nervous when I get chemotherapy ....................................... 0 1 2 3 4 
127. I become nauseated during and/or before chemotherapy .................... 0 1 2 3 4 
128. I vomit during and/or before chemotherapy ........................................ 0 1 2 3 4 
129. I feel sick when I think about my chemotherapy ................................. 0 1 2 3 4 
130. I feel nauseated after I receive chemotherapy ...................................... 0 2 3 4 
131. I vomit after chemotherapy ................................................................. 0 1 2 3 4 
132. I feel tired after my chemotherapy ....................................................... 0 1 2 3 4 
133. I have other side effects after chemotherapy ........................................ 0 1 2 3 4 
134. I have lost my hair and/or it is growing back slowly because of 
chemotherapy ..................................................................................... 0 1 2 3 4 
135. I feel fatigued after my radiation treatments ......................................... O 1 2 3 4 
136. I get nervous when I get radiation treatments ...................................... 0 1 2 3 4 
137. I feel nauseous or vomit after my radiation treatments ......................... O 2 3 4 
138. I have problems with ostomy care and maintenance ........................... 0 1 2 3 4 
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139. I have difficulty with my prosthetic device (artificial limb, breast 
prosthesis, etc.) ................................................................................... 0 1 2 3 4 
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A summary of items in the CARES 
questionnaire 
Items in Subscales and Higher-order Factors 
Physical 
Ambulation 
Activities of daily living 
Recreational activities 
Weight loss 
Difficulty working 
Pain 
Clothing 
Medical Interaction 
Problems obtaining information from medical team 
Difficulty communicating with medical team 
Control of medical team 
*Psychosocial 
Body Image 
Psychological distress 
Cognitive problems 
Difficulty communicating with friends/relatives 
Difficulty interacting with friends/relatives 
Anxiety in medical situations 
Worry 
*Interaction with children 
*At work concerns 
*Sexual 
Sex interest 
Sexual dysfunction 
*Marital 
*Communication with partner 
*Affection with partner 
*Interaction with partner 
*Overprotection by partner 
*Neglect of care by partner 
Miscellaneous Subscales 
*Dating 
*Chemotherapy-related problems 
*Radiation-related problems 
Compliance 
Economic barriers 
Miscellaneous Items 
Transportation 
Gain weight 
Procedures painful 
Diarrhea 
Bladder control 
*Ostomy 
*Prosthesis 
N 
··items 
26 
4 
4 
4 
5 
2 
4 
3 
11 
3 
6 
2 
44 
3 
6 
3 
7 
7 
6 
4 
3 
5 
8 
4 
4 
18 
6 
4 
4 
2 
2 
5 
9 
3 
4 
4 
7 
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Items numbers 
on CARES 
1-26 
1-4 
5-8 
9-12 
13-17 
18-19 
20-25 
24-26 
27-27 
27-29 
30-35 
36-37 
38-73, 89-96 
38-40 
41-46 
47-49 
50-56 
57-63 
64-69 
70-73 
89-91 
92-96 
74-77, 99-102 
74-77 
99-102 
103-120 
103-108 
109-112 
113-116 
117-118 
119-120 
121-125 
126-134 
135-137 
78-81 
82-83, 97-98 
84 
85 
86 
87 
88 
138 
139 
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PHYSICAL 
Ambulation 
_ 1. diff bend or lift 
_ 2. diff walkhnove around 
_ 3. diff do physical activ. 
_ 4. reduction m energy 
Activities of Daily Living 
- 5. diff drivin 
_ 6. diff hous~old chores 
_ 7. diff bathe, brush groom 
_ 8. diff prepare meals 
Recreational Activities 
_ 9. no interest recreat activ 
_ 10. not engage recreat activ 
_ 11. not enough enjoyable activ 
_ 12. diff planning activ 
Weight Loss 
_ 13. cannot gain weight 
_ 14. continue to lo~e weight 
_ 15. food unappealing 
_ 16. food tastes bad 
_ 17. diff swallowing 
Difficulty Working 
_ 18. cancer prevents worlc 
_ 19. cancer mterferes work 
Pain 
20. frequently has pain 
21. chrOnic pain scars/surgery 
22. pain not controlled medication 
23. pain controlled medication 
Clothing 
_ 24. clothes not look good 
_ 25. clothes not fit 
_ 26. diff find clothes 
_ SUM_#(1-4)26#Potential 
MEDICAL INTERACTION 
Problems Obtaining Info from Medical Team 
27. medical team withholds info 
- 28. doctors don't explain what do = 29. nurses don't explain what do 
Difficulty Communicating with Medical Team 
_ 30. diff ask doctors questions 
_ 31. diff ask nurses questions 
_ 32. diff express feelings MDJRN 
_ 33. diff tell doctor new symptoms 
_ 34. diff understand MD about cancer 
_ 35. diff understand RN about cancer 
Control of Medical Team 
_ 36. wants more control over MD 
_ 37. wants more control over RN 
_ SUM_#(1-4) 11 #Poten!ial 
*MARITAL 
Communication with Partner 
_ 103. diff talk feelings 
_104. difftalk fears 
_ 105. diff talk happen after death 
_ 106. diff talk future 
_ 107. diff talk cancer 
_ 108. diff talk wills/fmancial matters 
Affection with Partner 
109. doesn't feel like embrace,etc = 110. partner no ~eel like embrace, etc. 
_ 111. no interest !" touc~ parlner 
_ 112. partner no mterest m toueh 
Interaction with Partner 
113. not get along as well usual 
- 114. upset with other more often 
= 115. so much time together, on nerves 
_ 116. more distant than usual 
OVerprotection by Partner 
_ 117. partner not let do activ capable of 
_ 118. parlner provides too mucli care 
Neglect of Care by Partner 
_ 119. pllltner takes too little care 
_ 120. iliff ask partner to take care 
SUM #(1-4) 18,0 
- - # Poteutial Circle 
PSYCHOSOCIAL 
Body Image 
_ 38. embarrassed to show body 
_ 39. uncomfor show scars 
_ 40. uncomfor with body changes 
Psychological Distress 
_ 41. frequently anxious 
_ 42. frequently depressed 
_ 43. frequently angry 
_ 44. frequently upset 
_ 45. frequently overwhelmed by cancer 
_ 46. diff sleep 
Cognitive Problems 
_ 47. diff concentrating 
_ 48. diff remembering 
_ 49. diff thinking clearly 
Difficulty Communicat with Friends/Relatives 
_ 50. diff tell fmd/rel to come less often 
_ 51. diff tell frndlrel to leave when not well 
_ 52. diff ask fmd/rel to do fun things 
_ 53. don't know what to say to fma:trel 
_ 54. diff ask fmd/rel help 
_ 55. diff tell fmdlrel abOut cancer 
_ 56. diff ask fmdlrel to come more 
Friends/Relatives Difficulty Interacting 
_ 57. fmd/rel say look well when not 
_ 58. fmdlrel Wlthhold information 
_ 59. fmd/rel avoid talk cancer 
_ 60. fmd/rel do not visit enough 
_ 61. fmdlrel do not call enough 
_ 62. fmd/rel uncomfor visiting 
_ 63. fmd/rel diff talk about cancer 
Anxiety in Medical Situations 
_ 64. uncomfor see patients get treat 
_ 65. nervous going to hospital 
_ 66. nervous wait to see dOctor 
_ 67. nervous wait for test results 
_ 68. nervous have diagnostic tests 
_ 69. nervous get blood drawn 
Worry 
_ 70. worry whether treatments worlc 
_ 71. worry whether canceq>rogress 
_ 72. worry not able to care for self 
_ 73. worry how family will manage 
*Interaction with Children 
_ 89. diff care for child/grandehild 
_ 90. diff help children cope 
_ 91. diff help children talk about illness 
• At Work Concerns 
92. diff talk boss about cancer 
- 93. diff talk people at worlc 
= 94. diff tell employer cannot do work 
_ 95. diff ask time off for treatments 
_ 96. worried about being fired 
_ SUM_#{14) 44, 41, 39,36 
# Potential Circle 
SEXUAL 
Sex Interest 
_ 7 4. doesn't feel sex. attract 
_ 75. thinks not sexually attractive to partner(s) 
_ 76. not interested in having sex 
_ 77. doesn't think par!ner(s) interested in sex 
*Sexual Dysfunction 
_ 99. frequency of sex decreased 
_ 100. diff become sexually aroused 
_ 101. diff with erection (males) 
_ 101. diff lubrication (females) 
_ 102. diff reach orgasm 
_SUM _#(1-4)8,4 
# Poteutial Circle 
• Items may not apply to all patients 
MISCELLANEOUS 
Compliance 
_ 78. doesn't show for MD appoint 
_ 79. doesn't show for treatments 
_ 80. doesn't take medication 
_ 81. doesn't follow MD's instruct 
_SUM _#(1-4)4 #Potential 
Economic Barriers 
_ 82. financial problems 
_ 83. insurance problems 
_ 97. diff find new job•• 
_ 98. employers no hire CA hist** 
_SUM #(14) 4, 2 
- # Poteutial Circle 
*Dating 
_ 121. diff initiating dates 
_ 122. diff meet dates 
_ 123. afraid go places meet dates 
_ 124. diff tell date about cancer 
_ 125. afraid to initiate sex relatioo 
_SUM #(14)5,0 
- # Potential Circle 
*Chemotherapy-Related Problems 
_ 126. nervous get chemo 
_ 127. nauseated durinl!lbefore ehemo 
_ 128. vomit durinlllbelore chemo 
_ 129. sick when t1iink about ehemo 
_ 130. nauseated after ehemo 
_ 131. vomit after chemo 
_ 132. tired after chemo 
_ 133. otber side effects ehemo 
_ 134. lost hair/grow slow from ehemo 
_SUM #(14)9,0 
- # Potential Circle 
*Radiation-Related Problems 
_ 135. fatigued after rad 
_ 136. nervous get rad 
_ 137. nauseous/vomit after rad 
_SUM #(14)3,0 
- It Potential Circle 
*Ostomy 
_ 138. problems ostomy carehnaint. 
_SUM #(14)1,0 
- It Potential Circle 
*Prosthesis 
_ 139. diff with prosthesis 
_SUM #(14) 1, 0 
- # Poteutial Cirole 
Miscellaneous Items 
- 84. diff with transport 
_ 85. gain too mueh weight 
_ 86. diagnostic proced painful 
- 87. frequent diarrhea 
_ 88. poor bladder control 
_SUM_ #(1-4) 5 #Potential 
SUM ALL 8 MISCELLANEOUS 
SUMS ABOVE 
_ SUM_#(l-4) __ #Potential 
Global and Average Severity fOr 
CARES and 5 Subscales 
Scale SUM # # AVE GLOBAL 
Endor Poten Sever 
Physical 
Psychoso _________ _ 
Med lnt 
Marital 
Sexual 
Mlscell 
CARES 
CAncer Rehabilitation Evaluation System (CARES): Patient Profile 
Patient Information 
Name: __________________________ __ 
Date: ___ _ 
T-8core 
80_ 
-
75: 
70: 
65: 
so: 
-
ss: 
so: 
-
45: 
40: 
35: 
30: 
-
25: 
20-
CARES 
Global 
Score 
CARES 
#Prob 
Endorsed 
CARES 
Aver 
Sever 
Please Circle Normative Sample Used: 
1 . Female Breast Cancer Norm 
2. Female Other than Breast Cancer Norm 
3. Female Combined Cancer Norm 
PHYSICAL PSYCHOSOCIAL MEDICAL 
Global Global INTERACTION 
Score Score Global Score 
4. Male Prostate Cancer Norm 
5. Male Other than Prostate Cancer Norm 
6. Male Combined Cancer Norm 
MARITAL 
Global 
Score 
SEXUAL 
Global 
Score 
%Rank 
99 
98 
93 
84 
70 
50 
30 
16 
07 
02 
~I I -1 ~ I I I -T I I 
COPYRIGHT <0 1988 CARES Consultants 
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